An association study of PITX2 polymorphism in a cohort of patients with primary open angle glaucoma and considerations on the genetics of glaucoma by Vaideanu-Collins, Daniela
 University of Newcastle upon Tyne 
Faculty of Medical Sciences 
 
 
 
 
 
An association study of PITX2 polymorphism in a cohort of  
       patients with primary open angle glaucoma and  
           considerations on the genetics of glaucoma 
 
 
 
 
 
 
Daniela Vaideanu- Collins 
 
 
 
Thesis submitted to The University of Newcastle upon Tyne in candidature 
for the degree of Doctor of Medicine (MD) 
 
 
School of Medicine, Institute of Human Genetics, Newcastle upon Tyne 
 
March 2008  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ii 
 
 
Declaration 
No portion of the work referred to in the thesis has been submitted in support of an 
application for another degree or qualification for this or any other university or other 
institute of learning. 
 
Copyright Statement 
Copyright in text of this thesis rests with the author. Copies (by any process) either in 
full, or of extracts, may be only in accordance with instructions given by the author and 
lodged in the Walton Library, Newcastle upon Tyne. Details may be obtained from the 
librarian. This page must form part of any such copies made. Further copies (by any 
process) of copies made in accordance with such instructions may not be made without 
the permission (in writing) of the author. 
 
The ownership of any intellectual property rights which may be described in this thesis 
is invested in The University of Newcastle upon Tyne, subject to any prior agreement to 
the contrary, and may not be made available for use by third parties without permission 
of the University, which will prescribe the terms and conditions of any such agreement. 
 
Further information on the conditions under which disclosures and exploitation may 
take place is available from the Head of School of Medicine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii
 
ABSTRACT 
 
Background: Glaucoma is a major cause of blindness world-wide. There is a need for 
methods to identify individuals at risk of developing glaucoma, so that early treatment 
can prevent visual loss. Genetic screening tests offer the prospect of pre-symptomatic 
diagnosis of at risk individuals. There is now strong evidence that a number of different 
genes are associated with glaucoma susceptibility. Mutations in the PITX2 homeobox 
transcription factor gene disrupt normal development of the anterior segment and cause 
overt structural abnormalities. It is possible that, as yet undetected 
mutations/polymorphisms in PITX2 may produce subtle and undetected abnormalities in 
anterior segment structure and function that could predispose to glaucoma. 
 
Purpose: The aim of this thesis is two fold: 
1. Screening for the presence of single nucleotide polymorphisms in PITX2 gene in a 
cohort of 100 unrelated primary open angle glaucoma/ ocular hypertension patients, 10 
Posterior embryotoxon subjects and 100 age and ethnically matched controls to 
establish the mutation spectrum. 
2. Identification, phenotyping and recruitment for genetic studies of primary open angle 
glaucoma patients with strong family history of glaucoma. 
 
Materials and methods: 
1. 100 primary open angle glaucoma patients and 60 age and ethnically matched 
controls were enrolled in the study. Patients and controls were phenotyped and a blood 
sample for DNA extraction collected. PITX2 exon-specific primers were used to PCR 
amplify patient and control DNA. Direct sequencing was used to screen for sequence 
alterations in the entire coding sequence of PITX2 gene. Concurrently, polymorphic 
sites reported in the PITX2 gene were identified from the NCBI and Ensembl databases 
and the frequency of polymorphic sites was investigated. The SHEsis and UNPHASED 
software packages were used for statistical analysis. 
2. Patients diagnosed with glaucoma and strong family history were identified from 
Glaucoma Unit at Sunderland Eye Infirmary, phenotyped and enrolled in the study. The 
pedigrees were constructed and interested relatives enrolled in the study and 
phenotyped. A sample of blood for DNA extraction was collected from all people 
enrolled in the study. 
 iv 
 
Results: 
1. Direct sequencing did not identify any sequence variation in the coding region. 
26 PITX2 polymorphic sites were identified from the internet databases, including five 
in the coding sequence. Sixteen non coding SNPs were confirmed within our study 
group and SNP frequencies were examined. None of the coding sequence SNPs was 
identified in our cohort, demonstrating a high degree of sequence conservation. Also, 
none of the SNPs confirmed in this study group showed an increased frequency in the 
primary open angle glaucoma group compared with the control group. 
2. Thirty-three pedigrees were identified with strong family of glaucoma during the time 
allowed for patient recruitment. Of these, twenty-two agreed to take part in the study. 
Thirteen pedigrees are presented in this study, mostly demonstrating autosomal 
dominant inheritance. 
 
Conclusion: There is ample evidence to suggest that genetics play an important role in 
unravelling the pathogenesis of glaucoma. Identification and recruitment of patients for 
genetic studies is an essential step and the role of the clinician in this process is 
paramount. Also, developmental glaucoma genes are an important group of genes to be 
screened in primary open angle glaucoma/ocular hypertension patients, as they may 
play a role in the pathogenesis of this preventable blinding disease.  
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Chapter 1: INTRODUCTION 
 
1.1 WHAT IS GLAUCOMA 
 
The term glaucoma is first mentioned as a diagnosis by physicians in the Hippocratic 
Aphorisms. The word glaucoma is derived from the Greek glaukos meaning a dull, 
greyish green colour, which is descriptive of advanced glaucoma seen in those days 
(Kronfeld 1996). 
 
Glaucoma is a family of diseases that share an acquired optic neuropathy characterised 
by excavation (or cupping) of optic nerve head and thinning of the neuro-retinal rim. 
When loss of optic nerve tissue is significant, patients develop visual field loss. 
Approximately 50% of fibres can be lost before visual field loss occurs (Sommer 
1991b).
 
 
There are many classifications of glaucoma, e.g.: according to the anatomy of the 
anterior chamber (open angle, closed angle), age of onset (infantile, juvenile, and adult) 
and aetiology (primary, secondary). A definitive classification of glaucoma will be 
possible only when all of the etiological factors, including genetic loci and contributing 
factors, have been identified. 
 
For the purpose of this work, glaucoma will be broadly classified into three main types, 
although there can be a considerable overlap between these categories. (Shields 1996) 
 
• open angle 
• closed angle 
• developmental 
 
The structures of the anterior segment of the eye (cornea, trabecular meshwork, iris as 
well as both the lens and ciliary body) play an integral part in the regulation of the 
intraocular pressure. The anterior chamber angle is formed by the junction of the iris 
posteriorly and the cornea anteriorly. Aqueous secreted by the ciliary body leaves the 
eye via the trabecular meshwork, which is located at the anterior chamber angle. 
Developmental abnormalities of the migration and differentiation of neural crest cells 
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that contribute to the development of these structures may lead to impaired aqueous 
outflow. 
 
A procedure known as gonioscopy is used to differentiate between the different types of 
glaucoma. Gonioscopy involves examination of the anterior chamber with a lens that 
enables the observer to visualise the angle between the cornea-sclera and iris. 
 
In closed angle glaucoma, the anterior chamber angle is narrowed to the extent that the 
peripheral iris blocks aqueous outflow through the trabecular meshwork. This occurs 
with and without pupillary block. 
 
By contrast, primary open angle glaucoma (POAG) is a diagnosis of exclusion reached 
when the anterior segment appears normal and no cause for glaucoma can be identified. 
The disease has an adult onset (>40 years of age), is usually bilateral and has no 
noticeable symptoms in most patients until the later stages of the disease, when patients 
lose their central vision (European Glaucoma Society terminology and guideline for 
glaucoma 2008). 
 
Developmental glaucoma occurs in the young as a result of a defect developed during 
gestation or at birth. An association of developmental glaucoma is with anterior 
segment dysgeneses of the eye. 
 
Anterior segment dysgeneses (ASD) of the eye are a genetically heterogeneous 
spectrum of clinical disorders that result from malformation of neural crest derived 
endothelial tissues (Kupfer & Kaiser-Kupfer 1979, Shields 1983, Smelser & Ozanics 
1971). One condition that belongs to this group and is important for this thesis is 
Axenfeld-Rieger anomaly and syndrome-ARA/S (mutations in the gene investigated in 
this project can result in ARA/S). 
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1.2 ANATOMY AND PHYSIOLOGY OF THE EYE RELEVANT TO 
GLAUCOMA 
 
1.2.1 Ganglion cells and optic nerve anatomy 
 
The optic nerve and the retina are an extension of the Central Nervous System. The 1.2 
million axons of the ganglion cells of the retina converge towards the lamina cribrosa to 
form the optic nerve (ON) head. The distribution of these axons as they pass across the 
retina to enter the optic nerve head is the key to the interpretation of visual field loss in 
relation to optic nerve cupping in glaucoma. The nasal fibre enter nasally, the fibres 
temporal to the fovea  follow an arcuate path around papillomacular bundle (fig 1.1) and 
the fibres arising from macula follow a straight course to the ON head, forming a 
spindle shaped area (papillomacular bundle). 
 
Figure 1.1: Diagrammatic representation of nerve fibres layer course at 
retinal level (from Madeiros 2002) 
Ganglion cells axons exit from the eye through the lamina cribrosa of the scleral canal 
(fig 1.2), become myelinated posterior to the optic disc and form the optic nerve which 
travels towards the optic chiasma (Jakobiec 1982, Snell & Lemp 1998). 
Figure 1.2: Diagrammatic sagittal section of the eye (adapted from 
www.nci.nih.gov/eyean/) 
The optic cup is a small depression in the middle of the ON head which is not occupied 
by neural disc tissue. The neuroretinal rim is the tissue between the outer edge of the 
cup and the outer margin of the disc. A normal rim has a uniform width and a pink 
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colour. The retinal blood vessels enter the disc centrally and then course nasally 
following the edge of the cup (Figure 1.3). 
 
Figure 1.3: Colour photograph of a normal optic nerve head 
 
The diameter of the cup can be expressed as a fraction of the diameter of the disc, both 
horizontally and vertically and is one the parameters used in diagnosing and monitoring 
progression of glaucoma. The cup – disc ratio is a partially inherited trait. This has been 
demonstrated in twin and family based cohort studies (Armaly 1967a, Schwartz et al 
1975, Schwartz et al 1976, Klein et al 2004, Chang et al 2005, van Koolwijk et al 2007, 
Liu et al 2008). In these studies, the heritability of the cup disc ratio ranges from 0.48 to 
0.8. 
Normal cup-disc ratio in the horizontal meridian is 0.3 and it is larger than in the 
vertical meridian; only 2% of eye have a ratio more than 0.7 (Jonas et al 1988a).  
The neuroretinal rim in the normal eyes shows a characteristic configuration. It is 
usually broadest in the inferior rim, followed by the superior and nasal rims, and 
thinnest in the temporal disc region. This pattern of rim is known as the ISNT rule and it 
was originally described by Jonas et al (1988a). The ISNT rule is a clinically useful 
method to aid in glaucoma diagnosis. 
 
   Figure 1.4: Diagram demonstrating the ISNT rule (from Harizman 
et al 2006) 
 
 
  5
1.2.2 Aqueous humour physiology 
 
One of the strongest risk factors for POAG is the IOP, which is determined by the rate 
of aqueous humour secretion, the resistance in the outflow channels and the level of 
episcleral venous pressure. 
The aqueous is actively secreted by the non-pigmented ciliary epithelium, accounting 
for 80% of the production, the remaining 20% being produced by passive secretion 
(ultrafiltration and diffusion). The passive secretion is dependent on the blood pressure 
in the ciliary capillaries, the plasma oncotic pressure and the level of intraocular 
pressure (Brubaker 1991). 
This solution passes to the anterior chamber through the pupil and is drained through 
the trabecular meshwork, the uveoscleral route, and the iris (1-2%) to the episcleral 
veins (Figure 1.5). Direct measurements in human eyes have suggested that less than 
15% is drained by the uveoscleral route. However, indirect calculations have given a 
value of about 35% in young adults with a dramatic reduction to 3% in persons more 
than 60 years of age (Nilsson 1997, Alm & Nilsson 2009, McLaren 2009).  
 
Figure 1.5: Diagram demonstrating the dynamic of the aqueous humour in the eye (adapted from 
www.nci.nih.gov/eyean/) 
 
In most cases of glaucoma, there is an increased resistance to aqueous humor drainage 
through the trabecular pathway (Gabelt and Kaufman 2005, Tamm and Fuchshofer 
2007). 
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1.3 EPIDEMIOLOGY OF POAG 
 
Glaucoma represents a significant public health problem. It is estimated that glaucoma 
is the second leading cause of visual loss in the world, with 60.5 million people having 
the disease in the year 2000 and 6.7 million bilaterally blind from it (Quigley 1996). 
As the elderly population grows disproportionately, the risk of developing glaucoma 
increases accordingly, with 8.4 million people estimated to be bilaterally blind from 
POAG in 2010, rising to 11.1 million by 2020 (Quigley and Broman 2006). 
In England and Wales (prevalence estimated at 1.2% - Kroese et al 2002, Tuck and 
Crick 2003 ), the number of POAG cases is estimated to increase by a third by 2021, 
and then continue upwards to a similar pace to 2031.  
In the developed countries, fewer than 50% of those with glaucoma are aware of their 
disease. In the developing world, the rate of known disease is even lower (Quigley 
1996). POAG is the commonest type of glaucoma in European and African population 
and accounts for > 50% of all cases (McKusick 1994). Approximately 5% of people 
over 70 are affected and have variable ages of onset of the disease. 
 
The prevalence of glaucoma varies with age and race and ranges from 0.43% to 
8.8%.(Hollows and Graham 1966, Mason et al 1989, Tielsch et al 1991, Klein et al 
1992a,  Mitchell et al 1996, Tuck and Crick 1998,  Wolfs et al 2000, Weih et al 2001, 
Varma et al 2004, Rudnicka et al 2006) Data on glaucoma incidence has been derived 
from age-specific prevalence. Leske et al, (1981) calculated an incidence of 0.08/1000 
per year for those in their forties to 1.46/1000 per year for those in their eighties. 
 
In 2007, Leske et al, published the nine year incidence of open angle glaucoma in 
“Barbados Eye Studies”, which was found to be 4.4% or 0.5% per year, for definite 
glaucoma and 9.4% or 1% per year when the suspected/probable glaucoma cases were 
included in calculation. Quigley et al (1997), found the cumulative probability of POAG 
of 4.2% for white persons and 10.3% for black persons. Among those in whom POAG 
would ever develop, it would develop in 25% by age 64, 50% by age 72 and 75% by 
age 81 years for white population and about 10 years younger in each group for the 
black population. 
 
Even mild visual impairment secondary to glaucoma may cause difficulty with 
mobility, driving and social interaction (Spaeth et al 2006, Ramulu 2009). The loss of 
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peripheral vision and contrast sensitivity associated with glaucoma can have a major 
effect on individual’s life and the health service. 
 
Because glaucoma is treatable and because the visual impairment from glaucoma is 
irreversible, early detection of the disease is critically important. 
 
1.4 RISK FACTORS FOR DEVELOPING GLAUCOMA 
 
Although POAG is the most studied of all the glaucomas, the mechanism of optic nerve 
damage has not been fully elucidated. However, there is a list of risk factors for 
developing glaucoma that have been suggested and can be classified in: demographic, 
genetic, systemic and ocular. 
 
1.4.1 Demographic risk factors 
 
1.4.1.1 Age 
 
Prevalence and incidence of glaucoma show a sharp increase with age, usually in people 
over 40 years of age. The Collaborative Glaucoma Study identified age as the major 
independent predictor of incidence (Armaly et al 1980) and appears to be consistent 
across the studies (Hollows and Graham 1966, Leibowitz et al 1980, Tielsch et al 1991, 
Leske 1994, Mitchell et al 1996, Kroese et al 2002,, Varma et al 2004, Leske 2007b), 
 
1.4.1.2 Gender 
 
The gender as a risk factor for developing glaucoma is controversial, as some studies 
fail to show an association (Hollows and Graham 1966, Tielsch et al 1991, Klein et al 
1992a, Coffey et al 1993,). However, other studies have shown a slight increased risk 
for females (Leibowitz et al 1980, Mitchell et al 1996), whereas The Barbados Eye 
Study and The Rotterdam Study show an increased risk for males (Leske et al 1994 and 
2007b, Wolfs et al 2000). The Rudnicka et al (2006) performed a Bayesian meta-
analysis looking at variation in POAG by age, gender and race. The analysis found an 
estimated prevalence to be 23% higher in men than women, which appears to be 
consistent with a very large study looking at the prevalence of glaucoma treatment in 
the UK (Owen et al 2006). 
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1.4.1.3 Ethnicity 
 
The Rudnicka et al review (2006) quantifies the rate of change in the prevalence of 
POAG with age for different racial groups. Although the average prevalence at all ages 
was higher in black populations than in white or Asian populations, the rate of change 
of POAG prevalence with age appears highest in white populations (OR doubles per 
decade) - table1.1. 
 
Table 1.1: Estimated POAG prevalence according to age and race (Rudnicka et al, 2006) 
Predicted prevalence of OAG (95% CrI) Age range(Y) 
White Black Asian 
30-39 - 1.8(1.2-2.7) 0.4(0.3-0.6) 
40-49 0.4(0.3-0.6) 2.9 (1.9–4.4) 0.6 (0.4–1.0) 
50-59 0.8 (0.5–1.2) 4.6 (3.1–6.8) 1.0 (0.6–1.6) 
60-69 1.6 (1.1–2.5) 7.2 (4.9–10.6) 1.6 (1.0–2.4) 
70-79 3.3 (2.2–4.9) 11.2 (7.6–16.1) 2.5 (1.6–3.8) 
80-89 6.6 (4.4–9.7) 16.9 (11.7–23.8) 3.8 (2.3–5.9) 
90-95 10.8 (7.2–15.8) 22.5 (15.7–31.2) — 
 
1.4.1.4 Socioeconomic factors 
 
There is little work done regarding the role of these variables (Leske & Rosenthal 
1979). The data on the role of occupational factors are conflicting, with some studies 
reporting an increased risk with outdoor exposure and other a decreased risk (Packer et 
al 1964, Bjornsson 1967, Morgan & Drance 1975).  
Tielsch et al (1991) investigated the relation between the socioeconomic status and 
visual impairment and found an association between lower socioeconomic status and 
visual impairment. Fraser et al (2001) looked to identify socioeconomic risk factors for 
first presentation of advanced glaucomatous field defect and found that area and 
individual level deprivation were both associated with late presentation of glaucoma, 
thus increasing the risk of blindness from glaucoma. 
 
1.4.2 Genetic risk factors 
 
A positive family history of glaucoma is known to increase the risk of the disease 
(table1.2). Most POAG pedigrees do not show a simple Mendelian pattern of 
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inheritance; however both autosomal recessive and autosomal dominant transmission 
has been suggested (Leske 1983). The relatives of patients with glaucoma run an 
increased risk of developing the condition compared with general population, estimates 
of the prevalence range from 2.8% to 13.5% (Netland et al 1993).  
                                                                                                                                                                                                                                                                                                          
In the Baltimore Eye Survey, first-degree relatives of patients with POAG had 2.9 times 
greater odds of having glaucoma than non-relatives (Tielsch et al 1994) and  in The 
Rotterdam study, the life risk of glaucoma was 9.2 times higher in siblings and 
offspring of glaucoma patients than in sibling and offspring of controls (Hulsman et al 
2002). The Beaver Dam Eye Study (Klein et al 2004) found a strong familial effect on 
risk indicators of glaucoma. To note in this study is the consistent and strong 
quantitative correlation of intraocular pressure and optic cup dimensions in siblings and 
in parent and children and the lack of correlation of these parameters in spouses.  
A case control study on a Caucasian cohort of 175 POAG patients and 175 control 
subject showed that, for first degree relatives, a family history of POAG was a major 
risk factor with odds ratio of 7.67 (Charliat et al 1994). More specifically, there appears 
to be a strong familial component to the development of NTG, where the presence of a 
positive family history is reported to be about 40 % (Geijssen 1991). With regards to 
ocular hypertension, a clinic based study involving 150 patients, showed 43% of 
patients with OHT had a positive family history (Shin et al 1977) despite family history 
of glaucoma not being identified as a risk factor for developing glaucoma in the OHTS 
study.  
Further evidence that genetics is an important factor is supported by twin studies which 
have shown a higher degree of concordance among monozygotic twin (Teikari 1987, 
Gottfredsdottir et al 1999). In particular, Gottfredsdottir et al showed the concordance of 
open angle glaucoma in monozygotic twin pairs was significantly higher at 98 % 
compared to their spouses (70%).  
 
Taken together, these evidences strongly suggest that specific genetic defects contribute 
to the pathogenesis of POAG. 
 
The increased susceptibility of glaucoma patients to corticosteroid induced rises in 
intraocular pressure and HLA typing of glaucoma patients were considered to be 
promising indicators, however the evidence is inconclusive (Leske 1983). 
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Some studies have shown a seven to eightfold higher frequency of maternal than 
paternal history of glaucoma or eye disease (Morgan & Drance 1975, Shin et al 1977), 
which still remains unexplained. 
 
1.4.3 Systemic risk factors 
 
1.4.3.1 Diabetes 
 
Many studies have suggested that diabetes is associated with glaucoma (Armaly 1969, 
Becker 1971, Vacharat 1979). Katz & Sommer (1988) found a risk of 2.8 of having 
POAG if the subject was diabetic. Other large epidemiological studies failed to show an 
association between diabetes and glaucoma (Armaly et al 1980, Jonas & Gruntler 1998, 
Tielsch et al1991, Ellis et al 2000, Weih et al 2001, Vijaya et al 2007). 
 
However, a significant association between diabetes and IOP was found in Framingham 
study, where the prevalence of diabetes was 2 to 3 times as high in persons with 
pressure > 21 mmHg compared with the persons with pressure less than 21mm Hg 
(Kahn & Milton 1980). 
 
1.4.3.2 Blood Pressure 
 
A large review of systemic findings in patients with POAG (Pache & Flammer 2006) 
examines the evidence for association of high and low blood pressure with POAG. The 
studies reporting on the association between arterial hypertension and POAG conclude a 
positive, negative or no relationships (, Leske et al 1995, Tielsch JM 1996, Bonomi et al 
2000, Quigley et al 2001, Leske et al 2002,  Mitchell et al 2004). 
Regarding the association between progression of glaucomatous damage and arterial 
hypotension, there appears to be more evidence available for a positive relationship 
(Drance 1973, Kaiser & Flammer 1991, Gramer & Tausch 1995, Leske et al 1995, 
Bonomi et al 2000, Leske et al 2002). This evidence suggests that especially nocturnal 
drops in blood pressure may play a role in pathogenesis of glaucoma, possibly by 
reducing the ON head blood flow below a crucial level. 
In The Barbados Eye Studies (Leske et al 2007a) a lower systolic blood pressure and 
especially lower ocular perfusion pressure, doubles the risk of POAG. Lower systolic 
perfusion pressure and lower systolic blood pressure were found to be positively 
  11 
associated with glaucoma progression in the Early Manifest Glaucoma Trial (Leske et al 
2007b). Similar results were published by the Rotterdam Study group (Hulsman et al 
2007). 
 
Table 1.2: Summary of clinical risk factors for POAG (adapted from Shield’s Textbook of 
Glaucoma, 2005) 
GOOD EVIDENCE   
Risk factor  Relative risk 
Age (per decade over 40)   2 (, Klein et al 1992a, Sommer et al 1991a, 
Dielemans et al  1994, Congdon et al 2004,) 
Black ethnicity  4 (Tielsch et al 1991)  
First degree family history  2 to 4 (Tielsch et al 1994, Leske et al 1996,Wolfs et 
al 1998, Le et al 2003,) 
IOP compared to 15mmHg                               
19-21 mmHg  3 (Ekstrom 1993, Leske et al, 2001, Le et al 2003,  
Leske et al 2003a) 
 22-29 mmHg      13 
>30 mmHg 40      40 
Myopia  1.5 to 3 (Ekstrom 1993, Mitchell et al 1999, Weih 
     et al 2001, Wong et al 2003) 
Diastolic perfusion pressure (<55 mmHg)  3 (Tielsch et al 1995, Leske et al 1996, Bonomi et al 
2000, Leske et al 2003b,) 
FAIR EVIDENCE 
Large C/D ratio, diabetes mellitus, optic disc haemorrhage  
WEAK EVIDENCE 
Migraine (for NTG) 
 
1.4.4 Ocular risk factors 
 
1.4.4.1 Intraocular pressure 
 
Elevated intraocular pressure (IOP) is consistently reported as one of the primary risk 
factors for visual field loss. All large longitudinal glaucoma studies confirm that there is 
a direct relationship between the level of IOP and the progression of visual field loss 
(Drance et al 1981, Hovding & Aasved 1986, VanVeldhuisen et al 2000, Weih et al 
2001, Gordon et al 2002, Mukesh et al 2002, Nouri-Mahdavi et al 2004, Bengtsson and 
Heijl 2005, de Voogd et al 2005, Bengtsson and Heijl 2007, Leske et al 2007b, Miglior 
et al 2007a,, Vijaya et al 2007,).  
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The commonly accepted range for normal IOP in general population is 10- 22 mm Hg. 
In their paper on IOP distribution in a healthy Iranian population, Hashemi et al (2005) 
summarise the results of different studies on IOP in various geographic areas and racial 
groups (table 1.3). 
 
It is obvious from this table, that IOP distribution is different in different races and 
residents of different locations and may be a geographical or racial approach should be 
used for defining the normal IOP range. 
 
Heritability of intraocular pressure has been investigated in family and sibling based 
studies (Armaly 1967b, Klein et al 2004, Duggal et al 2005) and it was estimated to be 
from 0.29 to 0.50. Several twin studies (Kalenak and Paydar 1995, Parssinen et al 2007, 
Carbonaro et al 2008, Zheng et al 2009) show a higher heritability (around 0.60) in part 
due to shared common environment that twins have, such as same age, intrauterine 
environment and family background. The high heritability of intraocular pressure could 
be used to detect linkage in a genome wide analysis. 
 
Also, it is important to realize that the relative risk of glaucoma begins to rise from 16 
mm Hg onwards and not from 22 mm Hg (Davenger et al 1991, Sommer et al 1991a).  
 
The classical theory that increased IOP damages the optic nerve and produces 
characteristic changes in the visual field is not always true, especially in POAG. In 
some individuals, increased IOP does not cause any visual field loss, and this situation 
is termed – ocular hypertension (OHT). Also, in other individuals, glaucomatous 
cupping and visual field loss occur at pressure under 22mm Hg, and this group of open 
angle glaucoma is named normal tension glaucoma (NTG). 
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Table 1.3: Distribution of IOP and percentage of ocular hypertension in different studies (Hashemi et al, BJO 2005) 
Study 
Country, 
year 
Setting 
Age/ 
years 
Measurement 
tool for IOP 
M/F Group 
IOP (mean 
(SD)* 
OH 
(%)* 
Shiose Japan, 
 1988–9 
Population 
based 
40 NCT† 3031/ 
5095 
M 13.1 (3.0)‡ 1.8§ 
      F 13.4 (3.0)‡ 1.3§ 
      Nl 13.3 (3.0) NR 
      T 13.4 (3.1) 1.4§ 
Weih 
2001 
Australia, 
1992–6 
Population 
based, cross 
sectional 
40 Tono-Pen 
 (+ Goldmann) 
2230/ 
2514 
Nl 14.5 
(3.1)†† 
1.5 
      T 14.7 (3.5) 2.8 
Egna-
Neumarkt 
(Bonomi 
1998) 
Italy, NR 
1998 
Cross 
sectional, 
epidemiologic
al 
>40 Goldmann 1882/ 
2415 
M 15.1 (2.8) 2.7 
      F 14.9 (2.6) 1.6 
      Nl NR NR 
      T NR 2.1 
Lee 2002 Korea,  
1997–2000 
Healthy 
people 
examined at a 
health centre 
20–84 NCT 6684/ 
6528 
M 16.1 (3.2) 6.1 
      F 15.1 (2.9) 2.5 
      Nl 15.5 (3.1) 4.3 
Blue 
Mountains 
Australia,  
1992–4 
Population 
based 
49–97 Goldmann  M NR 3.8 
Mitchell 
1996 
     F NR 3.6 
      T 16.1 (2.9)† 3.7 
Baltimore 
 
US, 
 1985–8 
Population 
based 
40 Goldmann  White 17.2 (3.3) NR 
Sommer 
1991a 
     Black 16.0 (4.2) NR 
Rotterdam 
Dielemans 
1994 
Netherland  
1991–3 
Population 
cohort 
55 Goldmann 1226/ 
1836 
T 14.6 (NR) 2.2 
Beaver Dam US, NR Population 
based 
43–84 Goldmann 2135/ 
2721 
M 15.3 (3.4) 4.4 
Klein 
1992a&b 
     F 15.5 (3.3) 4.7 
      Nl 15.3 (3.2) NR 
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Table 1.3: Distribution of IOP and percentage of ocular hypertension in different studies (Hashemi et al, BJO 2005) 
Study 
Country, 
year 
Setting 
Age 
(years) 
Measurement 
tool for IOP 
M/F Group 
IOP 
(mean 
(SD)* 
OH 
(%)* 
Barbados 
Leske 1997 
Barbados, 
1988–92 
Population 
based 
40–84   M‡ 17.6 
(3.4) 
NR 
      F‡ 18.0 
(3.6) 
NR 
      Black 18.1 
(4.8) 
12.8 
Wallace 
1969 
Jamaica, 
 1965 
Epidemio- 
logical study 
35–74 Goldmann 232/ 
342 
M 16.8 
(2.8)†‡ 
NR 
      F 16.5 
(2.9)†‡ 
NR 
      T NR 7.4 
 
Rotchford 
2002 
 
South. 
Africa, NR 
 
Population 
based, cross 
sectional 
 
>40 
 
Goldmann + 
Tono-Pen 
 
280/ 
725 
 
Nl 
 
13.9 
(3.4) 
 
3.5 
Framingham US,  
1973–5 
Population 
cohort 
52–85 Goldmann 1030/ M 17.0 
(4.0) 
NR 
Khan 1977     1415 F 17.1 
(4.1) 
NR 
      T 17.0 
(4.1) 
NR 
TES 
Hashemi 
2005 
Iran, 2002 Population 
based, cross 
sectional 
10 Goldmann 1566/ M 14.4 
(2.7)†‡¶ 
0.4** 
     2267 F 14.5 
(2.5)†‡¶ 
0.4** 
      Nl 14.5 
(2.6)†¶ 
0.4** 
 
M/F, number of men/women; OH, ocular hypertension (IOP >21 mm Hg); M, male; F, female; Nl, healthy 
people/eyes; T, total sample; NCT, non-contact tonometer; NR, not reported; US, United States; TES, Tehran Eye 
Study (the current study). 
*Figures were rounded to one decimal point; †Right eyes IOP reported; ‡IOP measurements on healthy eyes 
excluding glaucomatous eyes; §IOP >20 mm Hg; ††In healthy non-hypertensive eyes; ¶15.1 (2.9) mm Hg for normal 
men, women, or people 40 years; **0.9 for men, women, or people 40 years (and 1.8% IOP >20 mm Hg in men, 
women, or people 40 years). 
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However, as stated above, epidemiological studies show that as IOP increases, there is a 
corresponding increase in the risk of glaucomatous optic nerve damage and visual field 
loss (Armaly et al 1980, Drance et al 1981, Sommer et al 1991a, Gordon et al 2002, 
Nouri-Mahdavi et al 2004, Bengtsson et Heijl 2007, Leske et al 2007a & b, Vijaya et al 
2007). Eye pressure more than 30 mm Hg commonly leads to the inference that the 
disease will soon be present. The Ocular Hypertension Treatment Study (OHTS) group 
calculated an estimated 5-year cumulative probability of developing POAG in ocular 
hypertension of 9.3%, and a 16.8% risk for the European Glaucoma Prevention Study 
placebo group (Gordon et al 2007). 
Table 1.4 presents prevalence and relative risk of POAG associated with increasing IOP 
as presented in Shield’s Textbook of glaucoma, 2005 
 
Table 1.4: Prevalence and relative risk of POAG with increasing IOP 
(adapted from Shield’s Textbook of Glaucoma, 2005) 
IOP (mmHg)  Prevalence Relative risk 
    <15      0.7      1.0 
   16-18      1.3      2.0 
   19-21      1.8      2.8 
   22-24      8.3    12.8 
   25-29      8.3    12.8 
   30-34     25.4    39.0 
   >35     26.1    40.1 
 
Although it is evident that IOP is a strong risk factor for developing glaucoma, most of 
the new cases of field defects in a population cannot be attributed to this factor (Leske 
1983).This infer that there must be other factors which contribute to certain people 
developing glaucoma. 
 
1.4.4.2 Optic nerve head 
 
In most individuals, the optic nerve and visual field changes seen in glaucoma are 
determined by both the level of IOP and the resistance of the optic nerve axons to 
pressure damage. 
There are two main theories regarding the mechanism of optic nerve damage. 
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• The mechanical mechanism (IOP related), in which it is suggested that the pressure  
has a direct effect on the lamina cribrosa of the nerve (Fechtner & Weinreb 1994). The 
lamina cribrosa has been shown to be weaker superiorly and inferiorly and these are the 
areas at which glaucomatous damage first appears. Experimental models of glaucoma 
have shown IOP induced interruption of axoplasmic flow at the lamina cribrosa 
(Weinreb et al 1997). In particular, research in animal models involving rats have 
proposed that impaired axonal neurotrophic factor delivery to the retina may contribute 
to retinal ganglion cell death (Quigley et al, 2000). Injection of neurotrophic factor, in 
particular brain-derived neurotrophic factor (BDNF) into the vitreous cavity of rats with 
experimentally elevated IOP increased the survival rate of retinal ganglion cells 
compared with untreated eyes (Ko et al 2001). Contrary to these findings, another study 
involving a rat model of glaucoma with raised IOP showed apoptosis of retinal ganglion 
cells prior to axonal obstruction and alteration in neurotrophin levels (Johnson et al 
2000). In addition, all of these studies have demonstrated that the interruption of axonal 
transport occurred at IOP levels of 40mmHg or even higher, which  does not correlate 
to the lower IOP readings normally seen in patients with POAG 
 
• The vasogenic mechanism, in which is felt that the damage is due to changes   
within the microcirculation of the optic disc capillaries (Fechtner & Weinreb 1994). 
Since the retina and the optic disc are dependent on local blood supply to replenish their 
high metabolic needs, local dysfunction of vascular autoregulation resulting in local 
ischaemia-hypoxia have been implicated to cause optic nerve damage (Sossi and 
Anderson 1983, Ulrich et al 1986,  Pillunat et al 1997). Animal studies involving rats 
have demonstrated that retinal ganglion cells death can occur with exogenous 
application of the vasoactive peptide endothelin-1, despite normal or low IOP (Chauhan 
et al 2004a). An immunohistochemical study has shown that the expression of hypoxia-
induced factor 1a (HIF-1a) is raised in the human glaucomatous retina and optic nerve 
head compared with healthy controls. This transcription factor is produced in response 
to low-cellular oxygen tension and induces activation of apoptotic genes whose 
functions are related to oxygen delivery and metabolic adaptation (Tezel and Wax 
2004). However, due to difficulty in its access for experimental assessment, the exact 
role of the ischaemic theory remains difficult to establish.  
 
Both theories have been recognised as a causative factor in the search for assessing the 
aetiology of glaucomatous optic nerve damage. For example, the observed differences 
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in glaucomatous visual field defects in patients with normal tension glaucoma and high 
tension glaucoma may suggest that ischaemia may be a predominant factor in 
glaucomatous eyes with IOP in the lower end of the scale, whereas a more direct 
mechanical damage of the pressure may exist in patients with raised IOP (Caprioli and 
Spaeth 1984) 
 
In a study by Jonas et al (1988b) investigating the morphometric characteristics of optic 
disc in POAG and comparing them with normal, no significant difference in overall 
optic disc size and form existed between normal and glaucomatous eyes. In a major 
review of the optic disc size and glaucoma, Hoffmann et al (2007), advises that it is 
important to accurately assess the features of the optic disc (neuroretinal rim and cup 
area), as these are used in the diagnosis and monitoring of glaucoma. It also emphasizes 
that so far there is no evidence that disc size is an independent risk factor for glaucoma. 
As mentioned earlier, cup-disc ratio is used in monitoring the progression of glaucoma.  
Large horizontal cup-disc ratio was one of the five best predictor factors identified in 
the Collaborative Glaucoma Study (Armaly et al 1980). Other studies identified that 
vertical cup-disc ratio is a predictor factor for field loss (Armaly 1972, Gordon et al 
2002, Miglior et al (EGPS) 2007b). 
 
Optic disc haemorrhages have also been associated with an increased risk for 
progression of the visual field loss (relative risk (RR) =1.02) as shown by the Early 
Manifest Glaucoma Trial (Bengtsson et al 2008) and the Collaborative Normal Tension 
Glaucoma Study (RR = 2.72 - Drance et al 2001).   
 
1.4.4.3 Central Corneal Thickness 
 
Central corneal thickness (CCT) has only recently been described as a predictive factor 
for progression of OHT to glaucoma (Miglior et al 2007b, Gordon et al 2002, Leske et 
al 2007a & b, Medeiros et al 2005, Zeppieri et al 2005), greater severity of visual field 
damage (Herndon et al 2004, Hewitt et al 2005) and more rapid progression of 
established visual field loss (Madeiros et al 2003, Kim & Chen 2004).  It has been 
demonstrated that CCT varies among racial and ethnic groups (Brandt et al 2001, La 
Rosa et al 2001, Shimmyo et al 2003) and may lead to misclassification of patients with 
NTG and OHT (Ehlers & Hansen 1974, Copt et al 1999). Several studies provided 
evidence that African-American, as a group, tend to have thinner corneas than 
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Caucasian counterparts and therefore have their IOP underestimated (Nemesure et al 
2003, Shimmyo et al 2003). 
 
It is possible that the predictive power of CCT may be due to its effect on IOP reading, 
however the possibility that the corneal thickness is related to other factor affecting 
susceptibility to glaucomatous damage cannot be excluded. (Gordon et al 2002). 
Pakravan et al (2007) reported that CCT is linked to disc size, thicker corneas being 
associated with smaller optic disc and Toh et al (2005) reported that CCT is one of the 
highly heritable aspects of ocular structure. 
 
So far there is no validated correction algorithm for IOP in relation to CCT. The 
implication for the clinical practice is that pachymetry should be performed in patients 
diagnosed with glaucoma or glaucoma suspects and the corneas should be categorized 
in thin, average or thick. This would have implications on patient treatment, leading to 
discontinuation of treatment in many overtreated patients with ocular hypertension and 
intensifying the treatment in patients with thin cornea, where treatment may be 
inadequate (Brandt 2007). 
 
1.4.4.4 Refractive status 
 
Myopia or high myopia (> 5 dioptres) has been identified as a risk factor for developing 
glaucoma in some studies (Georgopoulos et al 1997, Mitchell P 1999, Perkins et al 
1982, Ponte et al 1994, Ramakrishnan et al 2003, Xu et al 2007). However, most of the 
large epidemiological studies (The Barbados Eye Study, Ocular Hypertension 
Treatment Study and European Glaucoma Prevention Study) failed to identify myopia 
as a risk factor for developing glaucoma. 
The problem with myopic fundus changes is that it can give rise to field defects that 
resemble those found in glaucoma and the appearance of the optic disc in myopic eyes 
can be misleading, making the diagnosis of glaucoma more difficult (Leske 1983). 
 
1.4.5. Other proposed risk factors 
 
Alcohol intake and cigarette smoking have been addressed in a number of studies. So 
far, the results are inconclusive. However, most studies fail to show an association 
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between POAG and smoking or alcohol intake (Kahn & Milton 1980, Katz & Sommer 
1988, Klein et al 1993, Ponte et al 1994, Stewart et al 1994, Kang et al 2007). 
 
All the above data support the concept that glaucoma is a complex disease affected by 
multiple genetic and environmental factors. Although the pathogenic mechanism is not 
elucidated, it is mostly accepted that irrespective of what causes the damage in 
glaucoma, the end-result is ganglion-cell death most probably due to apoptosis, because 
of lack of trophic factors (Quigley 1995).  This theory is supported by research on 
animal models (Glovinsky et al 1991, Glovinsky et al 1993, Wygnanski et al 1995, 
Desatnik et al 1996, Weber et al 1998, Nickells 1999, Morgan et al 2000, Morisson et al 
2005, Urcola et al 2006,,). 
 
In addition, autoimmune reactions, increased concentration of nitric oxide, and raised 
concentration of glutamate may contribute to ganglion cell death in POAG (Dreyer & 
Lipton 1999, Yang et al 2001Ferreira et al 2004,, Gottanka et al 2004, Weinreb & Khaw 
2004, Gherghel et al 2005).  Figure 1.6 presents a diagram of the factors contributing to 
pathophysiology of glaucomatous neurodegeneration (adapted from Weinreb & Khaw 
2004). 
 
 
Figure 1.6: Diagrammatic representation of factors contributing to pathophysiology of glaucomatous 
neurodegeneration (from Weinreb & Khaw 2004) 
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Recently, Nickells (2007) suggested a theoretical sequence of events from ocular 
hypertension to ganglion cell death, which may explain many of the conflicting 
hypotheses of glaucoma pathogenesis. He hypothesizes that elevated IOP causes 
deleterious changes to glia in the optic nerve head (stage 1), which activates the 
autonomous self destruction of ganglion cell axons (stage 2), leading to loss of 
neurotrophic support and apoptotic death of ganglion cell somas in the retina (stage 3). 
In the initial wave of ganglion cell death, dying cells may adversely affect their 
neighbouring cells in a wave of secondary degeneration involving glutamate exposure 
(stage 4), which is followed by replacement of the lost neural tissue with a glial scar 
(stage 5) 
 
1.5. CLINICAL DIAGNOSIS OF GLAUCOMA 
 
Clinical diagnosis of glaucoma is based on: tonometry (measurements of IOP), 
gonioscopy (evaluation of the anterior chamber angle structures), examination of the 
optic disc and visual field testing (perimetry). 
 
1.5.1 Tonometry 
 
IOP is an important parameter for glaucoma evaluation, as it is one the strongest risk 
factor. Even when IOP is low and signs of glaucomatous neuropathy are present, 
reduction in IOP level has a beneficial effect on glaucoma progression (Collaborative 
Normal-Tension Glaucoma Study Group 1998, van Veldhuisen et al 2000, Leske et al 
2003, Leske 2007 b). 
The two main methods of measuring IOP are by applanation and indentation. The most 
widely used instrument in clinical practice is Goldmann tonometer. The accepted 
normal range for IOP is between 10 and 22 mm Hg in general population. However, as 
emphasised in the risk factor chapter, it is important that the IOP readings are 
interpreted in correlation with other ocular finding, for the diagnosis of glaucoma to be 
made. 
 
1.5.2 Gonioscopy 
 
The purposes of gonioscopy are to identify abnormal angle structures, estimate the 
width of the chamber angle and to visualize the angle during procedures like argon laser 
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trabeculoplasty and goniotomy. Figure 1.7 presents the view of the angle structures 
through a goniolens. 
 
   
Figure1.7: View of the anterior chamber angle through a goniolens 
 
The grading of the angle width is an essential part of the assessment of glaucomatous 
eyes. The aims are to evaluate the functional status of the angle, its degree of closure 
and the risk of future closure. There are three grading systems: Scheie (1957), Shaffer 
(1962) and Spaeth (1971). The most frequently used appear to be the Shaffer system 
(Figure 1.8), probably because it assigns a numerical grade to each angle with 
associated anatomical description, which allows for comparison of the width of 
different chamber angles. 
 
1. Grade 4 (35-45°) is the widest angle in which the ciliary body is visualised with 
ease and it is impossible of closure. 
2. Grade 3 (20-35°) is an open angle in which at least scleral spur can be identified 
and it is incapable of closure.  
3. Grade 2 (20°) is a moderately narrow angle in which only the trabeculum can be 
identified. Angle closure is possible, but unlikely. 
4. Grade 1 (10°) is a very narrow angle in which only Schwalbe’s line and may be 
the top of trabeculum, can be identified. Angle closure is not inevitable, however the 
risk is high. 
5. A slit angle is one in which there is no iridocorneal contact but no angle 
structures can be identified. This angle has the greatest danger of imminent closure. 
6. Grade 0 (0°) is a closed angle resulting from iridocorneal contact. The apex of 
the corneal wedge cannot be identified. 
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Figure 1.8: Shaffer grading system of angle structure (www.academy.org.uk/tutorials/gonio) 
 
In recent years some other techniques of assessing the angle width and structure have 
been used (ultrasound biomicroscopy, anterior segment optical coherence tomography, 
scanning peripheral anterior chamber analysis). Friedman and He (2008) present a 
comprehensive account of all these techniques in their excellent review “Anterior 
chamber angle assessment techniques”. 
 
1.5.3 Optic disc examination 
 
The optic nerve head can be clinically examined either with slit lamp biomicroscope 
with a condensing lens or with the direct ophthalmoscope through a dilated pupil. Slit 
lamp examination is superior, as it permits binocular stereoscopic view. 
 
The appearance of the optic disc varies even in “normal” subjects, according to the 
overall dimension of the globe, the number of the optic nerve fibres present and the 
configuration of the blood vessels crossing the nerve. 
 
Glaucoma causes a progressive loss of the retinal nerve fibres. The spectrum of disc 
changes in glaucoma ranges from highly localised tissue loss with notching of the 
neuroretinal rim to diffuse concentric enlargement of the cup. 
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1.5.3.1 Optic nerve characteristic in POAG 
 
A standard method of evaluating glaucomatous damage is the cup-disc ratio (Quigley et 
al 1992). The risk of developing glaucomatous visual field defects increases 
significantly with cup-disc (C/D) ratio of greater than 0.5. Despite this, even a ratio of 
0.8 can be normal, provided that the neuroretinal rim is healthy. Progressive increase of 
the C/D ratio is important because glaucomatous damage is superimposed on the 
amount of physiological cupping present before the onset of raised IOP (Figure 1.9.a & 
b). 
 
                          
  a            b 
 Figure 1.9: a: normal appearance of the optic disc; b: advanced cupping of  
 the optic disc 
 
Other characteristic changes in glaucoma are: splinter disc haemorrhages, focal 
(notching) and later generalised thinning of the neuroretinal rim, nasal displacement 
(nasalization) and change of the angle of the disc vessels (Jonas et al 1988a & b, 
Bengtsson 1989). Nerve fibre layer defects are detected on the retina corresponding to 
the area of damage of the disc. At the end stage the disc presents totally cupped and pale 
due to complete loss of the nerve fibres. 
 
1.5.3.2 Optic nerve imaging 
 
Traditionally, stereoscopic optic disc photographs are used most commonly for baseline 
assessment and follow up comparison. However, in recent years, imaging devices such 
as the confocal scanning laser ophthalmoscope, the retinal nerve fibre layer analyser 
(GDx) and optical coherence tomography (OC T) have been introduced to provide 
objective and reproducible analysis of optic disc morphometric parameters. They have 
higher reproducibility and lower interobserver variability compared with clinician 
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assessment of the optic disc and in addition they allow easy documentation and 
archiving of disc status, but they still require a degree of manual input (Chauhan 
2004b). 
 
1.5.4 Pachymetry 
 
CCT variation is known to affect the accuracy of IOP readings on applanation 
tonometry, with thick corneas giving falsely high IOP readings and thin cornea falsely 
low readings (Whitacre et al 1993, Feltgen et al 2001). Although there is no generally 
accepted correction formula (Brandt 2004) nomograms, based on varying CCT exist for 
adjusting IOP readings (Ehlers et al 1975, Whitacre et al 1993, Stodtmeister 1998). Two 
recent studies that adjusted IOP for CCT found that the correction did not alter the 
diagnosis of high tension glaucoma or normal tension glaucoma (Miyazawa et al 2007), 
and did not affect the relationship between the prevalence of POAG and IOP 
respectively (Francis et al 2008). However, even if the diagnosis is not going to be 
altered, pachymetry should become part of the routine assessment of patients with 
glaucoma. 
 
1.5.5 Perimetry 
 
1.5.5.1 Principle of visual field testing 
 
Perimetry is a method of evaluating the visual field. The visual field can be illustrated 
as an island (hill) with a central peak which corresponds to the macula. An area of the 
field that is not detected is called a scotoma. The optic disc produces a physiological 
scotoma which is detected only on testing. 
The loss of ganglion cell axons in glaucoma results in retinal areas deprived of “output”. 
As a consequence, these areas have reduced sensitivity to optical stimuli.  
An efficient way to measure the degree of optic disc damage is by evaluating ones 
ability to perceive small light targets which are presented randomly on an illuminated 
background.  
 
There are two main types of perimetry: static and kinetic. 
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Kinetic perimetry presents a contour map of the hill of vision at different levels while in 
static perimetry, vertical contours of the hill of vision are calculated along a selected 
meridian (Crick et al 1989). 
 
Perimetry can be performed either manual or automated. From the manual type, only 
Goldmann perimeter is still used quite frequently nowadays, otherwise, the automated 
method is the preferred one. 
 
The method of choice that is currently applied for glaucoma diagnosis and follow up is 
computerised static threshold technique (Agarwal et al 2000). Threshold is the level of 
brightness of a light target, which is detected 50% of the time. The values are saved and 
compared with data stored from normal subjects of matching age. Automated perimetry 
is fast and provides repeatable objective results (Asman and Heijl 1992) - Figure 1.10. 
 
1.5.5.2 Visual field defects in glaucoma 
 
Typical visual field defects in glaucoma are: nasal field loss, paracentral scotoma, 
arcuate field loss, and finally a central “tunnel” field of vision in the end stage. 
As glaucoma is usually a slow progressive disease, serial annual perimetry used to be  
recommended to assess the stability of the disease (Macri et al 1998).  However, more 
recent, Chauhan et al (2008) make the following recommendation regarding the 
frequency of visual field examination: 
 
1. perform sufficient examinations to detect change; 
2. six visual field examinations should be performed in the first 2 years, to rule out 
the presence of rapid progression and establish good baseline data; 
3. measure the rate of visual field progression, which is invaluable for guiding 
therapeutic decisions and the likelihood of visual impairment during patients’ 
life time; this may take several years; 
4. use the same threshold test; 
5. pay attention to examination quality. 
 
The authors conclude that these recommendations should be used in context with other 
risk factors, such as baseline damage, age, IOP before a decision on patient management 
is made. 
  26 
 
 
Figure 1.10: Automated perimetry (Humphrey visual field analyzer) demonstrating advanced 
glaucomatous optic neuropathy  
 
A review from American Academy of Ophthalmology on automated perimetry 
(Delgado et al 2002), presents different types of technology available (short-wavelength 
automated perimetry –SWAP, frequency doubling technology – FDT, blue on yellow 
high pass resolution perimetry, motion automated perimetry and Swedish interactive 
threshold algorithm- SITA). The conclusion was that while these new techniques can 
provide additional or confirmatory evidence, they mainly remain in clinical research 
domain. One exception is SITA, in which studies show significant reduction in testing 
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time without affecting diagnostic accuracy, making it a more patient friendly test than 
standard threshold automated perimetry.  
 
1.5.6 Sensory tests 
 
When a conversion from ocular hypertension to glaucoma occurs, the optic disc or 
retinal fibre layer changes often occur before the visual field defects (Sommer et al 1991 
b, Kerrigan-Baumrind et al 2000). Therefore, in recent years, other sensory procedures 
psychophysical as well as electrophysiological, have been devised that may indicate 
glaucomatous damage earlier than perimetry (Korth 1997, Martus et al 1998, Martus et 
al 2000, Stroux et al 2003). These tests are: temporal contrast sensitivity test, 
spatiotemporal contrast sensitivity test, the peak time of a blue-on-yellow visual evoked 
potential and the amplitude of a pattern reversal electroretinogram.  
However, it has to be noted that the conversion from OHT to glaucoma is relatively rare 
(1 to 2% per year- Lundberg et al 1987, Heijl et al 2002) and that most patients with 
glaucoma presenting to ophthalmologist already have established disease. For these 
patients, perimetry is probably still the most cost-effective way of monitoring the 
disease.  
 
1.6. MANAGEMENT OF GLAUCOMA 
 
1.6.1 Treatment algorithm for glaucoma 
 
Presently, the goal of treatment for patients with glaucoma is to prevent further loss of 
functional vision during the remainder of the patient’s life and to avoid an adverse 
impact on patient’s quality of life. This goal can be difficult to achieve, as both the 
treatment for glaucoma (medical or surgical) and the visual loss from the disease affect 
patient’s quality of life. 
  
 To reduce the rate of visual loss in glaucoma the aim is to lower the IOP to a level 
which is considered safe for the ganglion cells given the current amount of damage in 
the optic nerve head (target IOP). Once the target IOP has been achieved, the patient 
should be monitored at regular intervals. Progressive glaucomatous damage is 
determined by changes in the optic nerve head or in the visual field that are consistent 
with more ganglion cells loss. The development of new damage in the optic nerve head 
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or visual field requires reassessment of the target IOP and further lowering of pressure if 
possible (Coleman 1999). 
 
Topically applied ocular medication is usually the initial therapy in the developed 
countries. Although most of glaucoma therapy is applied topically to the eye, systemic 
side effects can occur, and can affect adversely the patient’s quality of life. Daily 
medical treatment is expensive and subject to poor compliance. Poor response to 
medical treatment or advanced glaucoma prompts surgical treatment. 
 
The European Glaucoma Society (EGS) recommends the following steps in their flow 
chart on the management of POAG: first medication, followed by argon laser 
trabeculoplasty if IOP not lowered sufficiently with medical treatment and finally 
incisional surgery (trabeculectomy) if the first two steps were ineffective. If the IOP is 
still not controlled after observing the above algorithm, then drainage devices or 
cyclodestructive procedures can be used. 
 
1.6.2 Neuroprotection in glaucoma 
 
 The role of neuroprotection in glaucoma is being actively investigated. Glaucoma 
neuroprotection offers potential as a complementary therapy to IOP-lowering for those 
patients in whom lowering of IOP does not adequately reduce the rate of disease 
progression. Also, offers potential as an alternative therapy for those patients in whom 
pressure lowering agents are not used, not tolerated or ineffective (Weinreb & Khaw 
2004). An N-methyl-D-aspartate antagonist –memantine- which has been assessed in 
two large clinical trials, unfortunately was proved to be unsuccessful as neuroprotectant 
in glaucoma (Allergan press release Jan 2007). 
 
1.6.3 Conclusion 
 
 In many cases, in spite of all efforts to maintain vision some patients will go blind. 
Ideally, we should be able to diagnose at risk individuals and prevent the onset of the 
disease. 
 Risk factors for blindness are: 
• increasing age ( Fraser et al 1999 and 2001)  
  29 
• race (African- Caribbean and African subjects have increased risk because of an 
earlier onset and more aggressive disease and possibly reduced contact with medical 
services – Sommer et al 1999 c) 
• social deprivation  (Tielsch et al 1991, Fraser et al 1999 and 2001)  
• educational level (Baltimore Eye Study found that years of schooling were inversely 
associated with the prevalence of blindness and visual impairment –Tielsch et al 
1991) 
• higher intraocular pressure at presentation  (Fraser et al 1999 and 2001) 
• longer interval since the subject has visited an optometrist (Fraser et al 1999 and 
2001) 
 
Because glaucoma is treatable, and because the visual impairment from glaucoma is 
irreversible, early detection of the disease is critically important. 
 
The development of genetic diagnostic tests that identify at risk individuals who can be 
offered early treatment, prior to visual field loss is a promising route for the 
development of new glaucoma strategies. In the longer term, better understanding of the 
molecular mechanism underlying glaucoma pathogenesis should lead to new therapies 
to be used in combination with pre-symptomatic genetic testing. 
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  Chapter 2: ANTERIOR SEGMENT DYSGENESES 
 
2.1 INTRODUCTION 
Abnormalities of the anterior segment that can lead to glaucoma have received attention 
(Gould & John 2002) as they often have large pedigrees and severe phenotypes.  
Although, relatively rare, they may provide important insights into one of the 
commonest forms of glaucoma –Open Angle Glaucoma (OAG).  
 
The gene investigated in the pilot study and presented in this thesis (PITX2) has been 
first discovered by positional cloning in patients with Axenfeld-Rieger Syndrome by 
Semina et al (1996). Since then, mutations in the same gene have been found to cause 
different phenotypes diagnosed as ASD. 
 
Therefore, in this chapter a brief description of anterior segment dysgeneses will be 
given, with Axenfeld-Rieger syndrome being more extensively described. 
 
The Anterior Segment Dysgeneses (ASD), at present, is an ill-defined group of 
developmental abnormalities that share some common features and a high prevalence of 
associated glaucoma. Idrees et al (2006) reviewed anterior segment dysgeneses, 
suggesting a new classification system, which takes into account the embryological 
contribution to various eye structures affected.  
 
The anterior segment of the eye comprises all the structures lying between the front 
surface of the cornea and the front surface of the vitreous, usually included within this 
definition are the eyelids. An Anterior Segment Dysgeneses is a developmental 
abnormality of the structures of the anterior segment. 
 
2.2 EMBRYOLOGIC DEVELOPMENT OF ANTERIOR CHAMBER 
 
An understanding of the embryonic development of the anterior segment of the eye is 
essential to understand the association of ASD with glaucoma. 
 
Through the course of ocular development the surface ectoderm will form the corneal 
epithelium and the lens while the neural ectoderm will form the retina and epithelia of 
both the iris and ciliary body (Kaufman, 1995). The corneal stroma, corneal 
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endothelium, sclera, iris stroma, ciliary muscle, ciliary stroma and TM are all derived 
from periocular mesenchyme, which consists of neural crest cells. These cells are 
neuroectodermal cells that migrate from the crest of the developing neural tube at about 
the 24 day of gestation (Tripathi and Tripathi, 1989).  
 
Cells derived from the neural crest are extremely important for ocular development in 
general and anterior segment development in particular (Bahn at al 1984, Beauchamp 
and Knepper 1984, Cook 1989, Kaiser-Kupfer 1989; Tsai and Grajewski 1994, Beebe & 
Coats 2000,) 
 
 An understanding of the migration and differentiation of neural crest cells (table1) and 
how these processes can go wrong is vital for an understanding of both the ocular and 
systemic features of the anterior segment dysgeneses and their association with 
glaucoma. 
 
ECTODERM 
Surface ectoderm Conjunctival epithelium 
 Corneal epithelium 
 Lens 
Neuroectoderm Sphincter and dilator muscles of iris 
 Pigmented iris epithelium 
 Pigmented ciliary epithelium 
 Non-pigmented ciliary epithelium 
 Zonules of the iris 
Cranial neural crest cells Corneal stroma and endothelium 
 Sclera (except temporal portion) 
 Trabecular meshwork 
 Schlemm’s Canal 
 Chamber angle 
 Thin layer of anterior iris stroma 
 Ciliary muscles  
 Ciliary stroma 
 Uveal and epithelial melanocytes 
MESODERM 
 Temporal portion of sclera 
 Endothelial lining of blood vessels 
Table 2.1: Embryonic derivatives that contribute to anterior segment formation (adapted from Idrees et al 
2006) 
 
The anterior segment of the eye consists of the cornea, iris, lens, ciliary body and the 
ocular drainage structures, which contains the TM and the Schlemm’s canal. The 
drainage structures are located at the iridocorneal angle where the cornea and the iris 
meet (Figure 2.1). These structures are formed by coordination of events involving 
induction and differentiation of three primary embryonic tissues: surface ectoderm, 
neural ectoderm and the periocular mesenchyme (Snell & Lemp, 1998) - Figure 2.2. 
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Figure 2.1 Cross section of a mature anterior segment chamber high-lighting 
important structures at the anterior chamber angle: 
(left); in depth view of the angle showing the different layers of trabecular meshwork; 
(center) gonioscopic view of a normal angle with a slit-lamp beam; (right) embryological derivatives 
forming the structures of the anterior chamber (red = surface ectoderm; blue = neuroectoderm; green = 
cranial neural crest cells).  
Cep = corneal epithelium; Cen = corneal endothelium; Cstr = corneal stroma; 
* = Schwalbe's line; ss = scleral spur; CB = ciliary body; Cp = Ciliary process; Cm = ciliary muscle; PCE 
= pigmented ciliary epithelium; SC = Schlemm's canal; TM = trabecular meshwork; IP = iris process; Iris 
S = iris stroma; L = lens; Z = zonule/suspensory ligament of lens (Adapted from Idrees et al, 2006) 
 
Neural crest cells are neuroectodermal cells that migrate from the crest of the 
developing neural tube at about the 24 day of gestation.  They migrate to many sites all 
over the developing embryo and give rise to many structures including the bone and 
cartilage of the skull, the meninges, the teeth, dermis, melanocytes, peripheral nerves, 
Schwann cells, the neuroendocrine system, cerebral and spinal ganglia (Bahn et al 1984; 
Tsai and Grajewski 1994) and of course many of the structures of the eye. 
 
Johnston et al (1966) studied the fate of neural crest derived cells in the chick eye and 
found that they form the sclera, melanocytes, fibroblasts, muscles of the uveal tract and 
pericytes of the vascular system. In the developing anterior segment, neural crest cells 
migrate between the surface ectoderm and the periphery of the optic cup i.e. the 
developing anterior chamber. Once at the anterior chamber, the neural crest cells form 
the corneal endothelium and keratocytes, iris stroma cells (i.e. the anterior iris) 
(Beauchamp and Knepper 1984; Kaiser-Kupfer 1989; Tsai and Grajewski 1994) and 
melanocytes, trabecular meshwork and juxtacanalicular tissue. 
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Figure 2.2: The development of the anterior segment of the embryonic and fetal eye.  
(a) At 5 weeks of gestation, the optic cup is surrounded by mesenchymal progenitor  
cells, mainly of neural crest origin. (b) Formation of the anterior segment is visible at 5 
months of human gestation. (c) Fully developed anterior segment depicting the lens, iris, 
irido-corneal angle and the cornea. The diagrams are colour coded to represent the 
embryonic origin of the anterior segment structures (adapted from Sowden, 2007) 
 
At the 6 week of embryonic development, a bi-layered embryonic optic cup from the 
forebrain neuroectoderm has formed, whilst the lens vesicle has formed through 
invagination and separation from the overlying surface ectoderm. The primordial eye is 
now surrounded by mesenchymal progenitor cells which are predominantly of neural 
crest origin (Figure 2.2a). 
 
As early as the 12 week a roughly wedged-shaped distinctive mass of mesenchyme, 
the trabecular primordium, is detected at the junction of the pupillary membrane (a thin 
central portion of the iridopupillary lamina occluding the pupil in fetal life which exists 
as a source of blood supply to the lens) and lateral margins of the cornea i.e. the anterior 
chamber angle (McMenamin, 1989a). The trabecular primordium consists of a dense 
collection of stellate mesenchymal cells and some loosely arranged extracellular matrix.  
The deep aspect of the wedge-shaped primordium is characterized by a row of small 
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capillaries and is lined by mesoderm-derived vascular endothelial cells. 
 
 
 
 
Figure 2.3: Embryonic development of the anterior chamber angle. 
(a) Electron micrograph of the trabecular primordium in a 13 week-old fetus. Arrows 
point to two small capillaries on the deep aspect of the trabecular anlage (TA). AC, 
anterior chamber; PM, pupillary membrane. (b) Electron micrograph of the TM in a 22- 
week-old human fetus. Note the intratrabecular spaces separated by connective tissue 
trabeculae and the Schlemm’s canal (SC) which has giant vacuoles (GV) in its inner 
wall. (c) Scanning electron micrograph of the inner surface of the trabecular anlage in a 
13-week-old human fetus showing numerous perforations to allow communication 
between the anterior chamber and the developing meshwork. (d) Summary of the 
morphogenetic changes that occurs during remodeling of the loose mesenchyme of the 
trabecular anlage to form the TM (Adapted from McMenamin, 1989) 
 
By 20-22 weeks of gestation, the anterior chamber is formed and well demarcated. The 
trabecular primordium consists of flattened endothelial-lined sheets and cords (early 
trabeculae) separated by intervening spaces (Figure 2.3) (McMenamin, 1989b; 
McMenamin, 1991; McMenamin and Krause, 1993). On the deep aspect of the 
undeveloped TM, the collection of small capillaries fuses to form a single elongated 
canal of Schlemm lined by endothelial cells derived from mesoderm. The giant vacuoles 
within the endothelium which are responsible for the passage of aqueous across the 
canal appear around 18-20 weeks of gestation. 
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Schlemm’s canal is formed by remodeling of vasculature in the corneoscleral transition 
zone (Hamanaka et al, 1992) and is also derived from periocular mesenchyme. Hence, 
cells that are derived from the neural crest, and the accurate specification and 
differentiation of mesenchymal progenitor cells are essential for anterior segment 
development (Kupfer & Ross 1971, Kupfer and Kaiser-Kupfer, 1979). 
 
 Up until 7 months gestation, neural crest cells form a continuous layer extending from 
the cornea to the trabecular meshwork and onto the anterior surface of the iris becoming 
continuous with the pupillary membrane and tunica vasculosa lentis (Keiser-Kupfer 
1989). However, intercellular gaps between endothelial cells that cover the iridocorneal 
angle have been demonstrated by scanning laser microscopy (Maumenee 1960).  This 
correlates with physiological evidence that some degree of aqueous drainage is effective 
by 17-18 weeks of fetal life, and gradually increases during development (Maumenee 
1960). 
 
At 7 months gestation, the trabecular meshwork is separated from the anterior chamber 
by the layer of neural crest cells and little aqueous can drain. It is thought that retraction 
of these cells allows exposure of the trabecular meshwork and therefore drainage of 
aqueous – this change correlates with the fact that aqueous outflow increases 
0.09µl/min/mmHg at 7 months to 0.3µl/min/mmHg at 8 months. 
 
Although many studies detail prenatal ocular development, few reports document 
postnatal development. Significant development of anterior chamber structure occurs in 
the postnatal period (Smith et al 2001, Baulmann et al 2002). This is especially true of 
the drainage structures that affect IOP and glaucoma. In the first 2-3 postnatal weeks, 
trabecular meshwork remodels to form a functional TM (Smith et al 2001). A major 
component of the functional TM is extracellular matrix (ECM) organized into a network 
of beams that are covered by trabecular cells. The ECM includes collagen, laminin, 
elastin, fibronectin and vitronectin (Yue 1996). Intratrabecular spaces, between the 
beams of functioning meshwork, allow aqueous humor to flow to endothelial wall of 
Schlemm’s canal in drainage structures known as giant vacuoles. The lumen of 
Schlemm’s canal connects to the venous system through collectors channels. Abnormal 
development of these iridocorneal angle structures can lead to elevated IOP and 
glaucoma (Gould et al 2004). 
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Since neural crest cells are a major contributing factor towards anterior segment 
development, one hypothesis for the underlying molecular mechanism involved in 
anterior segment dysgeneses is that defects in migration and/or differentiation of neural 
crest derived periocular mesenchyme could lead to abnormal anterior segment 
development and subsequently, raised IOP and glaucoma. Evidence in support of this 
proposal has been shown by fate mapping of cranial neural crest cells using quail-chick 
chimeras (Kupfer and Kaiser-Kupfer 1979, Kupfer and Kaiser- Kupfer 1978, Kaiser-
Kupfer 1989). These have lead to the creation of the model which has suggested that the 
majority of the anterior segment is derived from neural crest cells and that the 
developmental arrest of these cells causes ASD in humans. Indeed, transcription factors 
expressed in the periocular mesenchyme (PITX2, FOXC1 and LMX1B) (Semina et al 
1996,  Pressman et al 2000, Gage et al 2005, Viera et al 2006) play an important role in 
normal morphogenesis of the anterior segment and provide important insight to the underlying genetic 
mechanism of glaucoma. 
 
2.3 CLASSIFICATION 
 
The Review of anterior segment dysgeneses paper by Idrees et al (2006), suggests that 
ASD should be classified in ASD-neural crest (ASDnc), comprising conditions which 
affect only anterior segment structures derived from neural crest cell and ASD non-
neural crest (ASD
non-nc
), affecting structures which are mainly derived from non-neural 
crest cells. However, refining of the definition and difficulties in clinical diagnosis may 
only be resolved as the molecular genetics of these conditions becomes clearer.  
 
The ASDnc is a developmental abnormality of the cornea, angle or iris that can be 
recognised from a number of specific clinical signs. These occur with a number of other 
ocular or systemic abnormalities but may also occur in isolation in some patients. The 
abnormalities are likely to be caused by an underlying failure of neural crest cell 
migration or differentiation. These abnormalities are often associated with an increased 
risk of glaucoma. 
 
Within the ASDnon-nc type the authors have included other phenotypes affecting the 
anterior segment where the neural crest tissue is not thought to be the site of the primary 
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defect. These include aniridia, which is mainly a defect affecting the posterior iris, 
which develops from the periphery of the embryonic optic cup and is therefore of 
neuroectodermal origin (Ormestad et al 2002, Ramaesh et al 2003, Thut et al 2001).  
However,  it has to be mentioned that the lens is the source of an evolutionarily 
conserved signal that instruct cells of the presumptive neural retina to express genes 
characteristic of the developing iris and ciliary body (Thut et al 2001).  Therefore, it is 
considered that aniridia is due to gene mutations which act primarily in the lens. Other 
more recent identified conditions include Anterior Segment Mesenchymal Dysgeneses 
(Semina et al 1998). The causative gene mutations have been identified in these families 
and act primarily in the lens (which derives from surface ectoderm) with the defects 
found in the neural crest derived tissues of the angle probably occurring as a secondary 
consequence. Further characterisation of similar conditions may lead to greater 
refinement of the ASDnon-nc classification to include ASDn (ASD-neuroectoderm) and 
ASD
se 
(ASD-surface ectoderm) indicating the developmental origin of the affecting 
tissue. 
There have been numerous classifications of the ASD’s based on their clinical features. 
This classification remains useful at present but as the molecular genetics of the 
different conditions are unraveled it seems desirable that future classifications should 
reflect or incorporate the underlying genetic cause.  However, the fact that different 
members of the same family (who share the same gene mutations) can have quite 
different phenotypes indicates the limitations of these classifications. Most of the 
anomalies can have an association with systemic disease. 
 
The anomalies that make up the clinical spectrum of the ASDnc are: (Waring III et al, 
1975, de Louise et al, 1983, Shields et al, 1983, Shields et al, 1985) 
• Infantile Congenital Glaucoma (ICG) 
• Iris Hypoplasia 
• Axenfeld anomaly 
• Rieger anomaly 
• Peters anomaly 
• Congenital hereditary endothelial dystrophy (CHED). 
• Sclerocornea 
• Megalocornea 
• Unclassified. 
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2.4 PHENOTYPES 
In this chapter, a brief description of the above conditions and a flow chart suggesting 
genetic investigations is presented. The genetics of these conditions is discussed in the 
developmental glaucoma genetics chapter. 
 
2.4.1 Infantile Congenital Glaucoma (ICG) 
This is the commonest childhood glaucoma and usually presents within the first six 
months of life. Use of the term congenital suggests that it is present at birth; in fact 
although the angle abnormality may be present at birth, the intraocular pressure (IOP) 
rise may not occur until sometime after. Thus ICG should be reserved for those eyes 
without any other markers of ASD except in the angle. It is likely that ICG will be more 
fully understood when the genetics are fully elucidated. 
 
Infantile congenital glaucoma (ICG) is a type of developmental glaucoma and it is 
inherited in an autosomal recessive fashion, with variable penetrance (Sarfarazi & 
Stoilov 2000).The incidence is high in the Gypsy population of Slovakia being 
1:1250(Gencik 1989), and 1:2500 in the Middle East (Turacli et al 1992) whilst the 
incidence is less in Western countries ranging between 1:5000 and 1:10 000 (Francois 
1985). Sarfarazi & Stoilov (2000) discuss the association of ICG with chromosomal 
abnormalities and suggests that the association is either secondary to the host of other 
abnormalities or is purely co-incidental. 
 
The other features associated with ICG i.e. large eyes, thin sclera and breaks in 
Descement membrane (Haabs striae) are secondary to the rise in IOP rather than being 
an intrinsic abnormality of the disease itself.  
 
The underlying reason for the block to aqueous drainage has not been fully elucidated - 
reflecting our incomplete knowledge of the development of the trabecular meshwork. 
What is known to be an essential step in the formation of the angle is the apparent 
movement of tissues relative to each other so that the ciliary body moves backwards to 
expose the developing trabecular meshwork. Anderson (1981) suggests that premature 
and/or excessive formation of collagenous beams within the trabecular meshwork 
prevents this normal posterior migration of the ciliary body. 
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Otto Barkan (1938) first described a membrane over the angle which he considered to 
be a thin membrane impeding aqueous outflow. This, however, has not been shown to 
exist with light or electron microscopy (Maumenee 1958, de Louise 1983). 
Gonioscopically a membrane is not always seen in these children but characteristically 
the iris inserts into the trabecular meshwork i.e. the iris root is seen to be very anterior 
(Maumenee 1958, Shields et al 1985). The role of the neural crest cells is not fully 
understood but is likely to play a role. Kaiser-Kupfer (1989) has suggested that 
persistence of neural crest cells lining the angle is responsible for the resistance to 
outflow. ICG is, perhaps, indicative of our poor understanding of the details of angle 
development and the limitations of clinical observations in understanding aetiology. 
 
2.4.2 Iris Hypoplasia (IH)/Iridogoniodysgeneses anomaly (IGDA) 
This was first described by Berg in 1932 in a family who had thin, featureless irides and 
a very high incidence of glaucoma at a relatively young age (16-43 years). He described 
the three key features of IGDA as iris hypoplasia, goniodysgeneses and early onset 
glaucoma. It may also be added to this that the cornea is essentially normal with no 
embryotoxon or iris adhesions. 
 
There have been a number of pedigrees (Weatherhill & Hart 1969, Jerndal 1972, 
Waring III & Rodrigues 1980, Pearce et al 1982)
 
described since then - all with the 
characteristic grey/brown iris colour that represents the pigmented iris epithelium 
showing through the hypoplastic iris stroma . The glaucoma that occurs is thought to be 
due to goniodysgeneses, although unlike true primary goniodysgeneses (i.e. ICG) the 
angle may look normal on gonioscopy and there is a poor response to goniotomy. One 
feature of the iris that is often overlooked in IH/IGDA is that the iris collarette is absent 
or small and peripheral and this can be a useful phenotypic marker for IH/IGDA. Idrees 
et al (2006) suggest that the term Iridogoniodysgeneses should be replaced by the term 
Iris Hypoplasia as goniodysgeneses has not been proven (Chisholm & Chudley 1983, 
Heon et al 1995, Walter et al 1996, Alward et al 1998). 
 
2.4.3 Peter’s anomaly 
This anomaly is caused by the absence of corneal endothelium, Descemets membrane 
and posterior corneal stroma. Usually this occurs in the central cornea leading to a 
central corneal opacity – which is often present at birth. Classically iris synaechiae 
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extend from the collarette to this defect, as can strands from the lens. It may be 
unilateral or bilateral (Townsend 1974, Waring III et al 1975). 
The Peters phenotype is very variable. The corneal opacity can vary from subtle (when 
it appears as a small indentation on the posterior corneal surface – some authors call this 
posterior keratoconus (Kenyon 1975, Waring III et al 1975,  Krachner & Rodrigues 
1978, Frydman et al 1991) to so dense that the diagnosis can only be made using 
ultrasound (Haddad et al 1997). The opacity may be the only abnormality, or it may be 
associated with adherent iris strands, or there may be full-blown lens and iris adhesion. 
The opacity can improve a little with time - perhaps due to improved endothelial 
function in cells surrounding the defect. Glaucoma occurs in about 50% of cases but is 
only rarely present at birth (Waring III et al 1975). Lowering of IOP can sometimes 
improve the corneal opacity itself. 
 
Isolated Peter’s anomaly has been described in some pedigrees as autosomal dominant 
(Hanson et al 1994), autosomal recessive and in others as sporadic (Warring III et al 
1975).  Peter’s anomaly is phenotypically very variable, so much so that it has been 
suggested that it is a morphological abnormality likely to have a range of different 
causes (Townsend 1974). This is exemplified by the different syndromes in which it 
occurs. A number of the syndromes associated with Peter’s anomaly have dominant or 
recessive inheritance whilst others are caused by chromosomal abnormalities. Peter’s 
anomaly has also been described as part of the Foetal Alcohol Syndrome and Warfarin 
toxicity in pregnancy (Kerber et al 1968, Miller et al 1984) which further illustrates its 
multifactorial causes. 
 
2.4.4 Congenital Hereditary Endothelial Dystrophy (CHED) 
This is a complete or almost complete absence of the corneal endothelium and therefore 
presents with diffuse bilateral corneal oedema, which does not resolve or improve in the 
presence of a normal IOP. It has been classified within the ASD’s (Churchill & Booth 
1996, Waring III et al 1975)  as it probably represents failure of 
migration/differentiation of neural crest cells. 
 
Severity of disease and inheritance has led to two types of CHED being described. Type 
1 CHED is less severe than Type 2 CHED; the latter has an earlier age of onset with 
worse vision and a higher likelihood of nystagmus (Maumenee 1960, Kirkness et al 
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1987). Type 1 may well not present until sometime after birth and can have a relatively 
good prognosis. 
 
2.4.5 Sclerocornea  
This is a non-progressive scleralisation (i.e. opacification and vascularisation) of the 
cornea, probably caused by abnormal neural crest migration (Axton et al 1997). It may 
result from the disordered second wave of neural crest cell migration, which normally 
passes between the corneal epithelium and endothelium to form the stroma. It is usually 
bilateral, varying from mild and peripheral to diffuse. Both sclerocornea and 
megalocornea can occur as isolated abnormalities (Bloch 1965, Howard & Abraham 
1971) but are more often associated with other ocular (e.g. Peters) anomalies. Patients 
with cornea plana (flattening) usually have a degree of peripheral sclerocornea. 
 
Like other anterior segment dysgeneses, sclerocornea has a higher than normal 
incidence of raised IOP and glaucoma. 
 
2.4.6 Megalocornea  
Megalocornea can occur without associated anterior segment abnormalities or in 
association with other entities such as Axenfeld/Rieger anomaly. True or primary 
megalocornea is a corneal diameter of greater than 12mm in a newborn or greater than 
13mm at any age (Mackay et al 1991). This definition would also describe an eye with 
raised IOP in a neonate such as those with PCG. To differentiate primary megalocornea 
from raised IOP, it must be non-progressive, have an IOP within the normal range and 
have no breaks in Descement membrane or optic disc cupping. Corneal topography 
shows a normal cornea centrally; therefore the enlargement occurs at the limbus. 
Specular microscopy shows normal endothelial densities and morphology – unlike in 
PCG (Skuta et al 1983).  
 
The classification is complicated by the use of the term megalocornea in a description of 
the buphthalmic eye; this is really a secondary megalocornea. It is probably better to 
restrict the term megalocornea to the primary type only and to use buphthalmos to 
describe large eyes secondary to raised intraocular pressure (IOP) from any cause.  
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2.4.7 Unclassified 
Even those who are familiar with the ASD’s often find that certain patients do not fit 
into the categories described but do seem to have some sort of dysgeneses of their 
anterior segment often with a secondary glaucoma. From a clinical point of view often 
the only solution is to describe them (usually by looking for the characteristic features 
of ASD’s) and follow their glaucoma expectantly. From a diagnostic point of view it 
again seems likely that in the future, molecular genetics will hold the key to 
classification of these anomalies.  
 
The relative rarity of the anomalies described above can make diagnosis difficult and 
trying to remember the differing features can be confusing. In fact, their diagnostic 
features are quite limited and systematic examination of the anterior segment can often 
allow a logical diagnosis to be made. As with any anterior segment examination, 
description begins with the cornea, then the iris and if possible the angle. (figure 2.4: 
flow chart for the diagnosis of ASD/ adapted from Idrees et al 2006). 
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         Figure 2.4: Flow chart of the diagnosis of ASD 
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CYP1B1 
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2.5 AXENFELD RIEGER ANOMALY/SYNDROME (ARA/S) 
 
As mutations in the gene investigated in this study cause mainly ARA/S, the clinical 
findings in this entity will be presented in this sub-chapter. However, the genetics of 
this condition is exhaustively discussed in both the genetics of developmental glaucoma 
and PITX2 gene chapter and will not be discussed here. 
 
This condition was originally described by Axenfeld in 1920 as a bilateral, white line on 
the posterior aspect of the cornea with strands from the peripheral iris to this line 
(Axenfeld T 1920). In 1934, Rieger described the same changes but with the addition of 
changes in the iris structure such as pulling of the iris towards part of the angle 
(corectopia), thinning of the iris and if this is severe, hole formation in the iris , 
sometime mimicking multiple pupils ( polycoria )- fig 2.5 I-II. 
 
It has been noted that the severity of both anomalies can vary quite considerably, with a 
‘severe’ Axenfeld little different from a ‘mild’ Rieger and for this reason the spectrum 
of abnormalities is often called Axenfeld-Rieger anomaly (ARA - Shields et al 1985). 
For the moment, it may still be useful to attempt to separate classical Axenfeld type 
changes (i.e. only peripheral iris involvement) from classical Rieger type changes as it 
may be that they represent different mutations of the same gene (Alward  2000, 
Kozlowski  and Walter 2000, Lines et al 2002, Lines et al 2004). When they are 
associated with systemic anomalies they are given the suffix -syndrome i.e. Axenfeld-
Rieger syndrome (ARS). 
 
Around 50% of those with Axenfeld-Rieger anomaly develop glaucoma and a rise in 
IOP is most likely to occur later in childhood. The risk of developing glaucoma does not 
seem to be related to the severity of the phenotype (Shields 1983, Shields et al 1985). It 
can however, present at any time from birth to adulthood and patients need lifelong 
follow-up. If the rise in IOP occurs in the first two years of life it is important to 
differentiate ARA from ICG (either from the family history or if possible from 
examination) as the former tends to respond less favourably to goniotomy (McPherson 
and Berry 1983, Shields 1983). 
 
Various systemic abnormalities have been described in relation to Axenfeld-Rieger 
anomaly and the combination is called Axenfeld-Rieger syndrome. It has classically 
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been thought that the presence of systemic features indicated Rieger syndrome but in 
fact, in keeping with the spectrum of anterior segment anomalies, systemic features can 
occur in those with an Axenfeld or even IH/IGDA phenotype (Walter et al 1996).  
 
Whilst some authors use certain systemic features as criteria for the syndrome, Idrees et 
al (2006) suggest that Axenfeld-Rieger anomaly in association with any of the well-
described systemic abnormalities should be called Axenfeld-Rieger syndrome. Future 
information from molecular genetic studies should confirm features that are consistently 
part of the syndrome and those that are chance or incompletely penetrant associations. 
 
The ocular findings in ARA/S are varied and comprise: 
• Posterior embryotoxon (prominent, centrally displaced Schwalbe’s line – figure 
2.5.I) 
• Peripheral anterior synaechiae (iridocorneal adhesions) 
• Hypoplastic iris, often disrupted, with displaced pupil (corectopia) or “multiple 
pupils” (polycoria)-figure 2.5.II 
• Cornea can be thicker or thinner then average (mutations in PITX2 appear to 
cause reduced corneal thickness –Asai-Coakwell et al 2006, whereas mutations 
in FOXC1 appear to have thicker corneas – Lehmann et al 2003); if in addition 
to being thicker it also is cloudy and large (megalocornea), may be indicative of 
increased intraocular pressure. 
• Glaucoma – present in about 50% of the patients, is a major consequence (Reese 
and Ellsworth 1966). It can develop in infancy, but more frequent in adolescence 
or early adulthood. 
 
I                                II                   
            
Figure 2.5: I: posterior embryotoxon; II: iris hypoplasia with polycoria and corectopia 
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Well-described systemic associations in ARS 
 
• Facial and dental anomalies are probably the commonest systemic feature and 
often occur together (Rieger's (1934) original description was of malformation 
of the anterior chamber and dental abnormalities). 
 
• Hypertelorism is a wide separation of the two orbits with an increased 
interpupillary distance, it occurs when the axes of the orbits do not complete the 
shift from the 180-degree alignment to the normal angle of 71 degrees at birth. 
The clinical appearance of hypertelorism often includes broadening of the nasal 
bridge and pushing upward and forward of the frontal region to form a 
prominent forehead. Both of these have been described in Axenfeld-Rieger 
syndrome (Steinsapir et al 1990). 
 
• While hypertelorism implies an increased interpupillary distance, it should not 
be confused with telecanthus, which is defined as an increased distance between 
the two medial canthal angles with a normal interpupillary distance and is also 
described in Axenfeld-Rieger syndrome. 
 
• Maxillary hypoplasia is well described and consists of flattening of the mid-face 
and a short upper lip/philtrum (i.e. relatively protruding lower lip because the 
mandible is unaffected). Closely associated with these maxillary abnormalities is 
dental hypoplasia. Other dental anomalies described are: small teeth 
(microdontia), a decreased number of evenly spaced teeth (hypodontia), focal 
absence of teeth (oligodontia or anodontia/ Drum et al 1985, Shields et al 1985), 
characteristic conical shaped teeth, a single set of teeth and abnormalities in 
enamel resulting in large numbers of dental caries at a relatively young age. 
 
• Varying degrees of umbilical abnormalities have been described in relation to 
Axenfeld-Rieger anomaly (Friedman 1985) and these appear to represent a 
failure of involution of the periumbilical skin (Jorgenson et al 1978) rather than 
a true umbilical hernia – although a number of patients have been found to have 
true umbilical herniation. Toppare et al (1995) measured the peri-umbilical skin 
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in neonates and suggested that if the upper umbilical skin (i.e. the cranial side) 
was greater than 18.82mm this was consistent with Rieger syndrome. 
 
• Hypospadias has been described a number of times as has inguinal herniation in 
association with Axenfeld-Rieger type anomalies (Jorgenson et al 1978, 
Chisholm and Chudley 1983). 
 
• Anal stenosis appears to occur with some frequency (Crawford 1967, Brailey 
1890). 
 
• Pituitary abnormalities have also been described in different forms. Primary 
empty sella syndrome (Gould et al 1997), isolated growth hormone deficiency 
and short stature (Kleinmann et al 1981) and parasellar arachnoid cyst (Shields 
et al 1985).  A recent study (Meyer-Marcotty et al 2008) also found sella turcica 
bridge combined with a prominent posterior clinoid process followed by a steep 
clivus and an elongated sella turcica in a family with four members affected.   
 
Syndromes and rare associations with Axenfeld-Rieger anomaly 
Axenfeld-Rieger anomaly appears to be part of a number of syndromes and the majority 
of these are listed below.  
 
• SHORT syndrome (Brodsky et al 1996) was described in 1975 and consists of 
Short stature, Hyperextensible joints, Hernia, Ocular depression, Rieger 
anomaly and Teething delay. Eight separate cases have been described, seven 
had Rieger anomaly, and it is interesting to note that the other family member 
had megalocornea. 
 
• Atrial septal defect and sensorineural hearing loss (Cunningham et al 1998) and 
other cardiac abnormalities have been reported (Tsai and Grajewski 1994). 
 
• Busch et al (1960) found an association between myotonic dystrophy and Rieger 
anomaly. 
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• De Hauwere et al (1973) proposed Rieger anomaly with hypertelorism and 
psychomotor retardation as a separate syndrome. Learning difficulties have been 
described as a separate association. 
 
• Brooks et al (1989) suggested a new syndrome called ‘short-FRAME’ consisting 
of short stature, facial abnormalities (underdevelopment of maxilla and 
mandible), Rieger anomaly, mid-line anomalies (microcondyles, choanal atresia, 
anal atresia, scoliosis and kyphosis) and enamel defects. 
 
2.5.1 Posterior Embryotoxon 
 
This is the name given to a very prominent Schwalbe’s line seen on the peripheral 
posterior cornea. Although its origin is uncertain it does seem to be a hallmark of 
certain ASD’s. It has, however, been found to be present in 8-15% of, apparently, 
otherwise normal eyes (Waring III 1975).  
It can vary morphologically from a subtle thin strand on the posterior surface of the 
cornea to a very thick white band and can even be partially detached and hang from the 
cornea. It is seen three times more commonly temporally than nasally and is often not 
seen superiorly and inferiorly as the sclera extends further forward here. In the presence 
of other anterior segment anomalies the presence of a posterior embryotoxon indicates 
that the diagnosis is Axenfeld-Rieger anomaly. 
 
Posterior embryotoxon (PE) is a feature of ARA/S, but also found as an incidental 
finding in the normal population (Waring III 1975, Ozeki et al 1997, Rennie et al 2005). 
Interestingly, in the papers mentioned above some of the patients who were found to 
have PE on examination, were also found to have POAG. 
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Chapter 3: GENETICS OF GLAUCOMA 
 
The current understanding of the pathogenesis of glaucoma is limited and this creates 
problems for both diagnosis and management. Various risk factors have been identified 
and among these, raised IOP (over 21 mm Hg) is recognised as one of the most 
important (Sommer et al 1991a, Tielsch et al 1991, De Voogd et al 2005, Miglior et al 
2007a&b, Leske et al 2007b).  Hereditary predisposition to glaucoma was first 
suggested more than 150 years ago and subsequent epidemiological studies established 
that genetic factors play a major role in the aetiology of the glaucoma’s (Leske 1983, 
Klein et al 2004,). In this chapter an overview of the genetics of open angle glaucoma 
and developmental glaucoma will be presented. 
 
3.1. PRIMARY OPEN ANGLE GLAUCOMA 
 
3.1.1 Introduction 
 
POAG is considered a heterogeneous, multifactorial disease, in which probably multiple 
genetic and non-genetic factors are involved (Shin et al 1977, Charliat et al 1994, 
Hulsman et al 2002). However, it is difficult to discriminate whether familial occurrence 
of a multifactorial disease is the result of shared genetic or environmental factors.  
 
So far, no environmental factor has consistently been associated with the risk of POAG; 
either in clinic-based case controlled studies (Charliat et al 1994) or in population based 
studies (Leske 1983, Katz and Sommer 1988). A twin study in Iceland showed 
concordance of POAG in twins, but not in spouses, suggesting the involvement of 
genetic rather than environmental factors (Gottfredsdottir et al 1999). The same study 
also shows that several of the specific ocular parameters associated with glaucoma are 
also heritable. These include IOP, optic nerve cup-disc ratio, outflow facility 
responsiveness to steroids and ocular dimensions such as axial length and anterior 
chamber depth. 
 
Some forms of glaucoma exhibit a Mendelian pattern of inheritance consistent with the 
presence of a single gene defect (Raymond 1997). Although these are a minority of the 
total glaucoma cases, studies on such rarer glaucomas offer new insight into glaucoma 
pathology. These include the developmental glaucomas, caused by dominant mutations 
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in genes encoding transcription factors (for example, PITX2), as well as primary 
congenital glaucoma caused by recessive mutation of the cytochrome mono-oxygenase, 
CYP1B1 (Gould et al 2004). 
 
 POAG, the most common form of glaucoma is more complex and does not usually 
show Mendelian inheritance (Netland et al 1993) but does exhibit a significant 
heritability. A family history has been known to be an important risk factor for POAG, 
implying the involvement of genetic factors towards the pathogenesis of POAG. It has 
been shown that 20-60% of patients with POAG have a family history, and under-
reporting of a family history is a documented feature in glaucoma (Nemesure et al 1996, 
Wolfs et al 1998, McNaught et al 2000, Nemesure et al 2001). This is supported by twin 
studies which have shown a higher degree of concordance among monozygotic twin, as 
mentioned earlier (Teikari 1987, Gottfredsdottir et al 1999).                                                                                                          
 
Racial differences in prevalence of POAG exist, further supporting a genetic 
predisposition for glaucoma. The prevalence in Africans is estimated to be six time as 
high in certain age groups, as that in Caucasians (Hewitt et al 2006). Similar findings in 
Africans and African Americans lessen the likelihood that such differences are 
primarily due to external societal or environment specific confounders (Tielsch et al 
1991). 
 
In the majority of POAG cases it is likely that more than one genetic predisposition is 
required to manifest the disease. 
 
The search for the underlying pathogenic mechanism for POAG has been challenging 
due to the following factors:  
• the limited understanding of the biochemical and cellular mechanism involved in the 
IOP control and retinal ganglion cell function;  
• the complex genetics of POAG;  
• each causal gene is presumed to only make a small contribution to overall 
phenotype.  
 
So far, two types of approaches for gene mapping in POAG have been widely applied:  
• genome-wide linkage studies 
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• association studies using either a candidate-gene approach or a genome-wide 
association approach (figure 3.1) 
 However, with the advance in technology, microarray gene studies have recently 
become one of the most promising methods to search for POAG genes. 
 
3.1.1.1 Genome wide studies 
 
When the elementary pathophysiology of a disease is unavailable, genome-wide studies 
can be applied, in order to identify the genetic profile of the disorder. This method 
detects genetic markers that segregate with the disease in relatives more often than 
expected. The advantage of this approach is a comprehensive search across the genome, 
which has been successful in many monogenic Mendelian disorders (Jimenez-Sanchez 
et al 2001). It has been applied to the study of eye disease and has lead to the discovery 
of several disease genes including RP31 for autosomal dominant retinitis pigmentosa 
(Papaioannou et al 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                              
 
 
 
 
 
 
                                                             
 
Figure 3.1; Genome-wide and candidate gene approaches towards gene mapping  
(adapted from Fan et al, 2006). 
Candidate gene studies Genome-wide studies 
Association analysis Linkage analysis Association analysis 
Re-sequencing 
Disease causing mutation 
Disease genes 
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Linkage analysis has been less successful for complex diseases, probably because of its 
limited power to detect the modest effects of common genetic variants on disease.  
In the case of POAG, pedigree linkage studies had good power for detecting uncommon 
genes with major effect (MYOC and OPTN). However, identification of large pedigrees 
with many affected subjects and living relatives has proved to be hard to find. In their 
excellent review of “Complex genetics of complex traits: the case of primary open angle 
glaucoma”, Hewitt et al (2006) have identified some reasons why gene identification by 
linkage has encountered complications like: phenocopy and intrapedigree genetic 
heterogeneity (Sack et al 1996, Craig et al 2001), loss of statistical power introduced by 
obscurity of clinical diagnosis in early POAG, high age of functional impairment or 
manifestation of POAG. Also, it is possible that high false negative results were 
obtained in linkage studies of POAG pedigrees and sibling pairs using micro-satellites 
markers, the studies having insufficient power to detect true loci. This might be worth 
reinvestigating using SNP base platforms, as the high SNP density allows loci to be 
defined more precisely (John et al 2004). 
 
While a pedigree linkage analysis may be hindered by the high age at functional 
impairment or manifestation of the disease, it may improve the power of an association 
study, through conserved LD regions (non-random association of alleles at different loci 
in haplotypes– Lewontin 1964). For diseases with late age of functional impairment, 
evolutionary, may not have been under negative selection pressure, and therefore, 
founder haplotype, as has been identified for MYOC, may exist (Baird et al 2003). 
 
Compared with traditional linkage studies, association studies based on LD have two 
major advantages: only unrelated individuals need to be genotyped, making it possible 
to study large number of individuals and because LD reflects a large number of 
historical recombination events, rather than just those in a pedigree, it is possible to fine 
map disease causing mutations.  
 
 Its disadvantage is that they are much more expensive, as they need larger samples and 
more consumables (Hirschhorn and Daly 2005). This method is increasingly applied to 
elucidate genetic mechanisms in complex disease (Edwards et al 2005). 
 
Recently, the genome-wide association study by genotyping single nucleotide 
polymorphisms (SNPs) in case-control studies has become a more powerful tool to 
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identify genetic causes, especially for complex diseases. This approach surveys most of 
the genome for the casual variants (Zhang et al 2004). In a sense, the entire genome is 
tested for a relationship between a marker and a phenotype. This approach has the 
advantage of making no assumptions about the location of the causal variants, and 
represents an unbiased as well as a comprehensive method, when there is no pre-
existing evidence about the underlying biological mechanism of the disease. Because 
segments of LD are analysed using tens of thousands of bases, this approach has a 
greater power to identify the effects of common variants. 
 
3.1.1.2 Candidate gene studies 
 
This approach assumes that there is a known candidate gene based on biological 
hypotheses or location within known POAG loci. Association studies or re-sequencing 
approaches can be used, to confirm or reject the hypotheses. Association studies are 
simpler and cheaper than complete re-sequencing of candidate genes, and have been 
suggested as a powerful method to identify the common genetic variants that underlie 
multifactorial diseases (Jimenez-Sanchez et al 2001). 
 
3.1.1.3 Microarray gene expression studies 
 
Microarray gene expression studies have recently become one of the most promising 
methods to search for new POAG genes. Instead of studying one gene at the time, many 
tens of thousands of genes can be studied simultaneously by using high density gene 
chip. This global approach has created many new opportunities to study complex 
genetic diseases like POAG (Leung & Cavalieri 2003a, Leung et al 2003b). 
DNA microarrays allow the comprehensive genetic analysis of an organism or a sample. 
They are based on probes, which are immobilized in an ordered two-dimensional 
pattern on substrates, such as nylon membranes or glass slides. Probes are either spotted 
cDNAs or oligonucleotide and are designed to be specific for an organism, a gene, a 
genetic variant (mutation or polymorphism), or intergenic regions. Thus, they can be 
used for example for genotyping, expression analysis, or studies of protein-DNA 
interactions and in the biomedical field they allow the detection of pathogens, antibiotic 
resistances, gene mutations and polymorphisms, and pathogenic states and can guide 
therapy. Microarrays, which cover the whole genome of an organism, are available as 
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well as those which are focussed on genes related to a certain diagnostic application 
(Bilitewski 2009). 
 
The complementary use of genome wide DNA scanning by linkage/ association analysis 
and RNA level scanning by microarray technology and functional studies should 
enhance the identification of candidate genes for POAG (Fan et al 2006). 
 
3.1.1.4 Single nucleotide polymorphism (SNP)  
 
A SNP is defined as a polymorphic variation at a single nucleotide that occurs in at least 
1% of the population. They make up about 90% of all human genetic variation and 
occur every 100 to 300 bases along the 3 billion base human genome (International 
HapMap Project; http://www.hapmap.org/whatishapmap.html.en). SNPs can occur in 
both coding and non-coding regions of the genome and they are examples of the newest 
generation of genetic markers. 
 
One approach, which has proved useful in other complex diseases including association 
between variation in the gene encoding apolipoprotein E (APOE) and Alzheimer’s 
disease (Corder et al 1993), is to use SNP genotyping. This method can be used as a 
means to test candidate genes as genetic susceptibility factors (candidate genetic 
studies) or search across a region of the genome where markers segregate with the 
disease or trait, for susceptibility genes (genome-wide studies) (Hirschhorn and Daly 
2005). Because the majority of heterozygosity in the human population is attributable to 
common variants and because the evolutionary history of common human diseases is 
not yet known, one promising approach is to assess common genetic variations (such as 
SNPs) for association to medical conditions (Lander 1996, Risch and Merikangas 1996, 
Collins et al 1997). This approach is feasible because 4 million (Sachidanandam et al 
2001, Venter et al 2001) of the estimated 10 million SNPs (Kruglyak and Nickerson 
2001) are already known. SNPs are preferred to other genetic markers, because of their 
high abundance, relatively low mutation rate and easy adaptability to automatic 
genotyping. 
 
As mentioned above, SNPs can occur in gene coding regions as well as the intronic 
regions. So far, the majority of disease gene research has concentrated on coding region 
and to a lesser extent, the promoter region of the genes. However, recent evidence 
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suggests that intronic regions might be functionally more important than previously 
assumed (Hewitt et al 2006). Also, to note is relatively few genes are found in the 
human genome compared with other species (Collins et al 2004) and it has become clear 
that many genes can produce more than one protein (through alternate splicing), which 
can have dramatically different functional roles (Hewitt et al 2006). 
 
As already mentioned, genetic association studies can take two forms, termed direct and 
indirect. In direct association studies, one tests the hypothesis that a given SNP is a 
causative factor in a disease, by examining whether its frequency is increased in 
affected individuals. In the indirect approach of LD studies, one uses multiple SNPs to 
search for evidence for an ancestral haplotype that is enriched in affected individuals. 
The latter approach, does not require the discovery of each disease causing allele, but 
does require an extremely dense SNP map and significant increase genotyping capacity 
(Cargill et al 1999). 
 
The allele frequency of non-synonymous coding SNPs has implications for the sample 
size need it to perform disease association. Power calculations (Risch and Merikangas 
1996) show that detecting association with alleles having frequencies <5% will typically 
require thousands of patients (except in the rare cases in which the relative risk 
attributable to the allele is large). Therefore, association studies involving most non-
synonymous coding SNPs (cSNP) would require larger populations than are currently 
available for most phenotypes, as well as higher throughput genotyping technologies. In 
the near term, direct association with missense cSNPs may be the most practical and 
promising approach, as SNPs that affect the aminoacid sequence of a protein are likely 
to explain a significant fraction of disease variation (Cargill et al 1999). 
 
SNP association studies are valuable tools in identification of significant disease 
associated alleles, as they would be able to detect significant non-coding or silent 
sequencing changes within gene regulatory sequence, which may alter the levels of 
functional proteins and cause disease. These alleles may be identified by SNP 
associated studies, but would not be identified by standard mutation screening of coding 
sequence. However, interpreting the consequences of non-coding sequence variants is 
more complicated, as the relationship between promoter and intragenic sequence 
variation, gene expression level and trait phenotype is less well understood than the 
relationship between coding DNA sequence and protein function (Glazier et al 2002). 
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It is believed that SNPs maps will enable scientists to identify the multiple genes 
associated with complex diseases as cancer, diabetes, vascular disease, age related 
macular degeneration, glaucoma. These associations are difficult to establish with the 
conventional gene hunting methods, because a single altered gene may make only a 
small contribution to the disease phenotype. 
 
As emphasized above, single nucleotide polymorphism (SNP) is the most common type 
of genetic variant in human genome. Haplotype, defined as a specific set of alleles 
observed on a single chromosome, or a part of a chromosome, has been an integral part 
of human genetics for decades. Some studies demonstrated that the analyses of 
haplotype defined by the grouping and interaction of several variants rather than any 
individual SNP correlated with complex phenotypes (Judson et al 2000, Morris & 
Kaplan 2002). Indeed, SNPs based strategies for complex diseases have had recent 
success, with the identification of a single risk allele for age related macular 
degeneration in the complement factor H gene being achieved through a focused fine 
SNP mapping (Klein et al 2005, Edwards et al 2005, Hageman et al 2005, Haines et al 
2005). 
 
As human population has relatively limited genetic diversity, most of the heterozygosity 
in the population is attributable to common alleles (that is those that are present at a 
frequency of >1% in the general population). The infrequent variants include the 
primary cause of rare, Mendelian diseases, with these allele being usually recent 
mutations and highly penetrant. By contrast, it has been hypothesized, that the common 
variants may contribute significantly to genetic risk for common diseases (Cargill et al 
1999). 
 
It has been suggested that the haplotype has greater power than any individual SNP to 
track an unobserved, but evolutionarily linked, variable site. The study of genetic 
variation will promote our understanding of the differential predisposition to common 
diseases and variation in drug responses of individuals and ethnic populations (Ouyang 
& Krontiris 2006). In the case of glaucoma, some studies indicate the presence of 
disease causing founder haplotypes, especially for MYOC gene (Baird et al 2003, Fan et 
al 2005) and this is an avenue which receives a lot of attention in the research of 
complex diseases at present. 
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3.1.1.5 Haplotype and Linkage disequilibrium 
 
In interpreting genetic association studies, it is essential to understand the structure of 
haplotypes in the human genome. A haplotype is defined as a combination of alleles at 
multiple loci that are transmitted together on the same chromosome and yields 
information about recombination. When a new mutation occurs, it is located on a 
specific haplotype. The association between each mutant allele and its ancestral 
haplotype is disrupted in subsequent generation by recombination. It should thus be 
possible to locate disease-causing mutations through linkage methods using information 
on recombination. More specifically, statistical associations are assessed between two 
SNPs in the genome and this is known as linkage disequilibrium - (LD (defined as the 
non-random association of alleles at two or more loci). 
There are basically two measures of LD: D’ (a measure of how much two loci are 
associated together i.e. co-variance between loci) and r (the square of correlation co- 
efficient). Both measures are calculated, firstly by estimating pairwise haplotype 
frequencies through expectation-maximisation (EM) (Long et al 1995), then by 
assessing the statistical strength of association through a likelihood ratio test, by 
comparing the EM frequencies with haplotype frequencies estimated assuming no LD. 
Both measures of LD are based upon D, the basic pairwise disequilibrium coefficient, 
the difference between the probabilities of observing the alleles independently in the 
population: D = f (A1B1) - f (A1) f (B1) (Lewontin 1964). A and B refer to two genetic 
markers and f is their frequency. D' is obtained from D/Dmax 2 and does not take into 
account allele frequencies. R has a more strict interpretation than D' as it takes into 
account both LD and allele frequency. However since D' is more accurate with larger 
sample sizes and higher allele frequencies, if the population group is large enough and 
rarer SNPs are excluded then D' is utilised. D’ varies from 0 (complete equilibrium) to 1 
(complete disequilibrium). When D’ = 0, typing one SNP provides no information on 
the other SNP. When r = 1, two SNPs are in perfect LD (Carlson et al 2004, Pritchard 
and Przeworski 2001) and allele frequencies are identical from both SNPs, and typing 
one SNP provides complete information on other untyped SNPs that are in LD. A 
relatively stringent r threshold of > 0.8 would allow a selected tSNP to improve the 
correlation and resolve >80% of all existing haplotypes. 
Most studies use r > 0.8 when deciding on their study design but when viewing 
haplotype blocks, common SNPs are of value and these are represented more clearly 
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with D' which calculates a fairly accurate LD among such SNPs. The disadvantage of 
using D’ is that it is less sensitive to marginal allele frequencies. 
 
3.1.1.6 International HapMap Project 
 
The international HapMap project is a freely-available public resource to increase the 
power and efficiency of genetic association studies to medical traits. It provides 
information on SNP/haplotype frequencies and linkage disequilibrium within several 
population samples, including one with northern European ancestry (CEPH). The 
principle behind the method utilized by Gabriel et al (2002) was implemented by the 
HapMap project to constructed LD blocks. This is a methodical and quantitative way of 
constructing a haplotype map of the human genome by using common SNP markers to 
capture the majority of the diversity within a region of interest. 
 
3.2 POAG LOCI (GLC1A-N) 
  
Although not common, a number of POAG pedigrees do demonstrate a Mendelian 
pattern of inheritance. Pedigrees with autosomal recessive inheritance have been 
described and it has been suggested that this may be the commonest type of Mendelian 
inheritance in POAG (Booth et al 1997). 
Autosomal dominant pedigrees with penetrance varying from 60% to 100% and 
extremely rare X- linked inheritance have also been described (Stokes 1940, Fleck & 
Cullen1986). 
In the rare families that show dominantly inherited glaucoma, 13 different gene loci 
have been identified. (Libby et al 2005, Baird et al 2005, Pang et al 2006, Fan et al 
2007) and are presented in the table 3.1. However, so far only 3 genes which are 
involved in POAG have been identified. 
 
3.2.1 GLC1A 
 
The GLC1A gene encodes a trabecular meshwork protein, TIGR (this nomenclature has 
now been changed to myocilin and abbreviated as MYOC) and so far, screening 
suggests that mutations in GLC1A causes 3% of cases of POAG (Lichter 1994, 
Raymond 1997, Stone et al 1997, Polansky and Nguyen 1998) and over 10% of the 
Juvenile Open Angle Glaucoma (Fingert et al 1999, Aldred et al 2004). 
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In the 1960’s studies were done to investigate the relation between the IOP response to 
steroids and glaucoma. These studies led to the suggestion that not only was the 
observed IOP response to topical steroids inherited, but also that the genes controlling 
this response were also closely related to the inheritance of POAG (Armaly & Becker 
1965, Becker 1965, Armaly 1967c). 
 
The first gene to be associated with POAG was the same gene which was associated 
with Juvenile Open Angle Glaucoma (JOAG - open angle glaucoma with the age of 
onset before 40 years of age). JOAG was a logical start point for studying genetics of 
open angle glaucoma because it shows a strong autosomal dominant inheritance pattern, 
occurs at an early age, has obvious phenotypic signs and it is found in multiple 
generations. In 1997, Stone et al identified the GLC1A locus for juvenile onset open 
angle glaucoma and the mutant gene for this locus was found to be the previously 
described TIGR gene (trabecular meshwork induced glucocorticoid response). 
 
The TIGR gene has been found to be the same as the MYOC gene, described by the 
Kubota et al (1997), and in 1998 the Human Genome Organisation- Genome Database 
Nomenclature Committee assigned the gene the name myocilin (MYOC). The myocilin 
protein is associated with the cytoskeleton in the retina and it is present in a variety of 
ocular and non-ocular tissues (Fingert 1998, Fingert et al 2002). In the eye, it can be 
produced in greater amounts in time of stress. This stress protein role seems to be of 
protecting vital cellular proteins or enzymes (Kubota et al 1997). Some of the stress 
proteins are thought to bind to important cellular proteins, preventing them from 
unfolding or denaturating under stress - so called “molecular chaperones” (Ellis & van 
der Vies 1991, Wang & Spector 1995). Liu & Vollrath (2004) shows that mutant MYOC 
molecules induce endoplasmic reticulum (ER) stress and cell death in the trabecular 
meshwork (TM), due to accumulation of misfolded proteins. An increased susceptibility 
of TM cells raises the possibility that protein folding abnormalities and ER stress may 
contribute to glaucoma caused by other genes and that treatment which promote protein 
folding and secretion may have beneficial effects for IOP (Libby et al 2005). 
Also, because ER stress often causes apoptosis (Rao et al 2004), antiapoptotic treatment 
may also be beneficial by reducing cell death. 
As mentioned, myocilin protein is located in many ocular tissues relevant to glaucoma, 
including aqueous humour, trabecular meshwork, ciliary body and retinal ganglion cell 
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(Tamm 2002). The protein has an amino terminal signal sequence, a myosin like 
domain and an olfactomedin domain. Most of the pathogenic mutations occur in the 
olfactomedin domain (Tamm 2002). 
Libby et al (2005) look at the evidence for the role of MYOC protein in aqueous 
humour physiology and conclude that MYOC does not appear to be necessary for 
normal IOP homeostasis and that the pathogenesis of MYOC mutations is not due to 
loss of function. On the contrary, it would appear that myocilin associated glaucoma is 
due to gain of function (Morissette et al 1998, Wiggs & Vollrath 2001). Consistent with 
clinical findings, MYOC-knockout mice grow normally with normal IOP and ocular 
morphology (Kim 2001), suggesting that total absence of myocilin is harmless to IOP 
and visual field. In the trabecular meshwork, MYOC has been revealed to principally 
interact with optomedin, an olphactomedin related protein (Torrado et al 2002), as well 
as binding with flotin-1, a lipid raft protein (Joe et al 2005). Genes interacting with 
MYOC are potentially good candidate genes for future POAG investigation. 
 
The phenotypic expression of this gene appears to be variable (Fingert et al 2002). That 
is demonstrated in the case of two genetically identical twins who inherited the same 
copy of chromosome 1 from the affected father. One twin had severe glaucoma and the 
other one just minimal change (Wiggs et al 1995). This suggests that other genes or 
environmental factors might contribute to the full expression of POAG. 
 
So far, more than 50 mutations in MYOC gene sequence have been described, all 
associated with either JOAG or POAG (Fingert et al 2002, Funayama et al 2006), with 
the Gln368STOP mutation being the most common known individual glaucoma causing 
variant worldwide (Fingert et al 1999). 
To note is that individuals homozygous for some MYOC mutations do not manifest 
severe disease unlike their heterozygous counterparts (Morissette et al 1998, Hewitt et 
al 2006). This unusual situation may indicate specific biochemical interactions between 
the mutant and non-mutant MYOC subunits (Hewitt et al 2006). 
 
3.2.2 GLC1B 
 
Since the discovery of GLC1A, several other loci have been identified. 
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GLC1B locus on chromosome 2cen-q13, seem to possibly be implicated in the 
pathogenesis of normal tension glaucoma, as well as in those cases of POAG associated 
with only a modest rise in IOP (Stoilova et al 1996). 
 
Brinkmann et al (2005) investigated the role of VAMP5 and VAMP8 as potential 
candidate genes for POAG, on the basis of the genetic position (GLC1B locus), 
expression in the optic nerve and biochemical function (target  membrane transport 
processes). The study was done on 90 POAG patients and 60 controls and the results 
indicate that it is unlikely that these 2 genes are involved in glaucoma. 
 
Table 3.1: Genes and loci involved in POAG 
Locus 
name 
Chromosomal 
location 
Gene 
Identified 
Contribution to 
familial 
glaucoma 
References 
GLC1A 1q21-q31 MYO C 4.4% (Stone et al 
1997, 
Suzuki et al 
1997) 
Sheffield  et al 1993, Richards et 
al 1994, Graff et al 1995, 
Morissette et al 1995, Stone et al 
1997, Suzuki et al 1997 
GLC1B 2cen-q12   Stoilova et al 1996 
GLC1C 3q21-q24   Wirtz et al 1997, Samples et al 
2004 
GLC1D 8q23   Trifan et al 1998 
GLC1E 10p15-14 OPTN 16.7% of 
familial NTG 
(when all 
variants of 
OPTN are 
combined) 
(Rezaie et al 
2002) 
Sarfarazi et al 1998, 
Rezaie et al 2002 
GLC1F 7q35   Wirtz et al 1999 
GLC1G 5q22.1 WDR36 6.92% (Monemi 
et al 2005) 
Monemi et al 2005 
GLC1H 2p15- p16   Suriyapperuma et al 2007 
GLC1I 15q11-q13   Allingham et al 2005 
GLC1J 9q22   Wiggs et al 2004 
GLC1K 20p12   Wiggs et al 2004 
GLC1L 3p21-22   Baird et al 2005 
GLC1M 5q22   Pang et al 2006, Fan et al 2007 
GLC1N 5q23-24   Wang et al 2006a 
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3.2.3 GLC1C 
 
The GLC1C locus has been described on chromosome 3, 3q21-q24 (Kitsos et al 2001, 
Samples et al 2004, Wirtz et al 1997). The type I procollagen C-proteinase enhancer 
protein-like (PCOLCE2) gene as a candidate gene for this locus was studied, but no 
coding sequence mutation were detected. 
 
3.2.4 GLC1D 
 
The fourth locus for POAG, GLC1D has been assigned to chromosome 8q23. Trifan et 
al (1998) who discovered the GLC1D locus have suggested two possible candidate 
genes at this site. 
 
First candidate gene, Syndecan 2, belongs to a family of integral membrane 
proteoglycans that participate in cell matrix interactions and the modulations of growth 
factor response. The authors speculate that a mutation of the SYND2 gene would alter 
the adherence properties of adult oligodendrocytes, leading to a demyelinisation of the 
optic nerve fibres, rendering them more sensitive to other stress factors, such as elevated 
IOP. 
 
Another positional candidate gene is EGRα (early growth response alpha) gene. 
Functional analysis of this protein demonstrates that it could bind to, and stimulate 
transcription from, a basic transcription element consensus DNA sequence. Basic 
transcription element is a naturally occurring binding sequence in the promoter region 
of some cytochrome P450 members and function as transcription modulators. If EGR-α 
is the physiological regulator of the CYP1B gene, which has been shown to be 
responsible for primary congenital glaucoma (Sarfarazi et al 1995) than it is possible 
that mutations in EGR-α may also cause chronic open angle glaucoma. 
 
3.2.5 GLC1E 
 
The GLC1E locus has been assigned to chromosome 10p14-p15 (Sarfarazi et al 1998) 
and is associated with mild to moderately raised eye pressures in individuals with optic 
nerve damage. 
 
  64 
Optineurin (OPTN) gene has been linked to the GLC1E locus on chromosome 10. The 
study suggests that mutations in this gene may be responsible for 16.7% of families with 
normal tension glaucoma, with an additional attributable risk factor of 13.6% in both 
familial and sporadic cases (Rezaie et al 2002). 
 
The most common mutation is E50K and it was identified in a family with British 
descent. It has been suggested that a founder effect accounts for this mutation frequency 
in British patients and therefore estimates of OPTN mutation frequency in glaucoma 
should not be extrapolated from the original study (Alward et al 2003). Other extensive 
studies (Aung et al 2003, Baird et al 2004, Leung et al 2003a, Toda et al 2004) found 
similar mutation distributions in patients and controls. When all the studies are 
considered, OPTN mutations do not appear to be a common cause of glaucoma (only 
0.1% of unselected POAG cases –Alward et al 2003, Aung et al 2003). One possibility 
is that OPTN mutations do not induce glaucoma unless the genetic context is 
permissive, and that explain why mutations are also present in controls (Libby et al 
2005). 
 
OPTN is a 577 amino acid protein that appears to be secreted. Optineurin is expressed 
in trabecular meshwork, nonpigmented ciliary epithelium, retina and brain. Its 
expression in the glial cells of the retina and optic nerve indicates that it can affect 
retinal ganglion cells survival (Rezaie et al 2002). The authors speculate that the wild-
type Optineurin, operates through TNF-α (tumour necrosis factor alpha) signalling 
pathway and plays a neuro-protective role in the eye and optic nerve. However, when 
defective, it produces visual loss and optic neuropathy as typically seen in normal and 
high pressure glaucoma. Components of TNF-α signalling pathway can shift the 
equilibrium towards induction of apoptosis (Rezaie et al 2002). A Japanese study 
(Funayama et al 2004) found a possible interaction between polymorphisms in the 
OPTN and the TNF-ά genes that would increase the risk for glaucoma, which further 
supports the above hypothesis. 
 
3.2.6 GLC1F 
 
The GLC1F locus has been assigned to chromosome 7q35-q36 (Wirtz et al 1999). 
Two candidate genes have been identified by the authors for this locus. First one is 
C2H2-150, which is a KRAB domain-containing C2H2 type zinc-finger protein. C2H2-
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type zinc-finger proteins are transcription factors, and the KRAB domain may repress 
gene transcription (Becker et al 1997). 
Nitric Oxide Synthase also maps to this region (Janssens et al 1992). Nitric oxide 
synthase is an oxidative stress protein and a cytochrome P-450-type hemoprotein 
(White & Marletta 1992) and an association of a polymorphism in the 5’ region of 
Nitric Oxide Synthase in patients with familial POAG has been reported (Tunny et al 
1998). 
 
3.2.7 GLC1G 
 
The GLC1G locus was mapped to 5q22.1 by Monemi et al (2005). The candidate gene 
for this locus was identified as WDR36, which is a novel gene with 23 exons, encoding 
951 amino acids and a protein with multiple G-beta WD40 repeats. The gene is 
expressed in multiple organs throughout the body (heart, placenta, liver, skeletal 
muscle, kidney, pancreas and eye). In the eye, the gene is expressed in lens, iris, sclera, 
ciliary muscle, ciliary body, trabecular meshwork, retina and optic nerve (Monemi et al 
2005). 
 
The G proteins are a family of membrane associated proteins that act as intermediaries 
in transduction of the signals generated by trans-membrane receptors. The G-beta 
subunit is required for membrane anchoring and receptor recognition. Therefore, 
mutations affecting the structure of the WD40 repeats may interfere with interaction of 
WDR36 with other proteins. In the original study, a mutation rate of 5.02% was found 
for this gene (Monemi et al 2005). Subsequent studies, failed to find an association 
between WDR36 variants and POAG and suggest that may be WDR36 is a glaucoma 
modifier gene (Fingert et al 2007, Hauser et al 2006, Weisschuh et al 2007). 
 
3.2.8 GLC1H 
 
GLC1H locus was assigned to chromosome 2p15-p16 by Suriyapperuma et al (2007) 
and promising genes have been identified and are being investigated at present. 
However, screening of 35 of these genes has not yielded a causative mutation. 
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3.2.9 GLC1I 
 
GLC1I locus has been identified by Allingham et al (2005) and has been allocated to 
chromosome 15q11-q13.Variation in sequence in candidate genes in this region would 
appear to be associated with older age at diagnosis of POAG. This locus contains genes 
for autism, Prader-Willi and Angelman syndrome and is considered highly complex in 
genomic function and stability (Nicholls & Knepper 2001). The candidate genes 
identified by the authors are being investigated at present. 
 
3.2.10 GLC1J and GLC1K 
 
Wiggs JL et al (2004) identified two novel loci for early onset open angle glaucoma. 
These are: GLC1J located on chromosome 9q22 and GLC1K located on chromosome 
20p12. The authors compiled a list of genes for each locus which have significant ocular 
expression (15 genes for chromosome 9 and 23 genes for chromosome 20) and are 
being investigated at present. One gene the authors single out is the VSX1 gene, located 
on chromosome 20. Mutations in this gene have been shown to be responsible for some 
cases of posterior polymorphous dystrophy, a disease which can be associated with 
early onset glaucoma (Heon et al 2002). 
 
3.2.11 GLC1L 
 
Evidence for a new glaucoma locus –GLC1L- located on 3p21-22 has been published by 
Baird et al (2005) and a positive association between this region and Q368STOP 
mutation of myocilin has been demonstrated in affected individuals. 
 
3.2.12 GLC1M 
 
Finally, Pang et al (2006) and Fan et al (2007) have mapped a new locus for POAG, 
located on long arm of chromosome 5 at 5q22.1-q32 in a large autosomal dominant 
JOAG family from Philippines and it was designated as GLC1M. The same group, have 
identified another locus, designated GLC1N located at 15q22-q24 (Wang et al 2006a). 
Candidate genes at both loci are being investigated, but no results as yet. 
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The study carried out by Acharya et al (2007) on 200 patients and 100 controls, 
examines the Opticin (OPTC) gene, located on chromosome 1q31-32 as a candidate 
gene for glaucoma because of its expression in the trabecular meshwork (Friedman et al 
2002).  
 
Their results suggest that the “silent” change they identified is associated with 
glaucomatous phenotype. However, as this mutation was found in only one glaucoma 
patient out of 200, further investigation is warranted, before any firm conclusion can be 
drawn. A study published in 2002 (Friedman et al), screened for OPTC mutations in 97 
patients with sporadic POAG and although Leu268Pro variation was identified in 7 
patients, 8/55 controls had the same mutation. These results indicate that so far OPTC 
cannot be associated with glaucomatous phenotype. 
 
3.3 POAG ASSOCIATION STUDIES 
 
So far, the actual genes identified as causative for glaucoma, account for only about 
10% of all POAG cases. More information about the genetics of glaucoma comes from 
association studies. The reported genes and studies to date are presented in table 3.2. 
Most of the genes investigated are only reported in one or two studies although there are 
a few genes that have been the subject of multiple association studies. 
 
3.3.1 Apolipoprotein E 
 
Apolipoprotein E (APOE) has been reported to be a potent modifier gene for POAG 
(Copin et al 2002). The same positive association was found by Vickers et al (2002) on 
a group of 70 Tasmanian patients, by Mabuchi et al (2005) in a study of 310 of NTG 
Japanese patients and by Junemann et al (2004) on a group of 150 POAG German 
patients. However, 3 other studies (Lake et al 2004, Ressiniotis et al 2004, Zetterberg et 
al 2007) found no association on 137 (UK), 155 (UK) and 242 (Sweden) POAG patients 
respectively. 
 
Apolipoprotein E (APOE) is a lipid transporting protein produced in the liver and brain 
and it is unique among apolipoproteins through its relevance to nervous tissue. It is 
involved in mobilisation and redistribution of cholesterol in repair, growth and 
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maintenance of myelin and neuronal membranes during development or after injury 
(Junemann et al 2004). 
So far it is not obvious how the APOE alleles may be a source of genetic risk for 
glaucoma and it needs further investigation. 
 
3.3.2 OPA1 
 
Another gene which has received more attention in POAG patients is OPA1 gene, 
mutations in this gene being a cause of autosomal dominant optic atrophy (ADOA). 
ADOA is another condition that is characterised by progressive optic nerve damage, 
attributable to primary degeneration of retinal ganglion cells, followed by ascending 
atrophy of the optic nerve. The OPA1 gene has been shown to be expressed in the 
retinal ganglion cells and the optic nerve (Alexander et al 2000).  
 
Since different mutations in the same gene can cause widely different phenotypes, as 
demonstrated in glaucoma by FOXC1, MYOC, PITX2, Aung et al (2002) hypothesised 
that the similarities between glaucoma and ADOA make OPA1 a good candidate gene 
to examine in glaucoma patients. The study has found that polymorphisms in the OPA1 
gene is associated with glaucoma and may be a marker for the disease (Aung et al 
2002). Another study by Powel et al (2003) has found the same results as the initial 
study. However, 2 studies on ethnically different population (Woo et al 2004 –Korean 
population and Yao et al 2006 – African Caribbean population) did not find an 
association between polymorphism in OPA1 gene and POAG. 
 
3.3.3 p53 gene 
 
As suggested earlier, glaucomatous neuropathy appears to be a type of cell death by 
apoptosis (Nickells et al 1999, Osborne et al 1999). Therefore, some researchers have 
studied the association between p53 codon polymorphism and POAG (Acharya et al 
2002, Lin et al 2002, Ressiniotis et al 2004) as p53 genes is one of the regulatory genes 
of apoptosis (Smith et al 2003). 
 
The first study (Lin et al 2002) has found that the proline form of p53 gene codon 72 
appears to be a significant risk factor in the development of POAG in Chinese patients. 
However, another study published same year (Acharya et al 2002), could not find an 
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association between the p53 codon polymorphism and POAG in a cohort of Indian 
POAG patients. Ressiniotis et al (2004) have investigated the p53 haplotype and found 
a significant difference in distribution between cases and controls. This suggests that 
none of the polymorphisms investigated can account for the increased risk of POAG, 
but the true causative mechanism may be in linkage disequilibrium with the haplotype. 
 
3.3.4 TNF-alpha 
 
Few studies investigated the association between TNFα  and glaucoma, on the basis that 
OPTN is induced by TNFα and interacts with several proteins to regulate apoptosis, 
inflammation and vasoconstriction (Funayama et al 2004). Also, Vittitow and Boras 
(2002) demonstrated that sustained elevated IOP, TNFα  exposure and prolonged 
dexamethasone treatment significantly upregulated OPTN expression in the trabecular 
meshwork. 
 
Lin et al (2003 b) has found and association between the TNFα -308 polymorphism and 
POAG in a cohort of 60 Chinese patients. The association could not be demonstrated on 
a cohort of 114 Caucasian patients (Mossbock et al 2006b).  However, Funayama et al 
(2004) have found and increased frequency of TNFα-857T and OPTN/412 carriers in a 
group of 194 POAG patients and suggests that their findings show a possible interaction 
between polymorphisms in the OPTN and the TNFα genes that would increase the risk 
for glaucoma. 
 
3.3.5 MTHFR gene 
 
On the basis that moderate increase of levels of homocysteine have been found in 
patients with POAG,  and that homocysteine induces apoptotic cell death of retinal 
ganglion cells and also exerts gliotoxic effect, thus representing a hypothetical risk 
factor for POAG, a common polymorphism of methylenetetrahydrofolatereductase 
(MTHFR) has been investigated to test for an association with POAG. The C677T 
variant of MTHFR gene has been investigated for association in both POAG and 
psedoexfoliation glaucoma (PEXG) by Junemann et al (2005) and a positive association 
with POAG has been demonstrated. Also a positive association has been found between 
NTG and 677C/T MTHFR polymorphism in a Korean study (Woo et al 2009). 
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However, a Japanese study (Mabuchi et al 2006) and a Caucasian study (Mossbock et al 
2006a) failed to show a positive association. 
 
3.3.6 ADRB1 & 2 genes 
 
A couple of studies investigated the role of beta-adrenergic receptors polymorphisms in 
open angle glaucoma. The beta-adrenergic receptors (ADRB 1 and 2) genes are 
expressed in human ciliary body and trabecular meshwork and are also found in the 
human optic nerve and the wall of the microvessels of the optic nerve (Inagaki et al 
2006). Also the antagonists of the ADRBs (beta antagonists) are widely used as topical 
medication to lower intraocular pressure in patients with ocular hypertension and 
glaucoma. 
 
Gungor at al (2003) reported no differences in the common ADRB2 allele frequencies in 
both congenital glaucoma and open angle glaucoma in a Turkish population. However, 
Inagaki et al (2006) found that some alleles are associated with a younger age at 
diagnosis and a higher IOP at diagnosis in Japanese patients and that these ADRB2 
polymorphisms may influence the pathophysiology of glaucoma in this ethnic group. 
The most recent study of β2-adrenergic receptor gene in glaucoma looked at 2 different 
ethnic population (white Caucasians and Black- African) and found no difference in 
ADRB2 alleles and haplotypes  between POAG group and control group in either 
population (McLaren  et al 2007). However, the role of ADRB2 haplotypes in glaucoma 
as a risk factor of intraocular pressure fluctuation and variation in intraocular pressure 
response to β-blockers is still to be evaluated. 
 
3.3.7 Gene – gene interactions in POAG 
 
It is obvious from the above review of genetics of POAG that only a small portion of 
POAG follows the classical Mendelian pattern of inheritance and that a considerable 
fraction of POAG results from a large number of variants in several genes, each 
contributing a small effect. 
 
The exact mechanism of the genes implicated in susceptibility of POAG is still 
unknown. There are reports of gene-gene interactions (Copin et al 2002, Fan et al 2005, 
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Funayama et al 2004, Funayama et al  2006, Vincent et al 2002), that suggest that the 
inheritance pattern of glaucoma is polygenic. 
 
In 2002, Vincent et al published the results of a study which suggests that MYOC and 
CYP1B1 might interact through a common pathway and that the inheritance of 
glaucoma might be digenic in some cases. Funayama et al (2004) suggest that a possible 
gene-gene interaction between OPTN and TNF-ά increases the risk of POAG in 
Japanese patients. The same research group in a paper published in 2006, identifies a 
mutation in noelin2 (OLFM2) gene as a possible disease causing mutation in Japanese 
patients with POAG and also suggest that OLFM2, MYOC and OPTN may contribute 
interactively to clinical features in patients with POAG, indicating a polygenic 
aetiology. 
 
APOE polymorphism has been reported to interact with MYOC polymorphism to 
increase IOP in POAG patients (Copin et al 2002).  
Fan et al (2005) in their study on 400 POAG patients found possible gene-gene 
interaction between MYOC, OPTN and APOE, bringing further evidence that all these 
genes may interactively contribute to POAG, indicating a polygenic aetiology. 
 
3.3.8 Mitochondrial abnormalities in POAG 
 
Some research has been conducted in the role of mitochondrial DNA abnormalities in 
POAG. Although the pathogenesis of glaucoma is far from being unravelled, it is 
believed that ganglion cell apoptosis may play a role (Nickells 1999, Quigley 1999). It 
has also been described that some neurodegenerative diseases and some optic 
neuropathies (Leber’s hereditary optic neuropathy) are associated with abnormalities of 
the mitochondrial DNA (Sadun 2002, Howell 2003, Autere et al 2004,).  
 
Abu-Amero et al (2006) has identified mitochondrial abnormalities in a group of 27 
POAG patients. In a later study, the same group investigated the distribution of 
mitochondrial haplogroups in different types of glaucoma in an Arabic population and 
found that there is an association between a specific haplogroup and primary angle 
closure glaucoma; these patients were at higher risk of developing the disease (Abu-
Amero et al 2008). 
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Table 3.2: POAG association studies genes 
Gene symbol Gene name Chromosomal 
location 
Studies 
AGTR2 Angiotensin II receptor, type 2 Xq22-q23 Hashizume et al 2005 
APOE Apolipoprotein E 19q13.2 Copin  et al 2002;  
Vickers et al 2002, 
Lake et al 2004,  
Ressiniotis et al 2004, 
Mabuchi et al 2005,  
Lam et al 2006,  
Zetterberg et al 2007 
CDKN1A Cyclin-dependent kinase 
inhibitor 1A 
6p21.2 Tsai et al 2004, 
Ressiniotis et al 2005 
CYP1B1 Cytochrome P450, subfamily 1, 
polypeptide 1 
2p22-p21 Vincent et al 2002 
EDNRA Endothelin receptor, type A 4q31.2 Ishikawa et al 2005, 
Kim et al 2006 
GSTM1 Glutathione S-transferase, mu1 1p13.3 Juronen et al 2000 
IGF2 Insulin-like growth factor II 11p15.5 Tsai et al 2003 
IL1B and 
IL1ά 
Interleukin 1-beta and 
Interleukin 1-alpha 
2p14 Lin et al 2003 a,  
Wang et al 2007a &b,  
How et al 2007,  
Wang et al 2006b,  
 
MTHFR 5,10-methylenetetrahydrofolate 
reductase 
1p36.3 Junemann et al 2005, 
Mossbock et al 2006a,  
Mabuchi et al 2006, 
Woo et al 2009 
NOS3 Nitric oxide synthase 3 7q36 Tunny et al 1998,  
Logan et al 2005, 
 Pang et al 2005 
NPPA Natriuretic peptide precursor A 1p36.2 Tunny et al 1996, Jeoung 
et al 2007 
OCLM Oculomedin 1q31.1 Fujiwara  et al 2003, 
Leung et al 2000, Jansson 
et al 2003 
OPA1 Optic atrophy 1 3q28-q29 Aung et al 2002,  
Powell et al 2003, 
Woo et al 2004,  
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Yao et al 2006, 
 Mabuchi et al 2007 
TAP1 Transporter, ATP-binding 
cassette, major 
histocompatibility complex, 1 
6p21.3 Lin et al  2004 
TNF Tumour necrosis factor 6p21.3 Lin et al 2003 b, 
Funayama et al 2004, 
Mossbock et al 2006b 
ADRB1 and 
ADRB2 
Beta adrenergic receptors 10q24-q26 and 
5q32-q34 
Inakagi et al 2006, 
McLaren et al 2007 
 
 However, the group investigated was small and the findings would have to be 
replicated in a larger cohort and different racial groups for any conclusion to be drawn. 
A study by Andrews et al (2006), found no association between mitochondrial 
haplogroups and POAG in a cohort of 140 POAG patients and 75 controls. 
 
 A review by Kong et al (2009) provides evidence that age-associated mitochondrial 
dysfunction renders retinal ganglion cells susceptible to glaucomatous injury by 
reducing the energy available for repair processes and predisposing the ganglion cells to 
apoptosis. Eliciting the role of mitochondria in glaucoma pathogenesis may provide a 
different avenue for therapeutic targets to protect the optic nerve. 
 
3.4 SECONDARY OPEN ANGLE GLAUCOMA 
 
3.4.1 Psedoexfoliation glaucoma 
 
Exfoliation syndrome is an age-related, generalized disorder of the extracellular matrix 
characterized by the production and progressive accumulation of a fibrillar extracellular 
material in many ocular tissues (Ritch & Schlotzer-Schrehardt 2001).  
 
It is now understood to be the most common identifiable cause of open angle glaucoma 
world wide (Ritch 1994). The risk of developing glaucoma is 5 to 10 times more 
common in eyes with psedoexfoliation than in those without it. Patients with 
pseudoexfoliation are twice as likely to convert from having ocular hypertension to 
having glaucoma and when glaucoma is present to progress more rapidly (Grodum et al 
2005). Also, an increasing number of systemic associations have been reported more 
recently (Ritch 2008).  
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In his review of Genetics of pseudoexfoliation syndrome, Challa (2009) discusses the 
inheritance patterns and recent genetic advances in the study of this disorder. His 
conclusion is that pseudoexfoliation syndrome is a major cause for glaucoma that has a 
strong familial association. Recent studies confirmed that LOXL1 is a major gene 
associated with both pseudoexfoliation syndrome and pseudoexfoliation glaucoma, 
however the exact mechanism by which this gene leads to the development of these 
conditions has not been identified. He concludes that further studies are needed to 
answer this question. 
 
3.4.2 Pigmentary glaucoma 
 
Pigment dispersion syndrome and pigmentary glaucoma are characterised by a 
disruption of the iris pigment epithelium and deposition of the dispersed pigment 
throughout the anterior segment (Ritch 1996). The classic diagnostic triad consists of 
corneal pigmentation (Krukenberg spindle); slit like, radial, midperipheral iris 
transillumination defects and dense trabecular pigmentation. The iris insertion is 
typically posterior, and the peripheral iris tends to have a concave configuration. There 
is evidence to suggest that pigment dispersion syndrome is inherited in an autosomal 
dominant fashion, with phenotypic onset probably beginning in most people in the mid 
20s (McDermott et al 1987). That Caucasians are almost exclusively affected is also 
consistent with a genetic origin. 
 
The frequency with which pigment dispersion syndrome converts to glaucoma has been 
estimated to about 50% (Ritch et al 1993). However, a study by Siddiqui et al (2003), 
suggests that the probability of converting to glaucoma was 10% at 5 years and 15% at 
15 years.  
 
Pigment dispersion syndrome has been mapped to the 7q35-q36 locus by linkage 
analysis, but the candidate gene has not been identified yet (Andersen et al 1997). 
 
As pseudoexfoliation syndrome and pigment dispersion syndrome are two common 
disorders that can produce secondary glaucoma through trabecular blockage, the 
involvement of the three psedoexfoliation syndrome and glaucoma associated LOXL1 
polymorphisms were studied in two cohort of pigment dispersion and pigmentary 
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glaucoma patients (Rao et al 2008, Gramer et al 2009). However no significant 
association was found. 
 
Studies on mice indicate that mutations in genes encoding melanosomal proteins 
(Anderson et al 2002, Anderson et al 2006) can contribute to developing pigment 
dispersion syndrome and glaucoma. However, Lynch et al (2002) investigated DNA 
sequence variants in the tyrosinase-related protein 1(TYRP1) gene in a group of patients 
with pigment dispersion glaucoma and found no association. As with any other types of 
glaucoma, further studies are needed to help unravel the genetic contribution to this 
disease. 
 
3.5 CONCLUSION GENETICS OF OPEN ANGLE GLAUCOMA 
 
Notably so far, few genes have been robustly associated with POAG in the general 
population. Among the three identified genes, only MYOC is established as directly 
causative, while due to conflicting results, the exact roles of OPTN and WDR36 in 
POAG remain uncertain. Mutations in MYOC account for a small proportion of 
approximately 2-4% of POAG (Alward et al 1998, Alward et al 2002, Fingert et al 
1999, Stone et al 1997, Suzuki et al 1997). Fingert et al (1999) screened 1703 patients 
from five different populations (including Caucasians, African Americans and Asian 
patients from Japan) and despite different frequencies of specific MYOC mutations 
being found in each of the five populations, the overall frequency of MYOC mutations 
was similar (2-4%) in all populations. The combined contribution of MYOC, OPTN and 
WDR36 to POAG add up to only 10% (Fan et al 2006). Hence it is highly likely that 
other unidentified loci or genes still exist. 
 
It is obvious from the information presented in this chapter that a great deal of research 
goes into the genetics contribution to open angle glaucoma. Although, we are still far 
from unravelling its secrets further studies will add to the body of knowledge and get us 
a step closer to understanding the disease. 
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3.6 DEVELOPMENTAL GLAUCOMA GENETICS 
 
3.6. 1 Introduction 
 
Developmental glaucomas are associated with widespread malformations of neural crest 
derived tissues in the anterior segment of the eye (anterior segment dysgeneses) or 
systemic anomalies, but glaucoma may not manifest until the second or third decade 
(Lichter 1994). 
 
These forms of glaucoma often exhibit a Mendelian pattern of inheritance consistent 
with the presence of a single gene defect. The associated glaucoma may arise from the 
malformations seen from birth or may arise from continued expression of the gene 
product throughout life. 
 
Transcription factors expressed in the periocular mesenchyme (PITX2, FOXC1 and 
LMX1B) (Semina et al 1996, Pressman et al 2000, Gage et al 2005, Viera et al 2006) 
play an important role in normal morphogenesis of the anterior segment and provide important 
insight to the underlying genetic mechanism of glaucoma. 
 
Therefore the genes causing developmental glaucoma are an obvious group to test as 
genetic susceptibility factors for POAG. These genes have not been analysed in any 
association studies at the time the pilot study presented in this paper was set up, except 
for CYP1B1.  
CYP1B1 causes primary congenital glaucoma. It is also involved in cases of juvenile 
open angle glaucoma (JOAG) (Vincent et al 2002, Acharya et al 2006,) and a recent 
study identified a CYP1B1 polymorphism as a susceptibility factor for POAG 
(Bhattacharjee et al 2008, Melki et al 2005). 
   
The genes and gene loci involved in anterior segment development and in which 
mutations cause anterior segment dysgeneses are presented in table 2.3. 
 
3.6.2 CYP1B1 gene 
 
Three loci have been identified, designated GLC3A (Sarfarazi et al 1995), GLC3B 
(Akarsu et al1996) and GLC3C (Stoilov & Sarfarazi; IOVS 43: E abstract 3015; 2002b). 
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GLC3A has been mapped to region 21 on the short arm of chromosome 2 i.e. 2p21 
whilst GLC3B has been mapped to 1p36. Stoilov et al (1997) have discovered mutations 
in the CYP1B1 gene in the GLC3A linked families. 
 
The CYP1B1 gene codes for a member of cytochrome P450 enzymes, which is a 
multigene superfamily responsible for phase 1 metabolism of a wide range of 
structurally diverse substrates (Sarfarazi & Stoilov 2000). It has been suggested that 
CYP1B1 gene is involved in the normal development and function of the eye by 
metabolising essential endogenous and exogenous molecules, including steroids and 
retinoids (Murray 2001). 
 
 
Table 2.3: Genes involved in anterior segment development 
Gene 
Symbol/loc
us 
Gene name Chromosomal 
location 
ASD  
humans 
Reference 
BMP4 and 7 (bone 
morphogenetic 
protein) 
14q22-q23 for 
BMP4 
Chr 20 locus 
for BMP7 
TGFβ Transforming 
growth factor 
beta super-
family 
TGFβ activin/nodal 
branch 
1q41 
 Chang et al 2001, 
 Gould et al 2004,  
Wordinger et al 2002, 
 Wordinger et al 2007  
PAX6 Paired box gene 6 11p13 Aniridia 
ARA/S 
Peters 
IH 
Hanson et al 1994, 
Axton et al 1997, 
Hanson et al 1999 
Riise et al 2001, 
Baulmann et al 2002, 
Nanjo et al 2004 
Chavaria-Soley et al 
2006a 
Dansault et al 2007 
FOXC1 
and 
FOXC2 
Winged-helix/fork head gene 1 and 2 6p25 /FOXC1 
16q24.3/ 
FOXC2 
IGDA/ 
ARA/S 
Peters 
ICG 
Walter et al 1996 
Jordan et al 1997 
Mirzayans et al 1997 
Nishimura et al 1998 
Ekong et al 2004 
FOXE3 Winged-helix/fork head gene 3 1p32 ASD 
Cataract 
Semina et al 2001, 
Valleix et al 2006 
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PITX2 Pair-like homeodomain transcription 
factor 2 
4q24 IGDA 
AXRA/S 
Peters 
Heon et al 1995, 
Semina et al 1996, 
Alward et al 1998 
PITX3 Pair-like homeodomain transcription 
factor 3 
10q25 ASD 
Posterior 
polar 
cataract 
Semina et al 1998, 
Addison et al 2005 
Sakazume et al 2007 
LMX1B Lim homeobox transcription factor 9q34.1 Nail-patella 
syndrome 
Lichter et al 1997, 
Mimiwati et al 2006, 
Milla et al  2007 
CYP1B1 
(GLC3A) 
Cytochrome P450, family 1, subfamily 
b, polypeptide 1 
2p22-21 ICG 
Peters 
Sarfarazi et al 1995, 
Stoilov et al 1997 
Colomb et al 2003 
Coca-Prados & 
Escribano 2007 
Tyr Tyrosinase 11q14-q21  Libby et al 2003, 
Bidinost et al 2006 
GLC3B  1p36 ICG Akarasu  et al 1996 
GLC3C  14q24.3 ICG Stoilov et al 2002b 
EYA1 Drosophila eyes absent gene 8q13.3 Peters 
ASD 
Azuma et al 2000 
CHED1 Congenital Hereditary endothelial 
dystrophy 
21p13 CHED  Toma et al 1995 
MAF Muscoloaponeurotic fibrosarcoma 
oncogene homolog 
16q23.2 Cataract 
Peters 
Jamieson et al 2002 
 
Since 1997 (Stoilov et al), numerous mutations of CYP1B1 have been characterized in 
ICG patients in different populations (Michels-Rautenstrauss et al 2001, Panicker et al 
2002, Belmouden et al 2002, Stoilov et al 2002, Colomb et al 2003, Sitorus et al 2003, 
Hollander et al 2006, Reddy et al 2004, Alfadhli et al 2006, El- Ashry et al 2007, 
Messina-Baas et al 2007). Chavarria-Soley et al (2006 b) investigated some CYP1B1 
mutations which appeared more often associated with ICG and established that eight 
CYP1B1 mutations were found more than once, each of them presenting one identical 
haplotype in different individuals, confirming a founder effect. 
 
Interestingly, studies by Bejjani et al (2002) and Doshi et al (2006)  analysing the 
expression patterns of Cyp1b1 in mice found that it was not expressed in the trabecular 
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meshwork but is confined anteriorly to the ciliary body and posteriorly to the retinal 
neuroepithelium and around the optic nerve, but not in the nerve itself. 
 
Coca-Prados and Escribano (2007) review the evidence for the CYP1B1 expression in 
the eye and the pathogenesis of CYP1B1 associated glaucoma.  They observe that 
CYP1B1 has a higher expression in the fetal eyes than in the adult eyes, suggesting that 
the ciliary epithelium has a role in the regulation of normal development of the anterior 
chamber of the eye, particularly TM, and in maintaining some critical function in the 
adult eye. Therefore, this would infer that abnormalities of the development of the TM 
in glaucoma associated with CYP1B1 mutation may result from the diminished or 
absent metabolism of important endogenous molecules (morphogens) in the ciliary 
epithelium due to non-functional CYP1B1 enzyme (Doshi et al 2006). 
 
Mutations in CYP1B1 cause structural and functional abnormalities of the protein. They 
produce loss of enzyme function by various mechanisms: promoting an incorrect 
insertion of the protein in the ER membrane; impairing correct folding and protein 
stability; modifying substrate binding and damaging the active centre. The loss of 
function CYP1B1 mutations can produce ICG, POAG (Melki et al 2004, Acharya et al 
2006, Lopez-Garrido et al 2006) and even Peter’s anomaly (Vincent et al 2001). 
 
Coca-Prados and Escribano (2007) speculate that homozygous or compound 
heterozygous carriers of CYP1B1 mutations could suffer during development a dramatic 
reduction in the overall CYP1B1 activity (below a normal threshold) in the tissues of 
anterior segment of the eye, which would produce severe malformation in the drainage 
angle of the eye, leading to ICG. However, heterozygous carriers of hypomorphic 
CYP1B1 alleles, in which the total enzymatic activity is close to being below a normal 
threshold, will end up with clinically undetectable developmental abnormalities of the 
ocular drainage structures. These abnormalities may contribute to an elevated IOP over 
time, leading to POAG. From this reasoning it follows that it is possible that 
heterozygous carriers of low inactive mutations might maintain the enzymatic activity 
above the critical threshold to give rise to a normal phenotype. The threshold hypothesis 
has been suggested as a general mechanism to explain the difficulties in correlating 
mutations with phenotypes in Mendelian disorders (Dipple and McCabe 2000). 
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Also to note is that CYP1B1 oxidises all-trans-retinol to all-trans-retinal, the rate-
limiting step for retinoic acid biosynthesis. The reason this is of interest is that retinoic 
acid receptor mutations causes anterior segment dysgeneses (Chen et al 2000)
 
and 
mutations in the gene investigated in this study –PITX2- is an important cause of 
Axenfeld Rieger Anomaly/Syndrome (ARA/S), another ASD entity. In addition, 
mutations in CYP1B1 have been identified in patients with Peter’s anomaly, which is 
another condition that belongs to anterior segment dysgenesis (Vincent et al 2001). 
 
As mentioned in the POAG chapter, in 2002, Vincent et al, showed that there is a strong 
variability of expression and allelic heterogeneity for MYOC and CYP1B1 mutations 
and that congenital glaucoma and juvenile glaucoma are allelic variants, at least in some 
cases. They suggest that MYOC and CYP1B1 may interact through a common pathway 
and that the inheritance of glaucoma may be multiallelic in some cases. Also to note is 
the identification of MYOC mutations in 3 ICG patients, who did not harbour any 
CYP1B1 mutation (Kaur et al 2005). 
 
Revealing the identity of the CYP1B1 substrate is one of the most interesting questions 
in glaucoma research, since it can direct us to as yet unknown biochemical cascade(s) 
controlling the terminal stages of anterior chamber angle development. 
To date, the genes responsible for GLC3B and GLC3C have not been identified. 
 
Although ICG is often considered to be fully penetrant, the disease shows only 50% 
penetrance in some Saudi Arabian families (Bejjani et al 2000).  A higher prevalence 
has been observed in genetically inbred population and in certain ethnic and religious 
groups in which parental consanguinity, especially cousin-cousin marriages, is 
common. ICG has been reported to occur more frequently in males than females and is 
reported to be bilateral in 70% to 80% of cases. Familial cases tend to have an equal sex 
distribution (Papadopoulos et al 2007). The familial segregation of the nonpenetrance 
suggests a genetic modifier. 
 
Prompted by these observations, mice were used to identify a modifier gene that alters 
the phenotype in Cyp1b1 mutant mice. Cyp1b1 mutant mice have focal angle 
abnormalities similar to the ICG patients, but do not develop increased IOP and 
glaucoma. This suggests that modifier genes interact with Cyp1b1 to exacerbate the 
angle anomalies and enhance the likelihood of glaucoma. Tyrosinase (Tyr – a rate 
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limiting enzyme in the pigment production pathway) has been identified as a potential 
modifier gene. Although, angle abnormalities were more severe in mice with mutant 
Cyp1b1 and mutant Tyr, increased IOP was still not present. When mice with mutations 
in Cyp1b1, Tyr and Foxc1 have been engineered, raised IOP has been noticed in some 
of the mice (Libby et al 2003, Gould et al 2004). The authors speculate that mutations in 
multiple genes that contribute to developmental glaucoma affect L-dopa levels. L-dopa 
levels may be altered in neural crest cells from which the angle structures and iris 
stroma derive. Another possibility is that mutations in glaucoma genes affect the 
activity of tyrosine hydroxylase (TH) which produce L-dopa from tyrosine. Some of the 
genes that cause anterior segment dysgenesis and/or developmental glaucoma can 
promote either TH expression or the proliferation of TH expressing neural crest cells 
during the development of other tissues (PITX2 and PITX3 induce TH expression – 
Lebel et al 2001, Gould et al 2004). The diagram in figure 3.2 suggests some of the 
pathways in which these genes can affect the L-dopa levels. 
 
 
Fig. 3.2: Multiple genes implicated in anterior segment development and glaucoma may modulate L-dopa 
levels. Many of the genes implicated in anterior segment dysgenesis, elevated IOP and glaucoma may 
affect L-dopa levels. Most can be linked to L-dopa through tyrosine hydroxylase (TH, as discussed in the 
text). The dark arrows represent known direct relationships. TCFAP2, PITX2 and PITX3 can all directly 
bind to the tyrosine hydroxylase promoter. The fainter arrows and text indicate that the represented genes 
affects on TH and L-dopa may not be direct. BMP4, PAX6 and LMX1B can promote either tyrosine 
hydroxylase expression or the number of TH expressing neural crest cells during the development of 
other tissues, but how they do so is not known. How L-dopa modulates angle development also is not 
known. It is possible that either L-dopa itself or a catecholamine metabolite(s) of L-Dopa mediates an 
important signalling event(s) (adapted from Gould et al 2004). 
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ASD and congenital glaucoma has been reported in some humans with albinism 
(Catalano et al 1988), but so far has been considered a coincidence. These findings 
suggest that Tyr may play a role in congenital glaucoma in humans, by affecting L-dopa 
levels and can open new avenues for a possible therapy for reducing the incidence of 
glaucoma in certain high risk families. 
However, when the effect of TYR as a modifier gene in patients with ICG with a known 
CYP1B1 mutation was studied, this hypothesis could not be proven (Bidinost et al 
2006). But because the mode of interaction between CYP1B1 and TYR is not known, a 
modifier effect of TYR on other CYP1B1 human mutations cannot be excluded. 
  
3.6.3 FOXC1 gene 
 
FOXC1 gene encodes a forkhead/winged helix transcription factor which belongs to a 
family of genes with a characteristic 100-aminoacid motif and it was originally 
identified in Drosophila (Pierrou et al 1994). Forkhead transcription factors have a 
characteristic forkhead and winged helix DNA- binding domain and are required for 
various developmental processes. FOXC1 and FOXC2 are expressed in the 
mesenchyme from which the ocular drainage structures derive (Smith et al 2000); also, 
Fox factors are important in establishment of the body axis and the development of 
tissues from all three germ layers. 
 
FOXC1 gene is sensitive to altered gene dosage, increase or decrease in the number of 
copies resulting in ocular anterior segment developmental defects, demonstrating that 
precise dosage is critical for normal eye development (Lehmann et al 2003a). 
 
FOXC1 shares coordinated function and overlapping tissue expression with FOXC2 
with 97% aminoacid identity across their forkhead (DNA binding) domains. FOXC2 
causes lymphoedema-distichiasis in human, while mutations in Foxc2 in mice cause 
iris, trabecular meshwork and iridocorneal angle anomalies (Smith et al 2000). This 
raises the possibility of an unrecognised role for FOXC2 in iris and trabecular 
meshwork development (Lehmann et al 2003a). 
 
Also it has been suggested that forkhead proteins might have one function during 
embryonic development and organogenesis, and a completely distinct function in adult, 
differentiated tissues (Lehmann et al 2003a) 
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The importance of the locus 6p25 for anterior segment dysgeneses can not be 
underestimated and although the FOXC1 gene has been linked to a number of diseases 
which may merely represent allelic disorders it are possible that there may be other 
candidate genes close to this locus. This is supported by Davies et al (1999), 
discovering a child with microphthalmia and corneal clouding and a number of other 
dysmorphic features, including hypertelorism, micrognathia, and limb, ear and heart 
defects. Although this child had an interstitial deletion of 6p25-p24, it did not include 
FOXC1 but did include AP2-ά which they suggest as a possible candidate gene. 
The chromosome 6p25 region has also been implicated in ICG as well as other ASD’s 
(Vincent et al 2001). The Iris Hypoplasia/IGDA locus was mapped to 6p25 by Walter et 
al (1996) and the linkage of    IGDA to 6p25 was confirmed by Mirzayans et al (1997). 
    
It is interesting to observe that Axenfeld-Rieger anomaly (Fuse et al 2007, Gould et al 
1997, Lehmann et al 2002, Mortermousque B 2004, Panicker et al 2002) and Iris 
Hypoplasia/IGDA have all been mapped to 6p25 which has been linked to the FOXC1 
gene (Nishimura et al 1998) who also report 2 ICG patients with chromosomal 
anomalies involving 6p25. 
 
Deletions in 6p were identified in an aniridic family and a Peter’s anomaly family 
(Levin et al 1986). In fact Axenfeld-Rieger anomaly, Iris Hypoplasia/IGDA may merely 
represent allelic disorders arising from mutations of the FOXC1 gene. In addition 
duplications and deletions of the 6p25 region including the FOXC1 gene have been 
identified with the clinical phenotypes (Lehmann et al 2000, Lehmann et al 2002). 
 
Cella et al (2006) assessed the frequency of PITX2, FOXC1, CYP1B1 and GJA1 genes 
in patients with AXRS with glaucoma and identified a polymorphism in GJA1 (gap 
junction protein, alpha 1) in a patient with FOXC1 mutation and therefore suggest the 
possibility of its participation as a modifier gene. 
Another gene belonging to the forkhead box family is FOXE3, located on chromosome 
1p32. Mutations in this gene have been found in a family with anterior segment 
dysgenesis and cataracts (Semina et al 2001) and also in congenital primary aphakia 
(Valleix et al 2006). 
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3.6.4 PITX2 gene 
 
Heon et al (1995)mapped IH/IGDS to 4q25, which is the same locus for Axenfeld-
Rieger syndrome and mutations were found by Alward et al (1998) in these patients 
affecting the same gene (PITX2) implicated in Axenfeld-Rieger syndrome. Walter et al 
(1996) studied the IGDS patients reported by Chisholm and Chudley (1983) and 
established that in the family with the extraocular abnormalities shared by Axenfeld-
Rieger Syndrome (maxillary hypoplasia with dental anomalies, inguinal hernia, 
redundant periumbilical skin and hypospadias in males) linkage was to the 4q25 region, 
the locus for the PITX2 gene. They also demonstrated that in the family without 
extraocular abnormalities reported by Pearce et al (1982) and Pearce et al (1983)  there 
was no linkage to 4q25. Mutations in PITX2 gene have also been reported by Kulak et 
al (1998). 
 
The progress in identifying the genetic changes underlying these conditions has made it 
clear that the clinical phenotypes of Axenfeld-Rieger and Iris Hypoplasia/IGDA 
syndrome result from the same underlying developmental abnormality. The range of 
variable features between these conditions probably reflects differences in genetic 
backgrounds between individuals and the effect of specific gene mutations within a 
given gene. In the future it is very likely that this situation will become more 
complicated as other loci are found and candidate genes within these regions are 
identified. 
PITX2 gene will be discussed in detail in chapter 4. 
 
3.6.5 PAX6 gene 
 
Hanson et al (1994) described a mutation of the PAX6 gene, on chromosome 11p13, in 
a family with Peter’s anomaly. PAX6 is a homeobox developmental gene expressed in 
different parts of the body including the developing eye and known to be the cause of 
many cases of aniridia (Axton et al 1997, Prosser and van Heyningen 1998, van 
Heyningen and Williamson 2002). 
 
PAX6 plays an important role in ocular development by regulating the expression of 
genes that are involved in embryogenesis of the eye. The level of protein production 
from both normal copies of a gene is required by some cellular processes. PAX6 gene is 
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one such paired-box gene, disruption of one copy of this gene reduces the protein 
product, termed ‘haploinsufficiency’, resulting in abnormal development possibly by 
altering the expression of other genes (Tang et al 1997). As shown above mutations in 
the same gene (PAX6) can produce extensive phenotypic variability (variable 
expressivity- Sale et al 2002, Gehring & Kazuho 1999). 
 
 Mutant phenotypes therefore include Axenfeld-Rieger, Peter’s anomaly and Aniridia 
from amongst the ASDs (Hanson et al 1994, Prosser & van Heyningen 1998, Riise et al 
2001). Within the same family, Hanson et al (1994) describe patients with PAX6 
mutations but with variable phenotypes including a Rieger type-ASD. Doward et al 
(1999) reported a mutation in PITX2 gene producing Peter’s anomaly and a number of 
extraocular associations, including failure of involution of the umbilical skin and signs 
of abnormal dental development and Dansault et al (2007) describe new mutations in 
PAX6 gene causing ophthalmic phenotype associated with neurodevelopmental 
abnormalities. Also, Edward et al (2004) report mutations in CYP1B1 which cause 
Peters anomaly in Saudi Arabia population. 
 
Zhou and Kochhar (2003), suggest that inhibition of retinoic acid (RA) signaling 
pathway by RA receptor antagonist influence the expression of AP-2 transcription 
factors (a family of RA responsive proteins), thus missregulating the neural crest cell 
differentiation by increased apoptosis in the developing eye, in vitamin A deficiency 
model. This can result in the absence of endothelium, accompanied by other anomalies 
of iris and anterior chamber, consistent with Peters Anomaly. 
 
3.6.6 LMX1B gene 
 
In a recent study, Milla E et al (2007) identified a mutation in the LMX1B gene in a 
family with nail-pattela syndrome with variable expression of OAG. LMX1B protein is 
a homeodomain protein, which are a family of transcription factors frequently involved 
in pattern formation during embryonic formation. Most of the mutation reported in this 
gene lead to the absence or inactivation of the homeodomain, resulting in a protein 
unable to recognize its target genes.  
 
The LMX1B transcription factor protein is involved in normal patterning of the 
dorsoventral axis of the embryo during development and early morphogenesis of 
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glomerular basement membrane. Further molecular and immunochemical studies 
showed the involvement of lmx1b in collagen regulation (Milla et al 2007). Therefore, 
the authors speculate that the collagen defects in the eye could be responsible for the 
presence of glaucoma. The LMX1B gene is also expressed in the TM and many other 
ocular anomalies have been sporadically associated with nail-pattela syndrome 
(microcornea, sclerocornea, congenital cataracts, iris processes and pigmentation of 
inner margin of the iris). However, none of these are a specific trait of this syndrome 
(Milla et al 2007). 
 
A study carried out by Park et al (2009) on 272 POAG patients, 37 NTG, 58 OHT and 
276 controls shows that LMX1B haplotypes influence susceptibility to glaucoma in the 
general population, suggesting altered LMX1B function predisposes to glaucomatous 
damage and that this role may be independent of raised intraocular pressure. 
 
3.6.7 TGFβ super-family genes 
 
Another group of genes implicated in anterior segment morphogenesis is the TGFβ 
superfamily of secreted molecules that influence a spectrum of biological processes, 
including pattern determination, cell proliferation and differentiation, cell death, bone 
morphogenesis and wound repair (Graham et al 1994, Mabie et al 1999). The TGFβ 
super-family is divided in two similar but separate branches: The BMP/GDF (bone 
morphogenetic protein/growth and differentiation factor) branch and the 
TGFβ/activin/nodal branch.  
 
Each branch works through extracellular ligand binding to a membrane bound receptor 
complex consisting of Type I and Type II serine/threonine kinase receptors. Ligand 
binding initiates cytoplasmic signal cascade that activate SMAD (also called MADH) 
proteins. SMAD proteins enter the nucleus where they associate with transcription 
factors and participate in transcriptional regulation of target genes (Chang et al 2001, 
Miyazono et al 2001). 
 
BMPs proteins are a large subclass (more than 20 members) and have been found to be 
expressed in multiple tissues during embryonic development, including heart, lung, 
kidney, brain and eye (Hogan 1996). In the eye, Bmp4 expression is first identified in 
the distal optic vesicle and overlying surface ectoderm (Furuta & Hogan 1998). 
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Subsequently, expression was found in iris, ciliary body, and retinal pigment 
epithelium, endothelial cells of conjunctiva, retina and orbit (Chang et al 2001). 
Although no expression of Bmp4 was demonstrated in TM and Schlemm canal, 
haploinsufficiency of Bmp4 in mice, causes iridocorneal angle abnormality (small or 
absent Schlemm canal, hypoplastic or absent TM and iris attachments to peripheral 
cornea, hypoplastic or malformed iris and occasionally ciliary body; peripheral corneal 
thinning with neovascularisation, anterior and posterior subcapsular cataract, persistence 
of anterior hyaloids vessels, increased IOP, retinal abnormalities). Although the above 
study did not demonstrate expression of Bmp4 in the TM, a study by Wordinger et al 
(2002), demonstrates expression of BMPs proteins (2,4,5,7), all three BMP receptors 
and inhibitory BMP associated proteins in cultured human TM and ONH cells.  
 
Changes demonstrated in Bmp4 haploinsufficient mice are similar to the anterior 
segment dysgenesis observed in humans and it may be a good candidate gene to be 
screened in AXRS patients. It appears that BMP4 influences TM morphogenesis by 
regulating extracellular matrix features (including composition and signalling) that are 
important for mesenchymal migration, differentiation and/or remodelling (Gould et al 
2004). 
 
A recent study by Fuchshofer et al (2007), demonstrates that BMP-7 strongly 
antagonises in vitro the TGFβ induced expression of a broad panel of molecules, which 
would result in accumulation of TM ECM in situ and it is reasonable to hypothesize that 
it has the same effect in vivo. Therefore, pharmacological modulation of BMP-7 
signalling in the TM might be a promising strategy to treat POAG. 
 
TGFβ2 is a signalling ligand involved in anterior segment development. The cornea of 
mice with TGFβ2-/- have reduced accumulation of ECM and are thin with densely 
packed keratocytes; the corneal endothelium fails to differentiates and an anterior 
chamber never forms (Saika et al 2001).  
 
Miyazono et al (2001) have demonstrated that the BMP4 and TGF β2 pathways 
converge and overlap. Members of the TGF β signalling superfamily are important for 
normal ocular development and therefore, any gene that influence the balance of 
TGFβ/BMP signalling are candidates to affect anterior segment development and 
glaucoma phenotype. Also, some studies on the effect of TGF β2 on human trabecular 
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meshwork suggests that TGF β2 reduce outflow facility by increasing ECM in TM and 
producing alteration in the cytoskelatal proteins of these cells in glaucomatous eyes 
(Fuchshofer et al 2003, Gottanka et al 2004, Zhao et al 2004, Wordinger et al 2007). 
Increased levels of TGF β2 increases the expression of αB crystalline (Welge-Lussen et 
al 1999) and MYOC (Tamm et al 1999), and in the astrocytes of the optic nerve 
increases expression of fibronectin, type I collagen, tissue transglutaminase and 
plasminogen activator inhibitor as well as collagen type IV, which correspond with 
changes seen in glaucomatous eyes (Fuchshofer et al 2005). However, a study screening 
for TGFβ1 polymorphism in Indian patients with POAG have not found an association 
(Sripriya et al 2007). 
 
3.6.8 CHED genetics 
 
  Congenital Hereditary Endothelial Dystrophy (CHED) has been described as having 
autosomal dominant (CHED 1) and autosomal recessive (CHED 2) forms – with the 
recessive form being more severe and having an earlier age of presentation. Kirkness et 
al (1987) and Pearce et al (1969)
  
reported large pedigrees with AD inheritance. One of 
these families underwent linkage and a locus was found on chromosome 20. 
Interestingly, Toma et al (1995) analysed the evidence on cytogenetic location markers 
used in the mapping CHED and Posterior polymorphous corneal dystrophy and 
concluded that both loci were in the pericentric region of chromosome 20 i.e. 20p11.2-
q11.2. CHED1 has been mapped to 20p13.In 2004, Mintz-Hittner et al described a 
mutation in VSX1 (RINX) gene, located at 20p11.2 in a family with craniofacial 
anomalies, empty sella, corneal endothelial changes (CHED 1) and abnormal retinal and 
auditory bipolar cells. 
 
3.6.9 Axenfeld Rieger Syndrome genetics 
 
Autosomal dominant inheritance has been identified in Axenfeld-Rieger anomaly and 
syndrome for many years (Semina et al 1996). There is considerable genetic 
heterogeneity of Axenfeld-Rieger as suggested by affected individuals having a variety 
of chromosomal abnormalities, which include deletions of chromosomes 4, (Flomen et 
al 1998) and chromosome 13 (Phillips et al 1996) and the failure to find linkage to 4q25 
in one pedigree by Legius et al (1994). Deletion of 13q14 was described in 2 cases 
(Akazawa et al 1981 and Stathacopoulos et al 1987). 
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It is thought that there may be a number of genes that can cause Axenfeld-Rieger 
syndrome as a variety of chromosomal abnormalities have been reported to give rise to 
the classic features in addition to the 4q25 (sometimes referred to as Rieger syndrome 
Type 1 or RIEG1) and 13q14 (sometimes referred in the literature as RIEG2 or Rieger 
syndrome Type 2) loci (Gould et al 1997). 
Using linkage analysis, loci have been found for Axenfeld-Rieger on chromosomes 
4q25 (Murray et al 1992, Sarfarazi et al 1997), 6p25 (Gould et al 1997, Honkanen et al 
2003, Saleem et al 2003), 13q14(Philips et l 1996) and another potential locus for a 
candidate gene at 16q24 is being investigated (Ferguson & Hicks 1987, Smith et al 
2000). 
 
Semina et al (1996) cloned the PITX2 gene (originally called RIEG1 gene) from the 
4q25 region and identified six mutations in affected individuals. They also report a 
strong homology between the human (PITX2) and mouse (Pitx2) gene. This is important 
as mouse Pitx2 mRNA has been localised in the periocular mesenchyme, maxillary and 
mandibular epithelia, umbilicus, Rathke pouch and limb mesenchyme of the mouse - 
consistent with the sites of some of the abnormalities in ARS. The PITX2 gene is a 
member of the homeobox transcription gene family and appears to play an important 
role in embryogenesis. Homeobox genes are conserved throughout the animal kingdom 
and play a fundamental role in the genetic control of body patterning and development.  
 
PITX2 and DLX2 are transcription markers observed during early tooth development. 
Espinoza et al (2002) and Cox et al (2002) demonstrated that PITX2 binds to bicoid and 
bicoid-like elements in the DLX2 promoter and activates this promoter 30 fold in 
hamster ovary cells. They have shown that different PITX2 mutations have varying 
abilities to transactivate the DLX2 promoter and therefore different mutations can lead 
to residual activity of the mutant. The result is that certain ARS phenotypes may be less 
severe as DLX2 expression is required for tooth and craniofacial development. 
 
Physical or functional haploinsufficiency of PITX2 has been shown by Flomen et al 
(1998) as being the pathogenic mechanism for AXRS. They demonstrated that the 
syndrome can result from the haploid, whole gene deletion of PITX2 but also from a 
translocation break upstream from the gene. They suggest that there may be key 
regulatory region upstream important for the homeobox gene expression.  
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Kozlowski et al (2000) and Walter et al (2003) with recombinant techniques and 
transactivation studies demonstrated reduced activity of certain PITX2 mutations. They 
were able to show that those mutant PITX2 proteins that retained partial function result 
in milder anterior segment abnormalities where as non-functional mutant proteins 
produced ARS. Increasing use of mutational and functional analyses is yielding a 
greater insight into the pathogenesis of PITX2 and as more loci are investigated, the 
potential of discovering new causative genes or regulatory factors becomes a real 
possibility (Priston et al 2001, Saadi et al 2003). 
 
As described above the FOXC1 gene, a member of the forkhead/winged-helix 
transcription factor family, at 6p25 is particularly linked with Axenfeld-Rieger 
Anomaly (ARA) and it had been considered that mutations at 6p25 were not associated 
with extraocular phenotypes in the way that PITX2 is. Mirzayans et al (2000) have 
shown that ARS can result from mutations of FOXC1. Mutations in FOXC1, ranging 
from single missense mutations to null defects have been identified in patients 
suggesting haploinsufficiency accounts for this phenotype as well (Mears et al 1997, 
Mirzayans et al 1997, Nishimura et al 1998, Lehmann et al 2002, Komatireddy et al 
2003, Saleem et al 2003b).  
 
Mears et al (1997) excluded FOXC1 mutations in two families with ARA but with 
linkage to 6p25, which could suggest another gene at this locus. However, Lehmann et 
al (2000 and 2002) and Nishimura et al (1998 and 2001) have reported chromosomal 
duplication of the 6p25 region in patients as a possible alternative explanation to 
another gene at that locus. 
 
It seems likely that PITX2 and FOXC1 play equal important roles in the development of 
the eye, given that mutations of either gene produce virtually identical phenotypes 
(Lines et al 2002). 
 
Also, to note is that Riise et al (2001) reported an 8 year old girl with ARS who was 
found to have a small deletion of PAX6. 
 
Linkage analysis and chromosomal rearrangements indicate the presence of additional 
Axenfeld-Rieger malformation loci at 13q14 and 16q24 (Lines et al 2002), that remain 
to be cloned ( Ferguson et al 1987, Phillips et al 1996).  
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FOXC2 has been considered as a candidate gene; however mutations in this gene appear 
to produce lymphoedema- distichiasis syndrome rather than Axenfeld-Rieger 
malformations (Fang et al 2000). 
 
Also, a second relevant candidate gene has been identified at 16q. Mutation of the MAF 
transcription factor gene on 16q23.2 causes cataract, corneal opacity and microcornea, 
iris coloboma and anterior segment dysgenesis (Jamieson et al 2002). MAF is expressed 
in surface ectodermal component of the embryonic eye (lens placode and vesicle), 
suggesting a lens specific signalling defect blocking anterior chamber formation and 
may account for a proportion of AR malformation. 
 
Azuma et al (2000) have reported three missense mutations of the EYA1 (drosophila 
eyes absent) gene in patients who had congenital cataract and ocular anterior segment 
anomalies and the authors suggest that this gene, which initially was thought not to be 
involved in eye morphogenesis in humans warrants further investigation in patients with 
anterior segment anomalies. 
 
3.6.10 Summary of literature review 
 
The exact mechanism of these genes in POAG susceptibility remains unknown. It is still  
controversial as to whether the inheritance pattern of POAG is a simple monogenic 
inheritance or a complex polygenic inheritance. It could well be that variable 
expressivity, reduced penetrance or even phenotypic alteration by genetic modifiers 
(where certain mutations may only cause disease when present in a susceptible genetic 
context as in OPTN mutations) may confound genotypic-to-phenotypic associations and 
make it difficult to ascertain a monogenic inheritance.  
On the other hand, there is evidence to suggest that glaucoma may be affected by 
multiple interacting genes (APOE, MYOC, CYP1B1, TNF, OPTN) and that has been 
extensively discussed in chapter 3.3.7.  Evidence to further support the polygenetic 
inheritance of POAG include type II diabetes mellitus and steroid responsiveness from 
endogenous steroids (i.e. stress) and pharmacologic steroids increasing the risk of 
glaucoma (Zhang et al 2005, Pasquale et al 2006). 
 
Current evidence reveals only a small proportion of POAG exhibit Mendelian 
inheritance as demonstrated by the known POAG genes (MYOC, OPTN, WDR36) 
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accounting together for 10% of all POAG patients. It remains to be proven whether 
variants of several genes, each contributing small effects in a given individual increase 
the risk for developing POAG (Fan et al 2005), or whether there exist a single locus of 
large effect. 
 
Genes in which mutations causes anterior segment anomalies and glaucoma are strong 
candidates for glaucoma susceptibility genes in a wider population. As emphasised 
above, several gene loci for these developmental glaucoma have been identified (PITX2, 
FOXC1, PAX6, LMX1B, 6p25, 13q14). These genes may contribute to glaucoma more 
frequently than expected and possibly play an important role in the common forms of 
POAG. The fact that around 1-2% of individuals who are 40 years of age in the general 
population develop POAG (Sheldrick et al 1994 ), compared with 33-75% of patients 
who have mutations in the developmental glaucoma genes (Strungaru et al 2007), 
suggests that these genes are very good candidate risk factors. Mutational and functional 
analysis of their function promises to shed light on the underlying developmental 
mechanisms and may help in the understanding of pathogenesis of the prevalent adult 
onset glaucoma. 
 
Identification of the gene defects which cause glaucoma will provide improved 
understanding of glaucoma pathogenesis. Research into genotype-phenotype relations in 
families will be necessary even after the identification of disease causing genetic 
defects, to study possible modifier genes or environmental factors influencing their 
expression. It may also advance the development of genetic screening as a diagnostic 
test for at risk individuals. POAG is asymptomatic until significant, irreversible sight 
loss has occurred, so reliable testing and early treatment are of paramount importance if 
blindness from the disease is to be reduced. 
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                  Chapter 4: PITX2 GENE 
 
4.1 INTRODUCTION 
 
Paired like homeodomain transcription factor 2 (PITX2) mutation causes a range of 
anterior segment dysgeneses some of which are associated with dental and umbilical 
anomalies (collectively termed Axenfeld- Rieger syndrome), in which 50% of patients 
develop glaucoma (Alward  2000, Amendt et al 2000). 
 
An important part of this project focuses on the PITX2 which belongs to homeobox 
gene family. 
 
4.2 HOMEOBOX GENES STRUCTURE  
 
Homeobox genes belong to a gene family encoding products with large, highly 
conserved domains. A homeodomain is an evolutionarily conserved region found in 
many DNA-binding transcription factors that control biological processes such as cell 
type specification, embryonic pattern formation and determination of cell fate 
(McGinnis & Krumlauf 1992, Krumlauf 1992, Gehring et al 1994). 
 
The homeobox encodes a 60 amino acid residue polypeptide, called the homeodomain 
that represents the DNA-binding domain of the respective proteins. The homeodomain 
proteins have been also found in metazoan, fungi and plants and in the course of 
evolution, the amino acid sequence of the homeodomain has been conserved to a high 
degree, indicating a strong evolutionary pressure to preserve the amino acid sequence of 
the homeodomain (Gehring et al 1994). 
 
The homeodomain is responsible for recognising specific DNA sequences to bring the 
transcription factors to proper target genes. 
 
The three dimensional structure of the homeodomain has been elucidated by Gehring et 
al (1994).The 60-amino acid domain is composed of three helices and a flexible amino-
terminal arm (figure 4.1). The helices are folded into a tight globular structure: helix I is 
preceded by a flexible N-terminal arm and separated by a loop from helix II, which 
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forms with helix III a helix-turn-helix motif, which appears to be highly conserved 
among otherwise different species.  
 
The DNA - binding specificity of a homeodomain is determined primarily by its third 
helix, called the recognition helix, which inserts itself into the major groove of the 
recognition site. In addition the flexible amino-terminal arm wraps around DNA and 
makes specific contacts in the minor groove. The second helix of the homeodomain also 
makes backbone contacts, further contributing to specific homeodomain – DNA 
interactions. 
 
 The recognition sites for most homeodomains have a common 5’-TAAT-3’ core, which 
is followed by two residues that confer differential binding specificity. It has been 
proposed that the 9th position of the recognition helix (the 50th position of the 
homeodomain) plays a critical role in differential DNA recognition (Treisman et al 
1989, Treisman et al 1992). 
 
Genetic experiments indicate that the N-terminal arm of the homeodomain contributes 
significantly to the functional specificity of the homeodomain proteins (Gehring et al 
1994). Also, the DNA binding specificity and functional activity of homeodomain 
proteins depends upon combinatorial interactions with other transcription factors. These 
interactions may occur between free proteins in solutions or alternatively when the 
proteins are bound to the DNA (Gehring et al 1994). 
 
4.3 PITX2 GENE TISSUE EXPRESSION AND FUNCTION 
 
PITX2 gene (OMIM 601542) was isolated from within a cosmid contig (the goal of 
physical mapping is to produce a set of overlapping clones that encompass an entire 
chromosome or an entire genome. Sequence-tagged sites are particularly useful in 
aligning overlapping cosmids (vectors) into contigs (contiguous DNA material). As 
more clones are characterized, contigs grow to the size of entire 
chromosomes/http://www.ncbi.nlm.nih.gov/books/) encompassing two Rieger 
syndrome translocations at chromosome 4q25. The initial name designated by Semina 
et al (1996) was RIEG1, and the protein it encodes was called solurshin. 
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Solurshin is a 271 amino acid protein (33 kDa) showing sequence identity with the 
bicoid class of homeodomain proteins. These genes encode transcription factors which 
regulate tissue specific gene expression by binding to regulatory DNA sequences via 
their 60 amino acid homeodomain (Gehring et al 1994, Semina et al 1996). 
 
By in situ hybridization experiments, Semina et al (1996) showed that in mouse 
embryos Rieg/Pitx2 mRNA localizes in the periocular mesenchyme, maxillary and 
mandibular epithelia and umbilicus, which is consistent with the anomalies 
characteristic of Rieger syndrome. Expression persist in the mesenchyme and in the 
presumptive corneal stroma at E13.5 and by E18.5 Pitx2 expression is restricted to iris 
and iridocorneal angle (Hjalt et al 2000).This expression pattern is very similar to 
expression patterns of Foxc1 and Foxc2. Homozygous null mutant Pitx2 mice die by 
E15.5 (Lin et al 1999). At this stage, these mice have thickened, undifferentiated 
corneas that do not develop corneal endothelium or anterior chambers (Gage et al 1999, 
Lu et al 1999) similar to the eyes of Tgfb or Foxc1 knockout mice. Similar to humans 
with PITX2 mutations, heterozygote Pitx2 mice have variable degrees of ASD (Gage et 
al 1999). 
 
Also, the gene was expressed in the Rathke pouch, vitelline vessels and limb 
mesenchyme. Because of expression of the gene in Rathke pouch, it was suggested that 
the gene might play a role in anterior pituitary gland development. 
 
Further studies on mice by Gage and Camper (1997) proved the importance of the gene 
in differentiation and proliferation of the thyrotrope, somatotrope and lactotrope 
lineages, and designated the gene as Pitx2. 
 
Subsequently, it has been demonstrated that Pitx2 is asymmetrically expressed in lateral 
plate mesoderm and appears to exert critical roles in left-right situs (Kitamura et al 
1999, Logan et al 1998, Piedra et al 1998, Ryan et al 1998, Yoshioka et al 1998, Hjalt et 
al 2000).  
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Figure 4.1: Three dimensional structure of the homeodomain (adapted from: 
www.cbt.ki.se/groups/tbu/homeo/antp2) 
 
Franco and Campione (2003) suggest that altered left-right signalling due to impaired 
function of PITX2 underlies the aetiologies of several common congenital cardiac 
malformations. Also, Pitx2 has been found to be expressed in terminally differentiated 
neurons of the zona limitans intrathalamica and mammillary region and in gama-
aminobutyric acid (GABA) – producing neurons of the zona incerta and superior 
colliculus (Martin et al 2002 and 2004). 
 
Viera et al (2006) and Evans & Gage (2005) demonstrated that PITX2 is expressed in 
the human embryonic and foetal periocular mesenchyme at early developmental stages 
and it is well established that periocular mesenchyme makes a major contribution to the 
development of ocular anterior segment structures.  
 
Furthermore, significant PITX2 expression in the human developing ciliary body, ciliary 
processes, iridocorneal angle and corneal endothelium has been demonstrated by the 
same group and this provides a strong molecular basis for explaining the frequent 
occurrence of glaucoma in patients with ARS. Also, transfection of a dominant negative 
RhoA (Rhodopsin A protein, which belongs to the GTP-ase superfamily) mutant into 
perfused human anterior segment cultures increases aqueous outflow facility, 
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suggesting that PITX2 may be essential for intraocular pressure homeostasis in the 
prevention of glaucoma (Vittitow et al 2002). 
 
Gage et al (1999) have assessed the requirements or Pitx2 for the development of 
multiple organs and established that Pitx2 is required in a dosage-sensitive manner. 
Also, Diehl et al (2006) have demonstrated that Pitx2 gene dose regulates both 
morphogenesis and gene expression in developing extraocular muscles. The expression 
of key muscle specific transcription factor genes is regulated by Pitx2 gene dose, 
suggesting that sufficient levels of PITX2 protein are essential for early initiation of the 
myogenic regulatory cascade in extraocular muscles.  
 
The fact that other transcription factors (Foxc1, Tgfb) act in a dosage sensitive manner, 
demonstrates the importance of a narrow range of activity of various transcription 
factors for normal anterior segment development and reflects a delicate balance of 
signalling by interacting pathways (Gould et al 2004). 
 
There is evidence that Pitx2 is at least partly controlled by TGFβ superfamily signalling. 
Multiple studies show that TGFβ super-family member, NODAL, can induce Pitx2 
expression (Logan et al 1998, Piedra et al 1998). Pitx2 has a NODAL response element 
in its promoter and mice deficient for NODAL receptor have phenotypes very similar to 
mice deficient for Pitx2 (Lin et 1999, Lu et al 1999). 
 
Procollagen lysyl hydroxylase (Plod) genes are potential downstream targets for PITX2. 
The promoter regions of PLOD1 and Plod2 have multiple PITX2 binding sites. PLOD1 
and PLOD2 belong to a family of enzymes responsible for hydroxylating lysine 
residues in collagens. Hydroxylysine residues provide stability to intermolecular 
collagen cross-links (Kiviriko and Myllyla 1985). Therefore, disturbances of ECM 
stability and function may underline PITX2 phenotypes (Gould et al 2004) 
 
4.4 PITX2 STRUCTURE 
 
The PITX2 gene consists of six exons and so far there are four major isoforms identified 
- PITX2A to D- figure 3.2 (Semina et al 1996, Gage and Camper 1997, Kitamura et al 
1999, Cox et al 2002). 
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PITX2A and PITX2B are generated by alternative splicing mechanism and PITX2C and 
D uses an alternative promoter located upstream of exon 4. All isoforms contain 
dissimilar N-terminal domains, whereas the homeodomain and C-terminal domains are 
identical. The C-terminal domain contains a highly conserved 14-amino acid region 
described in the homeobox genes Otp, aristaless and rax which is called the OAR (Otp, 
aristaless, rax) domain.  
 
Cox et al (2002), who identified the fourth (PITX2D) isoform, have investigated the 
regulation of gene expression by PITX2 isoforms. 
 
This study, provide evidence that PITX2 isoforms differentially activate genes involved 
in development (Procollagen lysyl hydroxylase -PLOD1, Dlx2 and Prolactin 
Promoters) and that PITX2A, B and C isoforms have different transcriptional activities 
that are promoter-dependent. PITX2D isoform is generated by the PITX2C alternative 
promoter and differential splicing, and appears to be present only in humans. The 
PITX2D isoform acts to down regulate the transcriptional activities of PITX2A and 
PITX2C. Because the major PITX2 isoforms only differentiate in their N termini, they 
speculate that the N terminus must play a role in the differential transcriptional activities 
of these isoforms. 
 
Protein kinase C has been found to regulate the transactivating capacity of PITX2, and a 
C-terminal mutation affects phosphorilation (Espinoza et al 2005). There are several 
downstream transcriptional target genes suggested for PITX2 in different organs (PRL, 
PROP1, HESX1 and LHX3 in pituitary,PLOD1 in eye, TRIO in HeLa cells, DLX2, 
FGF8,BMP4 in tooth, ANF/NPPA in heart and CYCD2 in pituitary and heart – Hjalt and 
Semina 2005). 
 
Amendt et al (1999) investigated the role of Pitx2 homeodomain protein C-terminal tail 
and concluded that the C-terminal tail intrinsically inhibits the Pitx2 protein and that 
inhibition can be overcome by interaction with other transcription factors to allow 
activation during development. Work done by Kioussi et al (2002) and Wei et al (2002), 
places PITX2 in a signalling cascade that appears to modulate cell proliferation, 
differentiation and morphogenesis. Also, a study by Footz et al (2009), analysing the 
functional role of the C-terminal region of PITX2 and assessing the effect of previously 
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uncharacterized PITX2 missense mutations concludes that stringent control of PITX2 is 
required for normal ocular development and function. 
 
 
 
Figure 4.2: PITX2 major isoforms found in humans (adapted from Cox et al, 2002). 
 
 
4.5 PITX2 MUTATIONS 
 
Numerous mutations have been reported in PITX2, producing a continuum of clinical 
phenotypes, including ARS, IGD and IH, as well as rarer cases of Peters’ like anomaly 
(table 4.1 and figure 4.3). 
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Table 4.1: Mutation identified in PITX2 gene causing ocular phenotypes 
Nucleotide & protein 
change 
Effect on protein function Phenotype Reference 
Missense mutations    
Arg53Pro/ R53P 
 
 ARS Kozlowski and Walter 
2000 
C744T>A/ L54Q 
(1st helix of HD) 
Unable to bind DNA and 
deficient transactivation 
ARS Semina et al 1996, Amendt 
et al 1998 
C785A>C/ T68P 
(2nd helix HD) 
Unable to bind DNA and 
deficient transactivation. 
Pitx2 cannot transactivate 
dlx2 promoter leading to 
abnormal tooth 
development 
ARS Semina et al 1996, Amendt 
et al 1998 
Kozlowski and Walter 
2000 
C855G>C/ R91P 
(3rd helix HD) 
 ARS Semina et al 1996 
Arg46Trp 
C>T/ R84W/ HD 
Reduced DNA binding and 
transactivation. Dlx2 
promoter can be activated 
IH Alward et al 1998, 
Kozlowski and Walter 
2000 
789G>A/ R70H 
(position 31HD/ 2nd 
helix) 
Reduced DNA binding 
activity 
IGD Kulak et al 1998 
Arg31His/ R31H 
HD 
 IGDS Kozlowski and Walter 
2000 
Leu16Gln/ L16Q 
HD 
 ARS Kozlowski and Walter 
2000 
Lys88Glu/ K88E 
HD 
Defective DNA binding 
and transactivation, but has 
a dominant negative effect 
on wild-type protein 
ARS Perveen et al 2000, Saadi et 
al 2001 
851C>T/ R90C/HD  ARS Perveen et al 2000 
c.852G>C/ R90P   Phillips et al 2002 
c.896C>G/ L105V   Phillips et al 2002 
c.906A>C/ N108T   Phillips et al 2002 
c.744C>T/ P64L  ARS+ sella 
turcica 
anomaly 
Phillips et al 2002, 
Weisschuh et al 2006 
Meyer-Marcotty et al 2008 
c.710C>T/R43W  ARS Idrees et al 2006b 
c.744C>G/P64R  ARS Weisschuh et al 2006 
Gly137Val  ARS+ Fuchs’ 
ED 
Kniestedt et al 2006 
753C>G/F58L  ARS Vieira et al 2006 
742C>G/E55X  ARS Vieira et al 2006 
942C>A/Y121X  ARS Vieira et al 2006 
649C>A/Pro217Thr  Peters & 
PHPV 
Arikawa et al 2009 
Nonsense    
C981G>A W133X  ARS Semina et al 1996 
c.830G>C/ V83L       ARS Priston et al 2001 
IVS3(-1) G>T 
-1 position of the 3’ ss 
associated with exon 4 
 ARS Lines et al 2004, Maciolek 
et al 2006 
W133Stop Gain of function: increased 
DNA binding, 
transactivation and 
dimerization 
ARS Saadi et al 2006 
Splice-site mutations    
IVS3(-2)A>C  Peters Doward et al 1999 
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IVS3 (-11)A>G 
3rd intron (additional 
acceptor site, 5’ from 
normal one)splice site 
Protein with truncated HD 
is expressed at same levels 
as wild type protein 
ARS Semina et al 1996, 
Borges et al 2002 
IVS3(+5) G>C/ 
conserved position +5 of 
the 5’ splice site 3rd 
intron 
Poorly expressed truncated 
protein 
ARS Semina et al 1996, 
Maciolek et al 2006 
IVS3(-2)/ A>T  ARS Perveen et al 2000 
IVS2(-1)/ G>C  ARS Perveen et al 2000 
Deletions/insertions    
c.1272 del G 1-bp del 
exon 3/pos690/ 
Premature termination of 
PITX2 protein 
 ARS Borges et al 2002 
g.del 114/ 
exon 3/c697delG/ 
Frameshift(/large 
nonsense peptide 114 aa 
encoded) 
 ARS Lines et al 2004 
c.del 416/  
998delC/ frameshift 
from T139 onwards, 
encoding 15 mutant 
residues followed by 
premature stop codon 
 ARS Lines et al 2004 
c.del 366/959delC Frameshift( change in 
codon 122) D122FS 
ARS Saadi et al 2006 
c.717-720delACTT   Wang et al 2003 
c.1261delT   Brooks et al 2004 
1251 ins (CGA CTC 
CT) 
 ARS Vieira et al 2006 
g.20913G>T/G137V  ARS Kniestedt et al 2006 
Intragenic del/18,183 to 
21,242 del/end exon5, 
intron 6, part exon 6/ 
144 nc lost from HB 
  de la Houssaye 2006 
C ins 1083  ARS Perveen et al 2000 
A del 939  ARS Perveen et al 2000 
1235-1236 TA>AAG  ARS Perveen et al 2000 
AA del 868-869  ARS Perveen et al 2000 
7aaDup/c713-733dupl/7 
amino acids duplication 
of residue 6-12 Hd 
 ARS Priston et al 2001 
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Figure 4.3: Diagram of the PITX2A gene demonstrating all ocular phenotypes causing mutations in human reported to date (Vaideanu 2007) 
 
 
782566 
758031 
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Exon 1 
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39 98 
Legend: 
• black arrow – missense mutation 
• red diamond – nonsense mutation 
• black oval – splice mutation 
• ATG – translation starts 
• TGA – stop codon 
• Blue box - homeodomain 
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Although some mutations results in gain of function (Priston et al 2001, Saadi et al 
2001, Holmberg et al 2004, Saadi et al 2006), the majority of mutations cause 
deficiency of the normal PITX2 protein (haploinsufficiency). This is supported by the 
presence of large deletions that include PITX2 in some ARA/S patients and functional 
studies of proteins derived from mutant alleles (Maciolek et al 2006). Holmberg et al 
(2004), suggest a model for gain-or-loss-of-function in ARS (figure 4.4) 
 
 
 
 
 
Figure 4.4: Model for gain-or loss-of-function in Rieger syndrome 
 
 Known heterozygous defects in the PITX2 gene can cause eye disorders. The human 
and mouse homozygotes are early embryonic lethal. These mice develop hypertrophic 
corneas. Heterozygous mice develop phenotypes resembling human patients, even the 
hypomorphic variants, with PITX2 expression levels between heterozygous and normal. 
The Rieger-syndrome-causing mutation V45L elevates PITX2 transactivating activity. 
The Pitx2 mutant mice overexpress PITX2 in the cornea and iris, resulting in 
hypertrophic corneas like the mouse Pitx2 homozygotes, and Rieger syndrome-like 
effects including irido-corneal adhesions and retinal degeneration/glaucoma (adapted 
from Holmberg et al, 2004) 
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A correlation between the dosage of normal PITX2 protein and the severity of 
phenotype has been noted (Kozlowski and Walter 2000, Priston et al 2001, Saadi et al 
2001, Espinoza et al 2002). It can be observed that most of the human PITX2 mutations 
described thus far affect the region encoding the homeodomain or C-terminal domains, 
with only a few intronic mutations reported (table 4.1). 
 
4.6 GENE – GENE INTERACTION 
 
 PITX2 has been reported to function as a negative regulator for FOXC1 transactivation 
activity with its homeodomain (Berry et al 2006). It appears that the amounts of the 
PITX2 and FOXC1 genes expressed are crucial for triggering developmental or 
oncogenic abnormalities.  
It may be that protein interactions may explain the strict dosage sensitivity of PITX2 
and FOXC1: PITX2-PITX2 and PITX2-FOXC1 complexes may form in a concentration 
and/or cofactor dependent fashion and changes in the expression of either gene may 
alter the relative abundance of either complex.  
 
Depending on the cellular context, genetic alterations of FOXC1 or PITX2 could result 
in the loss of transcriptional activation or the loss of transcriptional repression of target 
gene activity (Berry et al 2006). Identification of target genes regulated by PITX2 and 
FOXC1 will enable further understanding of the underlying ARA/S pathology. 
 
In their review of anterior segment development relevant to glaucoma, Gould et al 
(2004), suggest a model for multiple genes interaction implicated in anterior segment 
development (figure 3.2). The diagram has been presented in chapter 3.6.2. 
 
4.7 PHENOTYPES CAUSED BY PITX2 MUTATIONS 
 
The eye phenotypes caused by mutations in PITX2 range from iris hypoplasia/ IGDA to 
ARA/S and have been discussed in previous chapters (Anterior segment dysgeneses and 
Developmental glaucoma genetics chapters) and therefore will not be discussed here 
again. 
 
However, it has to be mentioned that it was noted that in general ARS patients who 
display defects in other organ systems, such as teeth and umbilicus, have mutations of 
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the PITX2 gene, while in patients with isolated ASD, mainly FOXC1 mutations are 
detected. So far, no obvious correlation has been noted between the localization of a 
mutation in the PITX2 gene and the severity of the phenotype. Tumer and Bach-Holm 
(2009) in their excellent review of Axenfeld Rieger and spectrum of PITX2 and FOXC1 
mutation give the example of two consecutive missense mutations within HD, which 
lead to ARS and IH respectively. Subsequent functional studies demonstrated that one 
mutation was gain of function (resulting in a milder phenotype) and the other was loss 
of function, resulting in a more severe phenotype. 
Also, in a study published in 2007, Strungaru et al, examined genotype-phenotype 
correlations in 126 patients with ARS and found that 75% of the patients in this study 
had glaucoma that had developed in adolescence or early adulthood. Glaucoma in only 
18% of the patients with either PITX2 or FOXC1 genetic defects responded to medical 
or surgical treatment (used solely or in combination). They concluded that patients with 
FOXC1 mutations have the mildest prognosis for glaucoma development, whereas 
patients with PITX2 defects and patients with FOXC1 duplication have a more severe 
prognosis for glaucoma development. In this study, current medical therapies do not 
successfully lower intraocular pressure or prevent progression of glaucoma in patients 
with ARS who have FOXC1 or PITX2 alterations.  
4.8 PHENOTYPIC FEATURES OF Pitx2 KNOCKOUT MICE 
Homozygous null mutant mice of Pitx2, exhibit septal and valve defects, single atrium, 
abnormal cardiac positioning, pulmonary isomerism, omphalocele, early arrest in 
pituitary development, defect in tooth organogenesis, defective development of the 
mandibular and maxillary facial prominence and multiple eye defects (Gage et al 1999, 
Lin et al 1999, Lu et al 1999). 
Heterozygote Pitx2 mice have thinning of the ventral body, small body size, eye and 
tooth defects as described in some studies (Gage et al 1999, Lin et al 1999), whereas in 
other studies they do not show obvious haploinsufficiency phenotypes (Lu). Over 
expression of Pitx2 in mouse corneal mesenchyme and iris results in corneal 
opacification, corneal hypertrophy, irido-corneal adhesions and severely degenerated 
retina (Holmberg et al 2004). 
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4.9 MOLECULAR PATHWAY ARS 
 
Local control of cell signalling activity and integration of inputs from multiple 
signalling pathways are central for normal development but the underlying mechanisms 
remain poorly understood. 
In their review of molecular understanding of ARS, Hjalt and Semina (2005), suggest 
an upstream regulatory pathway for PITX2, demonstrated in figure 4.5.  
 
As seen in figure 4.5, there are at least two major regulatory pathways identified 
upstream of PITX2: the Wnt-β-catenin-Pitx2-CyclinD2 and the Nodal-Shh-Lefty2-Pitx2 
pathways.  
 
 Also, multiple direct downstream target genes of Pitx2 have been identified from many 
different functional groups: transcription factors, cell-cycle control proteins, growth 
factors, morphogens and modifying enzymes of extracellular matrix proteins. It is yet 
not known how nor if these pathways interact or if there are additional regulatory 
pathways upstream of Pitx2.  
 
However, it is almost certain that continuing research is going to add new levels of 
complexity to what we already know about PITX2 gene. 
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Figure 4.5: Upstream regulatory pathway for Pitx2 (adapted from Hjalt and Semina: Current molecular 
understanding of Axenfeld-Rieger syndrome (2005)/ Expert Rev Mol Med) Abbreviations: Dvl: 
dishevelled 1; EGF-CFC: epidermal growth factor-cripto; Fgf: fibroblastic growth factor; FoxH1: 
forkhead box H1; Lef1/Tcf: lymphoid enhancer-binding protein/T-cell specific transcription factor; Nkx2: 
NK2 transcription factor related; Pitx2: pituitary homeobox 2; Shh: Sonic hedgehog; Smads: mother 
against decantaplegic genes; lefty: left right determination factor; Cited2: CBP/p300- interacting 
transactivator with Clu/ASP-rich C-terminal domain 2; Wnt: wingless type MMTV integration site family 
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4.10 SUMMARY- PITX2 AS A GENETIC RISK FACTOR FOR POAG 
 
Taking into account the essential role of PITX2 for the development of the anterior 
segment implies that PITX2 is crucial for the normal development of drainage structures 
and preservation of normal IOP. This is emphasized by the observation that glaucoma 
occurs in a high percentage in ARS patients and that patients with PITX2 defects have a 
more severe prognosis for glaucoma development. 
 
Therefore, these features of PITX2 provide a strong basis to consider PITX2 as a 
candidate for the more common adult-onset POAG through hypothesizing that sub- 
clinical mutations/polymorphisms in PITX2 gene may produce subtle and undetected 
abnormalities in anterior segment structure and function through age related changes, 
which predispose to glaucoma and may be a significant susceptibility factor for the 
development of POAG. 
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Chapter 5. 
 HYPOTHESIS AND OBJECTIVES OF THE STUDY 
 
 
5.1 HYPOTHESIS PILOT STUDY 
 
Subclinical mutations/polymorphisms in PITX2 gene may produce subtle and 
undetected age related abnormalities in anterior segment structure and function, which 
predisposes to glaucomatous optic neuropathy and may be a significant susceptibility 
factor for the development of POAG. The arguments for choosing genes involved in 
ASD and why PITX2 in particular has been presented in Glaucoma Genetics (chapter 3) 
and PITX2 chapter (chapter 4) and will not be reiterated again here. 
 
5.2 OBJECTIVES OF THE PILOT STUDY 
 
 
1. To identify, phenotype and recruit 100 patients with POAG and 100 matched controls 
for genetic studies, using explicit inclusion/exclusion criteria. 
 
2. To recruit 10 patients with posterior embryotoxon for genetic studies. 
 
3. To genotype the coding sequence of PITX2 gene in patients and controls and the 
frequency of any polymorphism identified calculated.  If a difference in allele frequency 
was identified, significant association was to be tested by calculating the Odds Ratio. 
An Odds Ratio more than 1 would suggest an increased susceptibility to glaucoma is 
associated with the variant allele.  
 
4. To select appropriate PITX2 single nucleotide polymorphisms published in electronic 
databases and to ascertain if these allele predispose to POAG in general population 
composed of British subjects by performing a case-control genetic association study to 
compare the prevalence of PITX2 SNPs in a group of POAG patients with IOP at 
presentation > 30 mmHg and normal control group. 
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5.3 HYPOTHESIS AND OBJECTIVES OF FAMILY HISTORY OF 
GLAUCOMA STUDY 
 
Hypothesis:  
 
Recruiting families (ideally large pedigrees with living relatives in different 
generations) with multiple members affected of a disease is important for genetic 
studies as it allows mapping the disease loci by linkage analysis.  
Linkage analysis methods attempt to identify a region of the genome that is transmitted 
within families with the disease phenotype of interest and has been extremely useful in 
the identification of genes responsible for diseases with simple Mendelian inheritance. 
 
Therefore, second part of my project involved continuing to recruit POAG patients with 
family history of glaucoma from North East of England. 
 
The objectives for this part of the study were: 
 
1. Identify POAG patients with family history of glaucoma with more than 2 family 
members affected.  
 
2. Phenotype the POAG patients 
 
3. Construct the pedigrees 
 
4. Enrol relatives for the genetic studies 
 
5. Collect samples (blood or buccal mucosa) for DNA extraction 
 
6. Forward samples and clinical information to London, with a view to be sent on to 
Prof Sarfarazi laboratory for genetic studies 
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     Chapter 6. 
 AN ASSOCIATION STUDY OF PITX2 POLYMORPHISM IN A 
COHORT OF UNRELATED POAG/OHT PATIENTS AND 
MATCHED CONTROLS – A PILOT STUDY 
 
 
6.1 INTRODUCTION 
 
6.1.1 Hypothesis 
 
 
The characteristic ocular anterior segment abnormalities seen in Axenfeld-Rieger 
syndrome patients indicate that the PITX2 protein plays an essential role in the 
development of the cornea, iris and trabecular meshwork. The associated glaucoma may 
arise from malformations seen from birth or may arise from continued expression of the 
gene product throughout life. 
 
It is possible that varying amounts of residual PITX2 activity underlies the severity of 
the ocular phenotypes. It has been demonstrated that there is reduced activity of iris 
hypoplasia and iridogoniodysgenesis mutant PITX2 proteins, whereas the ARS mutant 
PITX2 proteins proved to be non-functional. These results are consistent with the 
hypothesis that mutant PITX2 proteins that retain partial function result in milder 
anterior segment aberrations (Kozlowski et al 2000). 
 
While mutations of PITX2 have been detected that disrupt normal development of the 
anterior segment and cause an overt structural abnormality, it is also possible that as yet 
undetected mutations/polymorphism in PITX2 may produce subtle and undetected 
abnormalities in anterior segment structure and function which predispose to glaucoma. 
This PITX2 allele may for example represent a significant susceptibility factor in 
patients currently assigned a diagnosis of POAG. 
 
Therefore, a pilot study was designed to address the following research question: Do 
PITX2 alleles predispose to glaucoma in the wider population? 
 
As the glaucoma associated with AXRS presents with very high IOP, we hypothesised 
that PITX2 variations would be more likely to be present in POAG/OHT patients with 
very high IOP at presentation.  
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The identification, recruiting, phenotyping of patients and controls and genetic studies 
execution and results are presented. 
 
6.1.2 Introduction to study design 
 
SNPs, already introduced in the genetics of g;laucoma chapter, are defined as a 
polymorphic variation at a single nucleotide that occurs in at least 1% of the population 
and make up about 90% of all human genetic variation. The human genome contains 
approximately three billion nucleotide and the SNPs as mentioned before occur 
approximately every 100 to 300 bases (Collins et al, 2004), making them more suited to 
high resolution genotyping (Nowotny et al 2001).  
 
Complex diseases are generally caused by intricate interactions of multiple genes and 
environmental factors, and although family based studies still have a place in the study 
of population association (in addition to linkage), this kind of research has more in 
common with classical epidemiological studies.  
 
It follows, that issues of study design and analysis have more in common with the rest 
of epidemiology. Although controversial, population based, case control study has been 
popular for genetic association analysis due to its cost-efficiency in collecting the data 
(Ioannidis 2001, Evangelou 2006). 
 
 To avoid bias, ideally, cases and controls should be identical samples from a single 
population, except for diagnosis. 
 
This pilot study was designed as a case-control study to assess the presence of PITX2 
variants in general population and to test for a significant association with glaucoma in 
patients with POAG/OHT.  
 
Significant association was to be tested by calculating an Odds ratio with 95% 
confidence intervals: a ratio greater than 1 would suggest an increased susceptibility to 
glaucoma is associated with a variant allele. 
 
In addition, investigation of PITX2 sequence variance was to be carried out on a panel 
of 10 individuals with posterior embryotoxon, but no glaucoma. 
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Approval for the study was granted by the local research ethics committee (research 
ethic committee number: 06/Q0508/8). The research followed the tenets of the 
Declaration of Helsinki. 
 
6.1.3 Definition of cases and controls for PITX2 screening 
 
Cases were defined as patients with POAG or OHT and the inclusion criteria were: 
• Presentation of the disease over the 40 years of age. 
• Highest IOP at presentation over 30 mm Hg. As the IOP in AXR patients 
associated with glaucoma is very high, it has been hypothesised that it is more 
likely to find PITX2 variations in a subset of patients with POAG/OHT with 
very high IOP at presentation and we chose 30 mm Hg as a cut off point. 
• Cupping of the OD and progressive VF loss in POAG patients. 
• Absence of glaucomatous optic disc cupping and  detectable glaucomatous field 
loss in OHT patients. 
• Open drainage angles (at least grade 3 according to Shaffer’s classification on 
gonioscopy). 
 
Exclusion criteria for the study were: 
Secondary types of glaucoma (psedoexfoliative, pigment dispersion syndrome, 
traumatic or steroid induced). 
• Non-glaucomatous field loss. 
 
Controls were defined as individuals who fulfilled the following criteria: 
• More than 40 years of age. 
• No glaucoma on ophthalmologic examination. 
• No family history of glaucoma. 
• Intraocular pressure on examination less than 22 mm Hg. 
 
 
6.1.4 Sample size 
 
 
As this was a pilot study of genetic association between the POAG and developmental 
glaucoma genes, it was considered that a sample size of 100 patients and 100 controls, 
matched for age, sex and ethnicity would be appropriate for the purpose of the study.  
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Considering that the frequency of a particular allele in general population (controls) is 
10%, for a cohort of 100 POAG/OHT patients and 100 controls, the study would have 
80% power to detect the difference between allele frequency of 10% to 26% in the two 
groups and 92.5% power to detect a difference of 10% to 30 % in the two groups, at a 
significance level of = 0.05. 
 
 
6.2 IDENTIFICATION OF PATIENTS AND CONTROLS FOR  PITX2 
SCREENING  
 
6.2.1. Identification of POAG/OHT patients 
 
The patients enrolled in the study were from the Glaucoma Unit at Sunderland Eye 
Infirmary (SEI), attended by 6,000 glaucoma patients per year.  
 
The protocol for the PITX2 study was as follows: 
Identification of the patients with glaucoma/OHT with IOP > 30mmHg from the 
patients who attended out-patient clinics or the nurse led glaucoma review clinics from 
clinical notes. All the patients were previously phenotyped by Mr Fraser, Consultant 
Ophthalmic Surgeon, with vast experience in glaucoma. 
Suitable patients were provided with a study information sheet (appendix 1), when 
checking in at reception  
Either the nurse or the doctor discussed the study with the patient 
If patient communicated willingness to assist, an appointment was organised with me, 
for recruitment to the study.  
At the appointment the following steps were followed: 
1. Discussion of the study.  
2. Written consent for taking part in the study was obtained. 
3. Clinical examination.  
4. A sample of venous blood was collected. 
The blood samples were stored at -80°C at the Institute of Human Genetics, until the 
laboratory work started in October 2002. 
Any result specific to an individual would be relayed from laboratory to Mr Fraser for 
genetic counselling purposes. 
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The examination protocol was standardised and it comprised: 
 
• Best corrected Snellen visual acuity assessment 
• Anterior segment examination with slit lamp 
• Goldman applanation tonometry 
• Gonioscopy 
• Fundus examination and optic disc assessment with a 90D condensing lens 
• All the patients had at least two reproducible visual field tests in the immediate 
past (Humphrey automated perimetry, 24-2 Carl Zeiss Meditec AG, Jena, Germany 
- a form of static perimetry which involves presentation of non- moving stimuli of 
varying illuminance).  
• All patients recruited from SEI had optic discs photographs.  
Details about other systemic and ocular conditions and glaucoma treatment as well as  
age at diagnosis were also recorded (clinical sheet – appendix 2). 
 
291 POAG/OHT patients were identified from the notes and were provided with study 
information sheet. Of these, 105 patients were enrolled in the study. 
 
6.2.2 Identification of controls 
 
Controls were identified from spouses of patients with POAG/OHT, accompanying the 
patient to their clinic appointment at SEI (30). The spouses of patients with 
POAG/OHT, who decided to take part in the study upon reading the information sheet 
(appendix 3), had an appointment organised with the Research Fellow. The controls 
enrolment from SEI followed the same protocol as the patient’s enrolment. 
The rest of the controls enrolled in the study (30) came from healthy volunteers enrolled 
at Royal Victoria Infirmary (RVI), Newcastle upon Tyne (collaboration). 
 
6.2.3 Identification of subjects with posterior Embryotoxon 
 
The subjects with posterior embryotoxon were identified by Mr Fraser (Consultant  
Ophthalmic Surgeon at SEI) from the patients attending his outpatient clinics. The  
inclusion criteria for the study were: 
• presence of posterior embryotoxon on examination. 
• no evidence of glaucoma. 
• no evidence of anterior segment dysgenesis. 
 
  116
If the patients agreed to participation in the study, the contact details of the patient       
were provided to Dr Vaideanu who contacted the patient and organised an appointment. 
 
6.3. STUDY EXECUTION 
 
 
6.3.1. Patients recruitment for PITX2 screening and phenotyping 
 
 
Once the patients and controls were identified and expressed interest in taking part in 
the study, an appointment was organised with Dr Vaideanu. The recruitment of patients 
took place between October 2001 and October 2002.  
 
105 POAG/OHT patients and 6 PE subjects were enrolled in the study. All the subjects 
with POAG/OHT and PE were obtained from patients attending SEI and peripheral 
clinics in area covered by Sunderland NHS Trust. 
 
At the appointment with Dr Vaideanu, the study was discussed, any questions the 
patients had were answered and consent for participating in the study was obtained. 
This was followed by a standardised ophthalmologic examination as described in 
chapter 6.2.1. Figure 6.1 presents a flow chart of the recruitment process for the 
patients. 
 
The VF data (Humphrey 24:2) and past ophthalmic and medical history was obtained 
and recorded in the clinical sheet (appendix 2) from the clinical notes. Also, family 
history of glaucoma was recorded. Following ophthalmic examination, 20 ml of venous 
blood for DNA extraction was collected, from the arm, by venupuncture, with a 20 ml 
syringe, after the area was sterilized with alcohol wipes.  The blood was then distributed 
in four 5 ml EDTA tubes, labelled with the name, date of birth of the patient and date 
blood extracted. The blood was then stored in -80°C freezer at the Institute of Human 
Genetics, Centre for Life, Newcastle upon Tyne, until the laboratory work started. 
 
6.3.2 Controls recruitment for PITX2 screening and phenotyping 
 
Before the enrolment of controls can be commenced, the local ethics committee had to 
be informed by letter. When the initial application for the study was submitted and 
approved (before I became involved with the study) it was focused in enrolling patients 
with POAG and strong family history of glaucoma. As this study was designed as a 
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case-control study, the chairman’s approval for enrolling controls had to be granted 
first. The delay in starting enrolling controls had a bearing on the number of controls 
finally recruited (60 instead of 100). 
 
30 controls were obtained from the spouses of patients with glaucoma, who were 
accompanying the patients to the SEI glaucoma nurse led clinic. Spouses accompanying 
the patient to the clinic were provided with an information sheet (appendix 3) for 
controls. Upon reading the information sheet, spouses who agreed to participated were 
given an appointment with Dr Vaideanu. 
 
At the appointment with Dr Vaideanu, the same steps for enrollement of POAG/OHT 
patients were followed. 
 
The other 30 controls were enrolled from healthy volunteers at Royal Victoria Infirmary 
(RVI), Newcastle upon Tyne (collaboration). The controls enrolled at RVI underwent 
the same standardised ophthalmic examination and in addition had their refractive status 
and VF assessed. None of the controls has any family history of glaucoma. 
 
All the clinical information of the patients and controls has been imputed in a database. 
 
All patients and controls recruited for the study were Caucasians, other ethnic groups 
being uncommon in the North-East of England. 
 
The demographics and clinical characteristics of the patients recruited for the 
association study, as well as treatment and associated ocular pathology are presented in 
the table 6.1.a-e. 
 
6.3.3 PE subjects recruitment for PITX2 screening and phenotyping 
 
PE subjects identified by Mr Fraser were contacted by Dr Vaideanu to organise an 
appointment for recruitment to the study, when they expressed interest in taking part in 
the study.  
Of the 8 patients identified during the recruitment period (October 2001-2002), 6 agree 
to take part in the study.  
Of the 6 PE subjects, 1 also had glaucoma. Although, this was an exclusion criterion, I 
decided to include the patient in the study; any PITX2 variation found in this patient but 
  118
not in any of the other POAG/OHT subjects would add more support to our hypothesis. 
Demographic and clinical details of the PE subjects are presented in table 6.1.f. 
 
Figure 6.1: Flow chart of the POAG/OHT patient recruitment to the pilot study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of patients suitable for the study from clinical notes the week before 
appointment to glaucoma clinic 
Information sheet about the study attached to the notes 
 
Clinic appointment 
Patient provided with the information sheet 
 
Interest for the study 
   Yes 
No 
Routine clinical examination 
Follow up appointment organised 
Appointment with Research Fellow organised 
Routine clinical examination Follow up 
appointment organised 
Appointment with Research Fellow: 
Study discussed 
Consent 
Clinical examination 
Blood collection 
 
Blood stored at IHG at -80°C 
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Table 6.1.a: Demographic and clinical details POAG patients 
ID sex age 
Age 
 dg FHx 
IOP  
RE 
IOP  
LE 
CD  
RE 
CD 
 LE VF RE VF LE Treatment 
Associated 
pathology 
30 M 74 65 no 31 28 0.3 0.4 inferior loss nil Med  
79 M 62 51 no 36 33 0.9 0.7 altitudinal defect nil Med + Trb BE Cornea guttata 
6 M 82 76 no 30 32 0.8 0.8 arcuate superior >90 arcuate superior <90 Med  
5 F 71 61 yes 56 42 0.9 0.7 concentric peripheral loss sup- temporal arcuate Trb BE  
78 M 71 67 no 39 29 0.9 0.6 concentric peripheral loss nil Med  
89 F 70 66 no 30 30 0.9 0.6 dense nasal defect  nil Med  
96 M 66 60 no 30 29 0.7 0.5 early arcuate nil Med  
95 M 75 72 no 23 37 0.8 1 early arcuate total loss Med  
10 M 52 50 no 36 30 0.6 0.4 early nasal step early nasal step Med  
59 M 41 41 no 34 34 0.7 0.7 early peripheral loss early peripheral loss Med  
93 F 79 51 no 30 26 0.8 0.7 early peripheral loss nil Med  
26 M 71 67 no 32 18 0.7 0.3 early superior loss nil Med  
28 M 74 65 no 33 33 0.8 0.8 early superior scotoma nil Med  
103 M 82 71 no 56 56 0.7 1 extensive loss complete VF loss Trb BE CRVO LE 
86 M 83 75 no 30 30 0.4 0.4 fluctuating  nil Med  
67 M 55 51 no 50 26 0.8 0.3 inferior arcuate nil Med  
66 M 72 66 yes 30 24 0.9 0.8 inf arcuate + sup nasal step small superior loss Trb BE  
43 M 87 73 no 30 28 0.8 0.6 inferior loss inferior loss Med  
74 M 65 48 no 30 30 0.9 0.8 inferior loss 90 inferior loss 90 Med  
40 F 77 77 no 34 24 0.4 0.8 inferior low reliability Med  
92 M 67 61 yes 32 30 0.5 0.6 nasal step nasal step Med  
25 M 67 66 no 39 22 0.6 0.4 nasal step nil Med  
100 F 73 58 no 34 28 0.7 0.6 nasal step nil Med + ALT  
24 M 80 70 no 20 30 0.6 0.6 nil amblyopia Med Amblyopia LE 
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Table 6.1.b: Demographic and clinical detail POAG patients 
ID sex Age  
Age 
 dg FHx 
IOP  
RE 
IOP  
LE 
CD 
 RE 
CD 
 LE VF RE VF LE Treatment Associated pathology 
72 M 69 62 no 19 54 0.4 0.9 nil complete loss Trb LE  
99 M 55 55 no 26 50 0.3 0.8 nil Severe loss Med  
88 M 67 64 no 21 34 0.5 0.9 nil early inferior loss Med  
16 F 71 71 no 34 38 0.5 0.6 nil early sup nasal step  Med  
17 M 59 59 no 30 38 0.5 0.5 nil early inferior nasal step  Med  
42 F 62 54 no 30 22 0.3 0.5 nil inferior nasal loss Med  
35 F 70 60 yes 33 32 0.8 0.7 nil nil Med  
41 F 55 55 no 30 27 0.8 0.6 nil nil Med  
52 M 68 64 no 30 29 0.4 0.8 nil nil Med  
70 F 68 55 no 30 23 0.6 0.4 nil nil Med + Trb RE  
94 M 74 66 no 30 28 0.7 0.6 nil nil Med  
62 M 60 46 yes 24 40 0.3 0.6 nil sup arcuate Med  
64 F 57 57 yes 24 36 0.3 0.7 nil sup arcuate Med  
105 M 43 43 yes 22 46 0.5 0.9 nil sup arcuate Med + Trb LE  
98 M 77 71 yes 24 42 0.5 0.8 nil sup loss Med  
61 F 78 75 no 28 36 0.3 0.3 nil sup loss Med  
3 M 70 63 no 24 35 0.3 0.9 nil temporal defect Med  
37 M 83 83 no 18 32 0.2 0.7 nil superior nasal step Med  
34 M 64 61 no 30 26 0.8 0.5 Peripheral  loss nil Med  
44 M 87 81 no 24 31 0.6 0.7 Peripheral  loss Peripheral  loss Med  
47 M 54 47 no 38 27 0.8 0.7 Peripheral  loss Peripheral  loss Med  
32 F 77 66 no 36 65 0.9 1 Peripheral  loss  total loss Med + Trb BE  
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Table 6.1.c: Demographic and clinical details POAG patients 
ID sex Age 
Age 
dg FHx 
IOP 
 RE 
IOP  
LE 
CD 
 RE 
CD  
LE VF RE VF LE Treatment 
Associated  
pathology 
12 F 53 40 no 52 26 0.9 0.5 peripheral loss 270 nil Med + Trb RE  
39 F 56 51 no 30 35 0.9 0.8 severe loss   severe loss/post staphyloma Med High myopia 
29 M 75 66 no 32 31 0.8 0.9 severe loss 180 severe 180 Med + Trb BE  
55 F 74 64 yes 32 32 0.6 0.7 small peripheral def nil Med  
71 F 55 51 yes 29 31 0.3 0.5 small sup defect nil Med  
91 M 72 72 no 26 42 0.5 0.8 small sup scotoma small sup scotoma Med  
51 M 55 47 no 29 29 0.5 0.5 sup + inferior arcuate sup + inferior arcuate Med  
87 M 81 59 no 28 30 0.9 0.9 sup +inferior mod def inferior def 90 Trb BE  
57 F 62 59 no 31 30 0.8 0.8 sup arcuate Hemifield sup loss Med  
33 F 51 48 yes 38 31 0.9 0.1 sup arcuate nil Med  
69 M 78 68 yes 35 29 0.6 0.3 sup arcuate sup arcuate Trb BE  
76 M 73 70 no 32 26 0.9 0.7 sup loss   early arcuate Med  
22 M 66 63 no 38 35 0.9 0.9 sup loss 180 sup-temp loss 120 Med  
60 M 68 60 no 30 30 0.7 0.7 sup nasal step early peripheral loss Med + Trb RE  
97 M 67 78 no 30 29 0.3 0.2 sup scotoma nil Med  
65 F 77 62 no 34 28 0.8 0.6 sup temp   sup temp loss Med + ALT + Trb BE  
63 M 82 55 no 49 53 0.8 0.9 sup temp wedge severe concentric loss Trb BE  
56 F 68 55 no 29 33 0.8 0.9 sup VF loss 180 concentric VF loss Trb BE  
27 M 80 55 no 30 32 0.8 0.8 nasal step  Nasal step Med + Trb BE  
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Table 6.1.d: Demographic and clinical details Ocular Hypertension patients 
ID sex Age 
Age  
diagnosis FHx 
IOP  
RE 
IOP  
LE CD RE 
CD  
LE VF RE+LE Treatment 
Associated 
 pathology 
1 F 84 84 no 45 40 0.4 0.2 nil Med  
4 M 78 69 no 48 48 0.2 0.2 nil Med  
7 M 69 58 no 34 27 0.5 0.4 nil Med  
9 M 40 40 no 28 32 0.4 0.5 nil Med  
11 M 74 74 no 26 31 0.2 0.4 nil Med  
13 M 75 69 no 32 29 0.6 0.5 nil Med  
14 M 73 67 no 35 34 0.3 0.3 nil Med  
15 M 72 58 yes 26 38 0.4 0.4 nil Med Asteroid hyalosis 
18 M 68 65 yes 30 29 0.4 0.2 nil Med Corneal scar 
19 M 54 50 no 30 32 0.5 0.4 nil Med  
20 F 69 59 no 34 35 0.5 0.5 nil Med  
21 F 61 61 no 24 33 0.5 0.6 nil Med  
31 M 60 40 no 30 28 0.7 0.6 nil Med  
46 F 75 67 no 32 34 0.5 0.6 nil Med  
48 F 71 68 no 30 36 0.4 0.7 nil Med  
49 F 61 50 yes 34 34 0.3 0.4 nil Med  
50 F 61 55 no 30 29 0.4 0.3 nil Stopped Med  
53 M 61 61 no 32 22 0.4 0.3 nil Med  
54 M 63 61 yes 27 30 0.7 0.8 nil Med  
58 F 76 76 no 31 29 0.2 0.3 nil Med  
73 M 76 62 yes 34 31 0.3 0.3 nil nil Med 
75 M 77 50 no 32 30 0.3 0.3 nil nil Med 
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Table 6.1.e: Demographic and clinical details Ocular Hypertension patients 
ID sex Age 
Age  
diagnosis FHx 
IOP  
RE 
IOP  
LE CD RE CD LE VF RE+LE Treatment 
Associated 
 pathology 
68 M 74 64 yes 33 34 0.5 0.6 nil Trb BE  
77 F 73 59 yes 29 30 0.7 0.8 nil Med  
81 M 74 66 no 31 28 0.8 0.8 nil Med  
82 F 72 62 no 33 30 0.5 0.4 nil Med CRVO RE 
83 F 64 51 yes 29 30 0.6 0.6 nil Med  
84 M 59 48 no 30 30 0.6 0.8 nil Trb BE  
90 M 62 62 no 30 26 0.5 0.3 nil None  
101 M 69 51 no 30 38 0.3 0.4 nil Med  
102 F 63 63 no 32 30 0.6 0.5 nil Med  
104 M 71 61 no 30 30 0.6 0.6 nil Med  
23 M 65 65 no 26 30 0.6 0.7 nil Med  
36 M 71 54 no 30 32 0.6 0.6 nil Med +Trb BE  
38 M 73 79 no 26 30 0.2 0.2 nil Med  
 
 
Table 6.1.f: Demographic and clinical details Posterior Embryotoxon subjects 
ID sex Age 
Age  
diagnosis FHx 
IOP  
RE 
IOP  
LE CD RE CD LE VF RE+LE Treatment 
Associated 
 pathology 
1 M 32 32 Yes 16 16 0.4 0.2 nil nil  
2 F 72 72 No 15 16 0.3 0.5 nil nil  
3 F 66 66 No 13 16 0.2 0.2 nil nil  
4 F 55 55 Yes 17 16 0.7 0.7 Sup field loss Med  
5 M 65 65 Yes 18 18 0.7 0.7 nil nil  
6 M 42 42 Yes 18 18 0.2 0.2 nil nil  
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Fig 6.2.a and 6.2.b shows the highest IOP and the worst CD ratio distribution in  
patients and controls. The demographics of the patients enrolled in the study are 
presented in the results chapter. 
 
Figure 6.2.a and b: Graphic representation for the distribution of highest IOP (a) and  
worst CD ratio (b) in patients and controls. 
Figure 6.2.a 
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Figure 6.2.b  
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6.4. GENETIC SCREENING – METHODS AND RESULTS 
 
6.4.1. Genomic DNA extraction 
 
Genomic DNA was isolated from participants’ blood, using the Nucleon BACC2/3 kit 
(Tepnel Life Sciences Plc), according to the protocol (appendix 4a). 
The presence and quality of high molecular weight DNA was assessed by running it on 
a 0.8% agarose gel electrophoresis (figure 6.3) 
 
 
Figure 6.3: Agarose gel demonstrating the presence of high molecular weight DNA 
 
The gel was examined for the presence of: 
• smearing of the fluorescent bands to detect DNA fragmentation 
• faint fluorescent bands that signify the presence of contamination 
If smearing or faint fluorescent bands were present, the DNA extraction was repeated. 
 
6.4.2 Polymerase chain reaction (PCR amplification) and sequencing 
 
As most of the significant mutations have been documented in the homeobox (fig 4.3), 
for the first stage of the study, the sequencing screening was done on the homeobox 
region. Second stage of the sequencing screening included the rest of the coding 
sequence. 
 
Four primer sets were designed to PCR amplify the isoform A coding sequence from 
four exons of the PITX2, including the exon-intron boundaries (fig 6.4). The primers 
were obtained from MWG (www.mwg-biotech.com) – table 6.2 
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Homeobox
P4
Primer Sets for 
Mutation screening 
PITX2A  GENE
P2P1
P5
1 2 5 6
39 98
ATG TGA
Exon
5-15kB 3.5kB
Translation start
11.5kB 3 kB
5’UTR
Stop
3’UTR
 
Figure 6.4: Diagrammatic representation of PITX2 gene and primer sets used for mutation screening 
 
Primer set 1 was designed to cover the homeobox, with the other three primer sets  
covering the rest of the coding sequence.  
 
 
   Table 6.2: Primer sequence, annealing temperature and product size 
Primer Oligonucleotide sequence Annealing 
 temperature 
PCR 
 cycles 
PCR  
product size 
(bp) 
1aF 
1R 
5’-CAG CTC TTC CAC GGC TTC T-3’ 
5’-CTC CCT TGA CAT TAG AGC GT-3’ 
60°C 33 472 
2F 
3R 
5’-GTA ATC TGC ACT GTG GCA TC-3’ 
5’-CCC CTT TTG TAC GAG ACA CT-3’ 
62°C 33 298 
4F 
4R 
5’-CTA TCC ACC AAG AGC TTC-3’ 
5’-GAC TCC TGT AGG GAA ACT-3’ 
60°C 33 621 
5F 
5AR 
5’- CTG AAG CCT AGC ACA CAG TA-3’ 
5’-GCA GGA GAA GGG GGT TCT TA-3’ 
62°C 33 191 
 
A 25 µl PCR reaction was used for each sample. The composition of the PCR mix is  
presented in table 6.3 and the protocol for PCR in table 6.4. 
 
Table 6.3: PCR reagents used for sequencing 
Reagent 1 x 25µl reaction 
(volume - µl) 
Forward primer 1 
Reverse primer 1 
Promega Taq DNA polymerase 0.25 
MgCl2 (1.5mM) 1.5 
dNTPs (2.5mM 2.5 
Master mix 
Promega buffer 2.5 
Genomic DNA (20ng/ µl) 1 
Water (distilled and autoclaved) 15.25 
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Table 6.4: PCR protocol for direct sequencing 
Reaction 
 step 
Temperature 
(°C) 
Duration 
 (min:sec) 
Nature of reaction Number  
of cycles 
1 95 03:00 Denaturation 1 
2 95 00:30 Separation of DNA 
strand 
3 Tm (60-62) 00:30 Primer annealing 
4 72 00:30 DNA synthesis 
(transcription) 
 
33 
5 72 10:00 DNA synthesis 
(elongation) 
1 
 
The presence of the PCR products for each primer set was assessed with a 1% agarose  
gel (figure 6.5).  
 
PCR product was purified using ExoSAP protocol (appendix 4b) and quantification of 
DNA present was done by running a 1.5% agarose gel (figure 6.6). Direct sequencing 
(protocol - appendix 4c) of the single stranded DNA was carried out, using the 
automated sequencer facilities (MegaBACE DNA Analysis System/Amersham 
Pharmacia). 
 
 
 
 
 
 
 
 
Figure 6.5: 1% agarose gel images demonstrating the presence of PCR product to be 
 used for sequencing. 
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Figure 6.6: 1.5% agarose gel, demonstrating quantification of DNA present after 
 ExoSap purification 
 
6.4.3 Sequencing analysis and results 
 
Sequencing results were analysed using BioEdit program – 
http://www.mbio.ncsu.edu/BioEdit/bioedit. (Hall 1999) and Sequencher – 
http://www.sequencher.com/  (Nishimura 2000) and Clustal W  
http://www.ebi.ac.uk/Tools/clustalw/  (Higgins and Sharp 1988) program was used for  
sequence alignment. 
 
6.4.3.1 Sequencing analysis programs 
 
Programs to import, manage and align sequences and to analyse the properties of DNA,  
RNA and proteins are essential for every biological laboratory. The most frequent used  
programs and the ones used to analyse the results of this work are a freeware BioEdit  
for MS Windows and a commercial program Sequencher for MS Windows and Apple  
MacOS. BioEdit and Sequencher offer functions such as sequence alignment and  
editing plus reading of sequence trace files. While Sequencher impresses with a very  
user-friendly interface and easy- to-use tools, BioEdit offers the largest and most  
customisable variety of tools. Sequences can easily be analysed for composition with a  
graphical output and BioEdit uses ClustalW for multiple sequence alignment  
(Tippmann, 2004) 
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6.4.3.2 Multiple sequence alignment programs 
 
One of the cornerstones of modern bioinformatics is the comparison or alignment of 
protein sequences. With the aid of multiple sequence alignments, biologists are able to 
study the sequence patterns conserved through evolution and the ancestral relationships 
between different organisms. Sequences can be aligned across their entire length (global 
alignment) or only in certain regions (local alignment). The most widely used programs 
for global multiple sequence alignment are from the Clustal series of programs. The 
first Clustal program was written by Higgins and Sharp (1988) and was designed 
specifically to work efficiently on personal computers. It combined a memory-efficient 
dynamic programming algorithm (Myers and Miller 1988) with the progressive 
alignment strategy developed by Feng and Doolittle (1987) and Taylor (1988). The 
multiple alignments are built up progressively by a series of pairwise alignments, 
following the branching order in a guide tree. The initial pre-comparison used a rapid 
word-based alignment algorithm (Wilbur and Lipman 1983) and the guide tree was 
constructed using the UPGMA method (Unweighted Pair Group Method with 
Arithmetic Mean is a sequential clustering algorithm, in which local topological 
relationships are identified in order of similarity, and the phylogenetic tree is build in a 
stepwise manner - Sneath and Sokal 1973). The third generation of the series, ClustalW 
(Thompson et al 1994), incorporated a number of improvements to the alignment 
algorithm. The rationale behind the development of the Clustal series has been to 
provide robust, portable programs that are capable of providing good, biologically 
accurate alignments within a reasonable time limit.  
 
6.4.3.3 Results 
 
105 patients with POAG and 60 controls were enrolled in the study. Of the 105 POAG 
patients, 5 were excluded, as the age when disease presented and were recruited for the 
study was below 40 years of age. For the posterior embryotoxon group, six subjects 
were recruited for the study. 
Demographics of the patients and controls are presented in the table 6.5.  
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 Table 6.5: Demographics of the patients and controls 
 PATIENTS CONTROLS   Posterior 
embryotoxon 
Female 33/100 (33%) 38/60 (63.3%) 3/6(50%) 
Male 67/100 (67%) 22/60 (36.7%) 3/6 (50%) 
Mean age + SDV 61.3 ± 9.6 (40-84) 73.8 ± 9.6 (41-90) 55.1 ± 15.8 
Median 61.5 75 60 
IOP 34.9 ± 6.91 (30-65) 16.6 ± 2.7 (10-22) 16.3 ± 1.8 
CD ratio 0.66 ± 0.2 (0.2-1) 0.33 ± 0.1 (0.1-0.7) 0.45 ± 0.22 
 
In the POAG group, 20% of patients enrolled had family history of glaucoma and 60% 
had a visual field defect. In the PE group, 66.6% (4/6) individuals had a family history 
of glaucoma and 1 patient had glaucoma.  
The work on this project has been carried on the PITX2A isoform and a diagram with 
the primer sets and SNPs published in the internet database 
(http//www.ncbi.nih.gov/SNP and www.ensembl.org) is presented in Fig 6.7.  
 
 
Homeobox
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Primer Sets for 
Mutation screening 
PITX2A  GENE
rs2739207 (G/C- V/L)  - codon 12, exon 2
rs1051887 (G/C- Q/E)  - codon 37, exon 5/codon 15 HB
rs1051888 (C/G)           - codon 151, exon 6
rs2739199 (C/A – K/N) - codon 157, exon 6
rs1051889 (G/C)           – codon 182, exon 6/3’UTR
P2P6 P1
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Figure 6.7: Diagram of the PITX2A isoform, indicating the position of the SNPs recorded in NCBI  
(http//www.ncbi.nih.gov/SNP) database and the primer sets used for PCR amplification. 
 
The sequence of the coding region, together with the position of the primers used for 
sequencing and position of the SNPs published in the NCBI 
(http//www.ncbi.nih.gov/SNP) database is presented below. 
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SNPs in the coding regions of genes or in regulatory regions are more likely to cause 
functional differences then SNPs elsewhere. Therefore, in the first stage, the homeobox 
sequencing has been prioritised (pink, underlined region), as any variation found in this 
region would be a very significant finding. The sequencing reactions were carried out 
for 105 patients and 60 controls, as well as 6 posterior embryotoxon patients, using 
primer set 1. 
 
Analysis of the traces did not identify any sequence variation in this cohort. This 
indicates a high level of sequence conservation in the homeobox region of PITX2 gene.  
 
A sample of sequence alignment for the primer set 1 (homeobox region) is presented. 
This sample is centred on the site of SNP 1051887, and it demonstrates that there is no 
sequence variation present in this cohort of patients. 
 
 
Alignment of sequences (1R) using Clustal W, demonstrating the site of SNP1051887  
 
IRSEI63 GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 276 
IRSEI9   GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 270 
IRSEI62 GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 271 
IRSEI70 GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 277 
IRSEI65 GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 272 
IRSEI66 GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 273 
IRSEI72 GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 276 
IRSEI71 GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 271 
IRSEI75    CGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 275 
1Rw        GCGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 347 
IRSEI79    CGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 273 
IRSEI67       GGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 269 
IRSEI73    CGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTC 280 
IRSEI78    CGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 274 
IRSEI77    CGGTTCCTCTGGAAAGTGGCCTCCAGCTCCTGGAGCTGCTGGCTGGTAA-AGTGAGTCC 271 
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PITX2A 
 
Exon 1 
 
6F: 5’-TTC TGG TCC TCC TTT CCA CA-3’ 
TGGGAGTCCGTGCTCCTGCTCCTCGGTTGGCTCCTAAGTGCCCCGCCAGGTCCCCTCTCCTTTCGCTCTC
CCGGCTCCGGCTCCCGACTCTTCGGCCCGCTGGCATCTGCTTCCCTCCCCTGCCTCGTTTCTCGTCGCCC
CTGCTCGCTCCCCCCGGCGCTCGCCCGGGCGCTGTGCTCGCTCCTGGATCGCCAGCCGCGCAGCCGGGC
TCGGCCGGCCGCCCGCGCGCCACTGTGCAGTGGAGTTTGGTGGAATCTCTGCTGACGTCACGTCACTCC
CCACACGGAGTAGGAGCAGAGGGAAGAGAGAGGGATGAGAGGGAGGGAGAGGA3’-
GAGAGAGTGCGAGACCGAGC-5’(7R-SNP 2739200) 
GAGAAAGCTGGAGAGGAGCAGAAAGAAACTGCCAGTGGCGGCTAGATTTCGGAGGCCCCAGTGCACC
CGTGGACTCCTTCGGAACTTGGCACCCTCAGGAGCCCTGCAGTCCTCTCAGGCCCGGCTTTCGGGCGCT
TGCCGTGCAGCCGGAGGCTCGGCTCGCTGGAAATCGCCCCGGGAAGCAGTGGGACGCGGAGACAGCAG
CTCTCTCCCGGTAGCCGgt 
6R:5’-CCA GAC TCG CAT TAT CTC AC-3’ 
 
Exon 2 
 
5F:5’-CTG AAG CCT AGC ACA CAG TA-3’ 
 
agATAACGGGGAATGGAGACCAACTGCCGCAAACTGGTGTCGGCGTGTGTGCAATTAGgt 
            SNP2739207 (G/C-V/L non synonymous change) 
 
5AR: 5’-GCA GGA GAA GCG GGT TCT TA-3’ 
 
Exon 5 
 
1aF: 5’-CAG CTC TTC CAC GGC TTC T-3’ 
 
AGAAAGATAAAAGCCAGCAGGGGAAGAATGAGGACGTGGGCGCCGAGGACCCGTCTAAGAAGAAGCG
GCAAAGGCGGCAGCGGACTCACTTTACCAGCCAGCAGCTCCAGGAGCTGGAGGCCACTTTCCAGAGGA
ACCGCTACCCGGACATGTCCACACGCGAAGAAATCGCTGTGTGGACCAACCTTACGGAAGCCCGAGTC
CGGGTTTGG 
                         SNP 1051887(Q/E-G/C-nonsynonymous change)) 
1R: 5’-GAG GGA ACT GTA ATC TCG CA-3’ 
 
Exon 6 
 
2F:5’-GTA ATC TGC ACT GTG GCA TC-3’ 
TTCAAGAATCGTCGGGCCAAATGGAGAAAGAGGGAGCGCAACCAGCAGGCCGAGCTATGCAAGAATG
GCTTCGGGCCGCAGTTCAATGGGCTCATGCAGCCCTACGACGACATGTACCCAGGCTATTCCTACAACA
ACTGGGCCGCCAAGGGCCTTACATCCGCCTCC 5’CTA TCC ACC AAG AGC TTC 3’(4F) 
CCCTTCTTCAACTCTATGAACGTCAACCCCCTGTCA3’TCA CAG AGC ATG TTT TCC CC-5’(3R) 
ACCCAACTCTATCTCGTCCATGAGCATGTCGTCCAGCATGGTGCCCTCAGCAGTGACAGGCGTCCCGGG
CTCCAGTCTCAACAGCCTGAATAACTTGAACAACCTGAGTAGCCCGTCGCTGAATTCCGCGGTGCCGAC
GCCTGCCTGTCCTTACGCGCCGCCGACTCCTCCGTATGTTTATAGGGACACGTGTAACTCGAGCCTGGC
CAGCCTGAGACTGAAAGCAAAGCAGCACTCCAGCTTCGGCTACGCCAGCGTGCAGAACCCGGCCTCCA
ACCTGAGTGCTTGCCAGTATGCAGTGGAC 
SNP1051888 (synonymous change C/G) rs2739199 (nonsynonymous change C/A-K/N) 
 
CGGCCCGTGTGAGCCGCACCCACAGCGCCGGGATCCTAGGACCTTGCCGGATGGGGCAACTCCGCCCT
TGAAAGAC 
   SNP1051889 (G/C-UTR) 
TGGGAATTATGCTAGAAGGTCGTGGGCACTAAAGAAAGGGAGAGAAAGAGAAGCTATATAGAGAAAA
GGAAACCACTGAATCAAAGAGAGAGCTCCTTTGATTTCAAAGGGATGTCCTCAGTGTCTGACATCTTTC
ACTACAAGTATTTCTAACAGTTGCAAGGACACATACACAAACAAATGTTTGACTGGATATGACATTTTA
ACATTACTATAAGCTTGTTATTTTTTAAGTTTAGCATTGTTAACATTTAAATGACTGAAAGGATGTATAT
ATATCGAAATGTCAAATTAATTTTATAAAAGCAGTTGTTAGTAATATCACAACAGTGTTTTTAAAGGTTA
GGCTTTAAAATAAAGCATGTTATACAGAAGCGATTAGGATTTTTCGCTTGCGAGCAAGGGAGTGTATAT
ACTAAATGCCACACTGTATGTTTCTAACATATTATTATTATTATAAAAAATGTGTGAATATCAGTTTTAG
AATAGTTTCTCTGGTGGATGCAATGATGTTTCTGAAACTGCTATGTACAACCTACCCTGTGTATAACATT
TCGTACAATATTATTGTTTTACTTTTCAGCAAATATGAAACAAATGTGTTTTATTTCATGGGAGTAAAAT
ATACTGCATACAAA 
4R: 5’-CTG AGG ACA TCC CTT TGA-3’ 
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Figure 6.8: Section of chromatograms for patient and control, demonstrating identical  
trace in patient and control at the site of SNP 1051887 
Control (1R) 
 
 
       rs1051887 
Patient (1R) 
 
 
       rs1051887 
   
The next stage consisted in sequencing the rest of the coding region of the PITX2 gene, 
using primer sets 2, 4 and 5. Some segments of the gene sequenced better than other and 
therefore the results are not complete for the entire coding sequence in all the patients. 
 
Analysis of traces, failed to identify any sequence variation in the samples in which 
good traces were obtained. 
Figure 6.9 presents an example of sequence alignment, using the Clustal W 
(http://srs.ebi.ac.uk) program. It highlights the sequence conservation for three of the 
SNPs sites published in the NCBI (http//www.ncbi.nih.gov/SNP) database within the 
coding sequence of the PITX2 in the region of primer set 4 (exon 6). 
 
Results
• 4F/4R
SNPrs1051888(C/G)
• F_w      CTGAGACTGAAAGCAAAGCAGCACTCCAGCTTCGGCTACGC 356
• FI_2      CTGAGACTGAAAGCAAAGCAGCACTCCAGCTTCGGCTACGC 299
• FI_4      CTGAGACTGAAAGCAAAGCAGCACTCCAGCTTCGGCTACGC 298
SNPrs2739199(C/A-K/N)
• F_w       CAGCGTGCAGAA CCCGGCCTCCAACCTG-AGTGCTT-411
• FI_2      CAGCGTGCAGAACCCGGCCTCCAACCTG-AGTGCTT- 354
• FI_4      CAGCGTGCAGAACCCGGCCTCCAACCTG-AGTGCTT- 353
SNPrs1051889(G/C)-UTR
• F_w   CCGCACCCACAGCGCCGGGATCCTAGGACCTTGCCGGATGGG 465
• FI_2   CCGCACCCACAGCGCCGGGATCCTAGGACCTTGCCGGATGGG 408
• FI_4   CCGCACCCACAGCGCCGGGATCCTAGGACCTTGCCGGATGGG 407
 
Figure 6.9: Example of sequence alignment for the region of primer set 4/exon 6 (Clustal W) 
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Figure 6.10: Section of chromatograms for patient and control, demonstrating sequence conservation at 
SNPs site: rs1051888, rs2739199, rs1051889 in the region of primer set 4 (exon 6) and rs2739207 in the 
region of primer set 5 (exon 2). 
 
Patient (4F) 
 
    rs1051888    rs2739199 
 
Control (4F) 
 
    rs1051888     rs2739199  
 
Patient (4F) 
 
    rs1051889 
Control (4F) 
 
 
          rs1051889 
 
Patient (5F) 
 
   rs2739207 
Control (5F) 
     
 
    rs2739207 
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6.4.3.4 Sequencing protocol review 
 
Problems with sequencing have been encountered, and that prompted a sequencing 
protocol review. 
Table 6.6 presents the number of sequencing reactions carried out for each primer set 
and the number of traces which could be analysed. 
 
Table 6.6: Sequencing reactions and output 
Primer sets Sequencing reactions  Good traces %patients & controls 
sequenced 
1aF1R 358 170 (47.4%) 98%patients/93.3%controls 
2F3R 323 129 (39.9%) 88%patients/45%controls 
4F4R 90 16 (17.7%) 10%patients/25%controls 
5AF5R 257 116 (45.1%) 45%patients/61.6%controls 
 
It is obvious from the above table, that the sequencing results were not completed for all 
primer sets and all samples.  
 When sequencing reactions are processed, a control reaction is set up and the role of 
this is to confirm the performance of the sequencing premix under specified and tested 
conditions. Although the control reaction in 99% of the cases would work well, the 
patients and control sequencing reactions did not always work. 
In the attempt to identify a reason why sequencing was not working, all the protocols 
were revised. 
 
Possible reasons for failure of sequencing are:  
1. Quantity and quality of the template (DNA) present in the reaction  
2. primer considerations (amount, design) 
3. contamination of reagents 
4. cycling conditions 
5. human error 
 
Every step in leading to the sequencing of the DNA template has been revised as a 
result of sequencing failure in quite a lot of the sample at the beginning of the 
experiments. 
 
 The double stranded DNA has been checked on an agarose gel and then has been 
checked by spectrometry, to asses the purity. If protein and phenols are present, then the 
product needs cleaning up.  
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Issues of quantity of DNA used for PCR reaction was dealt with by repeating reactions 
using various dilution (1:10; 1:5; 1:2) and an EZ Load Precision Molecular Mass Ruler 
(Bio-Rad ladder) has been used for quantification of the PCR product on an 1.4% 
agarose gel. 
 
With regard to the primer, the sequence of the primer has been revised (length, base 
composition) and it was found that the rules for designing a primer have been adhered 
to, so no change was necessary.  
Reactions with various concentrations and amounts of primer have been carried out, to 
optimise the amount which gives the best result. Again, in the end, there was no need to 
change the amount suggested in the protocol. 
 
Another reason for sequencing failure is contamination of reagents. Therefore, all 
reagents (primers, dNTPs, working DNA stock, etc) have been renewed. 
 
Finally, cycling conditions (numbers of cycles, annealing temperatures) have been 
revised as well; however no change to the protocol ensued, as no better results were 
obtained with different temperatures or more cycles. 
 
Due to all the problems with sequencing, this method was not cost and time effective in 
producing results. After discussion with all involved in the project, the decision to stop 
direct sequencing has been reached and other methods of high throughput screening 
were examined.  
 
One suggestion was to consider heteroduplex analysis using the Mega BASE; this 
method has been successfully used at ICH, UCL. However, when investigation on 
methodology was made, we were informed that the method used at ICH has not been 
published and therefore could not be used elsewhere until published.  
 
Around the time the problems with sequencing were encountered, the IHG acquired a 
Sequenom machine, which is capable of performing high throughput SNP screening.  
After studying the method and realising its potential, the decision to use this opportunity 
for screening SNPs in the PITX2 gene was made.  
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However, although it is a very cost effective method for screening a large number of 
SNPs, it is still expensive. Therefore, I had to prepare a proposal for extra funds in order 
to be able to continue the project. Securing the funds allowed the second part of the 
pilot study to take place. 
 
The second part of the study consists of genotyping and haplotype analysis of selected 
SNPs published in the NCBI (http//www.ncbi.nih.gov/SNP) and Ensembl 
(www.ensembl.org) databases. 
 
 
6.4.4 High throughput SNP screening using the Sequenom
TM 
 
The Sequenom TM uses the MassARRAY homogenous MassEXTENDTM (hME) Assay 
technology (www.SEQUENOM.COM). 
 
The hME assay is based upon annealing of the MassEXTEND primer adjacent to the 
polymorphic site of interest. The addition of a DNA polymerase, plus a cocktail mixture 
of nucleotides and terminators, allows extension of the primer through the polymorphic 
site, and generates a unique mass product. The resultant mass of the primer extension 
product is then analysed and used to determine the sequence of the nucleotides at the 
polymorphic sites. Through the application of matrix assisted laser desorption time-of-
flight (MALDI-TOFF) mass spectrometry to the analysis of primer extension products, 
SNPs can be accurately determined (Fig 6.11) 
Figure 6.11: Diagram of MassEXTEND genotyping assay (www.SEQUENOM.COM) 
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The recommended protocol for the Sequenom use at Institute of Human Genetics 
(IHG), Centre for Life, Newcastle upon Tyne, is as follow: 
•  Select SNPs within gene of interest 
•  Submit SNP sequences to technician for assay/primer design 
•  Assay design 
•  Order primers 
•  Amplify DNA by PCR 
•  Provide technician with PCR products, assay and sample information 
•  Genotyping by technician 
•  Generation of report by technician and e-mailing of results 
 
6.4.4.1 SNP selection for PITX2 gene 
 
The NCBI and Ensembl SNP database (http//www.ncbi.nih.gov/SNP and 
www.ensembl.org) was searched for polymorphic sites published for PITX2. 
 
The criteria for SNP selection were: 
•  Position of the SNP in the coding sequence, untranslated region (UTR) and 
intron-exon boundary 
• SNPs validation status. 
• Priority given to SNPs which cause an aminoacid change 
 
 26 SNPs (table 6.7) were selected from the database, including 5 in the coding area, 12 
in UTR and the rest in the intronic region of the coding sequence. The SNPs ids, 
position in the gene, base change, allele frequency and validation status are presented in 
the table 6.7. 
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Table 6.7: List of  SNPs screened 
 
SNP no SNP ID 
Base  
Position Gene Position 
Polymorphism/ 
base change 
Allele  
frequency/ 
 validation 
  1  rs2739202 111758171 3UTR C/G n/v 
  2 rs1051889 111758706 3UTR C/G n/v 
  3 rs2739199 111758781 
Exon6/Nonsynon 
Change A/C;N/K n/v 
  4  rs1051888 111758799 
Exon6/Syn 
Change C/G n/v 
  5 rs3796902 111759917 Intron C/T 0.399 v 
  6 rs2278783 111761573 Intron C/T 0.416 v 
  7  rs2278782 111761603 Intron C/T 0.354 v 
  8  rs1051887 111761864 
Exon5/Nonsynon 
Change C/G; E/Q n/v 
  9 rs2595110 111764772 Intron C/T v 
10 rs994978 111771847 Intron A/G n/v 
11  rs2595105 111772210 Intron A/G n/v 
12  rs2559104 111772582 Intron A/C n/v 
13  rs1530717 111773452 Intron C/T n/v 
14  rs2739207 111773567 
Exon2/Nonsynon 
Change C/G;V/L n/v 
15  rs2276966 111773643 5’UTR C/T n/v 
16  rs2595103 111773948 5’UTR C/T v 
17  rs2739206 111774158 5’UTR C/G 0.490 v 
18  rs2723321 111774448 5’UTR A/G 0.494 v 
19  rs3796898 111774643 5’UTR C/G 0.493 v 
20  rs2595101 111775872 5’UTR A/G v 
21  rs2595100 111775879 5’UTR A/G v 
22  rs976568 111776170 5’UTR A/C n/v 
23  rs2723324 111776469 5’UTR A/G 0.493 v 
24 rs2739204 111776709 5’UTR A/T 0.493 v 
25  rs2739200 111777860 5UTR C/G O.493 v 
26  rs1982361 111779872 Intron A/G 0.493 v 
 
Abbreviations: UTR = untranslated region; A = adenine; C = cytosine; G = guanine; 
 T = Thymine; N = aspargine; K = lysine; E = glutamic acid; Q = glutamine;  
 V = valine; L = leucine; v = validated; n/v = non validated 
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The primers were designed using MassARRAY Designer (Sequenom assay design software –table 6.8) 
 
Table 6.8: Forward, reverse and extension primers for each SNP  
 
SNP_ID Forward, reverse primer Extension primer 
rs2595105 
F:ACGTTGGATGTTCCCTCCTCCATCCCTTAC 
R:ACGTTGGATGAAAAGTCTCCAACCTACGCC GCCTTTCCTGAATTGAA 
rs2739200 
F:ACGTTGGATGTCCCCTCTCCTTTCGCTCTC  
R:CGTTGGATGGACGAGAAACGAGGCAGGG GGGAAGCAGATGCCAGC 
rs2595101 
F:ACGTTGGATGCCAAGGACTCTTGTTTTGGC  
R:ACGTTGGATGTGCTTTGCCATGGTTCCTCG CATGGTTCCTCGTCCTCC 
rs1051889 
F:ACGTTGGATGTCTTTCAAGGGCGGAGTTGC  
R:ACGTTGGATGTTGCCAGTATGCAGTGGACC GCACCCACAGCGCCGGGATC 
rs2276966 
F:ACGTTGGATGAACGTAGTCTCATCTGAGCC  
R:CGTTGGATGAACGTAGTCTCATCTGAGCC AGAAGAGAAGGAAGGCTGTA 
rs994978 
F:ACGTTGGATGAGCACTGGATCGCTTTAGAC  
R:ACGTTGGATGGTCTTGCATTGGAGTTTCCC GTGAATCTGAGAGAAAATGATC 
rs1530717 
F:ACGTTGGATGAAGAGGGCACTGGCCTGCG  
R:ACGTTGGATGTTCTGATTTCCTTCCTGCCC CAGGCTGGCCCCTCGGG 
rs976568 
F:ACGTTGGATGCTGAAAGTGTTCGACCCAAG  
R:ACGTTGGATGTGCCACAACGGGCCATGGAG CCAGAGGGAGGAAGTCT 
rs2595110 
F:ACGTTGGATGCCTGCTTGGACTTTAATGGC  
R:ACGTTGGATGGCCAAATAACCAATTTCAAGG CAGTCATTTTCTTTTCCC 
rs2595104 
F:ACGTTGGATGTCGCTCGTTATATCCCGCTG  
R:ACGTTGGATGATGAACCGCGCACCCACAAG GGCGTGGCTGAGAGCCTGAG 
rs2278783 
F:ACGTTGGATGAGCTCGTGAGATCGCGGGATG  
R:ACGTTGGATGTTCCCTCTCCGAGGCCGACA GAGGCCGACAGGACTGC 
rs2723324 
F:ACGTTGGATGTGCTTATGTGCTTTGTTTTC  
R:ACGTTGGATGCACACAAAATATCATTTTGGC TCATTTTGGCAGAAATCCA 
rs2595100 
F:ACGTTGGATGTTGCCTGCCTGCTTTGCCAT  
R:ACGTTGGATGGGACTCTTGTTTTGGCCAAC ACTACACGGCTAACGGAGGA 
rs1051888 
F:ACGTTGGATGGACTGAAAGCAAAGCAGCAC 
R:ACGTTGGATGCATACTGGCAAGCACTCAGG TTCTGCACGCTGGCGTA 
rs2278782 
F:ACGTTGGATGAGCTTTGCAAAGGCAGAAGG 
R:ACGTTGGATGAGTCCTGTCGGCCTCGGAGA GCCTCGGAGAGGGAACT 
rs2739202 
F:ACGTTGGATGTGTGTGAATATCAGTTTTAG 
R:ACGTTGGATGCAGGGTAGGTTGTACATAGC ACATCATTGCATCCACCA 
rs1051887 
F:ACGTTGGATGCTAAGAAGAAGCGGCAAAGG 
R:ACGTTGGATGAGCGGTTCCTCTGGAAAGTG CTGGAAAGTGGCCTCCAGCT 
rs2739206 
F:ACGTTGGATGATTCTGAAACGAACGGGCTC 
R:ACGTTGGATGAAAGTGGCTCCTGATGGATG TGATGGATGAGAGGCCCGAA 
rs3796902 
F:ACGTTGGATGAAACTACCCTTTCCGGGTTC 
R:ACGTTGGATGAGCAAAAGACCACCTCTTCG TTCGTCAGCTCGTTAACTCCA 
rs3796898 
F:ACGTTGGATGCCTCTCTCCACGCTAACCAG 
R:ACGTTGGATGACAACGCTTGCTCCCACCC TGGGCCCTCCGGTCGTC 
rs2739199 
F:ACGTTGGATGGACTGAAAGCAAAGCAGCAC 
R:ACGTTGGATGCATACTGGCAAGCACTCAGG CTCAGGTTGGAGGCCGG 
rs2723321 
F:ACGTTGGATGGCGCGTTAAATGCTTGGCTC 
R:ACGTTGGATGTAACTGCTACCCAGTTCTCC CTTTTTCACGTTTTCAACC 
rs2739207 
F:ACGTTGGATGATGACCCGGGCAGGAGAAG 
R:ACGTTGGATGGAAATGGAGACCAACTGCCG GCAAACTGGTGTCGGCGTGT 
rs2595103 
F:ACGTTGGATGAGAGAAAAGTCCTCTCCACC 
R:ACGTTGGATGCTTTCAAGAATCTCGGTGCC AACTCATCTGAACGCAATGGC 
rs1982361 
F:ACGTTGGATGTTTTTGCAGCCTCCCCATTC 
R:ACGTTGGATGGAGCGCCTCTTAATCTCTAC TCTACAAAATGAAAAGAAAAAAAG 
 
 
The extension primer was designed so that the 3’ end is immediately adjacent to the 
polymorphic site; the extension primer size is 16-25 nucleotide long (4800 to 7500 Da), 
with a melting temperature of 60°C or higher. 
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For each SNP an appropriate termination mix is chosen; the extension primer and 
termination mix combination should terminate at the SNP site for one allele (extension 
primer of just one nucleotide = the terminator) and as soon thereafter for the alternative 
allele (extension primer of two nucleotide, including the terminator). The mass of the 
extended primer should be within the mass range of 5000 to 8500 Da. 
The amplification primer optimal size, containing the SNP site is 70 to 150bp, and its 
mass should be different from the extension primer and its extension product. 
 
PCR amplification was performed in multiplex reactions as presented in table 6.9. 
 
Table 6.9: Multiplex reactions suggested by the MassARRAY Designer 
Multiplex reaction SNPs 
1 (6 plex) SNPrs1051888 + SNPrs2278782 +SNPrs2739202 + 
SNPrs1051887 + SNPrs2739205 + SNPrs379602 
 
2 (6 plex) SNPrs3796898 + SNPrs2739199 + SNPrs2723321 + 
SNPrs2739207 + SNPrs2595103 + SNPrs1982361 
 
3 (6 plex) SNPrs2595105 + SNPrs2739200 + SNPrs2595101 + 
SNPrs1051889 + SNPrs2276966 + SNPrs994978 
 
4 (4 plex) SNPrs1530717 + SNPrs976568 + SNPrs2595110 + 
SNPrs2559104 
 
5 (3 plex) SNPrs2278783 + SNPrs2723324 + SNPrs2595100 
 
6 (uniplex) SNPrs2739204 
 
 
 
6.4.4.2 Sequenom genotyping 
 
The following steps for Sequenom genotyping 
(http://www.ncl.ac.uk/ihg/research/facilities/sequenom) were followed: 
• The PCR reactions were performed in 96 well plates at final volumes of 10µl 
(the starting volume of PCR product required for the Sequenom system is 5µl per well 
in a 384 well plate) 
• 5µl is then transferred to a 384 well plate (ABgene 384 well plates to be used, 
sealed with ABgene adhesive PCR film) and the remainder was tested on 1% agarose 
gel. 
• Primers used were ordered (http://www.metabion.com/) in lyophilised state. The 
mass of the extension primer is critical to the assay working successfully and therefore, 
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extension primers were HPLC purified and MALDI TOF checked. PCR primers were at 
desalted purity. 
• Extension primers for hME SNP genotyping were resuspended at 100µM before 
being given to the technician (PCR primers contain an identical 10bp tail, which 
increases their mass to over 9000Da so they don’t interfere with the extension peaks. 
They also help to standardise the primers so that they will work more efficiently in 
multiplex). 
• Termination mixes have been chosen for each SNP. The termination mix brings 
about primer termination after 1 base addition for one allele, and 2/3 bases for the 
alternative allele. 
• When multiplexing, SNPs are grouped by termination mix it needs to be ensured 
that all possible products differ by at least 50Da. 
• The Sequenom touchdown PCR protocol (table 4.8) was followed. 
DNA amplification by PCR was performed for all samples following the protocol set 
for the Sequenom. Tables 6.10 and 6.11 present the reagents and the protocol for PCR. 
PCR reactions were checked on a 2% agarose gel, prior to continuing with the SNP 
genotyping. Quality control and quality assurance were provided by randomly including 
non-DNA containing well in the chip. 
Table 6.10: PCR reagents used for Sequenom reactions 
Reagent 
Initial 
concentration 
Volume 
(µl) 
Final 
concentra
tion 
ddH20 - 6.76 - 
Qiagen Hot Star 10x buffer 10 x (& 15mM MgCl2) 1.0 1 
Qiagen Hot Star MgCl2 25mM 0.4 2.5mM 
dNTPs 6.25mM each 0.32 0.2mM each 
Forward primer 1 to 6 25µM 0.08 each 0.2µM 
Reverse primer 1 to 6 25µM 0.08 each 0.2µM 
Qiagen Hot Star Taq 5U/µl 0.04 0.2 units 
DNA 2.5ng/µl 1 2.5ng 
Total volume (µl)  10  
 
 
Table 6.11: PCR touchdown protocol for Sequenom 
Reaction step Temperature 
(°C) 
Duration 
(min:sec) 
Nature of reaction Number of 
cycles 
1 95˚C 15 minutes Denaturation 1 cycle 
95˚C 20 seconds Separation of DNA strand  
56˚C 30 seconds Primers annealing 45 cycles 
2-4 
 
 72˚C 1 minute DNA synthesis (transcription  
5 72˚C 3 minutes DNA synthesis (elongation) 1 cycle 
 4˚C Forever   
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The report generated by the Sequenom technician has been entered in a database, which 
includes both the clinical details and the genotypes for all sites analysed. 
The figures 6.12 a-c presents various Sequenom screens with assays results. The first 
screen shows the results of a multiplex (six in this case) assay, which worked well. The 
second screen shows the image obtained when there is a machine failure (no extension 
primer visible) and the third screen shows a negative control (no DNA present), which 
is also the appearance of a failed PCR (no product in the well to be extended). 
Figure 6.12.a: Sequenom screen demonstrating a sample spectrum from sixplex genotyping assay 
obtained with MassEXTEND, with ID information displayed 
Figure 6.12.b: Sequenom screen demonstrating machine failure (no extension primer present) 
        
Figure 6.12.c: Sequenom screen demonstrating negative control or absence of DNA 
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6.4.5 Statistical methods for analysing Sequenom genotyping results 
6.4.5.1 Chi-square  
Chi –square test is a statistical test commonly used between two or more proportions 
(when there is a large number of observations) to compare observed data with the 
expected data obtained according to a specific hypothesis. An example to explain this 
more clearly would be as follows: 
 
According to Mendel’s law, half of 20 (i.e. 10) offspring would be male. But if the 
observed number of males was 8, then one would want to know about the “goodness to 
fit” between the observed and expected. Were the deviations (differences between 
observed and the expected) as a result of chance, or were they due to other factors. The 
χ 2 tests the null hypothesis, which states that there is no significant difference between 
the expected and observed result. More specifically, χ 2 is the sum of the squared 
difference between observed and the expected data, divided by the expected data: 
 
 
 
 
 
 
 
χ 2 utilizes numerical values, and not percentages or ratios. 
 
Using the chi-square distribution table (Table 6.12), the significance of the value is then 
determined (i.e. P < or > 0.05). In order to calculate this, the degrees of freedom (n–1, 
where n = number of variables) is determined and by finding the location of where this 
row meets the χ2 value, and by moving up this column, will provide the P value.   
 
For this study goodness-of-fit test was used to test for the following significance test: 
1. Whether allele frequencies for each SNP conformed to Hardy-Weinberg equilibrium 
(HWE). 
2. For differences in the distribution of sex and individuals with a family history of 
glaucoma between cases and controls using SPSS (version 15). 
3. For any significant differences in allele and haplotype frequencies between 
cases and controls using SHEsis (http://analysis.bio-x.cn/myAnalysis.php) and 
UNPHASED (http://www.mrc-bsu.cam.ac.uk/personal/frank/software/unphased). 
   
                (observed -expected ) 2       
  χ 2    =     
                        expected 
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Table 6.12: Chi square distribution table 
                                                     Probability Degree 
of 
freedom 
0.95 0.90 0.80 0.70 0.50 0.30 0.20 0.10 0.05 0.01 0.001 
1 0.004 0.02 0.06 0.15 0.46 1.07 1.64 2.71 3.84 6.64 10.83 
2 0.10 0.21 0.45 0.71 1.39 2.41 3.22 4.60 5.99 9.21 13.82 
3 0.35 0.58 1.01 1.42 2.37 3.66 4.64 6.25 7.82 11.34 16.27 
4 0.71 1.06 1.65 2.20 3.36 4.88 5.99 7.78 9.49 13.28 18.47 
5 1.14 1.61 2.34 3.07 4.35 6.06 7.29 9.24 11.07 15.09 20.52 
6 1.63 2.20 3.07 3.82 5.35 7.23 8.56 10.64 12.59 16.81 22.46 
7 2.17 2.83 3.82 4.59 6.35 8.38 9.80 12.02 14.07 18.48 24.32 
8 2.73 3.49 4.59 5.38 7.34 9.52 11.03 13.36 15.51 20.09 26.12 
9 3.32 4.17 5.38 6.39 8.34 10.66 12.24 14.68 16.92 21.67 27.88 
10 3.94 4.86 6.18 7.27 9.34 11.78 13.44 15.99 18.31 23.21 29.59 
                       Non- significant         Significant 
 
 
6.4.5.2 Hardy-Weinberg equilibrium (HWE) 
 
HWE is used to better understand the genetic characteristics of populations. Hardy– 
Weinberg principle states that both allele and genotype frequencies in a population 
remain constant, or are in equilibrium from generation to generation, unless specific 
disturbing influences are introduced. Those disturbing influences include non-random 
mating, mutations, selection, limited population size, random genetic drift and gene 
flow. Using this principle, population allele frequencies are used to calculate the 
equilibrium-expected genotypic proportions (Hardy 1908, Weinberg 1908). If p is the 
frequency of one allele (A) and q is the frequency of the alternative allele (a) for a 
biallelic locus, then the HWE-expected frequency will be p for the AA genotype, 2pq 
for the Aa genotype, and q for the aa genotype. The three genotypic proportions should 
sum to 1, as should the allele frequency (Hardy 1908, Weinberg 1908).  
                                                 p² + 2pq + q² = 1 
The most common method to assess HWE is through a goodness-of-fit test (Weir 2008). 
The null hypothesis is that alleles are chosen randomly, and the genotypic proportions 
thus follow HWE-expected proportions (i.e. p, 2pq, and q). In genetic association 
studies, testing for HWE is commonly used for quality control of large-scale genotyping 
and is one of the few ways to identify systematic genotyping errors in unrelated 
individuals (i.e. if P = =0.05 for HWE) (Gomes et al 1999, Hosking et al 2004, Weir  
2008). 
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For this study, allele frequencies for each SNP were tested for agreement with Hardy- 
Weinberg expectations (P>0.05) using a chi-square (p>0.05) goodness-of-fit test. This 
calculation was performed using a software package SHEsis and UNPHASED as above.  
 
6.4.5.3 Odds ratio 
 
The odds ratio (OR) is a way of comparing whether the probability of a certain event is 
the same for two groups. As case control studies begin with a selection of individuals 
with the disease (case) and another group without the disease (control), there is no way 
of knowing disease rates because these groups are not determined by nature but by the 
investigators’ selection criteria. Instead, OR is used. OR is defined as the odds that a 
case is exposed divided by the odds that a control is exposed. 
 
 
 
 
                    
 
An OR of 1 implies that the event is equally likely in both groups. An OR greater than 
one implies that the event is more likely to occur in the case group compared to the 
control group. An odds ratio less than one imply that the event is less likely to occur in 
the case group compared to the control group. As it is based on a sample collected from 
a population, it is essentially only an estimate. For this reason it is conventional to 
calculate the 95% confidence interval (CI) (defined as a 95% chance for the true OR of 
the population to lie within the interval) for the OR.  
 
6.4.5.4 Fisher’s exact test 
 
Fisher’s exact test is a statistical significance test used in the analysis of contingency 
tables where sample sizes are small. This is one of a class of exact tests, so called 
because the significance of the deviation from null hypothesis can be calculated exactly, 
rather than relying on an approximation that becomes exact in the limit as the sample 
size grows to infinity, as many statistical tests. Most uses of the Fisher test involve a 
2x2 contingency table. The p value from this test is computed as if the margins of the 
table are fixed. With larger samples, a chi-square test can be used in this situation (see 
                     Exposure rate to risk factor in cases 
Odds ratio =  
                      Exposure rate to risk factor in controls 
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above). However the principle of the test can be extended to the general case of an mxn 
table and some statistical packages provide a calculation for the more general case 
6.4.5.5 Summary of statistical methods used for analysing Sequenom genotyping 
and haplotyping results 
For the statistical analysis of the genotype (association tests for individual SNPs) and 
haplotype analysis the SHEsis (http://analysis.bio-x.cn/myAnalysis.php), UNPHASED 
version 3.0.12 - Dudbridge F 2003, (http://www.mrc-
bsu.cam.ac.uk/personal/frank/software/unphased) and SPSS version 15.0 
(www.spss.com) software packages were used. The SHEsis and UNPHASED programs 
were used for performing Hardy-Weinberg equilibrium, Fisher’s exact test, odds ratio, 
confidence intervals, chi-square tests and haplotype analysis. The SPSS was used for 
performing frequencies analysis. 
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6.4.6 Genotype and haplotype analysis of the SNP screening with Sequenom
TM 
 
6.4.6.1 Genotype analysis 
 
Second part of genetic investigations in this cohort of patients concerned screening of 
the PITX2 gene for SNPs already published in internet databases NCBI 
(http//www.ncbi.nih.gov/SNP) and Ensembl (www.ensembl.org).Figure 6.13 present 
the position of the SNPs chosen for high throughput genotyping with the Sequenom. 
The method of selection of SNPs from NCBI and Ensembl database has been presented 
above. 
Figure 6.13: Diagram of PITX2A gene SNPs site, from NCBI (http//www.ncbi.nih.gov/SNP) database, 
investigated with Sequenom 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The SHEsis (http://analysis.bio-x.cn/myAnalysis.php) and UNPHASED 
(http://www.mrc-bsu.cam.ac.uk/personal/frank/software/unphased/) programs were 
used to test every investigated SNP for association with POAG (Hardy-Weinberg 
equilibrium, Fisher’s exact test, odds ratio, confidence intervals and chi-square test). 
The results of the analysis are presented in the table 6.12 a-c. 
 
 
 
782566 758031 
P3/758171 
P16/758706 NP 
P8/758781 NP 
P6/759917 
P4/761864 NP 
P1/758799 NW 
P23/761573 
P2/761603 
P21/764772 
P18/771847 
P13/772210 
P19/773452 
P10/773567 NP 
P22/772582 
5’UTR                         Exon 1 Exon 2 Exon 5 3’UTR    Exon 6 
P17/773643 NP 
P11/773948 
P5/774158 
P9/774448 
P7/774643 NW 
P15/775872 NP 
P25/775879 
P20/776170 
P24/776469 
P26/776709 
Homeobox 
Legend: NP=non-polymorphic; NW= not worked; 
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Table 6.13.a: Results of single site association analysis 
Polymorphism Genotype/Allele OAG /OHT 
 probands 
 Controls  
  n % n % 
RS3796902/p6 CC 57 75 29 69 
 TT 1 1.3 1 2.4 
 CT 18 23.7 12 28.6 
 C 132 86.8 70 83.3 
 T 20 13.2 14 16.7 
 OR= 1.3 CI:0.6-2.7 P=0.4 X2=0.5  
  HW/P=0.7  HW/p=0.8  
RS2278783/p23 CC 66 73.3 34 73.9 
 TT 0 0 0 0 
 CT 24 26.7 12 26.1 
 C 156 86.7 80 87 
 T 24 13.3 12 13 
 OR=0.97 CI(0.4-2) P=0.9 X2=0.005  
  HW/P=0.1  HW/P=0.3  
RS2278782/p2 CC 52 78.8 21 75 
 TT 1 1.5 0 0 
 CT 13 19.7 7 25 
 C 117 88.6 49 87.5 
 T 15 11.4 7 12.5 
 OR=1.1 CI(0.4-2.9) P=0.8 X2=0.049  
  HW/P=0.8  HW/P=0.4  
RS2595110/p21 CC 6 6.2 5 8.3 
 TT 50 51.5 31 51.7 
 CT 41 42.3 24 40 
 C 53 27.3 34 28.3 
 T 141 72.7 86 71.7 
 OR=0.95 CI(0.5-1.5) P=0.8 X2=0.038  
  HW/P=0.5  HW/P=0.9  
RS994978/p18 AA 10 10.2 8 13.3 
 GG 42 42.9 27 45 
 AG 46 46.9 25 41.7 
 A 66 33.7 41 34.2 
 G 130 66.3 79 65.8 
 OR=0.97 CI(0.6-1.5) P=0.9 X2=0.008  
  HW/P=0.6  HW/P=0.5  
RS2595105/p13 AA 5 7.2 7 13 
 GG 25 36.2 27 50 
 AG 39 56.5 20 37 
 A 49 35.5 34 31.5 
 G 89 64.5 74 68.5 
 OR=1.2 CI(0.7-2.04) P=0.5 X2=1.12  
  HW/P=0.05  HW/P=0.2  
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Table 6.13.b: Results of single site association analysis 
Polymorphism Genotype/Allele OAG /OHT 
probands 
 Controls  
  n % n % 
RS2559104/p22 AA 9 9.2 8 13.3 
 CC 41 41.8 28 46.7 
 AC 48 49 24 40 
 A 66 33.7 40 33.3 
 C 130 66.3 80 66.7 
 OR=1.01 CI(0.6-1.6) P=0.9 X2=0.0038  
  HW/P=0.3  HW/P=0.4  
RS1530717/p19 CC 97 99 57 100 
 TT 0 0 0 0 
 CT 1 1 0 0 
 C 195 99.5 114 100 
 T 1 0.5 0 0 
 X2=0.58 P=0.4    
  HW/P=0.9  HW/P=1  
RS2595103/p11 CC 4 4.8 5 8.6 
 TT 45 53.6 35 60.3 
 CT 35 41.7 18 31 
 C 43 25.6 28 24.1 
 T 125 74.4 88 76.9 
 OR=1 CI(0.6-1.8) P=0.7 X2=0.07  
  HW/P=0.3  HW/P=0.2  
RS2739206/p5 CC 7 9.6 6 16.2 
 GG 29 39.7 14 37.8 
 CG 37 50.7 17 45.9 
 C 51 34.9 29 39.2 
 G 95 65.1 45 60.8 
 OR=0.8 CI(0.4-1.4) P=0.5 X2=0.38  
  HW/P=0.8  HW/P=0.3  
RS2723321/p9 AA 9 10 8 13.5 
 GG 37 41.1 27 45.8 
 AG 44 48.9 24 40.7 
 A 62 34.4 40 33.9 
 G 118 65.6 78 66.1 
 OR=1.02 CI(0.6-1.6) P=0.9 X2=0.009  
  HW/P=0.4  HW/P=0.4  
RS2595100/p25 AA 9 9.1 8 14.3 
 GG 41 41.4 27 48.2 
 AG 49 49.5 21 37.5 
 A 67 33.8 37 33 
 G 131 66.2 75 67 
 OR=1.03 CI(0.6-1.6) P=0.8 X2=0.02  
  HW/P=0.29  HW/P=0.2  
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Table 6.13.c: Results of single site association analysis 
Polymorphism Genotype/Allele OAG /OHT 
probands 
 Controls  
  n % n % 
RS976568/p20 AA 35 35.7 24 40 
 CC 11 11.2 9 15 
 AC 52 53.1 27 45 
 A 122 62.2 75 62.2 
 C 74 37.8 45 37.5 
 OR=0.9 CI(0.6-1.5) P=0.9 X2=0.002  
  HW/P=0.2  HW/P=0.7  
RS2723324/p24 AA 9 9.9 7 15.2 
 GG 38 41.8 22 47.8 
 AG 44 48.4 17 37 
 A 62 34.1 31 33.7 
 G 120 65.9 61 66.3 
 OR=1.01 CI(0.5-1.7) P=0.9 X2=0.003  
  HW/P=0.4  HW/P=0.2  
RS2739204/p26 AA 51 52 36 60 
 TT 5 5.1 5 8.3 
 AT 42 42.9 19 31.7 
 A 144 73.5 91 75.8 
 T 52 26.5 29 24.2 
 OR=0.8 CI(0.5-1.4) P=0.6 X2=0.2  
  HW/P=0.3  HW/P=0.29  
RS1982361/p12 AA 38 84.4 27 75 
 GG 4 8.9 5 13.9 
 AG 3 6.7 4 11.1 
 A 79 87.8 58 80.6 
 G 11 12.2 14 19.4 
 OR=1.7 CI(0.7-4) P=0.2 X2=1.59  
  HW/P=0.0001  HW/P=3.8e-
006 
 
RS2739200/p14 CC 9 11 8 14.3 
 GG 42 51.2 28 50 
 CG 31 37.8 20 35.7 
 C 49 29.9 36 32.1 
 G 115 70.1 76 67.9 
 OR=0.8 CI(0.5-1.5) P=0.6 X2=0.1  
  HW/P=0.3  HW/P=0.1  
 
SNP rs1982361 was not in Hardy-Weinberg equilibrium either in the patients or 
controls and therefore has been discarded. SNPs rs105889, rs2739199, rs1051887, 
rs2739207, rs2739202, rs2276966 and rs2595101 were not polymorphic in this cohort 
and 2 SNPs (rs1051888 and rs3796898) did not work. None of the SNPs are associated 
with POAG in this cohort of patients. All the sites which were not polymorphic in this 
cohort are the sites within the coding sequence (4 sites) or in the 3’UTR (2 sites) and 
5’UTR (1 site). The SNP rs1051888 which did not work in this assay was actually 
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covered by the sequencing of the gene with primer set 1 and the polymorphism was not 
present in this cohort. 
 
Figure 6.14 demonstrates the appearance of a Sequenom screen in a heterozygous 
sample for SNP rs3796902 (CG), showing peaks at both sites (C and G). 
 
Figure 6.14: Sample spectrum from genotyping obtained with MassEXTEND showing a heterozygous 
 assay (peaks at both the C and G site) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.4.6.2 Haplotype analysis 
 
Recently, many researchers investigating SNPs association in complex diseases have 
found that haplotype analysis can be more powerful when disease susceptibility might 
be conferred by a haplotype (Judson et al 2000). 
 
Haplotype analysis has been performed on this cohort of patients and controls, using the 
SHEsis and UNPHASED platforms as above. Initially, an analysis of all the sites found 
polymorphic and in Hardy-Weinberg equilibrium in this cohort was carried out.  
Subsequently, various haplotypes were constructed and analysed.  
 
Figure 6.15 demonstrates the r
2
 value, measure of linkage disequilibrium between the 
SNP sites investigated (r2 is a measure of LD and r2=1 can be described as complete LD 
because allelic association can be as strong as possible. Genotypes at SNPs which are < 
10kb apart tend to be correlated and a stringent r
2
 threshold of >0.8 would resolve > 
80% of existing haplotype of the SNPs tested).   
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From the diagram it is evident that there is a block of SNPs (p9-18, p20, p22, p24-26) 
which are in linkage and the haplotype analysis has been concentrated on this block. 
 
Table 6.14: Results of haplotype analysis block p9-p18, p20,p22,p24-p26 
P9 p11 p13 p14 p18 p20 p22 p24 p25 p26 
Case 
 freq % 
control  
freq % Χ2 p OR CI 
A C A C A C A A A T 20.9 26.8 19 25 0.06 0.7 1.1 
0.5-
2.2 
A T A C A C A A A A 2.96 3.8 5 6.6 0.6 0.4 0.5 
0.1-
2.4 
G T G G A A C G G A 0 0 1 1.3 1.03 0.3   
G T G G G A C G G A 45.8 58.8 47 61.8 0.14 0.7 0.88 
0.4-
1.6 
G T G G G C C G G A 5.1 6.5 4 5.3 0.11 0.7 1.2 
0.3-
4.8 
A C A C A A A A A T 1.07 1.4 0 0 1.04 0.3   
A T A C A A A A A A 1.04 1.3 0 0 1.01 0.3   
G C G G G A C G G A 1 1.3 0 0 0.9 0.3   
GLOBAL Χ2 = 118.1, df=6, p= 0.00e+000 
 
Table 6.15: Results of haplotype analysis p2 & p6 
P2 P6 
case 
f
r
e
q % 
control 
f
r
e
q % Χ2 p OR CI 
C C 112 87.5 49 87.5 0.01 0.8 1.06 0.5-2.7 
T C 0 0 1 1.8 2.2 0.1   
T T 15 11.7 6 10.7 0.04 0.8 1.1 0.4-3.04 
C T 1 0.8 0 0 0.14 0.7 0.88 0.4-1.6 
GLOBAL Χ2 = 135.5, df=1, p= 0.00e+000 
 
Haplotype analysis also failed to identify any significant association of a haplotype with 
POAG/OHT in this cohort. 
The implications of sequencing results, SNP screening and haplotype analysis will be 
discussed. 
 
Figure 6.15: Graphic representation demonstrating the r2 values (measure of linkage disequilibrium)  
between the SNP sites investigated in this study (obtained with SHEsis software platform) 
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6.5 DISCUSSION PILOT STUDY 
 
Open angle glaucoma is the major primary type of glaucoma in most population world 
wide and one of the main causes of blindness if left untreated. It is more prevalent in 
black than in white populations (Leske et al 1994, Tielsch et al 1991,) and  a Chinese 
population based cross-sectional study showed that glaucoma is the major cause of 
blindness and that POAG is an important form of the disease (Foster et al 2000). 
Demographic (age, gender, ethnicity, socioeconomic), genetic, systemic (diabetes, high 
or low blood pressure), ocular (elevated IOP, optic nerve head status, central corneal 
thickness, refractive status) as well as some other risk factors (smoking and alcohol 
intake) have been described, however, the pathogenesis of the disease is still unclear. 
   
It is generally accepted that POAG in most cases is inherited as a complex trait, 
resulting from interaction of multiple genes and environmental factors (Fan et al 2006b, 
Sieving and Collins 2007). This complex disorder results from diverse pathological 
process, not limited to involving only the aqueous outflow, but the RGC, the optic nerve 
and even cerebrospinal fluid, as suggested by Berdahl et al, 2008. 
 
6.5.1 Summary of the study 
 
 So far, genetic studies only identified three POAG genes (MYOC, OPTN and 
WDR36). Mutations in these genes account for only 10% of all POAG patients. 
Therefore it is very likely that other unidentified loci and genes still exist (Fan et al 
2006). An obvious group of genes to test as genetic susceptibility factors for POAG are 
the developmental glaucoma genes, which at the conception of this pilot study have not 
been analysed in any association study, with the exception of the CYP1B1 gene. 
 
The genes involved in anterior segment dysgeneses, play an important role in normal 
morphogenesis of the eye and especially anterior segment and can provide insight into 
the underlying genetic mechanism of glaucoma. Since these genes cause malformations 
of the drainage structure of the eye and elevation of IOP, patients with ASD are at an 
increase risk of developing glaucoma. Therefore, it is possible that these genes can 
contribute to age related glaucoma by causing subtle changes, which are not clinically 
visible, but which cause dysfunction with age. Also, in the mean time, an association 
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between LMX1B and POAG patients has been demonstrated (Park et al 2009). This 
study also used the cohort from the pilot study presented in this thesis. 
 
This pilot study screened for PITX2 gene variations in a cohort of 100 patients with 
POAG/OHT, six patients with posterior embryotoxon and 60 matched controls, and 
tested for a significant association with glaucoma in these patients. 
 
The patients with POAG/OHT were identified and enrolled in the study according to 
strict criteria. All patients were phenotyped by experienced glaucoma specialist and as 
such it represents a homogenous, well defined group. Genetic studies were carried out 
by Dr Vaideanu, at the Institute of Human Genetics, Centre for Life, Newcastle upon 
Tyne. 
 
First part of the genetic study consists of sequencing analysis of the coding region in 
PITX2 gene. Analysis of the traces did not identify any sequence variation in this 
cohort. This indicates a high level of sequence conservation in the homeobox region of 
PITX2 gene. 
 
Second part of the genetic study consists of high throughput screening of SNPs 
published in the internet databases. Genotype analysis demonstrates that none of the 
SNPs screened are associated with POAG in these patients. Haplotype analysis also 
failed to identify any significant association of a haplotype with POAG/OHT in this 
cohort. 
 
In this particular cohort, a large effect of PITX2 polymorphism in POAG has not been 
demonstrated. However, as mentioned above, a recent paper by Park et al (2009), 
demonstrates that certain LMX1B haplotype influence susceptibility to glaucoma, 
predisposing to glaucomatous damage independent of intraocular pressure. This finding, 
lends further support to the hypothesis that genes associated with anterior segment 
dysgeneses may predispose to glaucoma. Therefore, further studies into the role of 
developmental glaucoma genes in the pathogenesis of POAG are needed, as smaller, 
more subtle effect and /or possible gene-gene interactions might be demonstrated. 
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6.5.2 Patient and control identification and recruiting discussion 
 
As this study was set up as a pilot study, a sample of 100 POAG/OHT patients, 10 
posterior embryotoxon subjects and 100 matched controls was considered to be an 
appropriate size for answering the study question.  
 
Identification of the patients has been straightforward, as the details were checked in the 
notes and if the criteria for inclusion were met, the patient was offered the opportunity 
to take part in the study. Most patients, were very positive about taking part and about 
1in 3 accepted to be part of the study. 
 
The controls sample size was meant to be the same as the patient sample. However, this 
aim was not achieved. Two factors contributed to this situation.  
 
While, the ethical committee approval was already obtained for the POAG patient’s 
involvement in genetic studies, that was not the case for the controls. To get the ethical 
committee approval, a letter had to be written, explaining why the controls were needed. 
Therefore, the recruiting of the controls has been delayed until the approval was 
received. By that stage, about half of the POAG/OHT patients were already enrolled in 
the study. That made it more difficult to find spouses of POAG/OHT patients willing to 
take part in the study. The motivation to take part was not the same for relatives of 
patients who were not part of the study. 
 
The second factor which played a part in achieving a smaller number of controls was a 
misunderstanding on my part regarding the collaboration set up with Royal Victoria 
Infirmary. The collaboration was set up so that we would exchange DNA control 
sample, to help with boosting up the numbers. Once this has been agreed, my 
understanding was that I would give them a DNA sample of the 30 controls I already 
enrolled, and this would be reciprocated by getting the rest of the sample to make up to 
a hundred for me. This was not the case and the exchange was only sample for sample. 
This emphasises the naïveté of the clinician when getting involved with laboratory 
research. It was also a learning point for me in making sure everything is well 
understood and clear when these informal agreements are made. By the time all this was 
  157
resolved, I have already started the laboratory work. Time and being physically away 
from the recruiting centre made it difficult to start recruiting again. Therefore, I have 
settled on the number of control samples I already had, which was 60. 
 
Also, the aimed number of 10 subjects with posterior embryotoxon was not achieved. 
The reason was that only eight subjects with posterior embryotoxon came through Mr 
Fraser’s clinic during the recruiting period. Of these, six agreed to take part in the study. 
 
6.5.3 Genetic studies results discussion 
 
6.5.3.1 Sequencing results discussion 
 
As already stated, sequencing analysis of the coding region of PITX2 gene in this cohort 
has not identified any sequence variation in this cohort. The sequencing reaction worked 
well and on almost all patients and controls only on primer set 1, which covered mainly 
the homeobox. No sequence variation has been identified in this region in the cohort 
presented and this indicates a high level of conservation of this region. Considering the 
important role of the homeobox in cell type specification, embryonic pattern formation 
and determination of cell fate (Gehring et al 1994), and the fact that mutations in this 
region cause obvious structural abnormalities (Axenfeld- Rieger anomaly/syndrome, 
Peters), may be this finding is to be expected. The rest of the PITX2 coding region has 
been sequenced only partially and therefore a final statement about sequencing analysis 
cannot be made in this case. The reasons for sequencing not being complete have been 
discussed in chapter 6.4.3.1 and it will not be reiterated here.  
 
It could be argued, that if variations in the sequence which cause subtle structural 
changes were investigated, the search should have concentrated on the intron-exon 
boundaries and the UTR region of the gene. With hindsight, may be this would have 
been a better strategy, however, I think that the main coding region had to be screened 
regardless. Also, most of the UTR region was covered by the primer set 4. 
Unfortunately, this is the primer set the sequencing analysis was least successful in this 
study. 
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6.5.3.2 High throughput screening results discussion 
 
When this study was set up (2001), the hypothesis allowed for a fairly large effect 
caused by a sequence variation. Since then, technological advances (high throughput 
screening methods, development of internet SNPs database) and better understanding of 
genetics of complex diseases,  allowed the scientists to understand that most likely a 
smaller effect to the phenotypic expression is caused by any given sequence variation. 
 
The advantages of using SNPs for association studies have been explained in the 
introduction to the study design (chapter 6.1.2).Therefore, it was a logical step to take 
this study further, and screen the SNPs published in the internet database for an 
association with POAG/OHT in this cohort of patients and controls. 
 
As mentioned above, the fact that sequencing analysis did not work well in all samples 
and primer sets and technological advances during the duration of the study, allowed for 
further genetic studies in the form of high throughput SNPs screening using the 
Sequenom. The selection of the SNPs from the internet databases has been presented in 
the chapter 6.4.4.1. As, it is obvious from the table 6.7, there is a large number of SNPs 
selected and screened. Most likely, a smaller number of SNPs would have been enough 
to be screened, to get robust information for statistical analysis and this is explained 
next.  
 
When this study has been started, The HapMap project was in its beginnings and the 
tagSNPs program (www.hapmap.org) was not available. As the pace of technological 
progress in this area is very fast, I became aware of it after doing the SNP analysis. As 
mentioned previously, SNPs are a newest generation of marker to locate genes in DNA 
sequences. The problem with using SNPs as markers is their abundance (10 million 
common SNPs), which makes a direct association study unfeasible. Therefore, it is 
important to find biologically significant SNPs, as most have no effect. At present, only 
a few representative SNPs on the chromosomes of interest are genotyped. This is done 
in the hope that by determining the pattern of bases at a few selected positions, these 
can infer values of bases at intermediate SNPs which are not being measured, as genetic 
variants that are near each other tend to be inherited together. This is called haplotype 
tagging and relies on sufficiently representative set of tagging SNPs covering region of 
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genome under study (figure 7.6). The number of tag SNPs that are informative of the 
remaining SNPs is estimated to be about 300,000 to 600,000 which is much less than 10 
million common SNPs. R
2
 is a measure of LD and r
2
= 1 can be described as complete 
LD because allelic association is as strong as possible. Genotypes at SNPs which are < 
10kb apart tend to be correlated. A relatively stringent threshold of > 0.8 would allow a 
selected tagSNPs to improve correlation and resolve >80% of all existing haplotype. 
 
Therefore, the program has been used to identify if any of the PITX2 SNPs selected 
previously would be picked up. Indeed, 5 SNPs (out of 26 selected) were picked up by 
the program, suggesting that the SNP selection and analysis of the PITX2 gene is robust.  
The SNPs selected are: rs2739202, rs2278782, rs2595110, rs976568 and rs1982361.  
 
 
 
 
 
 
Figure 6.16 (a) SNPs are identified in DNA samples from multiple individuals. (b) Adjacent SNPs that 
are inherited together are compiled into "haplotypes." (c) "Tag" SNPs within haplotypes are chosen that 
uniquely identify those haplotypes (Diagram obtained from the HapMap Project – 
http//www.hapmap.org/) 
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6.5.4 Assessment of study design and data quality 
 
How can case-control genetic association studies be evaluated? The following criteria 
are suggested by Silverman and Palmer (2000) - table 7.5. 
 
Table 6.16: Evaluation of candidate gene case-control association studies (adapted from Silverman 
 and Palmer, 2000) 
Issue Key questions Possible solutions 
Is candidate gene biologically  
reasonable? 
Demonstration of biologically  
functional effect 
Selection of candidate 
gene 
 polymorphism Is the candidate gene a positional  
candidate? 
Within linked region in man or  
syntenic from animal model 
Matching on ethnicity 
Family based association  
designs 
Population stratification Are cases and control matched? 
Negative results with multiple  
unlinked markers 
Hardy-Weinberg (H-W)  
equilibrium 
Is control group in H-W  
equilibrium? 
Calculation of H-W equilibrium  
with goodness of fit test (2 alleles) 
 or simulation (multiple alleles) 
How many alleles were tested? Bonferroni correction Multiple comparisons 
How many genetic loci were tested? Estimation of empirical p values 
 
So, how does the current study evaluate against the above criteria? 
 
6.5.4.1 Selection of candidate gene polymorphism 
 
It has been demonstrated above why developmental glaucoma genes are good candidate 
genes to be studied for susceptibility to POAG The role of PITX2 in anterior segment 
morphogenesis and its function has been extensibly  described both under Genetics of 
developmental glaucoma and PITX2 gene chapters as well as in this chapter. In 
addition, the associated glaucoma can present at any time from birth to adulthood and in 
some affected family members with developmental glaucoma, the phenotype of the 
anterior segment malformation can be very subtle and easily missed, adding further 
support to the biological plausibility of these genes as candidate genes for POAG 
 
6.5.4.2 Population stratification 
 
The cases and controls have been carefully matched for age and ethnicity, so type I   
error is not a concern with this study (type I error occurs when the population sampled 
consists of several sub-populations that do not intermix and can lead to spurious false 
positives results, if the cases and controls are not well matched for ancestry and if 
disease rates and marker allele frequencies are different between ancestral populations). 
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The patients and controls enrolled in this study are of Caucasian origin and no 
significant population migration occurred in the North-East of England. It could be 
argued that this cohort is a sub-population of glaucoma patients, due to the strict 
inclusion criteria of IOP at presentation > 30 mm Hg. However, I have presented the 
reason why this particular IOP value has been chosen. If a positive association would 
have been demonstrated in this group, then the cohort would have to be enlarged and 
possibly patients with glaucoma with IOP < 30 mm Hg at presentation included in the 
study, to ascertain if the results can be reproduced. 
 
6.5.4.3 Is control group in H-W equilibrium? 
 
The control group is in H-W equilibrium for all the markers tested and the calculation is 
presented in table 7.2. SNPs which were not in H-W equilibrium have been discarded 
(SNP rs1982361). Also, as described above, the selection of markers is robust, allowing 
for a good coverage of the gene and resolving most of the haplotypes. 
 
 6.5.4.4   Statistical considerations 
 
As first stage of the study was to sequence the coding region of the PITX2 gene and 
identify any polymorphism, determine the frequency in the controls and then test for 
association with POAG, it was considered that a cohort of 100 POAG/OHT patients and 
100 matched controls would be sufficient for the purpose.  
 
To have an association with the disease, a polymorphism would have to have a 
frequency of at least > 1% in the general population, or if the frequency is < than 1% in 
the general population, than the effect of the polymorphism has to be quite large for an 
association with the disease to be detected.  
 
This is known as common disease, common variant (CD/CV) hypothesis, which 
questions why these diseases are so common and why are they maintained in the 
population at such high frequency. This hypothesis states, “the genetic risk for common 
diseases will often be due to disease-producing alleles found at relatively high 
frequencies (>1%)”-Becker 2004. The CD/CV hypothesis addresses the question of why 
these disorders are so common; because the underlying disease influencing alleles are 
common. Polymorphisms in the APOE gene in the context of late onset Alzheimer’s 
disease have been suggested as prototype for this hypothesis, due to high population 
frequency of APOE4 allele. Late onset Alzheimer’s disease is a common disorder 
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affecting up to 60% of the population after the age of 75. APOE4 is present in 15% of 
the population and is found in up to 50% of individuals affected with late onset 
Alzheimer’s (Cargill and Daley 2000). 
 
Considering that the frequency of a particular allele in general population (controls) is 
10%, for a cohort of 100 POAG/OHT patients and 100 controls, the study would have 
80% power to detect a 10 to 26% difference between the groups and 92.5% power to 
detect a difference of 10 to 30 % difference between the groups, significance level of  
0.05. 
 
However, for this study, only 60 controls were enrolled. Therefore, assuming the same 
10% frequency in general population, this study has 80% power to detect 10 to 30% 
difference between the groups, (p=0.05). 
 
It has to be mentioned that choosing to do calculations for an estimated SNP frequency 
of 10% is may be being too optimistic about the findings and also, not doing my 
background research regarding SNPs frequencies adequately. More realistic is to 
consider a 1% frequency as being quite a high value for the context of complex 
diseases. 
 
So, if the calculation is redone for an assumed allele frequency in the general population 
of 1%, then this study has 80% power to detect a difference from 1 to 11,5 % and 99% 
power to detect a difference from 1 to 22%, (p=0.05). 
 
From the above calculations it is evident that the study has enough power to detect a 
large effect, even if the frequency of the polymorphism in general population is 1%. 
However, as mentioned, in this cohort no association was found between PITX2 
polymorphism and POAG/OHT.  
 
It also has to be mentioned of 26 alleles chosen for this study from the published 
database only 10 had a frequency published, of which the highest was 0.494%. If any of 
these alleles would have shown an association that would indicate a very large effect. 
So, it may be isn’t a surprise that no association was shown for this size cohort and 
could be a good idea to repeat this study in a much larger cohort. 
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6.5.4.5 Adjustment for multiple testing 
 
The incidence of false positive error is proportional to the number of significance tests 
performed and multiple testing can lead to a potential false positive error. This has been 
addressed in the algorithm of the program used for analysis and also by using two 
different programs to do the same analysis (SHEsis and UNPHASED). 
 
6.6 LIMITATIONS OF THE PILOT STUDY 
 
6.6.1 Size of the cohort 
 
The main limitation of this study is the size of the cohort, which, despite being adequate 
to produce reliable results could include more samples. However, this would have not 
been feasible within the time framework of this project.  
 
 When this project was set up, the initial aim was to genotype the whole coding 
sequence, screen for SNPs and then calculate the frequency in the control and patient 
group and look for association with the disease. The sample size was thought to be 
appropriate for this aim, and it was demonstrated above that the study has enough power 
to detect a large effect from the gene variation, should one be present.  
 
After founding that no variation was present in the coding region and due to the 
development of the SNP database and rapid technological advances of high throughput 
genotyping during the course of the project, it become possible to perform SNP 
screening of the gene of inters in this cohort. 
 
Statistical work regarding genetic association case-control studies has received a lot of 
attention in last five years. If genotype frequencies would be known a priori, then 
standard statistical methods and software could be used to calculate power (Ambrosius 
2004). 
 
 Although a lot of statistical work has been done for family-based tests of association, 
there was not much work about unrelated case control genetic association studies. This 
received more attention when positive findings in the initial study could not be 
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replicated in subsequent studies. In their review of “Genetic association studies”, 
Cordell and Clayton (2005) emphasize that the standards of statistical proof that become 
acceptable in the general biomedical literature are not appropriate for genetic 
association studies and they suggest that Bayesian methods might be more appropriate. 
This might be resolved with the implementation of microarray studies.  
 
For this study, delay with getting ethical committee approval for control enrolment, 
further hindered the number of controls enrolled, and the initial objective of 100 
controls has not been achieved. Work at the Institute of Child Health, UCL has 
addressed issues of cohort size and sub-group stratification for both cases and controls 
and an association between POAG and LMX1B1 has been demonstrated (Park et al, 
2009). 
 
6.6.2 Visual field recording 
 
Another limiting factor for the study is the lack of objective assessment of the severity 
of Humphrey visual field using global indices (mean deviation, pattern standard 
deviation, corrected pattern standard deviation). On the plus side, all the visual fields 
tests showed reproducible fields defects that were compatible with the degree of 
glaucomatous cupping of the optic nerve head (defined by loss of neuroretinal rim) and 
were ensured to have satisfactory reliability score of <20% fixation loss, false positive 
of < 33% and/or false negative of <33%.   
 
6.6.3 Central corneal thickness 
 
The third limiting factor of this study is the absence of CCT measurements. CCT 
variation is known to affect the accuracy of IOP readings on applanation tonometry, 
with thick corneas giving falsely high IOP readings and thin cornea falsely low readings 
(Feltgen et al, 2001, Whitacre et al, 1993). In the current study the IOP measurements 
were checked by a Tono-Pen which is less affected by CCT (Bahn et al 2002) in 
addition to performing applanation tonometry. Although nomograms, based on varying 
CCT exist for adjusting IOP readings (Ehlers et al 1975, Stodtmeister 1998, Whitacre et 
al 1993), as yet there is no generally accepted correction formula (Brandt 2004). Two 
recent studies that adjusted IOP for CCT found that the correction did not alter the 
diagnosis of high tension glaucoma or normal tension glaucoma (Miyazawa et al 2007), 
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and did not affect the relationship between the prevalence of POAG and IOP 
respectively (Francis et al 2008). Even if a correction formula were to be applied with a 
10 µm change in the corneal thickness inducing a 0.2 mmHg change in IOP reading 
(Doughty and Zaman 2000), a 2-3 mmHg change would equate to a 100-150 µm change 
in the CCT, which is a considerable amount. Therefore, it is highly unlikely that the 
individuals with IOPs of 20 mmHg or below or IOPs of 24mmHg or higher would have 
their diagnosis altered. Assuming that the average CCT is approximately 537-550 µm 
(Shah et al 1999, Wolfs et al 1997), these subjects would require having either 
abnormally thin corneas or unusually thick corneas. 
 
Several studies have shown that increased CCT may occur in certain types of 
dominantly inherited developmental glaucoma, including iris hypoplasia (FOXC1 
duplication – Lehmann et al 2003b), aniridia (PAX6/Pax6 – Brandt et al 2004, Ramaesh 
et al 2003) and dysgenic lens (Foxe3 - Lehmann et al 2003b). Conversely, a reduced 
corneal thickness was associated with Axenfeld-Rieger malformation from PITX2 
mutation (Asai-Coakwell et al 2006). 
 
CCT data was not collected for the cases and controls in this study, as a pachymeter was 
not available at the time when this study was carried out. However, the POAG/OHT 
patients enrolled in this study have an IOP > 30mmHg (mean 34.9 ± 6.9), so even 
allowing for IOP overestimation, the IOP would still be very high. However, the role of 
IOP in POAG/OHT and the interactions between the IOP and genetic factors needs 
more clarification. 
 
6.6.4 C/D ratio recording 
 
A fourth limiting factor of the study is the lack of objective measurement of the C/D 
ratio as a measure for the severity of the disease, as this can be quite subjective, 
depending on the observer. Subsequent to the collection data for this work, newer 
imaging methods of the optic nerve have been developed, in the form of Optical 
Coherence Tomography and GDx nerve fibre analyser test. These are superior 
diagnostic tools, which will allow earlier detection of structural damage, and will 
provide more objective data for research purposes. However, the patients included in 
this study had photographs of the optic disc, which provides some measure of 
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objectivity, as well as being carefully examined by a consultant ophthalmologist with a 
special interest in glaucoma and experience in glaucoma phenotyping. 
6.7 FUTURE WORK PERTAINING TO THE PILOT STUDY 
1. Enlarging sample size for patients and controls as well as identifying and recruiting 
for genetic studies patients with strong family history of glaucoma 
2. Set objective criteria for phenotype description 
2. Extending the panel of ASD genes to be screened in POAG patients 
3. Any demonstrated association should be reproduced in an independent cohort 
4. If an association is demonstrated, then the future aim will be to isolate the causative 
variant(s). This can be achieved by identifying potentially functional genetic variations 
at the locus researched by sequencing all the exons, splice sites and conserved non-
coding sequences in the cohort studied. 
5. Functional analysis of any coding or non-coding SNPs could then be performed in 
order to isolate the causative variant(s) affecting the risk of developing POAG. This can 
be achieved in two ways. Firstly, identified non-synonymous amino acid variants can be 
investigated using DNA binding assays (e.g. electrophoretic mobility shift assay: this is 
an electrophoretic separation of a protein-DNA or protein- RNA mixture on a 
polyacrylamide or agarose gel. It is a common affinity electrophoresis technique used to 
study protein-DNA or protein-RNA interactions) and reporter assays to test differences 
between protein variants to activate transcription of artificial reporter genes and putative 
biological targets. Secondly, in order to assess whether non-coding variants are 
associated with altered expression levels of mRNA and protein levels of the gene 
investigated and downstream target genes, cadaver tissue and other appropriate cell 
lines can be analyzed. RNA and protein can be extracted from genotyped tissue 
samples. This will be followed by application of real time quantitative PCR to assess for 
mRNA expression levels. Extracted proteins can be analyzed by Western blotting for 
assessment of protein expression levels. In doing so, allelic differences in the expression 
levels of mRNA and proteins could be identified and therefore ascertain the responsible 
non-coding variants. 
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6.8 CONCLUSION 
 
Accurate standardization of the POAG/OHT cohort is very important, however still not 
100% objective. Despite the fact that the diagnosis of POAG /OHT on cases was 
definite, the effect of genetic factors on the progress of the disease on the existing 
cohort cannot be studied.  
 
The definition for POAG should be ideally based on objective criteria and not only on 
clinical examination. Digital photographs of the optic discs, together with imaging 
reports of sophisticated instruments such as the nerve fibre analyser or the OCT, could 
be assessed by experts in reference centres, to assure firm and unbiased diagnosis. 
 
 Automated perimetry examination must be uniform, performed by the same observer 
on a reliable machine, such as the Humphrey analyser, using the same software 
programme. This will limit the inter-observer and intra-observer variability, especially 
on parameters such as the C/D ratio, which is proven to be a very “soft” diagnostic and 
research tool. 
 
To note is that the cohort studied is solid, from the same population of the North East of 
England, with strict documentation and quality POAG/OHT and control subjects, 
carefully examined by a Glaucoma Specialist Consultant Ophthalmologist vast 
experience in the field. The laboratory and statistical analysis were rigorous, allowing 
accurate results. Reproducibility remains an issue, denoting the necessity for subsequent 
work that needs to be undertaken in order to unravel  the enigma of the POAG aetiology 
and which for this study has been addressed, by continuing the work on a cohort of 400 
patients and 400 controls at the ICH, UCL, London.  
 
As mentioned above, this work has now been concluded and it demonstrated an 
association between LMX1B and glaucoma (Park et al 2009). This is the first study to 
demonstrate an association between a gene involved in anterior segment dysgeneses and 
glaucoma. 
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                                   Chapter 7:   
              IDENTIFICATION, PHENOTYPING AND RECRUITMENT  
              FOR GENETIC STUDIES OF POAG PATIENTS WITH  
              STRONG FAMILY HISTORY OF GLAUCOMA 
 
 
7.1 INTRODUCTION   
 
 
It is generally accepted that a family history of glaucoma increases the risk of the 
disease, with a life risk of glaucoma of 9.2 times higher in siblings and offspring of 
glaucoma patients than in siblings and offspring of controls (Hulsman et al 2002). 
 
Identifying a family history of glaucoma is important for screening programmes, as it 
would appear that familial glaucoma is more aggressive and has a younger age of onset 
than sporadic glaucoma (Wu et al 2006) and therefore a screening programme will be 
more successful if it is developed with appropriate weighting towards those with a 
positive family history of the disease. 
 
Recruiting families (ideally large pedigrees with living relatives in different 
generations) with multiple members affected of a disease is important for genetic 
studies, as it allows mapping the disease loci by linkage analysis. Linkage analysis 
methods attempt to identify a region of the genome that is transmitted within families 
with the disease phenotype of interest and has been extremely useful in the 
identification of genes responsible for diseases with simple Mendelian inheritance. 
 
So far, 14 POAG loci have been mapped by linkage analysis and genome wide scanning 
in families with autosomal dominant mode of inheritance and age dependent penetrance.  
 
Ideally, when recruiting families, one would like to have a large number of affected 
members; a figure of 11 or more is considered to be ideal for conducting linkage 
analysis. 
 
The patient population at Sunderland Eye Infirmary (SEI) has not had the opportunity to 
take part in these studies. Collaboration between Mr Scott Fraser at SEI, the Genetics 
Department at St George’s Hospital, London and Professor Sarfarazi, USA has been set 
up with a view of identifying glaucoma pedigrees and recruiting them for genetic 
studies.  
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Part of my project was to continue with recruitment of POAG patients with family 
history of glaucoma from North East of England, construct the pedigrees, liaise with 
relatives of the proband, collect samples and forward the samples and clinical 
information to London. From London, the samples were sent to Professor Sarfarazi 
laboratory for the genetic studies.   
 
In the next chapter, some of the pedigrees identified from glaucoma patients in North-
East of England and the phenotyping details are presented, together with an update on 
the genetic work carried out on these patients so far. 
 
7.2 IDENTIFICATION OF PATIENTS WITH FAMILY HISTORY OF 
       GLAUCOMA, RECRUITING TO THE STUDY AND PHENOTYPING 
 
The protocol for the glaucoma family history study was as follows: 
 
• Identification of the patients with glaucoma who had a family history of the 
disease from the patients who attended out-patient clinics or the nurse led 
glaucoma review clinics 
• Suitable patients (at least two family members affected with glaucoma) to be 
provided with a study information sheet (appendix 1), by the consultant or the 
nurse 
• Either the nurse or the doctor will discuss the study with the patient 
• If the patient communicates willingness to assist, the details were passed on to 
the Research Fellow, to arrange an appointment for recruitment to the study 
• Upon receipt of the patient details, the patient was contacted and an appointment 
was organised with myself to: 
1. discuss the study  
2. obtain written consent for taking part in the study 
3. construct the pedigree and obtain as much information as possible about the 
relatives 
4. perform a clinical examination  
5. collect a sample of venous blood  
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• Upon receipt of information from the proband about relatives who are interested 
in taking part in the study, the relatives were contacted and appointments for 
clinical examination and sample collection was organised 
• Where the relatives were unable to come to the hospital, the blood collection 
was organised to the GP practice or at home 
• If clinical examination could not be done, information was requested from the 
optician, with consent from the family member involved or from 
ophthalmologists in the cases of affected relatives 
• The blood samples were sent to London, and were forwarded on to Professor 
Sarfarazi for genetic studies 
• Any result specific to an individual will be relayed from laboratory to Mr Fraser 
for genetic counselling purposes 
 
The examination protocol was standardised and it comprised: 
• Best corrected Snellen visual acuity assessment 
• Anterior segment examination with slit lamp 
• Goldman applanation tonometry 
• Gonioscopy 
• Fundus examination and optic disc assessment with a 90D condensing lens 
• All the probands and individuals with definite POAG diagnosis had at least two 
reproducible visual field tests in the immediate past (Humphrey automated 
perimetry, 24-2). Also, all the glaucoma patients recruited from the SEI had 
optic discs photographs 
• For the relatives participating in the study and unaffected, due to staff shortage 
and financial constraints, visual fields were not carried out. However, for the 
majority, copies of the visual fields were obtained from the optician 
 
Details about other systemic and ocular conditions and glaucoma treatment as well as 
age at diagnosis were also recorded. The study has local ethical committee approval and 
the GP’s of the individuals participating in the study were kept informed. Figure 7.1 A 
and B presents flow charts for recruitment of patients and relatives to the study. 
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POAG diagnostic criteria were: 
• Characteristic glaucomatous cupping of optic disc  
• Characteristic glaucomatous visual field defect, consistent with optic disc 
appearance 
• open angles on gonioscopy (grade 3/4 Shaffer classification) 
 
If 1 or 2 are present, with open angles on gonioscopy, depending on IOP values patients 
were diagnosed with either high tension glaucoma (IOP > 21 mmHg) or normal tension 
glaucoma (IOP < 21 mmHg).  
OHT diagnostic criteria: 
 
1. IOP > 21 mmHg 
2. non-glaucomatous appearance of optic disc 
3. normal visual filed 
4. open angles on gonioscopy (grade 3/4 Shaffer classification) 
 
Open angle glaucoma suspect diagnostic criteria: 
 
1. IOP < 22mmHg 
2. suspicious optic disc appearance (cup disc ratio >0.5) 
3. asymmetry of cup/disc ratio of > 0.2 between the 2 eyes 
4. normal visual field 
5. open angles on gonioscopy 
 
No corrections were made for corneal thickness, because this information was not 
routinely collected at the time of the patient ascertainment. 
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Figure 7.1A: Flow chart demonstrating the patient recruitment to the genetic studies in the family  
                      history study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• Identification of patients suitable for the study from out-patient  clinics and 
    nurse led glaucoma review clinics 
• Information sheet about the study provided by nurse/ consultant 
• Routine clinical examination 
 
Interest in participating in the study? 
Yes 
No 
• Contact details provided to the Research Fellow 
• Patient contacted and appointment organised 
Follow up appointment organised 
• Appointment with Research Fellow: 
• Study discussed 
• Consent 
• Pedigree construction 
• Clinical examination 
• Blood collection 
 
• Blood sent to London, to be forwarded to collaborator in USA 
• Contact details of relatives interested in the study provided 
• Relative contacted and appointment organised 
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Figure 7.1B: Flow chart demonstrating relatives’ recruitment to genetic studies in the family history  
                      study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Contact details of relatives received 
North East address? 
Can come to SEI? 
Information discarded 
• Relatives contacted 
• Study explained over the phone and information sheet sent out 
• Telephone call appointment made to be informed of their decision 
 
     Decision to take part in the study 
Yes 
• Appointment organised with Research Fellow at SEI 
• Study discussed 
• Consent 
• Clinical examination 
• Blood sample collected 
• Blood sample, copy of consent, clinical information  
       sheet and pedigree sent to London 
Within reach of London based research nurse 
  No 
• Contact details provided to the London based  
    research nurse 
• Appointment organised 
• Protocol followed 
• Blood collection pack sent to study  
    subject’s GP 
• Study subject asked to be examined  
   by an optician and take the clinical   
   sheet provided 
• Clinical examination sheet filled in 
by  
    optician and returned to me 
• Information passed on to London 
No 
Yes 
Yes 
No 
No 
• Blood collection pack sent to study subject’s GP 
• Study subject asked to be examined by an  
    optician and take the clinical sheet provided 
• Clinical examination sheet filled in by optician  
    and returned to me 
• Information passed on to London 
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The recruitment of patients for the study took place between October 2001 and October 
2002. During this period, 33 patients with strong family history (at least 2 members 
affected) of glaucoma were identified. Of these, 22 agreed to take part in the study. 
Eight patients couldn’t get any of the relatives to take part in the study, or most of the 
affected relatives were dead. However, a blood sample has been collected from them 
and the pedigree was constructed.  
 
13 of the pedigrees and the clinical details of the participants are presented in this 
chapter. Most of the pedigrees present an autosomal dominant inheritance, with variable 
penetrance. Apart from pedigrees GL1718/SEI 11 and GL1803/SEI 12, in which the age 
at diagnosis is lower than 40 years of age (JOAG), all the other have age at diagnosis 
over 40 years of age. Also, it appears that the IOP at presentation in majority of the 
affected subjects is high, frequently over 30 mm Hg.  
 
There are few pedigrees in which the type of inheritance is uncertain GL 1200/SEI2, GL 
1199/SEI3, GL 1424/SEI4, GL 1719/SEI 7 and GL 1449/SEI9). The proband in the 
pedigree GL 1424/SEI4, has both parents affected, and unless relatives from both sides 
of the family are taking part in the study, it is difficult to know from which parent the 
gene is inherited. In this case, the parents could not be recruited for the study, but some 
maternal relatives, one of which has glaucoma accepted to take part. This situation has 
been highlighted by Sack et al (1996) in the Glaucoma Inheritance Study in Tasmania 
(GIST). 
 
The GL 1719/SEI 7 pedigree is the only one with the diagnosis of normal tension 
glaucoma in this cohort. 
 
For the pedigrees with the adult onset OAG (SEI 1-6), the IOP at presentation for the 
individuals diagnosed with glaucoma was 31.5 ±10.2 mm Hg and the CD ratio was 0.68 
± 0.166. The mean age at diagnosis was 61.27 ± 12.9 (range 42 to 81). Of the 11 
individuals diagnosed with glaucoma in the 7 pedigrees, 4 were males and 7 females. It 
is interesting to observe that the presenting IOP in the affected individuals is very high 
(> 30 mm Hg). 
 
Also 2 pedigrees (GL 1423/SEI 1 and GL 1200/SEI 2) present family members with 
both glaucoma and OHT. Presumably, the individuals with OHT were diagnosed in the 
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light of the family history, rather by chance alone. It is likely that a proportion of these 
patients will develop glaucoma, however, because they are know to have OHT, the early 
signs of glaucoma, will hopefully be observed in time and adequate action taken which 
in turn will slow the progression of the disease. This emphasises the importance of 
family history in diagnosing and management of glaucoma. 
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7.3 PEDIGREES AND PHENOTYPES 
 
GL 1423/ SEI 1 
 
 
 
 
 
 
 
 
 
? # 
IV.5 
# 
 
II.6  
III.1 
# 
III.2  
# 
IV.1  
V.1 V.2 
IV.2  
V.3 V.4 
III.3  
17 
V.5 V.6 
# 
III.4 
# 
III.8 
N # 
IV.4  
V.7 V.8 V.9 
# 
III.5 
# 
III.9 
IV.6  
V.12 V.10   V.11 
N # 
IV.7  
V.13  V.14  V.15   V.16 
I.1 I.2 
II.1 II.2 II.3 II.4 II.5 
  177 
 
 
 
 
GL 1423/SEI 1: autosomal dominant 
ID 
no 
Pedigree 
ID Sex Age 
Age at 
diagnosis  VF RE VF LE 
CD ratio 
RE 
CD ratio 
LE 
VA 
RE 
VA 
LE 
Highest 
IOP RE 
Highest 
IOP LE 
Therapy 
RE 
Therapy 
LE Diagnosis 
1 III.4 M 71 58 N/A  N/A 0.7 0.7     32 35 Trb  Trb POAG 
2 III.8 F 71 n/a                 n/a n/a Spouse III.4 
3 IV.4 M 47 n/a N/A  N/A 0.5 0.5     18 18 nil nil Unaffected 
4 IV.5 F 42 41 
Inf-
temporal 
loss  Nil 0.4 0.5 6/5 6/5 25 21 Med Med POAG 
5 IV.7 F 44 n/a N/A  N/A 0.15 0.15 6/6 6/6 21 21  nil nil Unaffected 
6 III.2 F 79 70 
 Superior 
arcuate  
 Superior 
+ 
inferior 
arcuate  0.5 0.45 6/18 6/9 23 22 Med Med POAG 
7 IV.3 M 41 n/a Nil  Nil 0.2 0.2 6/5 6/5 19 19 nil nil unaffected 
8 III.9 M 69 n/a    .        n/a n/a Spouse III.5 
9 III.5 F 65 50 Nil  Nil 0.3 0.4 6/6 6/6 NK NK Trb  Trb OHT 
10 IV.1 F 52 52 Nil  Nil 0.3 0.3 6/5 6/5 29 21 Med  Med OHT 
 
Legend of abbreviations: VF = visual field; RE = right eye; LE = left eye; BE = both eyes; VA = visual acuity; sup = superior; inf = inferior; conc = concentric; periph 
= peripheral; Med = medical; Trb = trabeculectomy; ALT = argon laser trabeculoplasty; n/a = not applicable; NK = not known; MMC =mitomycin C 
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GL 1200/ SEI 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
I.1 
# 
V.4 
I.2 
II.1 
III.1 
IV.1 
V.1 
II.6 II.3 II.2 II.4 II.5 
III.2 
IV.2 
III.3 III.4 III.5 III.6 III.7 III.8 
IV.5 IV.3 IV.4 IV.6 IV.7 IV.8 IV.9 IV.10 IV.11 IV.12 IV.13 IV.14 IV.15 
III.9 
# 
III.10 
 
III.11 
IV.16 IV.17 IV.18 
# 
IV.19 IV.20 
? # 
III.12 
# 
IV.21 
N
# 
IV.22 
# 
III.13 
IV.23 
# 
IV.24 
 
V.5 V.6 V.7 
# 
III.14 
IV.25 IV.26 
V.2 V.3 
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GL 1200/SEI 2: inheritance uncertain 
ID 
Pedigree 
ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE VF RE VF LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE 
Therapy 
RE 
Therapy 
LE Diagnosis 
1 III.12 F 69 68 6/6 6/7.5 NIL NIL 0.6 0.6 19 17   Suspect 
2 IV.21 F 48  6/6 6/6 NIL Nil 0.3 0.3 18 18     Unaffected 
3 V.4 M 20  6/5 6/5 NIL Nil 0.3 0.3 19 19    Unaffected 
4 IV.19 M 46  6/6 6/6 Not done not done 0.2 0.2 20 20   Unaffected 
5 III.13 M 64 47 6/5 6/5 
Sup + inf 
nasal step 
Sup + inf 
nasal step 0.75 0.8 23 28 
Trb+ 
MMC  
Trb + 
Med POAG 
6 III.14 M 62 60 6/4 6/4 NIL Nil 0.2 0.2 28 28   OHT 
7 III.10 F 74 68 6/6 6/36 
Sup + inf 
arcuate 
scotoma Sup loss 0.7 0.7 25 27 Med Med  POAG 
8 IV.24   31  6/5 6/5 NIL Nil 0.2 0.2 20 21   Unaffected 
9 IV.22 M 47  6/18 6/4  not done not done 0.1 0.1 18 17   Unaffected 
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GL 1199/ SEI 3 
 
 
 
GL 1199/SEI 3:inheritance uncertain 
ID 
Pedigree 
ID SEX AGE 
AGE 
Dg 
VA 
RE 
VA 
LE VF RE VF LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE Therapy RE 
Therapy 
LE Diagnosis 
1 II.6 F 68    6/6  6/6 NIL NIL 0.2 0.4 18 17     Unaffected 
2 II.7 F 71 61 6/9 6/12 
Concentric 
peripheral 
loss Sup arcuate 0.9 0.7 56 42 Trb Trb POAG 
3 III.6 M 43 42 6/6 6/12 NIL Sup arcuate 0.5 0.9 22 46 Med  Med +  Trb  POAG 
 
 
 
 
 
? 
I.1 I.2 
II.1 II.2 II.3 II.4 II.5 
# 
II.6 
# 
II.7 
 
II.8 II.9 
III.1 III.2 III.3 III.4 III.5 
IV.1 
# 
III.6 
 
III.7 
? 
III.8 
IV.2 IV.3 IV.4 
III.9 
 ?  ?   9 
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GL 1424/ SEI 4 
 
 
 
 
GL 1424/SEI 4: inheritance uncertain 
ID 
Pedigree 
ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE VF RE VF LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE 
Therapy 
RE Therapy LE  Diagnosis 
1 III.11B F 44   6/5 6/5 nil nil 0.2 0.2 16 16     unaffected 
2 II.7B F 75 68 6/9 6/12 
sup 
arcuate nil 0.6 0.5 32 24 Med Med POAG 
3 III.10B F 46   6/5 6/5 nil nil 0.4 0.3 20 20     unaffected 
4 II.8B F 66   6/6 6/6 nil nil 0.4 0.4 18 18    Unaffected 
5 III.12B F 40   6/4 6/4 nil nil 0.2 0.2 17 17    unaffected 
6 III.1AB/P F 41 40 6/6 6/6 nil nil 0.6 0.6 20 21 nil nil suspect 
 
 
# 
III.12B 
II.3A 
I.1A I.2A 
II.1B 
I.1B I.2B 
II.2B II.4B II.5B II.6B 
# 
II.7B 
# 
II.8B   II.9B II.3B 
III.1B III.2B III.3B III.4B III.5B 
III.6B 
III.7B III.8B III.9B 
   # 
III.10B    III.11B III.13B III.14B 
 ?    # 
III.1AB III.2AB 
II.2A II.1A 
IV.1AB 
IV.2AB 
IV.3AB IV.4AB IV.5AB IV.1B IV.2B IV.3B IV.4B IV.5B IV.6B IV.7B IV.8B IV.9B       
      IV.10B 
IV.12B IV.13B 
IV.11B 
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GL 1143/ SEI 5 
 
 
 
 
GL 1143/SEI 5: autosomal dominant 
ID 
Pedigree 
ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE 
VF 
RE VF LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE 
Therapy 
RE 
Therapy 
LE Diagnosis 
1 II.4 F 71 69 6/6 6/12 nil 
paracentral 
scotoma 0.4 0.4 25 25 Med  Med POAG 
2 III.6 F 45 n/a 6/6 6/5 nil nil 0.1 0.1 20 20 nil n/a Unaffected 
3 III.7 M 41 n/a 6/5 6/6 nil nil 0.1 0.1 18 20 nil n/a Unaffected 
 
 
I.1 
? 
I.2 
# 
II.1 
# 
III.1 
# 
III.2 
II.2 
# 
II.3 
III.3 
IV.4 
# 
III.4 
IV.5 IV.6 
# 
III.5 
# 
II.4 
 N # 
III.6 
IV.7 
 N 
   
   # 
III.7 
IV.8 IV.2 IV.1 IV.9 
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GL 1427/ SEI 6 
 
 
 
 
GL  1427/SEI 6: autosomal dominant 
ID 
Pedigree 
ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE 
VF 
RE VF LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE 
Therapy 
RE 
Therapy 
LE Diagnosis 
1  III.7 F 40  6/5 6/5 nil nil 0.2 0.2 15 15     Unaffected 
2  III.5 F 43  6/6 6/6 nil nil 0.3 0.3 20 20     Unaffected 
3  II.5 F 69 69 6/6 6/5 
early 
nasal 
step 
early 
nasal 
step 0.6 0.7 21 27 Med Med POAG  
 
 
 
 
 
I: 1 I: 2 
? 
II: 1 II: 2 II: 3 II: 4 
III: 1 III: 2 
IV: 1 IV: 2 IV: 3 
# 
II: 5 II: 6 
III: 3 III: 4 III: 6 
# 
III: 7 III: 8 III: 9 III: 10 III: 11 
IV: 4 IV: 5 
III:12 
IV:6 IV:7 
III:13 
IV:6 IV:7 
III:14 
IV:6 
# 
III:5 
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GL 1719/ SEI 7 
 
 
GL 1719/SEI 7: autosomal dominant 
ID 
Pedigree 
ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE VF RE VF LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE 
Therapy 
RE 
Therapy 
LE Diagnosis 
1 II.2 M 74 72 6/6 6/6 
inf 
arcuate 
sup 
arcuate 0.6 0.7 20 20 Med Med NTG 
2 II.1   F  87   75 6/9  6/9  
Nasal 
step  nil 0.7  0.5  21  19  Med  Med  NTG 
3 II.3 M 68   6/6 6/6 nil nil 0.3 0.4 18 20      Unaffected 
4 II.4 F 68   6/6 6/6   not done 0.2 0.2 20 18      Unaffected 
5 III.1 F 53   6/6 6/6   nil 0.4 0.5 16 17      Unaffected 
6 III.2 F 49   6/6 6/6   not done 0.2 0.3 20 20      Unaffected 
 
 
 
 
I.1 I.2 
 
# 
II.2 
 N 
# 
II.3 
 
# 
II.1 
 N 
# 
III.2 III.3 III.4 
 N # 
III.1 
 N 
# 
II.4  
III.5  
IV.2 IV.3 
 
IV.1 
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GL 1798/ SEI 8 
 
 
 
GL 1798/SEI 8: autosomal dominant 
ID Pedigree ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE VF RE VF LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE 
Therapy 
RE 
Therapy 
LE Diagnosis 
1 III.2 F 66 61 6/6 6/6 nil nil 0.7 0.6 26 20 Med Med OHT 
2 III.1 M 72   6/5 6/5 nil nil 0.2 0.2 14 16     Unaffected 
3 IV.2 F 44   6/5 6/5  nil nil 0.1 0.1 21 19     Unaffected 
 
 
 
 
V:3 
# 
IV:2 
I:1 I:2 
II:1 II:2 
# 
III:2 
# 
III:1 III:3 III:4 
IV:1 
V:1 V:2 
IV:4 IV:5 IV:7 IV:10 IV:12 IV:13 IV:16 
II:3 II:4 
III:5 III:8 III:10 III:12 
II:6 II:5 
III:14 
II:7 II:9 II:8 
III:15 
II:11 II:10 
III:16 
IV:3 IV:6 IV:8 
V:4 V:5 
IV:9 
V:6 V:7 V:8 
IV:11 
V:9 V:10 
IV:14 
V:11 V:12 
IV:15 
V:13 V:14 V:15 
III:6 
IV:17 IV:18 IV:19 IV:20 
III:7 
IV:21 IV:22 
III:9 
IV:23 IV:24 
  III:11 
IV:25 IV:26 IV:27 
III:13 
IV:28 IV:29 
III:17 
IV:30 IV:31 IV:32 IV:33 IV:34 
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GL 1449/ SEI 9 
 
 
 
 
GL 1449/SEI 9: inheritance uncertain 
ID 
Pedigree 
ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE 
VF 
RE 
VF 
LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE 
Therapy 
RE 
Therapy 
LE Diagnosis 
1 IV.16 F 37   6/5 6/4 
not 
done  0.2 0.2 18 L17   Unaffected 
2 III.10 F 75   6/6 6/6 nil  0.3 0.3 20 19   Unaffected 
3 III.11 F 69   6/6 6/6 
not 
done  0.2 0.2 23 23   unaffected 
4 IV.19 F 40   6/5 6/5 
not 
done  0.2 0.2 15 15   unaffected 
5 III.12 F 61 61 6/6 6/9 nil  0.2 0.3 24 21 nil nil OHT 
 
 
 
I:1 I:2 
II:1 II:3 II:4 II:6 II:5 
III:4 III:5 III:6 III:7 III:8 III:9 
#
III:10 
#
III:11 
  ? #
III:12 III:13 III:14 
IV:18 
   N #
IV:19 IV:20 IV:21 
III:15 
IV:11 IV:12 IV:13 IV:14 IV:15 IV:17 IV:1 IV:2 IV:3 IV:4 IV:5 IV:6 IV:7 IV:8 IV:9 IV:10 
III:3 III:1 III:2 
II:2 
   N #
IV:16 
4 5 3 3
Australia 
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GL 1450/ SEI 10 
 
 
 
 
GL 1450/SEI 10: autosomal dominant 
ID 
Pedigree 
ID Sex Age 
Age 
Dg 
VA 
RE 
VA 
LE 
VF 
RE 
VF 
LE 
CD 
RE 
CD 
LE 
IOP 
RE 
IOP 
LE Therapy RE Therapy LE Diagnosis 
1  V.2 F 71 70  6/6 6/6 nil nil 0.6 0.6 25 23 nil  nil OHT 
2  VI.3 M 45   6/4 6/5 nil nil 0.3 0.2 19 22    Unaffected 
 
 
 
 
 
II:2 
I:1 
III:8 III:9 
IV:6 IV:8 IV:10 IV:12 IV:7 IV:9 IV:1
V:7 V:10 V:6 V:3 
# 
V:2 V:1 
# 
VI:3 VI:1 VI:2 
II:1 
III:1 III:2 III:4 III:6 III:3 
IV:1 IV:2 IV:3 
III:5 
IV:4 
Canada 
III:7 
IV:5 
I:2 
V:4 V:5 
VI:4 VI:5 VI:7 VI:6 
VII:1 VII:2 
V:8 
VI:8 VI: VI:10 
V:9 
VI:12 VI:11 
VII:3 
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GL 1718/ SEI 11 
 
 
 
GL 1718/SEI 11: autosomal dominant 
ID Pedigree 
ID Sex Age 
Age 
dg 
VA 
RE 
VA 
LE 
IOP 
RE IOP LE VF RE VF LE 
CD 
RE 
CD 
LE Therapy RE 
Therapy 
LE 
Diagnosis 
1 III.1 M 61 38 6/6 6/6 39 35 inf nasal inf arcuate 0.7 0.9 Trb  Trb+ Med POAG 
2 
IV.1 M 36 35 6/60 6/5 48 43 v.poor 
upper partial 
arcuate +nasal step 0.9 0.6 
Med/ refused 
surgery  Med  
POAG 
3 IV.2 M 31 N/A 6/5 6/5 20 19 Nil Nil 0.1 0.1 N/A  Unaffected 
4 III.3 F 60          N/A  Spouse III.1 
 
 
 
 
 
 
 
I.1 I.2 
II.1 II.2 II.3 
# 
III.1 
II.4 
III.2 
# 
III.3 
# 
IV.1 
# 
IV.2 
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GL 1803/ SEI 12 
 
 
 
 
 
 
 
III:5 
II:12 II:13 
III:10 III:13 
# 
III:12 
# 
IV:5 
# 
IV:7 
# 
III:15 III:14 
IV:8 IV:9 IV:10 IV:11 
III:16 
# 
III:17 
IV:12 IV:13 
III:9 III:8 
IV:2 IV:3 
# 
III:19 
# 
III:18 
# 
IV:14 IV:17 
# 
III:21 
# 
III:20 
# 
IV:19 
# 
IV:20 
# 
IV:22 
# 
IV:21   IV:18 
# 
V:11 
# 
V:12 
I:1 I:2 
II:2 II:1 
III:1 III:2 
IV:1 
II:9 II:3 II:4 
III:3 III:4 
II:7 II:8 II:5 II:6 
III:6 
?
III:7 
II:11 II:10 
IV:16 
V:9    V:10 
IV:15 
V:5 V:6 V:7    V:8 
III:11 
IV:4 
V:1 V:2 
IV:6 
V:3 V:4 
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GL 1803/SEI 12: autosomal dominant 
ID pedigree ID Sex Age 
Age at 
diagnosis  VF RE VF LE 
CD 
RE 
CD 
LE 
VA 
RE 
VA 
LE 
Highest 
IOP RE 
Highest 
IOP LE Therapy Diagnosis 
1 V.11 M 26 26 
Arcuate 
sup Nil 0.6 0.5 6/5 6/6 25 23 Med POAG 
2 IV.19 F 50 39 Borderline Nil  0 .5  0.4 6/5  6/5   26 22  
Med +Trb 
+ALT RE POAG 
3 III.21 F 76 51 
Arcuate 
sup Nasal step 0.6 0.8 6/9 9/9 25 26 Med POAG 
4 III.20 M 79 n/a Nil  Nil 0.2 0.2 6/9 6/9 20 21 n/a Unaffected 
5 III.19 F 75 66 Total loss 
Advanced 
loss 0.99 0.9 HM 6/9 25 35 Med POAG 
6 IV.14 M 46 n/a Nil Nil 0.2 0.2 6/5 CF 21 21 n/a Unaffected 
7 III.18 F 81 n/a Nil  Nil 0.1 0.1 6/9 6/9 14 13 nil 
Spouse III.13, 
POAG/ 
deceased 
8 IV.5 F 46 n/a Nil Nil 0.3 0.3. 6/9 6/5  27 24  n/a OHT 
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GL 1799/ SEI 13 
 
 
 
 
GL 1799/SEI 13: autosomal dominant 
ID 
pedigree 
ID Sex Age 
Age at 
diagnosis  VF RE VF LE 
CD ratio 
RE 
CD ratio 
LE 
VA 
RE 
VA 
LE Therapy 
Highest 
IOP RE 
Highest 
IOP LE Diagnosis 
1 II.4 F 74 74 
Sup + inf 
scotoma 
Early inf 
nasal loss 0.8 0.6 6/6 6/6 Med 26 26 POAG 
2 III.8 F 52 n/a Nil Nil  
Disc 
drusen 
 Disc 
drusen   n/a    Unaffected 
3 III.11 M 38 n/a Nil Nil 0.3 0.3 6/6 6/6 n/a 17 15 Unaffected 
4 II.6 F 70 66 Nasal step Nil 0.4 0.5 6/9 6/6 Med 28 24 POAG 
5 III.14 F 45 n/a Nil Nil 0.3 0.3 6/6 6/6 n/a 18 18 Unaffected 
6 II.3 M  n/a Nil Nil 0.1 0.1 6/5 6/5 n/a 15 15 Unaffected 
 
 
# 
III:11 III:4 
# 
II:6 
I:1 I:2 
II:2 II:1 
#
II:4 II:3 II:5 
# 
III:12 
#
III:14 
# 
III:8 
# 
III:10 
# 
III:1 
# 
III:3 
? # 
III:5 
 
III:13 
IV:13 IV:14 
III:9 
IV:10 IV:11 IV:12 
III:7 
IV:8 IV:9 
III:6 
IV:7 IV:4 IV:5 IV:6 
III:2 
IV:1 IV:2 IV:3 
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7.4 GENETIC SCREENING RESULTS OF THE FAMILY HISTORY STUDY 
      PATIENTS 
 
Our collaborator, Professor Sarfarazi, has communicated some available information 
regarding the screening of the patients from the above families.  
 
All SEI pedigrees have been screened for mutations in MYOC and WDR36, and no 
mutations have been found in these patients.  
 
M98K variation in OTN (10p13) was identified in GL 1143/SEI 5 and GL 1719/SEI7.  This 
is a risk associated DNA variation and not a disease causing mutation. This is probably to 
be expected for the pedigree GL 1719/SEI 7 as the diagnosis is NTG, however, for the GL 
1142/SEI 5 pedigree the highest IOP in the proband was 25 mm Hg. 
 
The GLC1D locus on chromosome 8q23 was screened in the following pedigrees: GL 
1143/SEI 5, 1200/SEI2, 1423/SEI 1, 1719/SEI 7, 1803/ SEI 12 but no concluding results 
have been obtained as yet. The work is still in progress. 
 
For the GLC1B locus on 2cen-q13 region and another unpublished locus on 2p25, the 
following candidate genes (NCK2, SLC5A7, SOX11, BX089860, TSSC1, MTCBP-1) have 
been screened in the above families, but no conclusive mutations have been identified. 
 
The GL 1423/SEI 1 and GL 1803/ SEI 12 have been screened for GLC1N locus on 
chromosome 15q22.1-q25.1, but no conclusion was reached. 
 
A number of single affected subjects from the above panel of families have been selected 
for a new genome-wide association study (using SNP markers), but the results will not be 
available for another year. Unrelated affected subjects were randomly selected from the 
families and included in a total of 750 unrelated POAG subjects for this particular study. 
 
Also, these families were included in a classical genome –wide screening study (using short 
tandem repeat polymorphisms –STRP - markers) that consisted of mainly the affected sibs. 
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However, due to the small size of the families and the limited number of affected sibs per 
family, many hits have been observed all over the genome. These regions have been 
systematically checked, and some extremely promising genes were sequenced, but so far all 
is proven non-conclusive and the work is still continuing. 
 
It is evident from the above information that so far no conclusive findings were made, 
despite intensive research. One of the reasons is that the size of the families is small and 
also the number of affected sibs per family, available for the study is small too. At the same 
time, it also, emphasizes the challenges posed to the genetic researchers into complex 
diseases and the importance of the clinician in identifying as large as possible pedigrees 
with affected relatives who are alive. 
 
7.5 DISCUSSION 
 
7.5.1 Identifying POAG pedigrees 
 
As mentioned previously, it is generally accepted that POAG has a strong genetic 
component. Family history is important clinically because the risk for POAG among first 
degree relatives of a POAG patient is 7-10 times higher than that of the general population 
(Tielsch et al 1991, Wilson et al 1987) and surveillance targeting these individuals is 
indicated for early detection and treatment for POAG. 
 
As early as 1949, Possner and Schlossman discuss the difficulties of pedigrees description 
for adult onset POAG in their excellent paper “Role of inheritance in glaucoma”. They 
observe that while pedigrees for JOAG and combination of POAG and JOAG can trace 
glaucoma back in six generations; this is not the case for pedigrees with only POAG, where 
there are very few pedigrees which have been followed for even 3 generations. This is 
explained by the difficulty in following hereditary disease later in life and also by the fact 
that some patients with potential glaucoma do not live long enough to reach the age at 
which they would have the disease. Of course, this poses the question whether there is any 
real difference between JOAG and POAG, as the main criteria for separating these entities 
is an arbitrarily chosen age of onset of the disease. However, the age of onset of the disease 
is difficult to pinpoint as the disease can run for many years with no symptoms, and 
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therefore what is actually used in classifying these diseases is the age at diagnosis. Also, it 
has been shown that the mutation in GLC1A gene is responsible for causing both JOAG 
and POAG (Morissette et al 1995, Vincent et al 2002), suggesting that these two entities are 
a continuum of the same disease.  
 
It is also important to note that due to the low penetrance of the disease it is possible that 
some sporadic cases are hereditary. To elicit that would necessitate genetic investigation 
and it becomes obvious that this would be very cost ineffective to be done on a large scale. 
 
Gong et al (2007) suggest a new classification of POAG according to the degree of familial 
aggregation into inherited, familial and sporadic categories. Inherited POAG is defined 
when three or more relatives inclusive of the proband are documented with POAG in two 
or more consecutive generations, one of which has to be a first degree relative of the other 
two. Familial POAG involves two or more first and/or second degree relatives and does not 
meet the criteria for inherited POAG. Sporadic POAG involves a single patient without 
affected first or second degree relatives. According to the authors, these classes of POAG 
appear to be distinct not only in inheritance pattern and the degree of familial aggregation 
but also in methodology and outcome in mapping POAG. 
 
Identification of large glaucoma pedigrees has been instrumental in discovery of glaucoma 
loci and genes. For most cases, the pedigrees described are for JOAG, and it helped identify 
most of the glaucoma loci (GLC1A-M), apart from 2 loci – GLC1B and E, which were 
discovered in NTG phenotype pedigrees (table 3.1). The methods used were positional 
cloning (GLC1A to I), genome wide screening (GLC1J and K) and Markov chain Monte 
Carlo multipoint estimations of identity by descent sharing and allele-sharing methods for 
GLC1L. Since the discovery of first POAG locus on chromosome 1, many more pedigrees, 
either JOAG or POAG have been described and patients screened for mutations in the 
known glaucoma genes. 
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7.5.1.1 Identification of POAG pedigrees from SEI patients 
 
Patients included in this study were referred from two sources: the glaucoma consultants 
(Mr Fraser and Mr Phelan) and the nurses from nurse led glaucoma clinic was one source 
and referral from consultants with other subspecialty interest was the second source.  
 
In order to make clinical staff aware of this study, a presentation at in house teaching and 
postgraduate regional teaching about the study was made by both Mr Fraser and Dr 
Vaideanu. The inclusion criteria were particularly emphasised and an appeal for everyone 
to help with referral was made. The first source provided a steady stream of referrals; 
however, the second source provided only sporadic referrals. One reason for that could be 
that the consultants with other subspecialty interest do not see quite as many glaucoma 
patients. However, to make sure they are reminded about the study, I have placed typed 
reminders in all clinical rooms. These were placed on the wall, above the desk, at eye level. 
 
Also, the study has been presented at two of the 3 monthly Glaucoma Support Group 
meeting, again by Mr Fraser and Dr Vaideanu. The aim of these presentations was to make 
patients aware of the risk of having family history of glaucoma, present the findings of 
genetic studies so far and encourage them to agree to take part in the study if requested. 
 
The nurses from the glaucoma unit at SEI had an important role in helping with referrals 
and organising appointments. Therefore, I provided them with a timetable for organising 
appointments.  
 
As mentioned above, 33 pedigrees with at least 2 family members affected were identified 
during the recruiting period. However, only 22 patients agreed to take part in the study and 
only 13 patients managed to get the relatives to take part. These pedigrees are presented in 
this thesis.  
 
According to Gong et al (2007) classification, the pedigrees GL 1423 (SEI 1), 1200 (SEI 2), 
1424 (SEI4), 1427 (SEI6), 1798 (SEI 8), 1449 (SEI 9), 1450 (SEI10), 1718 (SEI11), 1803 
(SEI12) are inherited and pedigrees GL 1199 (SEI 3), 1143 (SEI 5), 1719 (SEI 7), 1799 
(SEI 13) are familial. Pedigree 1143 (SEI 5) could possibly be inherited, however the 
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information we have is incomplete and for the time being makes it familial. This situation is 
highlighted in the Gong et al paper, emphasising that some of the pedigrees which appear 
familial due to lack of information may actually be inherited.  
 
7.5.2 Pedigree construction 
 
The relatively late age of onset of most forms of POAG has complicated the efforts to 
identify the mode of inheritance and the genes involved, but segregation analysis in several 
adult onset pedigrees has shown autosomal dominant inheritance to be the predominant 
mode. 
 
Therefore, the pedigrees published in literature fall in three categories:  
• those in which all the affected members have juvenile glaucoma 
• those in which, owing to anticipation, the parents and grandparents have adult 
glaucoma, while in succeeding generations the affected members have juvenile 
glaucoma 
• those in which all the affected members have adult glaucoma 
 
As mentioned above, most of the pedigrees published in literature demonstrate an 
autosomal dominant mode of inheritance for POAG. Regarding the role of autosomal 
recessive mode of inheritance in POAG, there is not sufficient data available to justify any 
conclusion, although it has been suggested that the autosomal recessive may be 
predominant (Booth 1997). In recessive heredity, the gene may become widespread in the 
population without manifesting the disease except may be as a result of chance mating of 
carriers, and that may be one explanation for the appearance of some of the sporadic cases. 
So far, there is one paper, by Yoon et al (1999) describing a Korean case of apparent 
autosomal recessive inheritance of JOAG. 
 
Most of the pedigrees identified from patients attending SEI and presented in this chapter 
appear to have an autosomal dominant mode of inheritance and therefore similar to the 
published pedigrees. However, the SEI pedigrees are of relatively small size and only in 
few we have managed to phenotype and collect samples in more than 5 members (SEI 1, 2, 
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4, 7, 9, 12 and 13). Also, the pedigrees identified from the North East population only have 
2 or 3 affected members, who are still alive; the only pedigree with 5 members affected 
alive being GL1803/SEI 12. Still, 5 of this group of pedigrees have at least 5or 6 members 
affected, with pedigree GL 1803 (SEI 12) having 9 member affected. Unfortunately, for the 
SEI pedigrees the clinical information from the deceased POAG patients is no longer 
available. 
 
 As discussed above, large pedigrees (at least 11 members affected) which exhibit 
Mendelian inheritance patterns can help in location of the genes associated with glaucoma, 
by using the standard linkage analysis.  
 
Although most of the pedigrees which helped in discovering the POAG/JOAG genes were 
very large, mutations in these genes, as well as identification of new glaucoma loci has 
been achieved with the help of smaller pedigrees (Wiggs et al 2004, Mackey et all 2003, 
Bruttini et al 2003, Forsman et al 2003). Also, a known mutation in a small pedigree can 
help characterize the phenotype associated with the specific mutation (Mackay et al 2003). 
For that reason, collecting pedigrees, even with only 3 members affected, it still provides a 
valuable resource for genetic research. 
 
However, the common types of glaucoma, including POAG, typically do not exhibit 
Mendelian inheritance patterns. Wiggs (2007) emphasises that the common age related 
ocular disorders do have a significant heritability, but the genetic contributions to these 
disorders are complex, resulting from interaction of multiple factors, and are susceptible to 
the influence of environmental exposures. 
 
7.5.2.1 Pedigree construction in SEI POAG patients 
 
Once the POAG patients with family history of glaucoma were identified and agreed to 
take part in the study, constructing the pedigree did not pose too much of a challenge. All 
the participants were very helpful at providing the information they knew. The patients with 
relatives, who did not want to take part in the study, were very prompt at informing me 
about the situation. A great deal of effort was made by some patients to find out 
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information about relatives who lived away (different part of the country, different country 
or continent) to help provide as complete a picture as possible. 
 
Invaluable help in both constructing the phenotype and contacting and collecting blood 
samples from relatives living in South East of England was offered by my liaison in 
London, Glen Brice (genetics research nurse at St George’s Hospital, London). He also, 
forwarded the clinical information and blood sample to Professor Sarfarazi. 
 
Communication with him was very important from logistic point of view (timing of 
sending the samples, storage, and feedback about other members of the family recruited to 
the study). 
 
The blood samples collected, had to be stored between few hours to a day before being sent 
to London. A fridge in the glaucoma unit which was being used for storing medication has 
been agreed as temporary storage, after discussion with all relevant people. 
 
7.5.3 Phenotyping 
 
Without sufficient knowledge of clinical aspects of the disease of interest (phenotype 
definition), genetic studies would be useless. Different forms and sub-phenotypes of 
glaucoma have been recognised, which helps with genetic studies. Within the sub-
phenotypes of POAG, different clinical manifestations such as myopia, disc haemorrhage, 
reduced corneal thickness might represent different genetic bases (Gong et al 2004). 
 
Rapid advances in genetics, provides us with the tools to look at a disease from “inside 
out”, by detecting the underlying genetic defect first and then their pathophysiological 
consequences. However, this approach is still dependable on accurate identification of the 
disease phenotype. Therefore, the role of the clinician is invaluable in inquiring about the 
family history in all patients, identifying individuals and families with a genetic trait, 
constructing the pedigree and then liaising with an investigator/laboratory that is 
performing or would be willing to perform molecular genetic studies. 
 
  199 
 It is generally accepted that in the future, genetic testing will become common and that the 
clinician will be likely to obtain a genomic profile on an individual and determine the risk 
of that person for developing simple Mendelian or complex inherited diseases. 
Identification of at risk individuals will make primary prevention possible for the first time. 
And while for complex diseases, the underlying genetic causes are still being unravelled, 
the identification of pedigrees and phenotyping of the patients remains very important in 
providing data for the genetic studies.  
 
The clinician has a crucial role in the success of all genetic linkage studies. Constructing 
the clinical features that define the affected status of a disease for linkage studies has to be 
done carefully and consistently by all clinicians involved in a study. Objective criteria for 
affected, suspect and unaffected must be clearly defined, this resulting in as homogeneous a 
phenotype as possible, therefore simplifying linkage analysis.  
 
Kroese and Burton (2003) discuss the problems provided by the lack of a consensus case 
definition for POAG, emphasising that there is considerable uncertainty about what is 
diagnosed and treated as POAG. This impact on the person diagnosed with POAG, on the 
commissioning and provision of clinical healthcare services, and on a firm basis for 
research into the condition. 
 
7.5.3.1 Phenotyping of the proband and relatives in SEI pedigrees 
 
The proband in the pedigrees collected from SEI patients, have been diagnosed by 
Consultants Ophthalmologist with vast experience in the field. Also, in most of the other 
pedigree members affected by glaucoma and included in the study, we have collected 
objective clinical information (visual fields, optic disc appearance, IOP values) which 
supports the diagnosis of glaucoma. 
 
For the unaffected subjects, only IOP, C/D ratio and anterior chamber angle details were 
collected. Some of them, had visual fields at the optician, and where possible we collected 
these. Otherwise, due to financial and time constraints, visual fields were not routinely done 
on unaffected members. 
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7.5.4 Genetic studies 
 
In the majority of POAG cases it is likely that more than one genetic predisposition is 
required to manifest disease and it is now generally accepted that POAG is a complex trait 
(Hewitt et al 2006). 
 
As mentioned earlier, investigating the genetics of pedigrees with late age of onset is 
difficult. The parents of POAG cases are often deceased (the case with many of SEI 
pedigrees), while the patients’ children are frequently too young to manifest the disease. 
Adding to the confusion, POAG can be discordant in time, differing in age of onset for 
some related cases and there is often considerable overlap between glaucoma families 
(Sack et al 1996). Despite these issues, large glaucoma pedigrees have been genetically 
linked and numerous loci have been identified (table 3.1). 
 
Once the disease has been linked to a locus and a gene has been identified, the gene can be 
sequenced and mutations identified. It is critical to ensure that a mutation is real (not just a 
polymorphism) by demonstrating it cosegragates with affected individuals and is not 
present in unaffected individuals and in population controls. 
 
The next step is to investigate the effect of the mutation on the protein, by expression 
studies and by using animal models. Once this has been understood, it may lead to 
understanding the pathogenesis of the disease and then to developing diagnostic tests and 
possibly gene/drug therapies with the final result of either disease prevention or cure 
(Damji and Allingham 1997). 
 
Once a mutation in a gene causing the disease has been identified, clinical information 
about the onset of the disease, course of the disease and response to therapy need to be 
collected (Wiggs 2007).  
 
The genotype-phenotype studies will answer the following questions: 
• What is the range of phenotypic variation of a given mutation (can one predict the 
prognosis of the disease if the mutation is known?) 
• Are certain mutations associated with particular aspects of the disease phenotype? 
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• Are certain mutations necessary, but not sufficient to cause the disease? Such a 
mutation would require other additional genetic defects or environmental factors to 
be fully manifest. 
 
By going back and analysing the clinical findings in a particular group of patients where a 
mutation has been identified, we can try and ascertain if there are certain characteristics of 
the group (i.e. higher IOP at presentation, certain characteristics of the CD ratio, etc). One 
such example is the study by Mackey et al (2003), where glaucoma phenotype in pedigrees 
with Myocillin Thr377Met mutation was analysed. The authors concluded, that this 
mutation is associated with POAG that, in the pedigrees studied, had a younger age at onset 
and higher peak intraocular pressure than in pedigrees with the more common 
Gln368STOP mutation, and that this group was more likely to have undergone glaucoma 
drainage surgery. This emphasises, that certain mutation produces more aggressive disease, 
and therefore, identifying and monitoring at risk individuals might catch the disease early 
and prevent morbidity. 
 
Factors which contribute to the challenge of discovering complex disease genes are the 
underlying molecular heterogeneity, imprecise definition of phenotypes, inadequately 
powered study designs and the inability of standard sets of microsatellite markers to extract 
complete information about inheritance. 
 
 Because genetic models cannot be defined, methods to identify genes responsible for these 
conditions are more complex than those used for Mendelian disorders. Genome scans and 
model free analysis have been performed using families demonstrating clustering of 
complex diseases (largely sibpairs), as well as families affected with rare forms showing 
apparent Mendelian inheritance (Wiggs 2007). 
 
One method to address genetic heterogeneity and strengthen linkage findings is to 
incorporate phenotypic sub-setting of the data. Most phenotypic stratification approaches 
require that subsets be identified before linkage studies. An alternative to traditional 
stratification approaches for incorporating a trait related covariate is ordered subset 
analysis. This method provides maximum evidence of linkage, by using the covariate 
without a priori specification of families to a subset. With this approach, families are 
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ordered by a phenotypic variable (e.g., age of onset, cup/disc ratio, IOP). Linkage analysis 
with a specific marker set is performed on the first family in the list and then repeated, 
adding one family each time. In this way, the subset of the families with greatest evidence 
of linkage can be determined. Subsets with evidence of increased linkage can be used for 
candidate gene analysis. This approach has been successfully used to confirm and narrow 
area of proposed linkage, as well as to define novel region of linkage in several complex 
traits, including diabetes, Alzheimer disease, macular degeneration (Allingham et al 2005). 
 
Adult onset glaucoma frequently occurs in multiple family members (familial aggregation), 
but does not usually follow a clear Mendelian inheritance pattern, suggesting that inherited 
risk factors can result in a susceptibility to the disease, but is not necessarily causative. 
Multiple risk factors and/or environmental factors may be responsible for this disease in 
older individuals.  
 
Although 14 loci have been identified for POAG, so far only three genes have been 
discovered (MYOC, OTN, WDR36) and each of these genes is only responsible for a small 
fraction of cases with POAG, reflecting the small percentage of POAG inherited as a 
Mendelian trait rather than a complex trait.  
 
In the North East of England POAG family history cohort, none of the patients had a 
disease causing mutation in the above genes and only a risk association DNA variation was 
identified in 2 pedigrees (GL 1143/SEI 5 and GL 1719/SEI 7). 
 
7.5.5 From bench to slit lamp 
 
Translating the genetic research into clinical settings still has large gaps. Glaucoma is a 
model disease to investigate, as genetic knowledge of the disease may be allowing the 
treating ophthalmologist the ability to detect and treat a disease with potentially blinding 
complications. 
 
Mapping, cloning and identification of novel mutations involved in the aetiology of 
glaucoma provide a significant opportunity for pre-symptomatic diagnosis, improved 
prognosis and better understanding of the aetiology of this blinding condition. 
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The development of genotype – phenotype databases for glaucoma genes will be an 
important step toward clinically useful DNA-based diagnostic testing for glaucoma. 
 
However, before achieving this goal, more research into unravelling the pathogenesis of 
glaucoma is necessary. The current state suggests that multi-staged design that 
encompasses data from linkage, association and molecular experiments when feasible is to 
be desired. In future, ocular genetic studies may rely on multicenter and community 
collaboration for mapping experiments (Iyengar SK 2007). 
 
Before incorporating genetic tests into the diagnosis algorithm, it is important to determine 
the significance of a disease variant. Understanding the sensitivity spectrum, prevalence 
and penetrance of gene sequence changes ensures that patients can be adequately informed 
of the likely implications of carrying such a gene. For all this to be achieved community 
based longitudinal studies, which incorporate both molecular and environmental 
components are required.  
 
 Hewitt et al (2006) suggest a cascade screening protocol, where once a POAG patient is 
identified as having a disease causing gene mutation, all of their first degree relatives can 
be tested for the same mutation. If they carry the mutation, then they are followed closely 
for early clinical signs of glaucoma and their first degree relatives are also tested.  
 
This process moves on in a stepwise direction from the index case until all relatives 
harbouring the mutation have been identified (this process has been successfully applied in 
cancer genetics). The perceptions of family members involved in cascade screening with 
MYOC glaucoma in a large Australian pedigree have been evaluated and found them to be 
positive (Healey et al 2004). 
 
With regards to this study, identification of POAG pedigrees, as large as possible and 
accurate phenotyping with the methods available at the time of patient enrolment represents 
a very valuable resource for further genetic studies, especially in the setting of rapid 
technological advances. By setting up collaborations with research groups nationally and 
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internationally, the large number of patients with a complex disease needed to draw 
statistically meaningful results are easier to add up.  
 
7.5.6 Conclusion 
 
The ability to identify individuals with a genetic predisposition for developing glaucoma, 
would allow efficient, cost-effective population based screening programs to be designed. 
When POAG is detected early and appropriate therapeutic intervention is initiated, 
blindness from glaucoma is preventable. 
 
Therefore, efforts should be made in collecting, phenotyping and enrolling in genetic 
studies POAG pedigrees. Although, so far the SEI pedigrees have not yielded any results, 
they represent a valuable resource for further studies. 
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Chapter 8. GENERAL DISCUSSION 
 
8.1 INTRODUCTION 
 
As emphasised all the way through this thesis, open angle glaucoma is the major primary 
type of glaucoma in most population world wide and one of the main causes of blindness if 
left untreated. Various risk factor have been described, however, the pathogenesis of the 
disease is still unclear.   
 
To date, ophthalmic based screening systems for POAG have proven cost ineffective for a 
community (Tuck and Crick 1997). Strategies to eliminate the blinding toll of glaucoma 
must be aimed at identifying at-risk individuals and therefore, screening regimen must be 
highly sensitive and specific to detect potentially serious disease (Harris 2005). As POAG 
is initially asymptomatic, effective screening techniques should identify people with no 
obvious signs or symptoms of the disease, allowing early diagnosis and management. 
 
8.2 OVERVIEW OF THE WORK PRESENTED 
 
It is generally accepted that POAG in the majority of cases, is inherited as a complex trait, 
where the disease results from the interaction of multiple genes and environmental factors 
(Fan et al 2006b, Sieving and Collins 2007). It is a complex disorder which results from 
diverse pathological process that is not just limited to involving the aqueous humor 
outflow, but the retinal ganglion cells, the optic nerve and even as suggested recently, the 
cerebrospinal fluid (Berdahl et al 2008).   
 
Genetic studies have identified some of the genes involved in different types of glaucoma 
presented in the   genetics of glaucoma chapter (chapter 3) which also present different type 
of studies employed in genetic investigation.  Paramount to the ability to do these studies is 
identification, phenotyping and recruitment of patients willing to help.  
 
This work presents two aspects of glaucoma genetics studies.  
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The first part of the study is a pilot study which was set up to test the hypothesis that genes 
involved in anterior segment dysgeneses may have a role to play in predisposing to OAG 
development. Since ASD leads to malformation of the drainage structures and elevation of 
IOP, patients with ASD are consequently at an increased risk for developing glaucoma in 
33-75% of cases (Strungaru et al 2007). It is possible that some of the developmental 
glaucoma genes contribute to age- related open angle glaucoma, where the ocular drainage 
structures have abnormalities that are not clinically visible but which cause dysfunction 
with age.  
 
For this pilot study the gene chosen was PITX2 as sub-clinical mutations/polymorphisms in 
this gene may produce subtle and undetected abnormalities in anterior segment structure 
and function, which predispose to glaucomatous optic neuropathy through the effects of 
raised IOP and may be a significant susceptibility factor for the development of OHT and 
POAG. 
 
The discussion chapter of the pilot study deals with issues of patients and controls 
identification and recruitment, phenotyping and the challenges of the genetic work itself. 
This study did not identify a relationship between POAG and PITX2 polymorphism and the 
possible reasons for this find are presented in the pilot study discussion chapter (chapter 6).  
Also, possible future studies stemming from this pilot studies are also presented. 
 
The second part of the thesis presents identification, phenotyping and recruitment to genetic 
studies as well as pedigree construction of patients with family history of glaucoma, with at 
least two members affected. The discussion at the end of family history chapter (chapter7) 
emphasises the challenges encountered especially in identification of the pedigrees with an 
adequate number of affected members and how that affects the amount of genetic 
information that can be obtained. 
 
In this final chapter after a short reflection on the work presented, considerations on the 
genetics of complex traits (mainly pertaining to glaucoma) and current and future status of 
glaucoma genetics will be discussed. 
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8.2.1 Reflection on the work presented 
 
So, what are the lessons learned from this work and what did it bring to genetic research of 
glaucoma? 
 
1. Get your statistics rights 
 
 If I were to start over again, the first thing I would do after I worked out the idea for the 
project would be to consult a statistician. As emphasized many times in this work, the 
statistics of genetic research are complex and the fact that I have not consulted a statistician 
at the beginning of the study showed my inexperience and naïveté. I have trusted the idea 
of the project as it was presented to me and not questioned the numbers of patients 
considered to be needed. That may be excused in a small proportion by the fact that the 
initial idea of the study (looking for polymorphisms in the PITX2 gene in general 
population and comparing it with findings in POAG/OHT population) varied slightly 
during the study and as a result made the statistics more difficult to explain. 
 
2. Get the numbers stated in the protocol  
 
Time constraints are always a factor when doing research for a limited period and there is a 
timetable to keep to. However, in retrospective, I wished that I sacrificed some of the lab 
time to finish the recruitment of the controls. I could have continued with recruitment of 
patients as well, as the DNA resource created in this way could always represent a valuable 
resource for further genetic studies. 
 
3. Get the finances sorted out 
 
May be one of the more important lessons was the financing of genetic research. I had no 
idea before starting in the lab how expensive lab equipment and especially consumables 
were. Although, an initial budget was made and funds were allocated accordingly, as I have 
stated before I have run out of funds midway through the project. This creates discontinuity 
and puts strain on ones work at the time. More time has to be spent finding more funds and 
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it can jeopardize the entire project if not found. A contingency fund should always be 
allowed for as unexpected spending will occur. 
 
 In retrospective, this work has been started with very little money for consumables. One 
need to make sure has adequate advice regarding how much things cost and have a back up 
plan if things do not go according to the protocol. 
 
4. Continuity in the lab 
 
As during the research period I was also doing some clinical sessions, the work in the lab 
did not have continuity. Potentially this could be a reason for having so many difficulties 
with the sequencing work. One solution for this would be to contract the work out to 
commercial labs. This however was not an option for me, as I already spent the money on 
buying consumables to do the work myself and also, the cost per reaction was I considered 
quite expensive at the time.  
 
May be if I did not find out about the Sequenom and still continued to have problems with 
the sequencing, I might have gone down that route. Would that have made a difference to 
the overall results? Probably not, as it has been shown by high throughput SNP screening 
that the homeobox (the region sequenced) is highly conserved which infers that  mutations 
in this region are more likely to produce overt structural abnormalities (ARS type). 
 
5. Speedy writing up of the thesis 
 
Writing up ones results as soon as possible after the work is finished is very important. It 
places the work in the context at the time and allows for further work to be done, building 
on the results of the initial report.  
 
In this case, the writing up of the thesis took much longer than expected and therefore 
makes the writing up of the pilot study results more difficult and may be somehow 
redundant. Also, in the mean time the work has been continued on an extended panel of 
DNA samples and multiple ASD genes and the results of that work has already been 
published.  
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So, is this study worth doing again? The answer is yes, only I would apply all the above 
points and get the numbers of patients and controls required for a statistical significant 
result for this type of study. Also, I would take advantage of the technological advantages 
and do high throughput screening straight from the beginning. The validity of the 
hypothesis has already been proven for the LMX1B gene (Park et al 2009) on work carried 
out on DNA samples which include the patients and controls from the pilot study too.  An 
attempt to sequence PITX2 gene on the extended POAG DNA panel has been made, 
however that proved difficult and as it didn’t yield enough data has been abandoned. 
 
I have stated above some of the lessons learned from doing work, pertaining mainly to the 
pilot study. With regards to the family history part of the study, which is important for any 
type of genetic research, the importance of patients and control identification, 
standardization of phenotyping and recruitment has been emphasised many times. May be 
when setting up a genetic study on families afflicted by a disease it is important to have 
very strict recruiting criteria and only recruit patients with family with a certain number the 
members affected, if the intention is to do linkage studies.  
 
 So, did this study bring anything to the genetic research of glaucoma? 
 
Firstly, the DNA samples collected for both the pilot study and the family history study and 
the clinical data-base represent a valuable resource to be used in further genetic studies. 
 
Secondly, the hypothesis for the pilot study, for which ample support has been presented 
throughout this thesis, has been an original idea for the first time tested with this study. 
 
On a personal level, although at times things did not go as smoothly as desired, it provided 
me with the opportunity of learning about genetic research and what it means to be a 
scientist. Should the opportunity arise in the future, I would like to use this knowledge. 
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8.3 CONSIDERATIONS ON THE GENETICS OF COMPLEX TRAITS 
 
The remarkable achievements in human genetics over the years have been due to 
technological advances in gene mapping and in statistical methods that relate genetic 
variants to disease. The vast majority of Mendelian genetic disorders have now been 
mapped to a specific gene or set of genes, but these discoveries have been limited to high-
risk variant alleles that segregate in rare families. With a working draft of the human 
genome now completed, the availability of high-throughput genotyping, a plethora of 
genetic markers and the development of new analytical methods, more and more scientists 
turn their attention to common complex disorders like diabetes, hypertension, Alzheimer 
disease and in ophthalmology open angle glaucoma and age related macular degeneration. 
 
Most researcher believe that complex disorders are oligogenic, the cumulative result of 
variants in several genes, or polygenic, resulting from a large number of genetic variants, 
each contributing a small effect. Other, have proposed that these disorders result from an 
interaction between one or more genetic variants and environmental or non genetic risk 
factors. 
 
The difficulty facing researchers who work on complex genetic disorders is in designing 
the appropriate studies to merge the richness of modern genome science with vast potential 
of population based, epidemiological research. 
 
While linkage analysis is considered the most powerful method for identification of rare, 
high risk alleles in Mendelian disease, many consider genetic association analysis to be the 
best method for identifying genetic variants related to common complex diseases. 
Association analysis is generally model free, or non-parametric, so the researcher does not 
have to assume a mode of inheritance is unknown. Unlike linkage analysis, where markers 
are identified, association studies determine whether or not a specific allele within a marker 
is associated with the disease. 
 
Association studies also have limitations. Because linkage disequilibrium, cosegragation of 
a series of genetic markers or alleles, is sustained only over a short chromosomal segment, 
a large number of loci need to be tested to cover a region. This increases the possibility of 
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false positive findings. With each test, the possibility of false positive results increases, 
requiring the need either for replication in an independent study or computer simulation 
(Mayeux 2005).  
 
Study design and interpretations of results must include appropriate statistical thresholds 
that take multiple hypotheses testing into account. Balancing the need for power to detect 
modest effects with cost of genotyping large number of markers will probably require a 
multistage design. 
 
Genome-wide studies have the potential to identify many genes for common diseases and 
quantitative traits, however care will be required with their design, performance, analysis 
and interpretation, and well conceived pilot studies might be valuable for understanding 
and minimising the pitfalls of this approach (Hirschhorn & Daly 2005). 
 
8.3.1 Epistasis 
 
For many Mendelian conditions, genotype-phenotype correlations remain inadequately 
correlated and the inability to predict the phenotype on the basis of genotype is now 
apparent in many disorders (Dipple and McCabe 2000). Broad variability in phenotypic 
expression within and between families with the same mutation characterizes many 
monogenic conditions -relevant to this thesis the case of ARS (Summers 1996). 
 
Additionally, gene mutations can lead to absence of a recognised phenotypic effect because 
of reduced penetrance (van Heyningen and Yeyati 2004). Also, it has been recognised that 
for many monogenic conditions, there may be important genes at other loci or 
environmental modifiers that change expression. 
 
The genes of an individual do not operate in isolation, but are functioning in a common 
cellular environment. Therefore, it is expected that interactions between genes (epistasis) 
may occur. Conditions showing complex pattern of inheritance often involve multiple types 
of genetic mechanisms, like modifier genes, triallelic inheritance, digenic inheritance, 
opposite transcripts (transcribed from the same genomic locus as their target but from the 
opposite DNA strand and form perfect pairs –Wang et al 2005)  
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The effect of modifier genes may include reduced penetrance, dominance modification, 
expressivity and phenotypic pleiotropy. These effects are commonly seen when mice with 
single gene mutations are crossed onto different genetic backgrounds (Gropman and Adams 
2007). Modifier genes also alter the onset, the range of symptoms and the severity of 
disease in humans. Modifier genes have become increasingly recognised as an important 
source of phenotypic variation that may explain the relationship between phenotype and 
genotype. They can also have small quantitative effects on the expression level of another 
gene. The products of modifier genes may affect splicing, transcription, translation, protein 
trafficking, glycosylation, protein expression, degradation or secretion.  
 
Modifier genes differ from susceptibility genes as follows: modifier genes are genetic 
variants that affect the clinical manifestation of disease (as opposed to liability), whereas 
susceptibility genes or loci affect genetic liability, generally for complex disorders 
(Gropman and Adams 2007). 
 
In the case of POAG, the exact mechanism of interaction of the identified associated genes 
(table 2.2) in susceptibility of the diseases remains unknown. The APOE polymorphism -
491A>T has been reported to interact with the MYOC polymorphism MYOC.mt1, to 
increase IOP in POAG patients (Copin et al 2002). Another study suggests that MYOC and 
CYP1B1 might interact through a common pathway and that the inheritance of glaucoma 
might be digenic in some cases (Vincent et al 2002). Also a possible gene-gene interaction 
between OPTN and TNF was also identified to increase the POAG risk (Funayama et al 
2004). In a large association study by Fan et al (2005), possible gene interactions were 
reported between MYOC, OPTN and APOE.  
 
In the case of anterior segment dysgeneses associated with glaucoma, Cella et al (2006) 
assessed the frequency of PITX2, FOXC1, CYP1B1 and GJA1 genes in patients with AXRS 
with glaucoma and identified a polymorphism in GJA1 (gap junction protein, alpha 1) in a 
patient with FOXC1 mutation and therefore suggest the possibility of its participation as a 
modifier gene. 
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Also, when the effect of TYR as a modifier gene in patients with ICG with a known 
CYP1B1 mutation was studied, this hypothesis could not be proven (Bidinost et al 2006). 
But because the mode of interaction between CYP1B1 and TYR is not known, a modifier 
effect of TYR on other CYP1B1 human mutations cannot be excluded. 
 
Other potential modifiers of gene expression that affect complex disorders are single 
nucleotide polymorphisms. These are single base pair positions in the human genome at 
which variation exists in the nucleotide sequence that gives rise to alternative alleles in 
normal individuals. As emphasised previously, it is believed that SNPs maps will enable 
scientists to identify the multiple genes associated with complex diseases as cancer, 
diabetes, vascular disease and age related ocular diseases like AMD and glaucoma. These 
associations are difficult to establish with the conventional gene hunting methods, because 
a single altered gene may make only a small contribution to the disease phenotype 
(Nowotny et al 2001). 
 
8.3.1.1 Other determinants of susceptibility 
 
Genetic susceptibility factors are important in determining whether a person develops 
glaucoma. In addition to factors already implicated in glaucoma through genetic studies, 
other factors that affect IOP and RGC survival are likely important. In their paper on the 
complex genetics of glaucoma Libby et al (2005) provide evidence for how genetic changes 
affecting aqueous production, outflow ocular development, outflow extracellular matrix 
and outflow-cellular stress and survival may alter susceptibility to IOP elevation in 
glaucoma. Also, they discuss the neural susceptibility to glaucoma, emphasizing its 
complexity and although some genes (APOE, OPA1, IGF2, and TNFα) have been 
suggested to increase this susceptibility, none has been definitely shown to be a major 
factor as yet. 
 
8.3.2 Quantitative traits analysis 
 
Another way to progress with unravelling the genetics of glaucoma is to investigate POAG 
constitutional anatomical or pathophysiological components. The study of intermediate 
phenotypes might be more powerful than just ascertaining whether disease is present or 
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absent and such a strategy has been implemented for IOP and CD ratios (Charlesworth et al 
2005).  
 
Quantitative trait linkage analysis of precursors of glaucoma, such as IOP and CD ratio, 
may have simpler genetic architecture than diagnosis of glaucoma, making it easier to map 
causative loci (Williams and Blangero 1999 a) and also it is particularly powerful in large 
families (Williams and Blangero 1999 b). 
 
Heritability of IOP and vertical CD ratio has been estimated by the Beaver Dam Eye Study 
investigators, providing evidence for the genetic determinants of these factors (Klein et al 
2004) and commingling analysis of IOP and glaucoma, suggested the existence of a major 
gene accounting for 18% of the variance of IOP in the Blue Mountains Eye Study 
population (Viswanathan et al 2004). The Beaver Dam Eye Study investigators found two 
possible linkage regions for IOP on chromosome 6 and 13 (Duggal et al 2005). 
Charlesworth et al (2005), revealed significant linkage for IOP to the long arm of 
chromosome 10 and suggestive linkage for vertical CD ratio on short arm of chromosome 
1. 
 
 The heritability of IOP and OD morphology has also been recently confirmed by a large 
Dutch study (Koolwijk et al 2007), which estimated that heritability for IOP at 0.35, 0.48 
for retinal nerve fibre layer thickness and 0.39 for neuroretinal rim area and that non 
genetic factors account for only a small proportion of the variance (< 0.13) in all three 
traits. Therefore they conclude that early, continuous markers of POAG are strongly 
determined by additive genetic effects. 
 
8.3.3 Twin studies 
 
With regards to the heritability and identification of disease causing gene, twin studies 
represent a major tool. Twin studies allow for well controlled association studies, as well as 
the study of genetic versus environmental contributions to the traits. Comparison between 
covariance of monozygotic and dizygotic  twin pairs allow estimation of the genetic and 
environmental contributions to the trait in question and it can be broken down into 
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dominant versus additive genetic components and shared versus non-shared environmental 
elements (Hewitt et al 2006).  
 
Once the components of a trait have been modelled and the effect of human differences has 
been determined, it is possible to locate the precise location of these genes, by using 
discordant sibling pair analysis of the dizygotic twins. The twin studies have been used 
successfully to demonstrate the role of heritability in the morphology of optic disc 
(Schwartz et al 1976, Teikari et al 1992, Hewitt et al 2007) and intraocular pressure 
(Kalenak & Paydar 1995, Parssinen et al 2007). 
 
 8.3.4 Statistical analysis challenges 
 
The rapid growth of human genetics created countless opportunities for studies of disease 
association. However, given the number of potentially identifiable markers and the 
multitude of clinical outcomes to which these may be linked, the testing and validation of 
statistical hypotheses in genetic epidemiology presents a task of unprecedented scale.  
 
One way this problem can be solved is to use meta-analysis, which provides a quantitative 
approach for combining the results of various studies on the same topic, and for estimating 
and explaining their diversity.  
 
An evaluation of 370 studies (addressing 36 genetic associations for various outcomes of 
disease) by meta-analysis demonstrated that significant difference between studies 
heterogeneity is frequent and that the result of the first study correlates only modestly with 
subsequent research on the same association (Ioannidis et al 2001).  
 
The first study frequently suggests a stronger genetic effect than is found by subsequent 
studies. Bias and genuine population diversity might explain why early association studies 
tend to overestimate the genetic component, however, systematic meta-analysis may assist 
in estimating population-wide effects of genetic risk factors in human disease.  
 
Also, contributing to this problem is publication bias and time-lag bias with small studies 
with “negative” statistically non-significant results taking longer to be published than 
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“positive” statistically significant studies (Easterbrook et al 1991, Ioannidis 1998). 
Estimates of the size of a genetic effect may be inflated, if only based on a single study 
with impressive results. Also, in some cases there may be large statistical uncertainty in the 
first study. Often, genetic associations of disease are of modest magnitude (OR >0.5 and < 
2) and single studies are underpowered to detect them.  
 
Isolated statistical significance does not guarantee a genetic association, and lack of formal 
statistical significance does not exclude the possibility of an association (Ioannidis et al 
2001). 
 
8.3.5 Current status and future directions of glaucoma genetic research 
 
8.3.5.1 Current status of glaucoma genetics 
 
Presently only a small proportion of glaucoma has been genetically accounted for. So far 
there is little understanding of the genetics of POAG and the cell biology underlying it. 
Linkage and association studies in human families have been essential in identifying loci 
and genes and these efforts need to be continued and combined with genomics and 
proteomics approaches to increase the rate of glaucoma gene identification. However, even 
with the genes identified, the situation is not as simple as first hoped. There appears to be 
phenotypic alteration by genetic modifiers and some mutations may only cause disease in a 
susceptible genetic context. This situation confounds the genotype-phenotype association 
and makes it even more difficult to characterize disease causing alleles in more complex 
cases of POAG in which multiple genes and environmental factors are likely to affect 
phenotype and the genetic changes may be subtle. For this reason animal studies are needed 
as an important complement to human studies. 
 
The ability to study effects of specific alleles in a defined genetic background and 
controlled environment makes mouse studies particularly valuable. So far mouse studies 
only marginally contributed to our understanding of glaucoma, but they will become more 
important in the future. Mouse models with potential relevance to glaucoma include the 
C57BL/6J mouse (strain of mouse which loses 50% of its RGG in the presence of normal 
IOP- important for studying NTG, Gould & John 2002), Colla1 mutant mice (this strain has 
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a mutation for the a1 subunit of collagen 1, a component of outflow pathway ECM, and has 
developed elevated IOP with almost 25% loss of their RGC (Marneros & Olsen 2003) and 
DBA/2J mice important for studying pigmentary glaucoma (Anderson et al 2002). 
 
The future combination of mouse approaches includes candidate gene mutation, addition of 
human genes and mutations, modifier genes characterization and sensitized mutagenesis 
screens. 
 
Although ASD phenotypes often exhibit dominant inheritance, variable expressivity and 
incomplete penetrance point to a multifactorial etiology. To date, most human ASD genes 
that are associated with glaucoma encode transcription factors and although the pathogenic 
mechanisms are not established, ocular tissue appear to be exquisitely sensitive to deviant 
activity levels of these transcription factors, suggesting that their levels are rate limiting for 
target gene modulation. 
 
Identification of new human genes based on linkage, association and candidate genes 
analysis will continue to produce results. Also, mouse studies will provide an important 
experimental system for dissecting developmental glaucomas. Genomics approaches such 
as microarray analysis and chromatin immunoprecipitation, to identify important 
developmental genes and how they are affected by specific mutations will also prove 
powerful. 
 
8.3.5.2 Future directions human genetics 
 
Human studies are essential and have identified a number of glaucoma genes. Genome-
wide studies suggest the existence of even more glaucoma loci and the identification of new 
genes will continue. However, it has been stated many times that glaucoma is a complex 
disease and therefore will be significantly more difficult to unravel (probably involving 
heterogeneous causes, genes of more modest effect and relatively subtle mutations in 
multiple genes). In family linkage studies, the number of affected individuals typically will 
be limiting. The multifactorial complexity has the potential to confound familial and non-
familial studies even when assessing candidate genes. Distinguishing a truly causative gene 
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from a closely linked gene of no consequence can also be problematic. So, what do we do 
next? 
 
1. The full array of genetic approaches should be used, including linkage studies, candidate 
genes analysis and sophisticated association studies. Also, given the likelihood of 
multifactorial interactions, it will be important to asses the role of multiple genes or loci on 
individual patients and not stop when a single mutant gene has been identified. As it has 
been mentioned above, there are some studies that strongly support the existence of 
modifier genes. 
 
 2. Continue to gather DNA samples (affected individuals and non-affected family 
members, as more cases develop with age). Analysis of large samples will facilitate 
detection of multifactorial interactions and will provide greater statistical power.  
 
3. Collecting as much family history, medical information, environmental history and 
lifestyle data as possible to accompany these samples it is also very important. 
 
4. As much as it is possible, analysis techniques, information gathering, and diagnostic 
criteria should be standardized and new epidemiological studies should be conducted. 
 
5. While safeguarding patient protection and privacy, it would be useful for genotype and 
all other relevant data to be incorporated in large scale shared databases. This would 
facilitate progress by enabling firstly interrogation by the research community using 
different approaches and secondly would increase the power of future human genetic 
analyses. 
 
8.3.5.3 Animal genetics 
 
Animal studies complement human studies and can provide important insight into genetic 
etiology and molecular mechanism for further assessment in people. Animal models and 
cell culture systems for studying glaucoma are well established and will continue to make 
important contributions to understanding glaucoma. At present, the mouse is the best suited 
mammalian model for deciphering complex genetic interaction that underlines glaucoma 
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susceptibility. The effect of genetic background effect on gene’s pathogenicity can be 
studied and help with identifying modifier genes. Such studies may help explain incomplete 
penetrance and currently discrepant genotype-phenotype relationships. Also, they will 
identify new molecular pathways that may contribute to glaucoma in patients. And finally, 
mutagenesis screens in mice will also contribute to elucidating genes and mechanisms that 
may interact to cause glaucoma in patients. 
 
8.3.5.4 Genomics and proteomics 
 
Genomics can be applied to human samples and to tissues from the many model systems 
that are used to study specific aspects of glaucomatous pathophysiology. Different 
expression patterns between treatments or between patients and controls will help prioritize 
the assessment of candidate genes (e.g.: microarray analysis is used to determine the 
molecular pathway that underlie elevated IOP in cultured TM cells and to determine 
changes in gene expression in response to elevated IOP). Identifying expression differences 
for specific genes will be especially useful when these genes or other members of the 
pathways they mediate reside in implicated chromosomal regions. Genomics tools are also 
used in examining neural responses to elevated IOP using a variety of models, including 
primates. These techniques can be used to ask precise questions about individual cell 
populations responses to glaucomatous insults.  
Proteomics is further said to contribute greatly to the understanding of gene function in the 
post-genomic era. Proteomics can be divided into three main areas:  
1. protein micro-characterization for large scale identification of proteins and their post-
translational modifications;  
2. “differential display” proteomics for comparison of protein levels with potential 
application in a wide range of diseases; 
3. studies of protein-protein interactions using techniques such as mass spectrometry or the 
yeast two-hybrid system. Because it is often difficult to predict the function of a protein 
based on homology to other proteins or even their three-dimensional structure, 
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determination of the components of a protein complex or of a cellular structure is central in 
functional analysis (Pandey et al 2000). 
8.4 CONCLUDING REMARKS 
 
The progress in understanding glaucoma has been great in the last few decades; however, 
an efficient strategy for detecting patients with glaucoma or at risk of developing glaucoma 
is still missing. Even in developing countries, half of people with POAG remain 
undiagnosed (Hollows & Graham 1966, Mitchell et al 1996). Strategies to reduce glaucoma 
blindness must be aimed at identifying individuals at risk.  
 
Identification of risk factors allows early diagnosis and treatment prior to loss of visual 
function. Cross sectional studies have suggested that more than 50% of all glaucoma is 
familial and a family history of glaucoma conveys up to 3 fold increase in the risk of 
developing POAG (Tielsch et al 1994, Weih et al 1972). 
 
 Also, as previously emphasized, there is an increased prevalence of POAG in first degree 
relatives of patients with the disease, and a recent study demonstrates that the severity of 
the disease is greater in familial glaucoma than in sporadic disease (Wu et al 2006).This 
study and another recently published study on the clinical and cost effectiveness of 
screening for open angle glaucoma (Burr et al 2007), suggest that the screening programs 
should target high risk groups (i.e. family history of the disease, black ethnicity).  
 
Establishment of a genetic screening program offers many advantages and these are as 
follows  
(Pang 1998): 
1. It provides an unequivocal test of high specificity 
2. It enables identification of non-symptomatic carriers, who are at risk of developing 
POAG 
3. And it provides information for genetic counseling.  
 
However, to establish a molecular diagnostic service, the disease-causing mutations must 
be identified. Furthermore: 
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1. the clinical information about the onset of disease, course of disease and response to 
therapy needs to be collected; 
2. the prevalence of the mutations in the population must be known to obtain a predictive 
value of the genetic testing; 
3. the pattern of inheritance of these mutations must be clarified in order for the genetic 
data to be used for genetic counseling (Pang 1998). 
 
Current genetic screening for glaucoma genes is limited to genes that are already 
recognized to be associated with POAG (mainly MYOC - Fan et al, 2006a) and is primarily 
diagnostic, rather than prognostic. With respect to OPTN E50K mutation, since this 
mutation has never been detected in unaffected controls, diagnostic testing of sporadic 
normal tension glaucoma cases for E50K mutation may be of value in the UK population. 
The striking difference in the prevalence between familial and sporadic cases should favor 
the implementation of targeted diagnostic testing for individuals with a family history of 
normal tension glaucoma.  
  
Commercially available kits that have been utilized to screen for MYOC mutation (such as 
Ocugene test from InSite Vision) have also yielded low sensitivity as it tests for only 3 out 
of the many identified disease causing variations (Alward et al 2002), and demonstrates the 
current drawbacks of genetic screening for POAG. Nonetheless, once it reaches a sufficient 
level of accuracy, genetic screening would provide a focused delivery of medical resources 
to a smaller proportion of at risk populations. 
 
Some strategies for current and futures studies have been outlined above, emphasizing the 
role of both the clinician and researcher. These strategies discuss mainly the future of 
genetic studies in glaucoma; however, the role of environmental factors in the pathogenesis 
of the disease should not be minimized. For a late onset disease it is likely that the 
genetically determined features are more sensitive to environmental influences because of 
disruption of normal physiologic homeostatic mechanisms. Therefore, future studies should 
include both evaluation of environmental factors that may be associated with glaucoma and 
investigations into specific gene-environment interactions in patients with POAG. 
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With regards to this study, identification of POAG pedigrees, as large as possible and 
accurate phenotyping with the methods available at the time of patient enrolment represents 
a very valuable resource for further genetic studies, especially in the setting of rapid 
technological advances. By setting up collaborations with research groups nationally and 
internationally, the large number of patients with a complex disease need it to draw 
statistically meaningful results are easier to add up.  
 
In the case of the second cohort of POAG/OHT patients enrolled in this study, the criteria 
for inclusion were very strict and therefore, again, they represent a valuable resource for 
studying the disease in a homogeneous, well defined population. In this particular cohort, a 
large effect of PITX2 polymorphism in POAG has not been demonstrated. This should be 
the basis for further studies into the role of developmental glaucoma genes in the 
pathogenesis of POAG, as smaller, more subtle effect and /or possible gene-gene 
interactions might be demonstrated. 
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Chapter 9: CONCLUSION  
 
Clearly, the current understanding of the underlying genetic architecture of a complex 
inherited disorder such as POAG continues to be limited, with the genetic basis of the 
majority of glaucoma cases still largely unknown. It is highly probable, as in many 
complex inherited disorders, the condition result from the independent actions of multiple 
genes as well as from interactions of multiple genes. As shown by this study, with the 
implementation of SNP-based technologies, a substantial increase in research and 
understanding into the molecular basis of complex inherited disorders is underway. The 
ultimate goal would be to discover a complete panel of genes that contribute to glaucoma 
and acquire diagnostic and prognostic correlates for the mutations.  
 
Victorian physician Sir William Osler wrote in 1892: “If it were not for the great variability 
among individuals, medicine might be a science not an art”. More than a century later, 
analysis of SNPs raises the prospect of understanding the factors driving this variability and 
tailoring treatment to the patient. 
 
The work done for this thesis offered me a fascinating insight into the world of molecular 
genetics, especially for someone with a clinical background. It also, emphasized the 
importance of the clinical aspect of setting up a genetic study. I was in the privileged 
situation of identifying, recruiting, phenotyping two different cohorts (the family history 
cohort and the high IOP POAG/OHT cohort) and then followed on with the genetic study 
of the high IOP POAG/OHT cohort. This situation allowed me to appreciate the importance 
of collaboration between clinicians and researchers, in the setting up and running of genetic 
studies, and it left me with huge enthusiasm for being part of future studies. 
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APPENDICES 
 
Appendix 1 
 
 
Tel: 0191 565 6256                                    Version 4.0 
Miss Daniela Vaideanu 
Mr Scott Fraser 
                                 PATIENT INFORMATION SHEET 
 
                                   Searching for Genes for Glaucoma 
 
Within the department of Ophthalmology we are carrying out research in order to discover the underlying 
cause of glaucoma. Before you decide, it is important for you to understand how the research is being done 
and what it will involve. Please take time to read the following information carefully. Ask us if there is 
anything which is not clear or if you would like more information. Take time to discuss this with your 
relatives and family doctor if you wish, to decide whether or not to take part. If you decide you do not wish to 
take part please contact us either by phone, email or letter and we will destroy any sample you have donated. 
We will acknowledge in writing that we have received your notification that you no longer wish to be part of 
the study. Thank you for reading this information sheet. 
 
What is the purpose of the study? 
Glaucoma is the third commonest cause of visual loss in the world. The most recent approach to preventing 
visual loss is to discover the underlying genes responsible in families and individuals with glaucoma, so that 
we may test the at-risk individual for visual loss, and treat at the earliest possible moment to prevent such 
loss. So far, through studying large family members who have inherited glaucoma through generations, 3 
inherited genes have been identified which may be involved in glaucoma. However, up to date, several studies 
have shown that these are rare causes of glaucoma and their role in the underlying cause of glaucoma still 
remains uncertain. We request your help in discovering the remaining genes. 
 
Why have I been chosen? 
Your ophthalmologist has selected you because of your diagnosis of glaucoma. Approximately 400 other 
people will be asked to assist in this study. 
 
Do I have to take part? 
This decision is up to you entirely. If you do decide to take part, please keep this information sheet. You will 
be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time and 
without giving any reason. This will not affect the standard of care you receive. 
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What will happen to me if I take part? 
A brief summary of your eye findings will be prepared by your ophthalmologist for inclusion in the study. We 
will ask for a small blood sample taken from an arm by an experienced doctor. This blood sample will be sent 
to the Institute of  Child Health where DNA will be extracted from this sample, and only the genes for 
glaucoma will be studied. This study may take us 2-3 years, since there are many genes involved. 
 
Are there any side effects of giving a blood sample? 
This procedure involves a momentary pain, like a mosquito bite, and may leave a small bruise. 
 
What are the possible benefits of taking part? 
We hope to find the cause of glaucoma in families in which there is a genetic cause. This should lead to 
preservation of vision in a more efficient way than was possible in the past. We also hope that by discovering 
the underlying genes causing glaucoma, we can use this new knowledge to find a more specific treatment or a 
screening test to identify those at risk of developing glaucoma. At present, we simply lower the eye pressure; 
we do not know why the visual loss occurs in the first place. 
 
Will my taking part in this study be kept confidential? 
We request your permission to restricted access to your medical records and the information collected about 
you in the course of the study. All information which is collected about you will be kept strictly confidential. 
Any information about you which is included in a research publication will have all identifying features 
removed, so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
Once we find a new gene which causes glaucoma, the results will be published in a scientific journal dealing 
with such information. In this way, it will be made available internationally, and other investigators can look 
at their glaucoma families to see if they have the same gene. However, the results will not be made available 
to you unless you have specifically requested it. 
 
You will not be identified in the publication. 
 
Who has reviewed the study? 
This study has been reviewed by your hospital Research Ethics Committee. 
 
Contact for further information? 
Please contact your ophthalmologist or a member of the genetics team on the number shown on page 1 for 
further information. Thank you for taking part in this study. This is your copy of the information sheet.  
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Appendix 3 
Tel: 0191 565 6256                                   Version 4.0 
Miss Daniela Vaideanu 
Mr Scott Fraser 
                                 PATIENT INFORMATION SHEET 
                          Searching for Genes for Glaucoma- control subjects 
 
Within the department of Ophthalmology we are carrying out research in order to discover the underlying 
cause of glaucoma. 
 
As part of this study we require a group of patients who do not have glaucoma who are willing to assist us. 
This group would act as a ‘control’ sample for comparison with those diagnosed with glaucoma. 
 
Before you decide, it is important for you to understand how the research is being done and what it will 
involve. Please take time to read the following information carefully. Ask us if there is anything which is not 
clear or if you would like more information. Take time to discuss this with your relatives and family doctor if 
you wish, to decide whether or not to take part. If you decide you do not wish to take part please contact us 
either by phone, email or letter and we will destroy any sample you have donated. We will acknowledge in 
writing that we have received your notification that you no longer wish to be part of the study. Thank you for 
reading this information sheet. 
 
What is the purpose of the study? 
Glaucoma is the third commonest cause of visual loss in the world. The most recent approach to preventing 
visual loss is to discover the underlying genes responsible in families and individuals with glaucoma. In order 
to confirm that a newly discovered gene causes glaucoma we need to compare the findings in patients who do 
not have glaucoma. Those who do not have glaucoma should not have the same abnormality in the gene. 
 
Why have I been chosen? 
You have been asked to help because you have been screened for glaucoma and found to be unaffected. 
Approximately 400 other people will be asked to assist in this study. 
 
Do I have to take part? 
This decision is up to you entirely. If you do decide to take part, please keep this information sheet. You will 
be asked to sign a consent form. If you decide to take part you are still free to withdraw at any time and 
without giving any reason. This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
A brief summary of your eye findings will be prepared by your ophthalmologist for inclusion in the study. We 
will ask for a small blood sample taken from an arm by an experienced doctor. This blood sample will be sent 
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to the Institute of  Child Health where DNA will be extracted from this sample, and only the genes for 
glaucoma will be studied. This study may take us 2-3 years, since there are many genes involved. 
 
Are there any side effects of giving a blood sample? 
This procedure involves a momentary pain, like a mosquito bite, and may leave a small bruise. 
 
What are the possible benefits of taking part? 
We hope to find the cause of glaucoma in families in which there is a genetic cause. This should lead to 
preservation of vision in a more efficient way than was possible in the past. We also hope that by discovering 
the underlying genes causing glaucoma, we can use this new knowledge to find a more specific treatment or a 
screening test to identify those at risk of developing glaucoma. At present, we simply lower the eye pressure; 
we do not know why the visual loss occurs in the first place. 
It is unlikely that you will benefit directly from this research as you do not have glaucoma. 
 
Will my taking part in this study be kept confidential? 
We request your permission to restricted access to your medical records and the information collected about 
you in the course of the study. All information which is collected about you will be kept strictly confidential. 
Any information about you which is included in a research publication will have all identifying features 
removed, so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
Once we find a new gene which causes glaucoma, the results will be published in a scientific journal dealing 
with such information. In this way, it will be made available internationally, and other investigators can look 
at their glaucoma families to see if they have the same gene. However, the results will not be made available 
to you unless you have specifically requested it.  
 
You will not be identified in the publication. 
 
Contact for further information? 
Please contact your ophthalmologist or a member of the genetics team on the number shown on page 1 for 
further information. Thank you for taking part in this study. This is your copy of the information sheet.  
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Appendix 4 
 
Protocols 
 
 
a. DNA extraction 
 
Genomic DNA was extracted from peripheral blood leucocytes, using a Nucleon BACC2/3 kit (Tepnel Life 
Sciences PLC). 
 
Blood was collected in 5 ml sodium EDTA tubes.  
 
The main steps in the Nucleon protocol are as follow:  
 
1. cell lysis 
2. deproteinisation with sodium perchlorate 
3. extraction with chlorophorm and Nucleon TM resin 
4. DNA recovery 
5. DNA washing  
 
Cell preparation from the whole blood:  
 
1. to 5 ml of blood add 20 ml of reagent A (4x the volume of blood) in a 50 ml Falcon tube 
2. shake at room temperature for 5 minutes 
3. spin at 1300g for 30 min  
4. discard supernatant  
5. warm reagent B at 37°C 
6. add 4ml reagent A then vortex briefly to resuspend pellet 
7. spin at 1300g for 10 minutes 
 
Cell Lysis 
 
1. add 2ml reagent B then vortex briefly to resuspend pellet 
2. incubate at 37°C for 10 minutes 
3. transfer to a 10ml Falcon tube 
 
Deproteinisation 
 
1. add 500µl Na perchlorate and mix by inverting at least 7 times 
 
DNA extraction 
 
1. add 2ml chlorophorm and mix by inverting at least 7 times (emulsifies phases) 
2. add 300µl nucleon resin and without mixing phases, spin at 1300g for 5 minutes 
3. transfer upper layer to a new 10 ml tube 
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4. add 2x the volume of cold 100% ethanol (approx 5 ml) and invert several times until the DNA is 
precipitated 
5. transfer precipitate to Eppendorph containing 1ml of sterile H2O 
 
b. PCR clean up for automated sequencing (ExoSAP protocol) 
 
ExoSAP protocol may be used for clean up of the PCR product prior to automated sequencing. 
 
Exonuclease I (E. coli)/New England BioLabs Inc. degrades excess single stranded primer oligonucleotide (in 
the 3’to 5’ direction) from a reaction mixture containing double stranded extension products. 
 
SAP (Shrimp Alkaline Phosphatase)/USB Corporation desphophorylation removes 5’-phosphates from 
double stranded DNA 
 
A 10µl PCR volume is mixed with 2µl Exo I at 1U/ µl and 2µl SAP at 10U/ µl by gentle vortexing, then 
briefly centrifuged. This is then incubated at 37°C for 20 minutes in a thermal cycler. This is followed by the 
inactivation of the ExoSAP by heating to 80°C for 20 minutes as step two in the thermal cycler. 
 
 
c. Sequencing protocol DYEnamic ET (Dye terminator cycle sequencing kit for MegaBACE DNA analysis 
systems/ Amersham Biosciences) 
 
96 well microtiter plate (Eppendorph) was used 
Primer diluted at a concentration of 5pmol/µl 
 
Sequencing reaction: 
Template DNA                4 µl 
Primer    1 µl 
Water    7 µl 
Sequencing reagent premix 8 µl 
 
Total volume   20 µl 
 
 
Control reaction 
M13mp18 control template 1 µl 
Control primer   2.5 µl 
Water    8.5 µl 
Sequencing reagent premix 8 µl 
 
Total Volume   20 µl 
 
The plate was briefly centrifuged at 700 rcf, for 1 minute. 
The plate was then placed in the thermal cycler with the following cycling program running: 95°C for 
20seconds, 60°C for 1minute (the 50°C for 15 seconds step has been omitted as the melting temperature for 
these samples was >60°C) for 25 cycles. Following cycling, the plate was briefly centrifuged, so that the 
reaction mixture was collected at the bottom of the wells. 
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Post-reaction clean up using the isopropanol precipitation 
 
To the 20 µl volume in the wells, 80 µl of 80% isopropanol was added to each well. The plate was then 
spanned at 2800rcf, 15°C for 30 minutes (SH-3000/Sorval Legend RT) 
The plate was inverted on paper and spanned again at 700rcf for 1 minute, to remove the supernatant.  
The DNA pellet was washed with 70% ethanol and centrifuged briefly. The supernatant was removed by a 
brief inverted spin and then air-dried and submitted for sequencing. 
 
 
d. Agarose gel electrophoresis and visualisation 
 
 
DNA fragments were separated by electrophoresis on an agarose gel, with ethidium bromide as an 
intercalating dye. DNA was electrophoresed in 0.8% to 2% (w/v) agarose 1x TAE gel. Agarose was dissolved 
in 1x TAE buffer containing 0.4ng ethidium bromide (Sigma), heated in a microwave and allowed to cool.  
Molten agarose was then poured into a horizontal gel apparatus (Scotlab) and allowed to polymerise. Samples 
and Hyperladder IV (Bioline) were mixed with TAE loading buffer and electrophoresed at a constant 100V in 
a 1x TAE buffer. DNA was visualised by exposure to UV using an Alphamager™ 2200 (Alpha Innotech).  
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MATERIALS 
Chemicals and reagents 
All chemicals were of molecular biology grade and solutions were prepared with autoclaved (120°C, 1.8bar, 
20mins) nanopure water (anH2O). 
             DNA extraction, purification and precipitation 
Nucleon DNA Extraction Kit BACC2/3  Tepnel Life Sciences PLC 
Isopropanol       Sigma 
Phenol                      Sigma 
Chloroform      Sigma 
Isoamyl alcohol                    Sigma 
Sodium Acetate                    Sigma 
Glycogen       Sigma 
Ethanol AnalaR                    Sigma  
MilliQ ultrapure water                   Millipore 
WizardR DNA clean-up system                  Promega 
Polymerase Chain Reaction  
HotstarTM Taq Polymerase     Promega 
- Supplied with 10x Reaction Buffer  
dNTPS (dATP, dTTP, dCTP and dGTP)               Fermentas 
Oligonucleotide primers                 Promega, MWG Biotech  
PCR Master Mix                  Promega 
PCR clean up for automated sequencing 
Exonuclease I (E. coli)                 BioLabs 
Shrimp Alkaline Phosphatase                 USB 
Sequencing 
DYEnamic ET Dye Terminator Cycle Sequencing Kit for MegaBACE DNA 
 Analysis Systems     Amersham Biosciences 
Primers for Sequenom     Metabion 
Agarose gel electrophoresis 
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Agarose      Helena Biosciences 
 Ethidium Bromide    Sigma 
 Eppendorf TAE (50x)    Helena Biosciences 
Hyperladder IV     Bioline  
1Kb Plus DNA Ladder    Invitrogen 
EZ LoadTM Molecular Rulers   BioRad 
Loading Buffers 
 Orange G     Bioline   
EQUIPMENT AND CONSUMABLES 
Equipment 
Alphamager™ 2200     Alpha Innotech 
Bench top microfuge     Eppendorf 
Gilson Pipetteman P2     Gilson 
 Gilson Pipetteman P20     Gilson 
 Gilson Pipetteman P200     Gilson 
 Gilson Pipetteman P1000     Gilson  
Horizontal gel electrophoresis: 
 Model E132     Consort 
 Model E802     Consort 
 Model HU10     Scotlab 
 Model HU13     Scotlab 
Incubation Oven      Cell Path 
MasterCycler™      Eppendorf 
MilliQ ultrapure, water purification system   Millipore  
 VortexGenie™      Scientific Industries  
 MegaBACE DNA Analysis System    Amersham Pharmacia 
 SequenomTM      SequenomR 
Consumables 
 Eppendorf 0.2ml tubes    Eppendorf   
  307 
 Eppendorf 0.5ml tubes    Eppendorf 
 Eppendorf 1.5ml tubes    Eppendorf 
 96 well plates     ABgene 
 384 well plates     ABgene 
 Falcon tube 15ml     BD Biosciences 
 Falcon tube 50ml     BD Biosciences 
Gilson Tips     Eppendorf 
 Parafilm      Jencon  
 Adhesive PCR film    ABgene             
Solutions and Buffers 
 DNA loading buffers ;   
-0.25% (w/v) Orange G    Sigma 
-30% (v/v) Glycerol    Sigma 
 Electrophoresis Buffer;  
-40ml 50xTAE in 2L of MilliQ ultrapure water Eppendorf 
 -80µl Ethidium bromide    Sigma 
 
COMPUTER  PROGRAMS  AND  ONLINE RESOURCES 
Genetic analysis 
BioEdit v 7.0.0 (http://www.mbio.ncsu.edu/BioEdit/) 
Sequencher (http://www.sequencher.com) 
Clustal W (http://www.ebi.ac.uk/Tools/clustalw) 
SHEsis (http://analysis.bio-x.cn/myAnalysis.php) 
UNPHASED v 3.0.12  
(http://www.mrc-bsu.cam.ac.uk/personal/frank/software/unphased) 
 Online resources 
  NCBI (http://www.ncbi.nlm.nih.gov/) 
  Ensembl (www.ensembl.org) 
 Institute of Human Genetics, Centre for Life, Newcastle upon Tyne 
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              (http://www.ncl.ac.uk/ihg/research/facilities/sequenom) 
 HapMap (www.hapmap.org) 
 SPSS v. 15.0 (https://ras.ncl.ac.uk/Citrix/MetaFrame/default/default.aspx) 
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Abstract. The anterior segment dysgeneses are an ill-defined group of ocular developmental 
abnormalities that share some common features and have a high prevalence of glaucoma. 
Current classification of what are and what are not anterior segment dysgeneses seems to 
vary and our knowledge of them is incomplete. As the limits of classical clinical medicine 
based on evaluation of signs and symptoms are reached, further advancements increasingly 
will come from molecular medicine and genetics. In this article we review the normal and 
abnormal development of the anterior 
segment (concentrating primarily upon neural crest derived dysgeneses), describe the 
various clinical entities produced and their diagnosis, and discuss the current knowledge of 
the genetics of these disorders. We also suggest a new approach to the classification of 
anterior segment dysgeneses, based upon the embryological contribution to the formation 
of the anterior segment of the eye. (Surv Ophthalmol 51:213--231, 2006. _ 2006 Elsevier 
Inc. All rights reserved.) 
Key words. anterior segment dysgeneses _ developmental glaucoma _ genetics _ glaucoma 
_ neural crest 
 
I. Introduction The anterior segment dysgeneses, at present, are an ill-defined group of developmental 
abnormalities that share some common features and a high prevalence of associated glaucoma. Classifications 
of what is and what is not an anterior segment dysgeneses seem to vary and our knowledge of them is 
incomplete. Throughout the whole of medicine a revolution is occurring as the limits of classical clinical 
medicine based on the evaluation of signs and symptoms is reached and further advances are increasingly 
coming from the fields of molecular medicine and molecular genetics. These new disciplines are un-
doubtedly going to allow us a far greater understanding of many diseases including the anterior segment 
dysgeneses. However, if we are to understand how alterations in genetic code cause functional abnormalities 
we must be sure that we can differentiate between what is normal and abnormal. Just as we systematically 
discover the nucleotide sequence of a particular gene we must be sure that we have systematically described 
and categorized the possible phenotypic changes that the gene could produce. Abnormalities of the anterior 
segment that can lead to glaucoma have recently received attention 
45 as they often have large pedigrees and severe phenotypes. Although relatively rare, they may provide 
important insights into one of the most common forms of glaucoma—chronic open-angle glaucoma (COAG). 
This article reviews the normal and abnormal development of the anterior segment concentrating primarily 
upon neural crest derived dysgeneses. It describes the various clinical entities  
213 
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A Novel Homeobox Mutation in the PITX2 Gene in a Family 
With Axenfeld-Rieger Syndrome Associated With Brain, 
Ocular, and Dental Phenotypes 
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Axenfeld-Rieger Syndrome (ARS) is a genetically heterogeneous birth defect characterized by mal-formation 
of the anterior segment of the eye associated with glaucoma. Mutation of the PITX2 homeobox gene has been identified as a 
cause of ARS. We report a novel Arg5Trpmissensemutation in the PITX2 homeodomain, which is associated with brain 
abnormalities. One patient had a small sella turcica likely to reflect hypoplasia of the pituitary gland and consistent with the 
critical role identified for Pitx2in pituitary development in mice. Two patients had an enlarged cisterna magna, one with a 
malformed cerebellum, and two had executive skills deficits one in isolation and one in association with a below average 
intellectual capacity. The mutation caused a typical ARS ocular phenotype. All affected had iris hypoplasia, anterior iris to 
corneal adhesions, and corectopia. The ocular phenotype varied significantly in severity and showed some asymmetry. All 
affected also had redundant peri-umbilical skin, a hypoplastic maxilla, microdontia, and hypodontia missing between 20 and 27 
teeth with an unusual pattern of tooth loss. Dental phenotypes were documented as they are often poorly characterized 
in ARS patients. All affected individuals showed an absence of first permanent molars with variable absence of other rarely 
absent teeth: the permanent upper central incisors, maxillary and mandibular first and second molars, and the mandibular canines. 
Based on the distinctive dental anomalies, we suggest that the dental phenotype can assist in predicting the presence 
of a PITX2 mutation and the possibility of brain abnormalities. _ 2006 Wiley-Liss, Inc. 
KEY WORDS: PITX2; glaucoma; tooth hypodontia; cisterna magna; cerebellar vermis hypoplasia 
 
INTRODUCTION 
Malformation of the anterior segment of the eye with dental hypoplasia (hypodontia) was first identified as a dominantly 
inherited disorder by Rieger (MIM 180500). The PITX2 homeobox gene was identified as the Rieger syndrome type 1 
gene on chromosome 4q25; two further loci have been mapped to 13q14 (Rieger syndrome type 2; MIM 601499) and 16q24 
[Phillips et al., 1996; Semina et al., 1996; Smith et al., 2000].Clinical reports of Rieger syndrome describe a range of 
associated features including maxillary hypoplasia, anal stenosis, hypospadias, growth hormone deficiency, congenital 
heart defects, hearing defects, hydrocephaly, and psychomotor retardation (MIM 180500, MIM 601499, and MIM180500). 
Semina et al. [1996] noted that families with PITX2 mutation typically present with ocular and dental features together with 
failure of involution of periumbilical skin. However, other clinical features have not been associated with PITX2 mutation. 
Deletion of the homeobox gene, PAX6, was identified in a single case of Rieger syndrome [Riise et al., 2001]. Mutation of 
the forkhead gene FOXC1 has also been reported in families with features resembling Rieger syndrome [Mirzayans et al., 
2000; Riise et al., 2001; Honkanen et al., 2003]. PAX6 mutation is more commonly associated with aniridia and FOXC1 
mutation with anterior segment defects without other systemic features [Hanson et al., 1993] MIM106210; [Mears et al., 
1998; Nishimura et al., 1998] MIM 601090. As there is considerable overlap in the anterior segment phenotypes 
caused by mutations in the PITX2, FOXC1, and PAX6 genes [Alward et al., 1998; Kulak et al., 1998; Mears et al., 1998; 
Nishimura et al., 1998, 2001; Lehmann et al., 2000; Mirzayans et al., 2000] the term, Axenfeld-Rieger syndrome, ARS, 
has been proposed to encompass this genetically heterogenous clinical spectrum [Alward, 2000]. The ocular features 
of ARS include iris hypoplasia, anteriorly displaced and prominent Schwalbe’s line (posterior embryotoxon), 
This article contains supplementary material, which may be viewed at the American Journal of Medical Genetics website 
at http://www.interscience.wiley.com/jpages/1552-4841/suppmat/index.html. 
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